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Background:$ Periodontitis! (PD)! is! a! chronic! inflammatory! disease.! The! lowKgrade!





with! PD! and! controls! to! assess! the! differences! in! intimaKmedia! thickness! and!
endothelial! function! between! cases! and! controls,! 2)! a! Randomized! controlled! trial!
investigating! the! effect! of! periodontal! therapy! on! mitochondrial! oxidative! stress,!
systemic! inflammation,! endothelial! function! and! metabolic! control! in! patients! with!
type!II!diabetes!mellitus!and!periodontitis!3)!a!randomized!controlled!trial!investigating!
the! effect! of! periodontal! treatment! on! the! carotid! intima!media! thickness! 4)! a! RCT!
controlled! trial! investigating! the! effect! of! remote! ischemic! preconditioning! on! the!
endothelial!dysfunction!following!periodontal!treatment.!
Results:$Study!I!demonstrated!that!there!is!an!association!between!PD,!flow!mediated!
dilation!and!carotid! intima!media! thickness,!measures!of! cardiovascular! risk.!Study! II!
reported!the!benefit!of!periodontal!therapy!on!the!endothelial!function,!mitochondrial!
oxidative!stress!and!glycemic!control!in!patients!with!Type!2!diabetes!and!PD.!In!Study!
III!we! reported! the!beneficial! effect! of! periodontal! treatment! on! the! carotid! intimaK
media! thickness!and! lastly! in!Study! IV!demonstrated! the!protective!effect!of! remote!







collaborative! work! between! the! Periodontology! Unit! of! the! UCL! Eastman! Dental!
Institute,! the! Vascular! Physiology! Unit! at! the! Institute! of! Cardiovascular! Sciences! as!
well!as!the!Department!of!Biomaterials!and!Tissue!engineering.!All!studies!included!in!
this!thesis!are!original!in!concept!and!design.!I!performed!most!of!the!work!outlined!in!
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Periodontitis! (PD)! is! a! chronic! inflammatory! disease! triggered! by! a! dysbiosis! of! the!
subgingival! microbiome! and! affecting! the! tissues! supporting! the! dentition! called!
periodontium1.! This! includes! gingivae,! periodontal! ligament,! root! cementum! and!
alveolar!bone!and!they!are!all!affected!by!the!course!of!PD2.!Its!progression,!depending!
on! the! level! of! severity! and!extent,!may! affect! the! stability,! and! the! function!of! the!
involved! dentition! having! an! impact! on! the! patient’s! quality! of! life! and! ultimately!
leading! to! tooth! loss! in! its! advanced! forms.! PD! treatment! relies! mainly! on! the!
mechanical!removal!of!the!dental!biofilm!(pathogenic!bacteria)!from!the!root!surfaces!
by!means!of!hand!and!ultrasonic!instruments!performed!on!a!regular!basis3.!Over!the!
last! 20! years,! accumulating! evidence! supported! an! association! of! PD! with! multiple!
chronic! diseases! with! an! established! etiologic! inflammatory! component! including!
diabetes! and! cardiovascular! disease! suggesting! the! hypothesis! of! a! potential!
contribution! of! PD! in! their! onset! and! progression4K6.! The! systemic! impact! of! the!
periodontal!infection!and!its!treatment!has!been!investigated!providing!evidence!on!a!
number!of!putative!mechanisms!of! association!between!PD!and! chronic!diseases! 7,8.!
The! immune! response! is! known! to! be! involved! in! both! the! defense! and! collateral!
damage! of! the! periodontal! tissues9.! A! characteristic! systemic! inflammatory! profile!
associated!with!PD!has!been!shown!to!be!modulated!by!periodontal!treatment!(with!
acute!inflammation!increase!in!the!short!term!and!reduction!of!systemic!inflammation!
over! the! long! term)10,11.! Periodontitis! treatment,! therefore! represents! not! only! a!
therapeutic! procedure,! including! tissue! damage! and! bacterial! dissemination! in! the!
blood! stream!but! an! opportunity! to! study! systemic! inflammation! in! humans! and! its!
impact!on!various!organs.!It!has!been!previously!reported!a!twoKfold!impact!of!PD!and!




The!aim!of! this!project!was!to! investigate!the!magnitude!of! the!association!between!




The!periodontium! (peri! =! around,! odontium!=! tooth)! is! formed!by! tissues! “investing!









Together!with! the! surface!of! the!hard!palate! it! forms! the! region!of! the!oral!mucosa!
called!masticatory!mucosa!covering!part!of!the!alveolar!process!and!the!cervical!area!
of! the! teeth.! Its! width! comprises! the! region! from! the! gingival!margin! to! the!mucoK
gingival! junction.!The!change! in!the!tissue!color! from!the!coral!pink!of!the!gingiva!to!
the!dark!red!of!the!apical!alveolar!mucosa!contribute!to!their!distinction.!Based!on!the!




and!according! to! the! relationship!with! teeth,! three!different! epithelial! layers! can!be!
identified:!!
• oral,!(keratinized,!stratified,!squamous)!facing!the!oral!cavity.!





Different! cell! populations! can! be! detected! in! the! epithelial! layer;! keratinocytes,!
representing! the! majority,! melanocytes,! Langerhans! cells,! Merkel’s! cells! and!
inflammatory!cells.!The!gingival!sulcus!represents!the!starting!point!of!the!periodontal!
infection! characterized! by! a! microbial! accumulation! and! related! host! immune!
response.!
1.1.1.1.2. Gingival!connective!tissue!
The!connective! tissue!compartment!accounts! for! the!majority!of! the!gingival!volume!
and! is! represented! by! collagen! organized! in! fiber! bundles! forming! the! gingival!
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forces!applied! to! the! teeth.!The!dentition!mobility!depends!on! the! state!of! the!PDL.!





damage.! Its! content! comprises! a! high! mineral! component! (65%)! represented! by!
hydroxyapatite! and! has! a! cellular! component! consisting! of! cementocytes.!
Cementoblasts! of! the!PDL!produce!different! cementum! layers! distinguished!by! their!
histological! properties.! The! cementum! undergoes! new! layer! apposition! within! the!
ageing! process! becoming! thicker! throughout! life.! The! fibers! of! the! periodontal!
ligament! are! subject! to! a! mineralization! process! becoming! embedded! in! the!
cementum!contributing!to!the!attachment!apparatus!of!the!dentition!to!the!bone.!
1.1.1.4. Alveolar"bone"





proper! interface! the! dentition.! Its! resorption! due! to! inflammatory! periodontal!
processes!affects!the!dentition!stability!and!position.!!!
1.1.2. Classification$
Since! the! 1920,! different! classifications! of! the! diseases! affecting! the! periodontium!
have!been!proposed.!Their!evolution!was!driven!by!the!request!for!a!higher!precision!
in!the!definition!of!different!clinical!conditions.!The!classification!proposed!in!1999!by!
the! American! Academy! of! Periodontology,! even! if! it! states! that! “The! present!
knowledge!of!the!periodontal!disease!seems!to!be!insufficient!to!classify!them!on!the!







A.!Localized!! ! ! ! A.!Necrotizing!ulcerative!gingivitis!(NUG)!
B.!Generalized! ! ! ! B.!Necrotizing!ulcerative!periodontitis!(NUP)!
III.!Aggressive!Periodontitis†! ! VI.!Abscesses!of!the!Periodontium!
A.!Localized! ! ! ! A.!Gingival!abscess!


























gingivitis! since! it! involves! the! irreversible! disruption! of! the! periodontal! tissues.! It! is!

















































































in! the! methodology! adopted! for! the! diagnosis! of! periodontal! diseases! have!
contributed! to! the! difficulty! in! defining! its! global! prevalence.! The! assessment! of!
periodontal!tissues! inflammation,!presence!of!periodontal! lesions!and!the! loss!of!the!
dentition! support! have! been! evaluated!with! a! variety! of! clinical! indices.! The! lack! of!
uniform! criteria! in! epidemiological! research! reduces! the! validity! of! comparisons!
between!multiple! observational! studies.! The!majority! of! the! epidemiological! studies!
have!been!performed!in!the!developed!world!and!just!few!of!them!have!used!systems!
allowing! the! estimation! of! a! general! trend.! Today! there! is! no! definitive! data! on! the!
prevalence!of! periodontal! diseases!worldwide.! The!Adult!Dental!Health! Survey! 2009!
reported!that!45%!of!the!population!in!England!presented!with!at!least!1!periodontal!









(NHANES)! indicated! that! 47%! of! US! dentate! adults! aged! 30! years! and! older! had!
periodontitis,! moderate! and! severe! forms! affected! 38%! of! the! adult! population! 30!
years!and!older!and!64%!of!adults!65!years!and!older18.!!
1.1.4. Etiology$




several! factors! responsible! for! a! different! susceptibility! observed! in! the! general!




Dental! plaque! consists! of! a! biofilm! containing!more! than! 500! species! of! bacteria! of!
which! we! have! not! cultured! many! species22.! The! presence! of! dental! plaque! is!
detectable!after!the!dentition!eruption.!The!initial!colonization!is!lead!by!Streptococci!
and! Actinomyces! species.! Within! maturation! of! the! biofilm! there! is! a! switch! from!
mainly! Gram! positive! aerobic! bacteria! to! primarily! Gram! negative! motile! rods23,24.!
Extensive!microbial! research! has! aimed! to! identify! a! single! or! a! group! of! pathogens!
directly!responsible!for!the!onset!and!progression!of!periodontitis.!For!the!time!being!
it! is! still! not! possible! to! draw! conclusions! on! bacterial! role! in! the! etiology! and!
pathogenesis! of! the! disease.! A! classic! experiment! has! reported! the! association! of!
specific!microbial!species!(Tannerella!forsythia,!Porphyromonas!gingivalis,!Treponema!
denticola),!defined!as!the!red!complex,!with!the!presence!of!disease25.!Aggregatibacter!
actinomycetemcomitans! has! been! also! frequently! detected! specifically! in! aggressive!
forms!of!periodontitis26.!The!presence!of!the!above!species!is!reported!in!periodontal!
lesions! and! their! elimination! seems! to! be! linked! to! a! favorable! prognosis! after! the!
treatment.!In!addition,!their!release!of!virulence!factors!give!biological!plausibility!to!a!
putative!role!in!the!development!of!the!disease.!Other!species!(Prevotella!intermedia,!
Prevotella! nigrescens,! Peptostreptococcus! micros,! Fusobacterium! nuc.! vincentii,!
Fusobacterium!nuc.!nucleatum,!Fusobacterium!nuc.!polymorphum!and!Fusobacterium!
periodonticum.! Eiknella! nodatum,! Campylobacter! gracilis,! Streptococcus! constellatus!
and! Capnocytophaga! rectus),! called! the! amber! group,! have! been! identified! less!
frequently! in! sites! of! periodontal! destruction25.! The! limitations! to! the! microbial!
primary!pathogenic!role!are!that!the!species!of!the!red!and!amber!complex!cannot!be!




periodontal! lesions!mainly! in! sites!with!presence!of!plaque!and!calculus27.!Therefore!
the!main!etiologic!hypothesis,!defined!the!nonKspecific!plaque!hypothesis,!was!related!
to! the! volume! of! plaque! and! calculus! accumulated! on! the! diseased! dentition.!
Experimental! gingivitis!models! proved! that!plaque! is! the!main! factor! responsible! for!
gingivitis28!and!it!was!believed!that!periodontitis!was!the!next!step!in!the!progression!
of! the! gingival! inflammation.! Subsequent! observational! studies! on! the! natural!
progression! of! periodontal! disease! on! laborers! from! tea! estates! in! Sri! Lanka!
demonstrated! that! in! a! population! with! poor! oral! hygiene! and! generalized! plaque,!
calculus!and!gingival! inflammation!there!were!three!groups!responding!differently!to!
the!same!microbial!trigger.!The!susceptibility!to!the!disease,!with!no!difference!in!the!
volume! of! plaque,! was! moderate! in! 81%! of! the! population,! severe! in! the! 8%,!
meanwhile! there!was!no!development! in!11%!of! the! sample.!As!a! consequence,! the!
nonKspecific!plaque!hypothesis!has!been!universally!rejected!introducing!other!factors!





the! composition! of! the! local! microbiota.! Microbial! shift! or! dysbiosis! suggest! that! a!
decrease! in! the! number! of! beneficial! symbionts! and! an! increase! in! the! number! of!
pathogens!could!be!involved!in!the!pathogenesis!of!several!conditions.!In!PD,!the!oral!




deteriorates! until! a! state! of! clinical! disease! occurs.! Simultaneously,! a! succession! of!
microbial!complexes!develops.!!
1.1.5. Pathogenesis$




characterized!by! vasodilatation,! loss!of!perivascular! collagen,!margination!and!active!
migration! of! neutrophils! and!monocytes! into! the! periodontal! tissues! and! junctional!




It! is! observed! after! 7K14! days! of! plaque! buildKup! and! corresponds! to! the! gingivitis!
clinical! picture.! Neutrophils! and! lymphocytes! represent! the! main! immune! response!
cells! detectable! below! the! basal! cells! of! the! junctional! epithelium! (Figure! 3).! This!
migration! is! facilitated! by! the! breakdown! of! the! gingival! connective! tissue.! Matrix!
metalloproteinases! (MMPs)! derived! from! the! biofilm! and!
host! response! contribute! to! the! reduction! of! the! collagen!
fibers32.!
Figure"3"Early"lesion"





Histologically,! the! inflammatory! infiltrate!moves! towards! the! oral! epithelium! and! is!
represented!mainly!by!plasma! cells! but! in! younger!patients! lymphocytes! remain! the!









fibers.! At! this! stage,! the! junctional! epithelium! apical! migration! modifies! the! sulcus!
anatomy!leading!to!a!periodontal!pocket.!The!periodontal!damage!is!mediated!by!an!
increased!osteoclast!activity,!MMPs!release!and!dysregulation!of!host!derived!factors!
such! as! proteinases! and! proteinase! inhibitors,! matrix! metalloproteinases! and! tissue!
inhibitors! of! metalloproteinases! (TIMPs),! proKinflammatory!
cytokines!such!as! InterleukinK1α!(ILK1α),! InterleukinK1β!(ILK1β),!












against!the! invasion!of! infectious!agents.!Fluids!such!as!saliva,! tears,!urine,!GCF!have!
also!a!clearing!washing!action.! In!addition! they!contain!antiKbacterial!molecules.!The!
intact!gingival!epithelium!is!an!obstacle!to!bacterial! invasion!and!secretes!substances!
toxic! to! various! microorganisms.! The! saliva! explicates! a! both! a! mechanical! and!
chemical!action!flushing!the!oral!cavity!and!providing!agglutinins!and!antibodies.!The!
GCF! has! the! same! function! in! the! gingival! sulcus.! Furthermore! the! resident! nonK
pathogenic!bacterial!community!competes!with!harmful!microorganisms!for!nutrients!
and! attachment! sites! and! produces! substances! to! limit! their! colonization.! Following!
physical! damage! of! the! host! barrier! with! subsequent! bacterial! invasion,! the! innate!
immune! response! acts! starting! the! inflammatory! process,! classically! defined! by! the!
Latin!terms!dolor,!rubor,!calor!and!tumor.!Its!aim!is!to!stop!the!bacterial!invasion!but!it!
might! have! also! detrimental! effects! such! as! the! chronic! inflammatory! damage!
observed!during!periodontitis.!!
1.1.7. Risk$factors$









There! are! several! subgingival!microorganisms! in!periodontal! lesions,! however!only! a!
small!number!has!been!associated!with!the!progression!of!the!disease.!GramKnegative!
anaerobic!rods!and!spirochetes!represent!the!majority!of!the!species!detected!in!deep!
lesions.! Porphyromonas! gingivalis! and! Aggregatibacter! actinomycetemcomitans! are!




Smoking! represents!a!major! risk! factor! for!all! cause!mortality;! it! is! related! to!both!a!
higher! rate! of! periodontitis! progression! and! tooth! loss.! Cigarette! smoke! contains!
thousands! of! toxins,! such! as! carbon! monoxide,! oxidizing! radicals,! carcinogens! and!
nicotine.!Strong!evidence!suggests!that!tobacco!smoke!has!a!detrimental!effect!on!the!
periodontium42.! First! of! all,! cigarette! smoking! was! found! to! select! for! specific!
periodontal! pathogens,! including!P.! gingivalis,! Treponema!denticola! and!T.! forsythia,!
suggesting! a! shift! of! the! oral! microflora! towards! a! more! pathogenic! one! with! an!
increased! risk! for! the! onset! and!progression! of! the! disease43.! Secondly,! even! at! low!
doses,!nicotine!is!linked!to!peripheral!vasoconstriction!and!vascular!dysfunction44.!That!
accounts! for! the! lower! gingival! bleeding! and! inflammation! observed! in! smokers!
compared! to! nonKsmokers.! The! subsequent! vasoconstriction! could! plausibly! reduce!
the! oxygen! tension! in! the! periodontal! lesion! favoring! anaerobes! species! growth.!!
Nicotine! action! can! also! alter! neutrophils! function! including! their! proliferation! and!
chemotaxis!as!well!as!affecting!fibroblasts!homeostasis.!It! is!well!known!that!tobacco!
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of! periodontitis46.! Evidence! from!observational! studies! suggests! a! linear! relationship!
between!number!of! alcohol! units! per!week! and! clinical! attachment! loss47.!However,!
more! studies!are! required! to!elucidate! the!mechanisms!by!which!alcohol!affects! the!
periodontium.!!
1.1.7.1.4. Medications!
Using! specific! medication! may! interfere! with! the! oral! homeostasis.! Various! drugs!
including! antihypertensive,! narcotic! analgesics,! some! tranquilizers! and! sedatives,!
antihistamines,! and! antimetabolites! can! decrease! the! salivary! flow48.! Furthermore!









Obesity! and! overweight,! assessed! by! body! mass! index,! waist/hip! ratio,! waist!
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circumference,! body! weight,! and! bodyKweight! changes,! are! a! major! public! health!
problem.!More!than!oneKthird!of!the!adult!population!and!about!oneKfifth!of!children!
and! adolescents! classified! as! obese.! The! accumulation! of! adipose! tissue! is! linked! to!
insulin! resistance!and! chronic! systemic! inflammation.!Being!overweight! is! associated!
with! increased! risk! of! coKmorbidities! including! diabetes,! cardiovascular! disease! and!
cancer.! Evidence! indicates! that! obese! individuals! are!more! susceptible! to! infections!
due!to!an!altered!immune!response!caused!by!increased!systemic!inflammation!52.!
Periodontitis!has!been!repeatedly!associated!with!adiposity,!suggesting!a!potential!role!
of!adipose!tissue! in! increasing! local!and!systemic! inflammation!and!subsequently!the!
susceptibility!to!PD!itself.!A!systematic!review!of!observational!studies!(crossKsectional)!
confirmed! an! increased! prevalence! and! severity! of! PD! in! obese! and/or! overweight!
individuals,!with!a!doubled!odds! ratio! for!diagnosis!of!PD! (OR=2.13,!95%!confidence!
interval:!1.40–3.26)53.!
A! number! of! mechanisms! have! been! proposed! to! explain! the! association! between!
obesity! and! PD! including! altered! microflora! (overgrowth! of! T.! forsythia)! and!
differences!in!saliva!composition!and!immune!responses.!There!is!a!body!of!evidence!






individuals54.! This! could! be! explained! with! the! longer! period! of! time! in! which! the!




destruction! and! bone! loss! are! seldom! seen! in! individuals! under! the! age! of! 40.!
Therefore! it! is! not! clear! if! age! leads! to! increased! susceptibility! or! that! there! are!
cumulative!factors!that!control!the!onset!of!periodontitis.!
1.1.7.2.2. Gender!








Specific! genotypes! are! significantly! associated! with! the! severity! of! periodontal!
diseases58.! Severe!periodontitis! affects!only! around!10%!of! the!population15.! Studies!
investigating! familial!aggregation,! report! that!aggressive!PD! is!an! inherited! trait!with!




Diabetes!mellitus! (DM)! is!a!group!of!diseases!characterized!by!hyperglycemia!due! to!
the! alteration! of! the! glucose! metabolism! regulated! by! the! hormone! insulin61.! It!
represents!a!global!matter!affecting!more!than!8%!of!the!population!only!in!the!USA62.!
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It! is! associated! with! increased! mortality! and! its! main! complications,! such! as!
cardiovascular! and! renal! diseases! are! responsible! for! a! high! level! of! morbidity63.!
Periodontitis!and!diabetes!are!both!common!chronic!conditions!which!often!coKexist!in!
the! same! patients.! Patients! with! diabetes! often! present! with! poor! oral! health! and!
increased! prevalence! of! periodontitis! 64.! In! addition,! periodontal! infection! could!
worsen! the! glycemic! control! defining! a! potential! bidirectional! relationship! between!
these! two! diseases! 65.! Numerous! large! observational! studies! on! the! Pima! Indians!
population! reported! that! the! severity! of! PD! is! higher! in! patients! with! uncontrolled!
DM66.!DM!could!affect!the!periodontium!by!a!number!of!mechanisms!mainly!linked!to!
upKregulation!of! local!and!systemic! inflammatory!response.!Patients!with!PD!and!DM!
exhibit! higher! levels! of! proKinflammatory! mediators! in! the! GCF! and! increased!
monocytes!production!of!proKinflammatory!cytokines!when!compared!to!patients!with!







mandibular! osteopenia! and! loss! of! alveolar! crestal! height! and! tooth! loss! in!
postmenopausal! women68.! However! there! is! a! difference! between! osteopenia,!







long! term! structured! treatment! plan! that! is! divided! in! different! stages.! Firstly,!
providing!oral!hygiene!instructions!to!each!patient!in!order!to!reach!an!optimal!supraK
gingival! plaque! control! and! removing! any! retentive! factor! represented! by! faulty!






Evidence! from! different! systematic! reviews! reports! a! consensus! on! the! efficacy! of!
supra! and! subKgingival! debridement! in! the! reduction! of! the! periodontal! lesions! and!
improvement! of! clinical! attachment! level3,69.! The! instrumentation! of! the! affected!
dentition,! scaling! and! root! planing! (SRP)! with! ultrasonic! or! hand! instruments,! in!
association!with! optimal! daily! oral! hygiene!measures! is! aimed! to! alter! the!microbial!
biofilm!and!reduce!the!host! local! inflammatory!response.!The!nonKsurgical!treatment!
can! be! delivered! either! divided! per! jaw! quadrant! in! different! sessions! or! in! a! fullK
mouth!manner! in!order!to!prevent!the!reKinfection!of!the!treated!sites70.!There!does!




Nonsurgical! periodontal! treatment! leads! to! an! improvement! in! clinical! attachment!
levels! and!a! reduction/elimination!of! the! inflammation.!However,! surgical! therapy! is!
indicated!in!specific!clinical!situation!in!which!there!is!a!persistence!of!the!periodontal!





periodontal! maintenance! include! an! update! of! the! medical! and! dental! histories,!
examination!of!extraK!and!intraoral!soft!tissues,!dental!examination,!evaluation!of!the!
patient's! oral! hygiene! performance! and! supraK! and! subKgingival! removal! of! bacterial!















ischemia! of! the! tissues! located! distally! to! the! lesions! due! to! either! stenosis! of! the!
blood!vessel!or,!in!the!majority!of!the!cases!thrombus!formation!caused!by!the!rupture!
of! an!atherosclerotic!plaque73.!According! to! the! location!of! the!artery!occlusion,! the!
subsequent! ischemia! may! induce! stroke,! myocardial! infarction! or! peripheral! artery!
disease.!Atherogenesis!occurs!already! in! childhood!but! its! clinical!manifestations!are!
normally!observed!starting!from!the!middle!age74.!Coronary!heart!disease!and!stroke,!
mainly!due!to!atherosclerosis,!are!responsible!for!the!majority!of!the!death!worldwide.!




to! the! body! from! the! heart! to! the!
peripheries! at! high! pressure76.!
Depending!on!the!dimensions,!they!can!
be! divided! in! large! or! elastic! arteries,!
medium!or!muscular!and!arterioles.!The!
arterial!wall!consists!of!3!layers,!tunicae!
that,! according! to! the! vessel! size! and!




The! inner! layer! of! the! artery! is! represented! by! the! tunica! intima,! a! narrow! region!
separating!the!bloodstream!from!an!elastic!layer,!the!internal!elastic!lamina!(IEL)77.!In!
conduit! arteries,! there! is! also! an! underlying! stroma! containing! multiple! layers! of!





It! forms! the! inner! layer! of! the! human! vascular! tree! and! is! directly! involved! in!
atherogenesis! since! its! functions! can! be! directly! affected! by! many! inflammatory!
stimuli.! ! It! can! cover! an! area! of! approximately! 7m2! including! 1013cells78.! The!
endothelium! lies! on! a! basement!membrane! surrounded!
by!smooth!muscle!and!connective!tissue!according!to!the!




The! endothelium! can! regulate! the! vessel! tone! in! response! to! either! chemical! or!
mechanical! stimuli! releasing! different! vasoactive! mediators! including! prostacyclin,!
nitric! oxide! (NO),! hydrogen! peroxide! (H2O2)! to! relax! the! surrounding! VSMCs! or!
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thromboxane,! endothelin! or! angiotensin! II! to! contract! it81.! In! addition,! the!




is! subject! to! regulation! by! the! endothelial! cells.! The! interKendothelial! gap! junctions!
allow!the!exchange!of!small!molecules!but!large!solutes!require!a!vesicular!transport79.!




stopped.! It! requires!vasoconstriction,!platelets!adhesion!and!activation!at! the! site!of!
the!injury!and!the!formation!of!a!fibrin!plug!that!seals!the!vessel.!!The!endothelium,!in!
normal!conditions!does!not! initiate!the!hemostasis!however,!during!an! inflammatory!
process,! it! can!produce!a! specific!molecule! (tissue! factor,!TF)!which! in! turn!activates!






mechanism! to! be! identified! to! repair! any! endothelial! damage.! PreKexisting! cells!
duplication!and!migration!from!a!vessel!could!allow!growth,!remodeling!and!healing!of!
the! endothelium84.! An! additional! mechanism! called! vasculogenesis,! could! be!
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responsible! for!endothelium!homeostasis.!Cells!originated! in! the!bone!marrow!could!
be!converted!into!new!endothelial!cells.!Endothelial!progenitor!cells!(EPC)!have!been!
identified! and! characterized! as! regulators! of! endothelium! repair! in! various! districts,!
however!their!exact!role!is!still!a!matter!of!investigation85.!!
1.2.1.1.1.5. Response"to"inflammation"
The! endothelial! response! to! a! pathological! process! is! based! on! the! production! of!
inflammatory! mediators! and! adhesion! molecules! to! increase! the! leukocyte!
recruitment86.!In!physiological!conditions,!these!pathways!are!localized!and!reversible,!
however! a! perpetuated! inflammatory! response! is! related! to! endothelial! dysfunction!
and! may! be! the! first! step! towards! atherosclerosis! and! CVD.! The! endothelium! can!
release! cytokines! and! chemokines! in! response! to! numerous! in" vitro" or" vivo!
inflammatory!stimuli!such!as!lipopolysaccharide!(LPS),!tumor!necrosis!factorKα!(TNFKα),!
shear!stress,!infection!or!hypoxia.!Cytokines!such!interleukinK1!(ILK1)!and!interleukinK6!
(ILK6)! can! trigger! fever,! production! of! acuteKphase! reactants! and! activation! of!
lymphocytes.!Chemokines!such!as! InterleukinK8!(ILK8)!and!monocyte!chemoattractant!
protein!(MCPK1)!can!recruit!and!activate!neutrophils,!monocytes,!T!cells,!dendritic!and!
natural! killer! (NK)! cells.! The! upKregulation! of! adhesion!molecules! on! the! vessel!wall!
determines! a! higher! interaction! between! leukocytes! and! the! vessel! wall! increasing!
their!recruitment.!P!and!E!selectins!adhesion!molecules,!expressed!by!the!endothelium!
during! the! inflammatory! response,! facilitate! the! rolling! of! leukocytes! on! the!
endothelial!surface.!The!chemokines!activate!the!white!cells!causing!an!upKregulation!
of!their!surface! integrins!responsible!for!the! interaction!with!endothelial! intercellular!





It! represents! the!middle!and! thickest! coat!of! the!arterial!wall.! It! is! contained!by! the!
internal! and! external! elastic! lamina.! Multiple! layers! of! low! proliferative! rates! of!
VSMCs,! together! with! longKlived! elastic! and!more! rapid! turnover! of! collagen! fibers,!
compose! the! tunica! media.! The! media! layer,! except! from! cases! of! pathological!







to! nonKinvasively! study! arteries! and! their! structure.! However,! the! thickness! of! the!
intima!alone! is!below!the!resolution!of!the!ultrasound!equipment,!and!therefore!not!
possible!to!measure.!The!combined!intima!plus!media!complex,!is!possible!to!measure!
and! therefore! an! increased! intima!and!media! complex! thickness! (IMT)! is! used! as! an!
early!sign!of!atherosclerosis88,89.!
1.2.1.4. Tunica"Adventitia"




Precursor! lesions! of! atherosclerosis! (intimaKmedia! thickening)! may! occur! during!
adolescence,! but! the! incidence! of! definite! atherosclerotic! lesions! remains! low! until!
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middle!age! in!men!and!the!onset!of!menopause! in!women.!Within!the!5Kyear!period!
following!menopause! the! incidence! rates!of!women!are!similar! to! those!observed! in!
men! of! equal! age.! However,! in! some! subjects,! the! disease! can! progresses! rapidly!
during!their!third!decade!of!life.!It!has!been!estimated!that!in!USA!alone,!12.6!million!
people! suffer! from! CHD! and! 4.6! million! people! from! stroke90.! Great! Britain! and! in!
Scandinavia! report! the!highest! rate91!of! atherosclerotic!manifestation,!particularly! in!
Scotland! and! Finland.! In! the! past! twenty! years,! the! incidence! rates! have! been!
decreasing! in! several! industrialized! countries! but! not! in! the! developing! world.! This!
most!likely!is!due!to!the!public!health!initiative!increasing!prevention!of!atherogenesis!
via! management! of! common! risk! factors:! serum! cholesterol! concentration,!
hypertension!and!smoking91.!!
1.2.3. Risk$Factors$
Current! major! cardiovascular! risk! factors! are! summarized! in! Table! 4.! Seminal!
epidemiological!work,!such!as!the!Framingham!Study92!helped!identify!the!classical!risk!
factors! for! CVD! including:! male! sex,! increasing! age,! family! history,! smoking! habit,!









Most! of! these! risk! factors! interrelate! in! some! way! either! directly! or! indirectly.!
Excluding! the! nonKmodifiable! factors! including! age,! sex! and! family! history,!
management!of!atherosclerosis!is!achieved!by!controlling!its!main!risk!factors!such!as!










Markers! of! endothelial! activation/damage:! oxLDL,! sICAMK1,! NO,! brachial! artery!
reactivity,!glutathione!dysfunction!!
Thrombotic!markers:!tKPA,!PAIK1,!DKdimer,!vWF,!homocysteine!!










as! a! fatty! streak,! it! is! initially! composed!by! lipidKladen!monocytes! and!macrophages!
(foam! cells),! together! with! TKlymphocytes! within! the! arterial! wall.! Subsequently,!
smooth!muscle!cells!migrate! towards! the! fatty! streaks,!TKcell!are!activated!by! tumor!
necrosis! factor! (TNFKα),! interleukinK2! (ILK2),! and! granulocyte–macrophage! colony!
stimulating! factor.! Upon! stimulation! from! oxidized! lowKdensity! lipoprotein,!
macrophage! colonyKstimulating! factor,! TNFKα,! and! interleukinK! 1! (ILK1),! recruited!
macrophages! develop! into! foam! cells.! In! response! to! an! injury,! a! fibrous! healing!
response!is!observed.!Finally,!platelets!adhere!and!aggregate!to!the!plaque!subsequent!
to!endothelial!injury!.!This!is!the!result!of!stimulation!from!integrins,!PKselectin,!fibrin,!
thromboxane!A2,!and! tissue! factor,!and! is!accountable! for! leukocyte!adherence.!The!
lesions!develop! from!an! intermediate! stage! to!an!advanced! level! in! association!with!
fibrous!cap!formation!near!to!the!walls!of!the!lesion.!The!fibrous!cap!covers!a!mixture!
of!leukocytes,!lipids,!and!debris,!which!can!cause!the!formation!of!a!necrotic!core.!The!
continuous! adhesion! and! entry! by! leukocytes! causes! lesions! to! expand! at! their!
shoulders.! Macrophage! colonyKstimulating! factor,! monocyte! chemotactic! proteinK1!




of! plateletKderived! growth! factor,! transforming! growth! factor! ß,! ILK1,! TNFKα! and!
osteopontin.! The! rupturing! or! ulceration! of! fibrous! caps! usually! occurs! in! thinning!
regions!that!cover!advancing!lesions.!The!fibrous!cap!starts!to!thin!because!there!is!a!







The! prevention! of! atherosclerosis! represents! a! longKterm! effort! to! all! health! care!
professionals!and!the!basis!of!many!public!health!policies.!The!aim!of!both!individual!




suggests! lifestyle! interventions!evaluated! in! randomized!clinical! trial! relying!primarily!
on!biomarkers!or!surrogate!endpoints! rather! than!“hard”!cardiovascular!outcomes93.!
The!health!risks!related!to!tobacco!should!be!provided!encouraging!smoking!cessation.!
Similarly,! ! prudent! dietary! and! physical! activity! habits! for! maintaining! ideal! body!
weight! should! be! recommended.! Both! National! Institutes! of! Health! (NIH)! and! AHA!
statements!recommend!at!least!30!min!of!moderateKintensity!physical!activity!per!day.!
Obesity,! specifically! the!male!pattern!of! centripetal!or! visceral! fat! accumulation,! can!
contribute!to!the!onset!of!metabolic!syndromes.!!
1.2.5.2. LipidKlowering"intervention"
Statins! are! medications! administered! to! decrease! the! lowKdensity! lipoprotein! (LDL)!
cholesterol!and!multiple!trials!have!reported!their!benefit!on!the!CV!mortality!and!on!
the! risk! of! major! cardiovascular! events94.! The! linear! relationship! between! LDLK
cholesterol! and! cardiovascular! risk! suggested! that! statins! main! benefit! was! related!
only! to! the! reduction!of! LDLKcholesterol.!However,!a!number!of!additional!effects!of!
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statins! have! been! suggested! to! contribute! to! their! efficacy! in! CVD.! The! Heart!
Protection! Study! reported! that! simvastatin! reduced!mortality! and!morbidity! even! in!
patients! with! 'normal'! LDLKcholesterol! levels95.! Their! potential! benefit! could! also! be!
explicated! by! improvements! in! endothelial! function,! halting! or! retardation! of!
atheroma!development,!reduction!in!inflammation!and!antithrombotic!effects96.!!
1.2.5.3. AntiKPlatelet"intervention"
The! potential! benefit! of! the! antiKplatelet! therapy! is! related! to! the! reduction! of!
thrombus! formation! and! vascular! inflammation97.! Aspirin! has! been! widely!
experimented! for! secondary! prevention! in! patients! with! established! atherosclerotic!
vascular!disease.!In!addition,!the!combination!of!statin!and!aspirin!are!associated!with!




The! coagulation! cascade! involves! an! interaction! between! the! contact! activation! and!
the! tissue! factor! pathway! leading! to! the! conversion! of! factor! X! to! Xa,! initiating! the!
common! pathway99.! The! subsequent! conversion! of! proKthrombin! to! thrombin,!
catalyzing! the! formation!of! fibrin,! leads! to! the! formation!of! a! firm! clot! stabilized!by!
aggregated!platelets100.!Initially,!vitamin!K!antagonists,!such!as!warfarin,!were!the!only!
anticoagulant! treatment! widely! available! for! human! use.! Approximately! 65,000!
patients!are!treated!in!US!emergency!departments!annually!for!anticoagulantsKrelated!
hemorrhagic!events101.!The!high!rate!of!adverse!events!requesting!a!strict!monitoring!
of! the! patients! stimulated! the! research! of! potentially! safer! medications.! Targeting!
different!steps!of! the!coagulation!process!allowed!the! introduction!of!multiple!novel!
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as! effective! in! the! reduction! of! recurrent! acute!myocardial! infarction! (AMI),! sudden!
cardiac! death! and! total! mortality! in! patients! with! AMI103.! Their! beneficial! effect! is!
related!to!the!reduction!of!the!heart!rate!and!blood!velocity!with!a!consequent!lower!
flow!turbulence!and!vascular!wall!stress.!In!addition,!recent!analyses!support!a!positive!
effect! of! βKblockers! on! the! progression! of! atherosclerosis104.! Furthermore,! reninK






support! the! inflammatory! pathogenesis! of! atherosclerosis106! supporting! the! role! of!
inflammatory!biomarkers! as! independent! risk! factors! for! acute!CV!events107! and! the!
involvement! of! LDL! particles! and! their! contents! to! ! activate! innate! and! adaptive!
immunity108.!Furthermore,!animal!models!of!atherosclerosis!targeting!the!disruption!of!
cholesterolKregulating! genes! leading! to! atherosclerosis! report! that! interfering! with!
immune! signalling! and! inflammatory!mediators! has! an! antiKatherogenic! effect109K111.!







a! deficiency! in! the! body's! ability! to! produce! insulin! or! due! to! a! resistance! to! its!
action112.! !Diabetes! is!associated!with!a!higher!risk!of!vascular!damage!observable!as!





The! diagnosis! of! diabetes! is! based! on! the! glycemic! level! above! which! there! is! an!
increase! of!microKvascular! complications.! The!World!Health!Organization! (WHO)! has!









The! diagnosis! requires! the! confirmation! on! a! different! day! of! any! of! these! criteria.!
With! regards! to! the! impaired! glucose! tolerance,! it! is! based! on! the! oral! glucose!




fasting! glucose.! The! hemoglobin! A1c! test! is! used! to! monitor! the! overall! glycemic!
control!in!subjects!with!diagnosed!diabetes.!
1.3.2. Classification$




and! other! forms! such! as! gestational! diabetes.! In! 1985! it! was! suggested! to! use! the!
terms!IDDM!and!NIDDM!proposing!to!classify!the!patients!according!to!their!treatment!
rather! than! following! the! pathogenesis117.! The! terms! Type! I! and! Type! II! were!
introduced!to!describe!a!form!related!to!pancreatic! islet!betaKcell!destruction!for!the!
former!and!diabetes!resulting!from!defects!in!insulin!secretion!for!the!latter.!In!1997,!




mediated! process! that! leads! to! the! lack! of! insulin! secretion.! The! higher! incidence! is!
observed!during!adolescence!but!approximately!15K30%!of! the!cases!can!occur!after!
30!years!of!age118.!The!alteration! in! the!glucose!metabolism!due!to! the!reduction!or!
absence!of! insulin! secretion! requires! the!administration!of!exogenous! insulin! for! the!













heart! and! circulatory! system,! may! already! be! occurring! during! preKdiabetes.! The!












highest! T1DM! incidence! with! more! than! 30! cases/year/100,000! people! meanwhile!
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Asia! has! the! lowest! number! of! new! cases! with! 0.5! cases/year/100,000125.! The!
prevalence! of! T2DM! is! estimated,! only! in! the! U.S.,! to! be! approximately! 16! million!
people! and! an! additional! 30–40! million! with! impaired! glucose! tolerance126.! Native!
Americans!seem!to!be!the!most!affected!population.!!
1.3.4. Risk$factors$




for! diabetes.! An! important! risk! factor! is! also! a! pancreatic! damage! deriving! from! a!
trauma!or!a!disease.!For!T2DM!obesity,!diet,!physical!inactivity,!increasing!age,!insulin!
resistance,! family! history! of! diabetes,! genetic! factors,! and! race! and! ethnicity! are! all!
recognized!risk!factors.!Specific!genetic!variations!are!related!to!its!onset!and!certain!
ethnic!groups!such!as!African!Americans,!Mexican!Americans,!American!Indians,!native!
Hawaiians!and! some!Asian!Americans!have!a!higher! incidence!of! T2DM!with!African!




glucose! levels.! The! hyperglycemia! stimulates! the! secretion! of! insulin! from! the! beta!
cells! of! the! pancreas! to! allow! cell! glucose! intake.! Insulin! binds! to! specific! cellular!





Similarly,! a! lack! of! the! insulin! function! at! a! cellular! level! may! also! affect! the!
glycaemia127.!!
1.3.6. Treatment$of$Diabetes$
Diabetes! is! considered! the! sixth! leading! cause! of! death! by! disease! in! the! U.S.! Its!





The! diet! adjustment! is! a! fundamental! tool! in! the! treatment! of! diabetes.! It! aims! to!
reduce! the! weight! and! to! regulate! the! glucose! and! lipid! daily! absorption128!





A! regular! physical! exercise! has! beneficial! effects! since! it! favors! weight! loss! and!
improves! the! cardiovascular! fitness.! Moderate! intensity! activity! can! decrease! the!









All! the! patients!with! T1DM,! T2DM!and! gestational! diabetes! patients! in!whom!other!
measures! are! not! sufficient! to! control! the! glycaemia! require! insulin! therapy.! It! is!
provided! via! subcutaneous! injection.! Its! main! side! effects! are! increased! risk! of!
hypoglycemia!and!weight!gain131.!The! insulin! formulation!available!can!differ! in! their!
pharmacological! properties132! with! the! aim! of! reduce! the! risk! of! hypoglycemia.! It!
normally! consists! of! a! bolus! dose! given! subcutaneously! with! a! syringe.! Otherwise!










their! action! requires! the!presence!of! glucose134.! !Due! to! their! rapid!onset! and! short!





Metformin,! a! secondKgeneration! biguanide,! is! a! common! glucoseKlowering! agent!
acting!on! the! inhibition!of! the! liver!gluconeogenesis!and! the! reduction!of! the! insulin!
resistance135.! !Metformin! reduced! the! incidence!of!T2DM!by!31%! in! individuals!with!
impaired! glucose! tolerance! or! impaired! fasting! glucose130.! It! is! effective! as! a!monoK
therapy,! not! associated! with! weight! gain! and! the! risk! of! hypoglycemia! is! low.! It! is!




in! cases! of! insulin! resistance.! Adverse! effects! include! increase! in! body!weight,! fluid!
retention,!and!plasma!volume!expansion,!slight!decreases!in!the!hemoglobin!level!and!
rarely!hypoglycemia.! The! risk!of!hepatotoxicity! related! to! their!use! requires!periodic!
measurements!of!transaminases.!
1.3.6.2.2.5. αPGlucosidase"inhibitors"
They! lower! the! glucose! entry! in! the! bloodstream! inhibiting! the! breakdown! of!
carbohydrates!by!specific!enzymes!in!the!small!intestine.!The!delay!in!their!digestion!to!














to! the! decline! of! this! hypothesis.! Since! the! last! decade! of! the! XX! century,! a! new!
research! trend! investigating! the! potential! role! of! periodontitis! as! a! contributor! to!
systemic! disease! has! flourished139.! Numerous! evidences! link! PD! to! several! systemic!




Multiple!microorganisms!have!been! linked! to! the!atheroma;! for! instance,!Chlamydia!
pneumonia,! a! bacterium! responsible! for! respiratory! tract! infections,! have! been!
isolated! from! the! arteries! of! CV!patients141! and!detected! in!higher! levels! in! patients!
with! CHD! compared! to! controls142.! ! The! first! observational! study! linking! poor! oral!
health! to! CVD! analyzed! 211! patients! who! suffered! from! a!MI! comparing! their! oral!
health!status!to!366!controls.!!The!investigators!reported!a!lower!level!of!periodontal!
health! in! the! test! group143.! Subsequently,! epidemiological! evidence! from! multiple!
observational! trials! has! linked! PD! to! cardiovascular! events144K154.! However! not! all!
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observational!data!supports!this!association155K157.!The!majority!of!the!trials!have!been!
conducted! in! US! with! up! to! 23! years! as! a! followKup! period! subsequent! to! the!
periodontal!examination.!The!assessment!of!periodontitis!varied!between!the!studies!
ranging! from! radiographic! assessment! of! the! bone! loss,! total! dental! index,! Russel’s!
periodontal! index! and! surveys.! Cardiovascular! events! represented! by! MI,! stroke,!
hospitalization! for! CHD! were! considered! as! outcomes.! The! potential! confounders!
adopted! for! the! adjustment! of! the! results! were! classic! risk! factors! for! CVD.! The!
estimates!of!the!association!reported!a!relative!risk!(RR)!from!1.2!to!7.0158.!However,!
the! robustness!of! these!data!could!be!undermined!by!an! incomplete!adjustment! for!






the! exposure! was! only! assessed! at! baseline! 154.! A! systematic! review! of! 31!
observational! studies! identified! a! positive! link! between! PD! and! CVD,! stroke! or!
peripheral! vascular!disease158.! Furthermore,! a!metaKanalysis! of!observational! studies!
assessing!the!relationship!between!PD!and!total!CHD/CVD!reported!that!patients!with!
periodontitis! had! an!overall! adjusted! future! risk! of! CHD!1.15! times! (95%! confidence!
interval![CI]:!1.06!to!1.25;!P!=!0.001)!higher!than!otherwise!healthy!individuals.!The!RR!
calculated! for! future! CVD! was! 1.17! (95%! confidence! interval! [CI]:! 1.03! to! 1.34;! P! =!
0.001)159.! !This!association!has!been!systematically!reviewed!several!times!during!the!
last! decade160K163! and! recently,! the! American! Heart! Association! working! group!
concluded! that! PD! is! associated! with! atherosclerosis! independently! of! known!
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confounders164.!Furthermore!the!consensus!report!of!the!Joint!EFP/AAP!Workshop!on!
Periodontitis! and! Systemic! Diseases! concluded! that! robust! epidemiologic! evidence!
support! periodontitis! as! a! contributor! to! an! increased! risk! for! future! cardiovascular!
disease165.!
1.4.3. Periodontitis$and$Diabetes$
Strong! evidence! link! DM,! a! group! of! metabolic! disorders114,! to! the! prevalence! and!
severity!of!gingival!inflammation!and!PD!suggesting!the!glycemic!control!as!a!potential!
determinant!of!this!association166,167.!Adolescent!affected!by!Type!1!diabetes!present!a!
higher! level! of! periodontal! inflammation! affecting! approximately! double! of! the! sites!
compared!to!controls!with!the!same!amount!of!plaque168,169.!In!addition,!in!the!same!
population,! poor! glycemic! control! is! associated! with! the! severity! of! the! oral!
inflammation170! showing! a! negative! correlation! between! level! of! glycaemia! and!
gingivitis171,172.! 263! patients! with! type! 1! diabetes! compared! to! 59! relatives! without!
diabetes! and! 149! unrelated! controls! were! screened! for! PD.! 13.6%! of! patients! with!
diabetes!had!PD!between!the!age!of!13!and!18!years!with!an!increased!prevalence!of!
39%!among! those! aged!19! to! 32! years.! The!prevalence! in! controls!without! diabetes!
was! lower! than!3%168.!The!same!correlation!has!been!reported! in!adults!with! type!1!
diabetes173!and!data!from!a!longitudinal!study!on!experimental!gingivitis!suggest!that,!
with! the! same! level! of! plaque! control,! adults!with! Type! 1! diabetes! develop! gingival!
inflammation!more!rapidly!and!with!a!higher!severity174!than!controls.!!
Type!2!DM!has!been! strongly! linked! to!PD! 175.!Observational! studies! report!a!higher!
extent! and! severity! of! PD! in! T2DM66,176K178.! A! metaKanalysis! of! four! studies177,179K181!
including! 3.524! adults! with! diabetes! reports! that! the! overall! estimated! correlation!
coefficient! was! 0.19! (95%! confidence! limits! 0.16! to! 0.22)166.! Pima! Indians,! a! Native!
American!of!Arizona!population!with!the!world!highest!prevalence!of!T2DM,!present!
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incidence! of! PD! 2.6Kfold! higher! in! patients! who! also! had! diabetes! 181.! Further!
observational!data! from!a!cohort! study!with!2!years! followKup! study,! suggested!a!4K
fold!risk!of!bone!loss!in!T2DM!patients!when!compared!to!controls182.!The!onset!and!
progression! of! PD! in! patients! with! diabetes! is! related! to! the! metabolic! control.!
Established!diabetic!complications!such!as,!retinopathy!or!nephropathy!are!detected!in!
poorly! controlled! subjects131,183,! however! such! complications,! even! if! with! a! lower!
prevalence,! can! be! present! in! wellKcontrolled! patients.! PD! has! been! historically!
considered! the! sixth! diabetic! complication! of! diabetes! 184.! Analysis! of! 4343!
participants,!aged!45K90!years,!of!the!National!Health!and!Nutrition!Examination!Study!




of! bone! loss! progression! compared! to! controls! with! no! diabetes! or! wellKcontrolled!










Inflammation! is! a! human! phenomenon! firstly! described! by! the! Roman! doctor!
CorneliusKCelsus! in! the! 1st! century! AD! as! the! sum! of! four! clinical! events:! Rubor"
(redness!due!to!hyperaemia),!tumor"(swelling,!caused!by!increased!permeability!of!the!
microvasculature! and! leakage! of! proteins! into! the! interstitial! space),! calor" (heat!
associated! with! the! increased! blood! flow! and! metabolic! activity! of! the! cellular!
mediators! of! inflammation),! and! dolor" (pain,! in! part! due! to! changes! in! the! periK
vasculature! and! associated! nerve! endings).! Much! later,! in! 19th! century,! Augustus!
Waller!and!Julius!Cohnheim!explained!inflammation!and!its!physiological!basis191.!They!
suggested! that! the! acute! inflammatory! response! consists! of! the! migration! of!
leukocytes! from! the! blood! vessels,! vasodilation! and! leakage! of! plasma! into! the!
interstitial! space.! In! the!middle!of! the!19th!century,!a! fifth!postulate!of! inflammation!
termed!functio"laesa"was!introduced!by!Rudolph!Virchow!to!identify!organ!dysfunction!
linked! to! the! inflammatory! process192.! The! introduction! of! the! concept! of! cellular!





of! high! sensitivity! assays! for! inflammatory! markers! has! greatly! increased! our!
understanding! of! the! pathophysiological! mechanisms! involved! in! inflammatory!





Acute! inflammation! represents! an! adaptive! response! to! abnormalities! due! to!








inflammatory! response,! for! its! less! aggressive! component!but!prolonged!duration,! is!
considered! a! major! contributor! to! various! medical! conditions195.! For! instance,! a!
chronic!inflammatory!state!is!believed!to!contribute!to!the!alteration!of!the!hormone!
insulin! production! leading! to! type! 2! diabetes! and! to! the! onset! and! progression! of!
atherosclerosis196.!
1.5.2. Inflammatory$pathways$
The! mechanisms! involved! in! any! inflammatory! pathway! comprise! four! main!
components:! inducers,! sensors,!mediators,!and!effectors197.!An! inducer! is!any!trigger!




They!can!be!divided! into! two!broad!categories!depending!on! their!microbial!or!nonK
microbial!source.!In!addition,!the!nonKmicrobial!inducers!are!subdivided!in!two!classes:!
Allergens,! irritants,! foreign! bodies! and! toxic! compounds! as! one! group! and! a! second!
category! represented! by!molecules! deriving! from! tissue! or! organ! damage.! However!
the! inducers! involved! in! numerous! inflammatory! conditions! such! as! obesity,!
atherosclerosis,!neurodegenerative!diseases,!and!cancer!remain!still!unknown.!Specific!




PathogenKassociated! molecular! patterns! (PAMPs),! a! variety! of! conserved! molecular!
patterns! commonly! expressed! on! pathogenic! or! commensal! species! but! not! in!
mammals198,! allow! the! recognition! of! microbial! inducers! by! different! scavengers! or!
tollKlike! receptors! (TLR)! of! the! immune! system! cells! such! as! macrophages! or! mast!
cells199.! Lipopolysaccharides! (LPS),! surface! phosphatidylserine,! aldehydeKderived!




the! latter200,201.! The! production! of! mediators! triggers! an! inflammatory! exudate!
consisting!of!plasma!proteins!and!white!cells,!mainly!neutrophils,!that!reach!the!site!of!
the! invasion! interacting! with! the! adhesion! proteins,! selectins,! expressed! by! the!





proteinase!3,! cathepsin!G!and!elastase203.!However,! the! substances! released!are!not!
specific!for!the!pathogens!therefore!can!cause!collateral!damages!hitting!the!host.!The!
inflammatory! molecules! released! can! vary! according! to! the! type! of! invasion.! For!
instance,!viral!infections!stimulate!the!production!of!interferons!and!the!activation!of!
cytotoxic! lymphocytes!meanwhile!parasites! lead!to!histamine,! interleukins!release!by!
basophils!and!mast!cells204,205.!!
1.5.2.1.2. NonKmicrobial!inducers!
Different! groups! represent! this! category.! Allergens,! irritants,! toxic! compounds! and!
foreign! bodies! compose! the! first! one191.! For! both! allergens! and! irritants! the!
inflammatory!reaction!consists!of!the!activation!of!basophils!and!mast!cells206.!Foreign!
bodies! involve!mainly! the!macrophage!phagocytosis207.!The!second!group!consists!of!
intraK! and! extraKcellular! molecules! that! in! normal! condition! are! contained! in! intact!
tissues!and!can!be!exposed!after!acute!damages.!For!instance,!the!endothelium,!after!
a! vascular! injury,! regulates! the! plasma! proteins! and! platelets! migration! to!








On! the! base! of! the! biochemical! properties! expressed,! there! are! seven! categories! of!
inflammatory! mediators:! Cytokines,! chemokines,! vasoactive! amines! and! peptides,!
complement! components,! lipid!mediators,! antibodies! and! enzymes.! Their! impact! on!
effectors! may! determine! a! variety! of! changes! that! will! result! in! the! clinical!
manifestations!of!the!inflammatory!response208.!
1.5.2.2.1. Cytokines!
The! term! cytokine! was! firstly! introduced! on! 1974! to! define! a! group! of! proteins!
intervening! in! the! inflammatory! response209.! They! were! initially! believed! to! be!





interferons! which! are! produced! by! a! wide! variety! of! cells! in! the! body,! play! an!
important!role!in!many!physiological!responses,!are!involved!in!the!pathophysiology!of!
a! range! of! diseases,! and! have! therapeutic! potential”210.! According! to! our! current!
















K! Pleiotropic! action:! triggering! several! different! cellular! responses! depending! on! cell!
type,!timing,!and!context.!










The! main! producers! of! cytokines! are! lymphocytes! TH! and! macrophages! during! the!
regulation! of! the! immune! response.! The! biological! processes! in!which! cytokines! are!









proKinflammatory!mediators! (ILK1α,! ILK1β,! ILK18,! ILK33,! ILK36a,! ILK36b,! ILK36c)212.! Even!
detected! at! low! concentration! in! the! human! body,! they! have! a! huge! inflammatory!
effect.! ILK1α! and! –β! are! two! agonist! forms! with! similar! effects! and! ILK1! receptor!
antagonist! (ILK1ra)! competitively! inhibits! the! binding! to! their! receptors.! The! balance!
between! ILK1β! and! its! receptor! antagonist! (ILK1ra)! level! influences! its! relative!
physiologic! or! pathophysiologic! effects213.! The! surface! of! their! target! cells! has! two!
receptors!(ILK1R1!and!ILK1R2).! ILK1!seems!to!be!central! in!the!defense!from!infection.!
Some!of!them,!such!as!ILK1β!and!ILK18,!are!released!in!a!form!of!inert!proKpeptide!that!
require!cleaving! to!bind! their! receptor!and!have!a!biological!effect.!ProKILK1β! can!be!
cleaved! by! inflammasome! activation,! neutrophil! production! of! serine! proteases! (i.e.!
proteinase!3!and!elastase)!and!mast!cellKderived!serine!proteases!(i.e.!chymase).!ILK1!is!
a!major!mediator!in!inflammatory,!infectious!and!degenerative!disease!(Table!9).!ILK1β!
is! released! by! hematopoietic! cells! including! blood! monocytes,! tissue! macrophages,!
skin! dendritic! cells,! and! brain! microglia,! activated! complement! components,! other!


















Robust! evidence! link! ILK1! to! the! development! of! periodontitis215.! It! is! detected! in!
higher! level! in! periodontal! lesions.! LPS! or! other! bacterial! components! promote! its!
production.!A!genetic!polymorphism!of! ILK1! is!associated!with!higher!susceptibility!to!
periodontitis216.! Briefly! ILK1! has! a! central! role! in! the! homoeostasis! of! periodontal!





in! presence! of! ILK1β! and! in! experimental! models! of! atherosclerosis,! a! slower!




factors! including! hyperlipidemia,! diabetes! mellitus,! smoking! and! hypertension.! A!
polymorphism! in! ILK1ra! known! to! increase! levels! of! ILK1ra! was! associated! with!
decreased!mean! coronary! artery! plaque! area.! In! addition,! the! inhibition! of! ILK1β! in!









ILK6! is! a! cytokine! released! by! various! cell! such! as! macrophages,! neutrophils,!













induces! the! acuteKphase! reactants! release! but! also! down! regulates! the! neutrophil!
recruitment!and!the!expression!of!proKinflammatory!cytokines.!!
1.5.2.2.1.1.2.1. ILK6!and!PD!
ILK6!has!been!detected! in!endothelial! cells,! fibroblasts,! and!macrophages!of! subjects!




it! on! the! long! term.! Therefore,! to! date,! the! main! role! of! ILK6! in! periodontitis!
pathogenesis!is!the!modulation!of!the!response!to!the!bacterial!challenge!that!leads!to!
the! local! and! systemic! inflammatory! response.! An! excessive! ILK6! release! has!




stages! of! the! atherosclerotic! inflammatory! process.! In! the! development! of! the!
atheroma,! endothelial! cells! respond! to! ILK6! production! releasing! chemokines! and!
increasing! surface! adhesion!molecules.! In! addition,! the! differentiation! of! TKcell! in! TK
helper! contributes! to! the! inflammatory! process.! Inducing! the! expression! of! the!
monocyte! tissue! factor! ILK6! has! also! proKcoagulant! activity.! Infections! could! be! the!
main! trigger! for! the! ILK6! production,! specifically! respiratory! tract! infections,! are!





ILK6! to!mice!with! fatty! lesions!determines! their!5.1! fold! increase.! ILK6! release! results!
from!acute! infection,! chronic! inflammation,! obesity,! and! physiological! stress! causing!
inflammatory! response,! acuteKphase! reactants,! and! increased! coagulation.! It! seems!
that!having!a!variant! in! the! ILK6!receptor! leads!to!a!decreased!risk!of!CVD,! therefore!








ILK8! is!a!chemokine!belonging!to!the!CXC!subfamily.! It! is!secreted! in!the!extracellular!
space! in! response! to!a!variety!of! stimuli!by!a!wide! range!of!nucleated!cell! types!but!
being! monocytes! and! macrophages! its! main! source.! It! is! primarily! involved! in! the!
recruitment!of!macrophages!and!neutrophils!by!means!of!a!chemotactic!gradient!that!
attracts! the! inflammatory! cells! towards! the! area! of! increased! chemokine!
concentration.! Additionally,! ILK8! has! the! function! of! activating! neutrophils! and!
monocytes.! It! can! resist! to! temperature,! proteolysis,! acidic! environment! and! it! is!
relatively!longKlived!in!sites!of!acute!inflammation!remaining!active!up!to!weeks!after!
the! onset! of! the! inflammatory! process.! This! is! in! contrast! to! the! majority! of! the!
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ILK8!has!been!associated!with! the!pathogenesis!of! periodontitis! and! specifically!with!
the! recruitment! and! activation! of! neutrophils.! ! Bacterial! byproducts! have!
demonstrated! to! affect! both! the! production! and! the! activity! level! of! ILK8.! It! can! be!
released! in!periodontal! lesions!by!activated!polymorphonuclear! leukocytes,!epithelial!
cells!and!gingival!fibroblasts.!!
1.5.2.2.1.1.3.2. ILK8!and!atherosclerosis!
ILK8!has!been!detected! in!sites!of!vascular! injury!suggesting! its!potential!contribution!
to! the! pathogenesis! of! the! atheroma.! In! vitro! and! animal!models! reported! that! ILK8!
was! highly! represented! in! the! human! arterial! atherosclerotic! wall! compared! with!
normal!intima.!In!addition,!macrophages!were!identified!as!the!main!source!of!ILK8!in!
atheroma.! An! observational! study! suggested! that! increased! levels! of! ILK8! are!










released! by! antigen! presenting! cells! (APC)! in! response! to!microbial! components.! Its!
functions! include! the! induction!of!TKbet!and!control!of! the!differentiation!of!naive!T!




importance! of! ILK12! is! not! limited! to! the! onset! but! also! may! contribute! to! the!
maintenance! of! the! immune! response! since! Th1! responses! rapidly! decrease! in! the!
absence! of! ILK12.! Increased! levels! of! ILK12!were! detected! in! both! serum!and!GCF! of!
subjects!affected!by!periodontitis.!The!cysteine!proteinases!(gingipains)!released!by!P.!
Gingivalis!can!hydrolyze! ILK12!and! lower! the! IFNKγ!production.! Inactivating! ILK12!may!
also! affect! the! cytokine! balance! in! periodontal! lesions! leading! to! increased! TKh!
activities.!!!
1.5.2.2.1.1.4.2. ILK12!and!atherosclerosis!
ILK12! influences!development!of! T! lymphocytes! to! the! Th1! and! Th2!phenotypes! and!
expressed!in!macrophages!of!human!atherosclerotic!lesions.!Vaccination!against!ILK12!
seems! to! reduce! lesion! formation! in! the! carotid! artery! of! mice! and! also! daily!
administration! of! ILK12! enhances! lesion! formation! in! ApoEK/K!mice.! These! evidences!






ILK12!has!been! related! to! the! induction!of!Th1!cellKmediated!autoimmune!disease! in!
multiple! experimental!models222.! ILK12! administration! seems! to! increase! the! level! of!
pancreatic! cells! destruction! and! targeting! its! action! has! a! protective! effect! in! the!
development! of! T1DM! in! animal! models.! In! addition,! a! new! locus! associated! with!
human!T1DM!has!been! identified!near! the!gene!encoding! ILK12!suggesting! its! role! in!
the!prediction!of!highKrisk!individuals!for!autoimmune!diseases223.!
1.5.2.2.1.1.5. The"tumor"necrosis"factor"(TNF)"
The! tumor! necrosis! factor! (TNF)! superfamily! is! composed! of! 19! ligands! and! 29!
receptors! and! contributes! to! a! wide! range! of! body! functions.! TNFKα! is! a! cytokine!
initially!identified!for!its!ability!to!kill!tumor!cells!in!vitro.!T!cells!can!release!TNFKα!even!
if!mononuclear!phagocytes!are! its!main!cellular! source.! It! is! considered!a!pleiotropic!
proKinflammatory!cytokine!in!part!through!activation!of!the!transcription!factor!NFKkB!
and! has!multiple! biological! effects! (Table! 11).! Although! TNFKα! has! physiologic! roles!
including!proliferation!and!differentiation!of!B! cells,! it! also!has!been!associated!with!












Among! its! effects,! TNFKα! can! promote! collagenase! production! and! bone! resorption!
inducing!periodontal!tissues!breakdown.!It!can!activate!osteoclasts!and!trigger!the!ILK1!




TNFKα! has! multiple! actions! on! endothelial! cells! promoting! coagulation! and!
inflammation.! It! has! been! associated! with! an! elevated! risk! of! recurrent! MI! and!
cardiovascular!death!after!a!first!MI.!Its!serum!profile!is!related!to!ankleKbrachial!index!
and!used!to!predict!the!severity!of!peripheral!arterial!disease.!In!addition,!it!correlates!
with! the!burden!of! atherosclerosis! as! assessed!by! carotid!ultrasound!among!healthy!
middleKaged!men.!!
1.5.2.2.1.1.5.3. TNFKα!and!diabetes!
Several! studies! have! reported! elevated! levels! of! TNFKα! in! individuals! with! insulin!
resistance! and! clinically! diagnosed! diabetes224.! TNFKα! seems! to! inhibit! insulin!
transduction,! and! has! an! effect! on! glucose! metabolism225.! Perturbations! of! TNFKα!
metabolism!may!affect! the!onset!of! type!2!diabetes!mellitus! and! the!progression!of!
the!disease.!
1.5.2.2.1.1.6. Interferons"(IFN)"
Interferons! are! key! cytokines! involved! in! the! antiKviral! response,! firstly! described! in!
1957!as!an!antiviral!agent!during!studies!on!virus!interference.!To!date,!three!types!of!







and! adaptive! immune! responses! involved! in! the! antitumor! immunity! and! the!
elimination!of!viral!infections.!!
1.5.2.2.1.1.6.1. IFNKγ!and!PD!
A! signiﬁcant! increase! in! the! level! of! IFNKγ! has! been! detected! in! periodontal! lesions!
compared! to! healthy! sites! in! patients!with! chronic! periodontitis226.! Therefore,! IFNKγ!
could!contribute!be! involved! in! the!stimulation!of! the!phagocytic!activity!of! the!host!
cells! and! amplification! the! innate! immune! response! to! the! periodontal!
pathogens227,228.!
1.5.2.2.1.1.6.2. IFNKγ!and!atherosclerosis!
IFNKγ!has! various!effects!on!endothelial! cells.! It! can! increase! ICAMK1!expression!and!
induce! the! synthesis! of! proteins! of! alternative! complement! pathway.! It! seems! to!
inhibit! endothelial! cells! growth! and! increase! adhesion! molecules! specifically! for!
lymphocytes.! IFNKγ! also! modulates! the! expression! of! TNFKα.! Macrophages! are!
abundant! in! the! atherosclerotic! lesion! and! are! activated! on! IFN! stimulation.! IFNKγ!





to! inhibit! their! proliferation! and! collagen! I! and! III! production! increasing! the! plaque!
vulnerability.!
1.5.2.2.1.1.6.3. IFNKγ!and!diabetes!




Among! the! cytokine! network,! potentially! with! the! exception! of! ILK1,! all! the! antiK
inflammatory! molecules! might! have! a! proKinflammatory! role.! The! effect! on! the!







































Production.! Inhibition! of! Th1K
type!lymphocyte!responses!




















ILK10! represents! the!main! antiKinflammatory! cytokine!of! the!human! immune! system!
being!a!strong!inhibitor!on!the!ThK1!inflammatory!mediators!such!as!ILK1!and!IFNKγ!and!
monocytes/macrophages!cytokines! including!TNFKα,! ILK1,! ILK6,! ILK8,! ILK12,!granulocyte!
colonyKstimulating! factor,!MIPK1α,!and!MIPK2α.! In!addition,! ILK10!reduces!the!surface!
expression! of! TNF! receptors! and! induces! the! shedding! of! TNF! receptors! into! the!
systemic!circulation.! ILK10! is!mainly!released!by!Th2,!monocytes!and!B!cells.!After!an!
experimental! administration! of! ILK10! to! human! volunteers! subsequent! to! endotoxin!
injection,! individuals!presented!with! less! inflammatory!symptoms!when!compared!to!
placebo!control.!!
1.5.2.2.1.2.1.1. ILK10!and!PD!
The! antiKinflammatory! action! of! ILK10! can! reduce! the! synthesis! of! ILK1,! ILK6,! TNFK!,!
nitric!oxide,!gelatinase!and!collagenase.!Therefore!it!regulates!the!bone!homeostasis!in!
both!physiologic!and!pathologic!conditions!such!as!periodontitis.!The!lockout!of!ILK10!
may! result! in! accelerating! alveolar! bone! absorption! and! decreasing! bone! formation!
and! in! ILK10! knockout!mice! there! is! a! clear! role! in! the! development! of! periodontal!
disease.! A! polymorphism! of! the! ILK10! gene! could! be! at! the! base! of! a! higher!
susceptibility!to!PD.!The!haplotype!ATA!of!ILK10,!causing!low!production,!is!considered!





been!explored! in!many!trials! investigating! its!potential!cardiovascular! risk!prediction.!
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Elevated! ILK10! serum! profile! was! related! with! a! significantly! improved! outcome!
independently!of!elevated!troponin!levels!suggesting!low!serum!ILK10!level!as!a!marker!
of! plaque! instability.! In! addition,! increased! ILK10! serum! levels! are! associated! with!
improved!endothelial! function! in!patients!with!elevated!CRP!serum! levels.!Therefore!
the! proK! and! antiKinflammatory! balance! could! be! a! key! factor! in! the! endothelial!
homeostasis.!!
1.5.2.2.1.2.1.3. ILK10!and!diabetes!




Adhesion! molecules! are! a! group! of! cell! surface! glycoproteins! expressed! on! a! wide!
range! of! cells.! They! mediate! the! attachment! of! cells! to! each! other,! regulating! the!
recruitment!of!immune!cells!to!the!inflammatory!site.!Their!soluble!form!detectable!in!
the!bloodstream!derives! from!the!cleavage!of! the!extracellular!portion!expressed!on!
the! activated! cell! membrane.! However! some! types,! such! as! PKselectin! are! also!
produced!in!a!soluble!form.!!
1.5.2.2.2.1. Intercellular"adhesion"moleculesP1,"2,"3"(ICAMP1,"ICAMP2,"ICAMP3)"
ICAMK1! (CD54)! and! ICAMK2! (CD102)! are! membrane! glycoproteins! belonging! to! the!
Immunoglobulin! family.! They! are! both! expressed! by! endothelial! cells,! neutrophils,!
platelets! and! different! leukocytes! subKpopulation.! ICAMK1! is! also! present! on!
fibroblasts,!epithelial!cells!and!pericytes!and! located!only!on!the!endothelial! surface.!
ICAMK2! is! present! also! on! the! cellular! junctions.! The! endothelium! can! increase! the!
expression! of! ICAMK1! following! inflammatory! stimuli! such! as! TNFKα! and! IFNKγ! or!
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EKselectin! is! highly! selective! and! is! only! transiently! expressed! by! the! activated!
endothelium! facilitating! the! rolling! of! leukocytes! along! the! endothelial! layer! as! a!
prelude!to!leukocyte!adhesion.!Its!soluble!form!has!been!detected!in!the!supernatants!
of! TNFα! and! ILK1! stimulated! endothelial! cells! and! it! is! studied! as! diagnostic! and!





platelets,! the! endothelium! and! leukocytes,! thus! playing! a! key! role! in! vascular!




TM! is! a! glycoprotein! presents! on! the! majority! of! the! endothelial! cells! representing!
approximately!60%!of!the!thrombinKbinding!site!and!responsible!for!the!anticoagulant!
features!of! the!endothelium.! It! is! also! found! in!blood!plasma,!platelets,! neutrophils,!
monocytes,! urine,! and! placenta.! TM! regulates! the! blood! coagulation! contributing! to!
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the!maintenance!of!its!liquid!state!avoiding!intravascular!coagulation.!!Once!bound!to!
TM,! thrombin! does! not! favors! the! fibrinogen! conversion! into! fibrin! and! platelet!
aggregation.! In! soluble! form,! sTM! is!detectable! in!plasma!and!urine!and! it! is! related!
mainly!to!endothelial!damage!and!not!to!its!physiological!activation.!Therefore!sTM!is!
a! validated! marker! of! endothelial! damage! directly! correlating! with! its! degree.! Its!
profile!has!been!reported!to!be!elevated!in!multiple!pathological!conditions!including!
diabetic! microangiopathy,! systemic! lupus! erythematosus! (LES),! peripheral! and!
coronary!atherosclerosis!and!cancer.!
1.5.2.2.4. Acute!phase!reactants!(APRs)!
APRs! are! a! class! of! plasma! proteins! detectable! in! different! inflammatory! conditions!
including! infections,! autoimmune! disorders,! cancer! and! trauma.! ProKinflammatory!
cytokines! such! as! ILK1,! ILK6,! TNFKα! stimulate! the! APRs! hepatic! production! that!
represents!their!main!source!however!macrophages,!endothelial!cells,!fibroblasts,!and!
adipocytes!can!participate!to!their!synthesis.!This!category!includes!various!molecules!





CRP! is! a! plasma! protein! produced!mainly! by! the! liver! hepatocytes! during! the! acute!
phase! reaction.! Its! properties! range! from! the! stimulation! of! cytokine! production,!
complement! activation,! recruitment! and! activation! of! inflammatory! cells! and!
promotion! of! atherogenesis.! Its! plasma! profile! in! healthy! individuals! is! normally!
between!1!to!3mg/L!but!it!can!reach!10mg/L.!It!recognizes!and!binds!microbial!surface!
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polysaccharides! activating! the! complement! pathway! and! opsonizes! them! to! induce!
phagocytosis.!!!
1.5.2.2.4.1.1. CRP"and"PD"
Numerous! studies! suggest! that! PD! is! associated! with! an! increased! CRP! level.! Its!
biological! plausibility! is! related! to! the! higher! local! production! of! inflammatory!
cytokines! in! PD! that! in! turn! triggers! a! systemic! inflammatory! response.! A! recent!




CRP! has! been! identified! as! a! risk! factor! for! future! cardiovascular! events! in! the!
asymptomatic! population.! It! has! been! observed! in! atheromas! and! damaged! vessels!
that!contribute!in!a!small!extent!to!its!release.!A!large!trial!on!healthy!individuals!with!
normal!cholesterol! level!but!elevated!CRP!comparing!the!administration!of!statins!to!
placebo!has! reported! that! lowering! level! of!CRP! is! associated!with!a! reduced! risk!of!
future!cardiovascular!events.!!
1.5.3. Inflammatory$resolution$and$chronic$inflammation$
The! inflammatory! cascade,! consequent! to! cellular! and! tissue!damage,! aims! to! tissue!









fibrosis! interfering! with! the! organ! function! representing! a! major! problem! in!
inflammatory!processes!of!the!arteries.!Therefore,!a!persistent!inflammatory!condition!
and!a!deficient!inflammatory!resolution!process!cause!chronic!inflammation.!This!is!a!
major! contributor! to! the! progression! of! multiple! clinical! conditions! such! as!
atherosclerosis107,! arthritis232,! neurodegenerative! disease233! and! periodontitis234.! The!
inflammatory! inducers! involved! in! the! acute! response! can! also! trigger! chronic!
reactions.!Their!source!can!be!microbial!or!not!and!the!pathways!involved!depend!on!
the! inflammatory! trigger.! T! cells! normally! replace! neutrophils! and! macrophages!
infiltrate! if! microbial! inducers! are! not! completely! removed235.! The! switch! from! the!
innate!to!the!adaptive!response! involves!the! interaction!with!the!surface!antigens!of!
the! inducers236.! The! initiation! of! the! adaptive! immunity! starts! when! immature!
dendritic! cells! ingest! and! degrade! a! pathogen237.! The! activation! of! the! dendritic! cell!
transforms! it! in! an! effective! APC238.! Their! role! is! to! carry! the!microbial! antigens! to!
peripheral!lymphoid!station!interacting!with!T!lymphocytes.!The!cytokines!secreted!by!
the! APC! have! an! action! on! both! innate! and! immune! activities.! T! cells! react! to! the!
antigen! recognition! activating! cytotoxic! T! cells! and! stimulating! the! antibodies!
production! by! B! cells239.! T! cells! have! also! the! feature! of! differentiating! in! either! T!
helper! 1! cells! (Th1)! or! TKhelper2! (Th2)! subKphenotypes! both! involved! in! multiple!
inflammatory!processes240,241.!Th1!are!involved!in!both!the!response!to!pathogens!and!
hypersensitivity! skin! reactions.! They! secrete! ILK2,! TNFKα,! and! IFNKγ! stimulating!
chemokines!production,!a!link!between!innate!and!adaptive!immunity242.!If!there!is!a!
continuous! inflammatory! induction!not!eliminable!by!macrophages!and! the!adaptive!
immunity,! the! formation! of! granulomas! or! lymphoid! tissues! might! follow243.! A!
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granuloma! is! consequent! to! either! persistent! microbial! exposure! or! nonKmicrobial!
inducers.!The!macrophages!encapsulate!the!inflammatory!trigger!with!multiple!layers!
counteracting!the!induction!of!further!immune!response.!This!condition!might!endure!






to! define! true! radical! and! reactive! compounds! that! are! able! to! from! radicals.!
Antioxidants! are!molecules! able! to!maintain! a! body! balance! between! oxidative! and!
reduction!activities.!Oxidative!stress!is!a!state!in!which!the!oxidant!processes!are!not!
balanced!by! their!counterpart!either!by!higher!production!of! radicals!or! reduction! in!
antioxidants! activity246.! It! is! associated! to! potential! cellular! damage.! Radicals! can!
derive!from!exogenous!and!endogenous!sources:!







mechanism! to! kill! invading!microorganism247.!When! inflammation!becomes! systemic!
as!in!inflammatory!response!syndrome!there!is!loss!of!control!of!RS!production!leading!
! 95!
to! nonKdiscriminant! injury! of! tissues! and! organs! in! the! host247.! Oxidative! stress! has!
been! shown! to! cause! secondary! damage! through! delayed! cellular! death! and!
inflammation248.!Several!diseases!such!as!diabetes249,!hypertension250,!heart!failure251,!
Parkinson! disease252,! renal! disease253,! epilepsy254,! ! Alzheimer's255! and! other!
neurodegenerative! diseases256! have! been! linked! to! oxidative! stress! .! Therefore,!




production,! first! target! of! ROS.! Mitochondria! consume! the! majority! of! the! cellular!
oxygen! during! the! normal! cell! energy! production.! ! A! small! percentage! of! oxygen! is!
converted!to!RS!and,! in!certain! individuals,!defective!mitochondria!could!produce!an!
increased!level!of!RS.!The!in!situ!generation!of!oxidant!has!promoted!the!production!of!
antioxidants! within! the! mitochondria! such! as! mitochondrial! manganese! superoxide!





The! indirect!mechanisms!by!which!ROS!can!cause!an! increased! inflammatory!burden!





Each" intracellular" macromolecule" can" be" damaged" by" increased" bioavailability" of"
oxygen"radical"species."Oxidative"damage"to:"A)"proteins"leads"loss"of"catalytic"activity,"
B)" nucleic" acids" leads" to" activation" of" the" DNA" damage" response" or"modification" of"
mRNA,"causing"arrest"of"cell"cycle"and"cellular"senescence"or"apoptosis,"C)"lipids"leads"
to" increase" membrane" permeability" and" loss" of" the" transPmembrane" homeostasis."
These"processes"can"lead"to"activation"of"the"immune"system,"either"because"structural"
changes"make"macromolecules"recognized"as"foreign"bodies"by"the"immune"systems"or"




 1.! ROS! can! react! with! cell! membrane! fatty! acids! and! form! lipid! peroxides,!
resulting! in! permanently! impaired! fluidity! and! elasticity! of! the! membrane,! and!
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consequent! cell! rupture258! (Figure!9).! Similarly,!overproduced! radicals! can! react!with!
protein! amino! acids! leading! to! their! oxidation! and! crossKlinking.! RadicalKprotein!
reactions!can!permanently! impair!the!function!of! important!cellular!and!extracellular!
proteins,! including! enzymes! and! connective! tissue! proteins! (Figure! 9).! It! has! been!
estimated!that!oxidized!protein! in!old!rats!may!comprise!30K50%!of!the!total!cellular!





 2.! Structural! changes! induced! by! free! radical! damage! have! the! potential! to!
transform! inert!macromolecules! into! potent! inflammatory! inducers.! One! example! is!
the! conversion! of! inactive! low! density! lipoproteins! (LDL)! into! their! highly! proK
inflammatory! counterparts! (oxKLDL),! a! process! determined! by! oxidation! of! the! lipid!
and!protein!components!of!the!lipoproteins107.!!
 3.! Functional! changes! induced! by! free! radicals! in! membranes,! proteins! and!
nucleic! acids! lead! to! progressive! cellular! and! tissue! damage,! followed! by!
desequestration!of!endogenous!antigens! (Figure!9).!For! instance,! increased!exposure!
to! oxidative! stress! seriously! damages! endothelial! cells! which! not! only! become!
dysfunctional,! but! also! lose! integrity,! progress! to! senescence,! and! detach! into! the!
circulation202.!As!previously! discussed,! sites!of! “disendothelization”! represent!potent!
activators!of!the!Hageman!factor,!which!interacts!with!components!of!the!extracellular!
matrix! and! initiates! the! inflammatory! response! by! stimulating! the! kallikreinKkinin,!
coagulation,! fibrinolytic!and!complement!cascades.!Oxidative!damage! to! intracellular!
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induce! chronic! inflammatory! responses! by! direct! mechanisms.! Several! studies!
demonstrated!that,! the!proKinflammatory!effects!elicited!by!the!oxidative!damage!to!
cellular! macromolecules,! gene! expression! of! proKinflammatory! ILK1β,! ILK6,! TNFKα,!
cycloKoxygenaseK2! (COXK2),! lipoxygenase! (LOX),! and! inducible! nitric! oxide! synthase!
(iNOS)! are!enhanced!during! aging!by! the! redoxKsensitive! transcription! factor!nuclear!
factorKκB! (NFKκB)259,260.! Similarly,! current! research! suggests! a! central! role! for! RS! of!
mitochondrial!origin! (mtRS)! in!mediating! the! increased! inflammatory! levels!observed!
in! the! elderly261.! While! mitochondria! are! crucial! for! normal! cell! functions,! their!
respiratory!activity! is! coupled!with! release!of!high! levels!of!RS!which,! in! turn,! act! as!
signaling!molecules,!directly!triggering!proKinflammatory!cytokine!production262,263.! In!
order! to! prevent! excessive! accumulation! of! mtRS,! cells! developed! a! complex!
mechanism,!known!as!mitophagy!(more!generally!known!as!“autophagy”),! to!control!
the! number! of! mitochondria! within! a! cell! by! removing! those! which! become!
dysfunctional! and! produce! high! amount! of!mtRS264.! Autophagy! is! an! essential! cytoK
protective! pathway! and! consists! in! the! formation! of! autophagosomes,! doubleK
membrane!vesicles!that!sequester!organelles,!proteins,!or!portions!of!the!cytoplasm,!
which!then!fuse!with!lysosomes265.!As!a!result,!the!sequestered!contents!are!degraded!
by! lysosomal! enzymes,! and! recycled! as! a! source! of! energy265.! Autophagy!may! occur!
either!as!a!general!phenomenon,! for! instance!when!cells! lack!nutrients!and!mobilize!
their! energy! reserves,! or! it! can! specifically! target! distinct! cellular! structures! such! as!
damaged! mitochondria! (“mitophagy”)266.! Inhibition! of! autophagy! results! in! the!
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accumulation!of!damaged!mitochondria! in!human!cells,! leading!to!an! increase! in!the!
net! amount! of! mtRS! and! proKinflammatory! cytokine! production263.! Interestingly,!
autophagy!appears!to!decline!with!age,!and!gene!expression!of!key!regulators! in!the!
autophagic! pathway! (i.e! ATG5! and! ATG7)! are! reduced! in! aging! individuals267.!
Additionally,! major! human! ageKrelated! diseases! characterized! by! an! increased!
inflammatory!burden!such!as!Parkinson’s!and!Alzheimer’s!disease!have!been!linked!to!
defects! in! mitochondrial! autophagy268.! This! data! strongly! supports! a! possible!
contribution! of! mtRS! to! the! ageKdependent! increase! of! the! inflammatory! burden.!
Interestingly,! conditions! that! promote! autophagy,! such! as! caloric! restriction! and!
exercise,! delay! agingKassociated! degeneration269,! suggesting! that! autophagy! exerts!
important!roles!also!in!controlling!the!evolution!of!aging.!Stimulation!of!autophagy!can!
increase! the! healthy! lifespan! in! multiple! model! organisms! including! mice! and!




Systemic! inflammation! is! involved! in! the! pathogenesis! of! several! acute! and! chronic!
conditions272K276.! In! addition,! sepsis,! the! acute! systemic! response! to! infections,! is!
responsible!for!a!large!number!of!deaths!in!intensive!care!units277.!In!order!to!achieve!
a!better!understanding!of!the!pathways!involved!in!the!inflammatory!response,!human!







addition,! the! bacterial! byproducts! can! be! used! to! study! the! human! innate! immune!
response! in! vivo.! Recognition! molecules! present! in! the! bloodstream! or! on! the! cell!
surfaces! can! initiate! the! inflammatory! process! by! opsonic! activity,! endocytosis! or!
activating! inflammatory! cells280.! The! human! endotoxin! model! represents! the! most!
common!model!of!systemic!inflammation!because!of!its!high!reproducibility!of!effects;!
purified! LPS! from! Escherichia! coli! or! other! GramKnegative! bacteria! is! administered!
intravenously!to!healthy!volunteers!allowing!the!observation!of!human! inflammation!
in! a! doseKdependent!manner! qualitatively! similar! to! the! early! phase! of! sepsis281,282.!
Within!1!hour!after!the!administration,!volunteers!experience!varying!degrees!of! fluK
like! symptoms! such! as! chills,! headache,! myalgias! and! arthralgias,! nausea! and!
photophobia!with!a!large!interKindividual!variation!and!in!a!doseKdependent!fashion283.!
!These!symptoms!tend!to!attenuate!within!2!to!6!hours!in!parallel!with!the!reduction!
of! the! proKinflammatory! response.! Tachycardia! and! a! temperature! increase! of!
approximately! 2°C! are! the! most! reproducible! clinical! findings.! LPS! triggers! the!
production! of! proKinflammatory! mediators! such! as! TNFKα! and! ILK1β,! chemokines.!!
Within! the! first! hour! after! LPS! administration,! TNFKα,! soluble! TNFKα! receptor,! IFNKγ,!
and!ILK6!appear!in!plasma.!Of!these,!TNFKα!shows!a!monophasic!peak!after!90!minutes,!
whereas! ILK6! and! IFNK! γ! peak! after! 120! minutes284,285.! ILK1β! peaks! after! TNFKα,! but!
before!ILK6286.!The!antiKinflammatory!mediators!are!detectable!subsequently!response;!
ILK10!peaks!3!hours!after!the!exposure!to!LPS287.!Higher!profile!of!chemokines!such!as!
ILK8,! monocyte! chemoattractant! protein! (MCP)K1,! and! neutrophil! attractant! protein!
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(NAP)K1! can! also! be! detected! subsequent! to! the! administration! of! LPS288.! The! acute!
phase! proteins! profile! rise! on! the! following! 12! to! 24! hours282.! ! Furthermore,! the!
hypothalamic–pituitary–adrenal! axis! rise! within! 2–3! hours! and! the!
adrenocorticotrophic! hormone,! cortisol,! and! the! adrenal! androgen!
dihydroepiandrosterone! profile! increase! acutely289.! The! endotoxemia! model! is! not!
comparable! to! sepsis! since! it! is!not!based!on!equivalent!doses! required! for!a! similar!
response;! in!addition,! the!healthy! subjects! rather! than!highKrisk!populations!and! the!
LPS! rather! than! living! bacteria! represent! clear! limitations! of! this!model.!However,! it!





of! recombinant! cytokines! has! been! adopted! to! evaluate! the! body! response.! TNFKα!
infusion!causes! fever,!pituitary!and!stressKhormone!secretion! together!with!an!acute!
phase! response.! These! effects! and! Infusion! of! ILK6! are! comparable! to! the! LPS!
model294,295.!!
1.5.5.3. Typhoid"vaccine""









The! body! response! to! physical! exercise! has! some! similarities!with! the! inflammatory!
response! detected! after! trauma! or! infections;! therefore! it! has! been! proposed! as! a!
model!of!systemic!inflammation!and!several!studies!have!evaluated!the!inflammatory!
response!following!exerciseKinduced!muscle!damage298.!The!muscle!damage!following!
eccentric! cycle! ergometry! triggers! cytokines! release299.! ILK1β! was! elevated! in! the!
muscle! tissue! of! individuals! who! performed! 45! minutes! of! downhill! running300! and!
higher!level!of!LPS!was!detected!after!a!triathlon!competition301.!
It! is! plausible! that! exercise! could! induce! ischemia! of! the! gastrointestinal! system!
increasing! gut! permeability! to! allow! penetration! by! bacterial! toxins! triggering! the!
inflammatory! response! via! immune! cell! response.! Strenuous! exercise! seems! to!
stimulate! the! secretion! of! cytokines! in! a! similar!manner! to! subclinical! inflammation!
and!sepsis302!with!the!initial!release!of!TNFKα!and!a!subsequent!rise!of!ILK6,!ILK1β!!and!
ILK1ra.! A! 100Kfold! elevation! of! ILK6!mimic! the! increase! of! this! cytokine! during! sepsis!





inflammation.! PD! can! be! described! as! a! chronic! lowKgrade! infection! mainly! due! to!
anaerobic! gramKnegative! bacteria.! Periodontal! therapy! is! primarily! based! on! the!
mechanical! removal! of! the! bacterial! biofilm! and! hard! deposits! from! the! diseased!
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dentition.!The!consequent!acute!bacteremia!and! soft! tissue!damage!could!provide!a!
model! to! study! the! transient! host! response.! Following! an! intensive! session! of! subK
gingival! mechanical! instrumentation! under! local! anesthesia,! the! inflammatory!
response! was! assessed! at! day! 1! and! day! 7! followKup! visits! (Figure! 10).! An! acute!
increase!of!inflammatory!mediators!such!as!TNFKα,!ILK6!and!CRP!was!observed.!!TNFKα!
profile! was! higher! at! day! 1! visit.! ILK6,! CRP! and! Fibrinogen! plasma! levels! were! also!
increased! 24! hours! after! periodontal! treatment! and! returned! to! value! similar! to!
baseline! only! after! 1! month.! There! was! an! increase! in! circulating! neutrophils! and!
monocytes.!Lymphocytes!decreased!at!day!1!and!then! increased!7!and!30!days!after!
treatment.! Furthermore,! erythrocyte! numbers,! and! hemoglobin! concentration! were!











contribute! to! the! increased! prevalence! and! severity! of! PD! observed! in! diabetes.!
Diabetes! is! related! to! an! altered! function! of! immune! cells! such! as! neutrophils,!
monocytes! and! macrophages306.! Neutrophils! features! including! adherence,!
chemotaxis,! and! phagocytosis! can! be! impaired! reducing! their! efficacy! in! eliminating!
bacteria! in! the! periodontal! lesions! with! a! consequent! increase! in! periodontal!
damage307.!In!addition,!monocytes!and!macrophages!exhibit!an!increased!response!to!
the! bacterial! challenge! raising! the! release! of! proKinflammatory! mediators308.! ! In!
diabetes,! Porphyromonas! gingivalis! antigens! trigger! a! higher! quantity! of! TNFKα! by!
blood!monocytes!compared!to!controls308.!This!evidence!is!supported!by!data!from!an!
animal! model! of! diabetes! in! which! P.! gingivalis! inoculation! resulted! in! a! prolonged!
inflammatory! response! due! to! TNF! stimulation309.! Furthermore,! the! GCF! analysis! of!
patients! with! PD! and! diabetes! report! an! increased! level! of! inflammatory!mediators!
supporting!this!hypothesis310.! It!seems!also!that!the!GCF! inflammatory!profile!relates!
to! the! level! of! glycemic! control;! GCF! levels! of! ILK1β! were! approximately! doubled! if!
HbA1c! levels!were!over!8%311.!Alterations! in! the!connective! tissue!metabolism!could!
also!be! a! contributor! to! the! increased! level! of! bone! loss! as!hyperglycemia!has!been!
associated! to! impaired! bone! healing! and! turnover312! and! an! increased! rate! of!
apoptosis! in! response! to!P.! gingivalis! infection313.! Furthermore,! high! glucose! level! in!
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the! GCF! may! affect! the! fibroblasts! wound! healing! action! required! maintaining! a!
healthy! periodontium314.! The! microKvascular! complication! of! diabetes! include!
abnormal!growth!and!impaired!healing!of!the!vessels!are!detectable!at!a!periodontal!




its! normal! homeostatic! transport! properties.! This! change! in! homeostasis! may! alter!
wound!healing!responses!to!chronic!microbial!damage!of!the!periodontium.!Numerous!
evidence!have!suggested!a!potential!impact!of!PD!on!the!metabolic!state!in!diabetes318!
worsening! the! glycemic! control.! Data! from! a! 2Kyear! longitudinal! trial! report! that!
patients! with! diabetes! and! severe! PD! had! a! sixKfold! increased! risk! of! worsening! of!
glycemic!control!over!time!compared!to!controls319!.!Furthermore,!an!increased!risk!of!
other! diabetic! complications! has! been! observed! in! a! caseKcontrol! study;! 82%! of!
diabetic! patients! with! severe! PD! experienced! at! least! one! major! cardiovascular,!
cerebrovascular,!or!peripheral!vascular!events!compared!to!only!21%!of!controls320.!!A!







The! inflammatory! mediators! detected! in! both! PD! and! CVD! ha! been! proposed! as! a!
potential! contributors! to! the! link! between! these! two! conditions.! The! inflammatory!
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Consequently,! the! endothelium! would! upKregulate! the! adhesion! molecules! and!
promote! the! cytokine!production! contributing! to! the!pathogenesis! of! the! atheroma.!
However,! there! is! no! strong! evidence,! for! the! time! being,! supporting! this!
hypothesis323.!!!
1.6.2.1.2. Bacteremia!
A! second! potential! mechanism! could! be! related! to! the! bacteremia! associated! with!
periodontitis;! transient! LPS! concentration! can! be! detected! in! the! circulation.!





Additionally,! specific! crossKreactive!antibodies! induced!by!periodontal!pathogens!can!
increase! the! risk! for! atherosclerosis! or! accelerate! its! course! by! promoting! the!
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endothelial!inflammatory!response,!macrophages!endocytosis!of!lipid!and!contrasting!
the! antiKatherogenic! actions! of! protective! molecules.! ! The! immune! response! to!
microbial! heatKshock! proteins! (HSPs)! could! represent! a! mechanism! linking! bacterial!
infections!to!atherosclerosis.!!In!humans,!HSPs!transport!protective!proteins!to!the!cell!
surface.! During! the! inflammatory! response,! HSPs! will! be! expressed! by! tissues! and!
regulated! by! the! immune! system.! AntiKHSP! reactive! antibodies! can! be! detected! in!
serum! of! patients! with! atherosclerosis! and! HSPs! can! interact! directly! with! TollKlike!
receptors! (TLRs)! and! thereby! induce! inflammatory! responses! in! macrophages! and!
endothelial! cells.! Bacteria! can! express! antigens! resembling! human! HSPs! stimulating!
the!production!of!antibodies!and!the!TKcells!activation.!Therefore,!molecular!mimicry!
inducing! crossKreactive! cells! and! antibodies,! may! be! a! link! between! infection! and!
atherosclerosis327.! Periodontal! pathogens! such! as! P.! gingivalis! can! express! HSPs! and!
stimulate! macrophages! to! release! inflammatory! cytokines! 328K330.! Fusobacterium!
nucleatum! can! also! express! HSPs,! antibodies! for! its! HSPs! have! been! detected! in!
periodontal! patients331.! Fusobacterium! nucleatum! HSPs! could! enhance! foam! cell!
formation,!activate!endothelial!cells!with!increased!monocyte!adhesion!and!migration!
and! promotion! of! coagulation331.! Furthermore,! animal! models! support! a! potential!
interaction!of!bacterial!HSPs!and!promotion!of!atherosclerosis332!supporting!the!role!of!




Ultimately,! PD! is! associated! with! elevated! serum! concentrations! of! potentially!
atherogenic! lipids! such! as! LDLs,! triglycerides! (TGs)! and! very! lowKdensity! lipoproteins!
(vLDLs).! In! vitro! studies! suggest! that! PD! is! associated! with! changes! in! serum! lipid!
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concentrations!and! lipid!modification.!The!properties!of!serum! lipids!can!be!affected!
by! infections;! the! response! to! bacteremia! could! interact! with! serum! lipids! and!
stimulate! the! liver! cholesterol! biosynthesis! promoting! dyslipidemia.! Periodontal!
patients! present! higher! cholesterol! and! LDL! profile! compared! to! controls333,334.!
Elevated! LDL! and! lower! HDL! were! observed! in! PD! irrespectively! of! the! smoking!
status335.!In!addition,!increased!serum!levels!of!oxLDL!and!modified!LDL!were!detected!
in!PD336,337.!
1.7. Evidence$ that$ periodontal$ treatment$ improves$ CVD$ and$ Diabetes$
Outcomes$
CVD! namely! coronary! heart! disease,! stroke,! congestive! heart! failure,! and! peripheral!
artery!disease,!became!the!leading!cause!of!chronic!disease!morbidity!and!mortality!in!
industrialized! countries! in! the! twentieth! century338.! CVD! incidence! is! now! increasing!
also! in! the!developing!countries!as!a!consequence!of! the!better!control!of! infectious!
diseases! and! due! to! the! obesity! and! diabetes! epidemic339.! A! bulk! of! evidence! is!
available!on!the!beneficial!effects!of!controlling!a!number!of!recognized!CVD!risk!factor!
including! hypercholesterolemia,! hypertension,! smoking340! and! sodium! intake341.!
However!the!incidence!of!CVD!is!still!increasing!as!controlling!all!recognized!risk!factors!
might! not! be! sufficient! at! controlling! CVD! impact! on! the! health! of! the! general!
population.! There! is! emerging! evidence! that! inflammation! plays! a! key! role! in! the!
development! of! CVD! ! from! atheroma! formation! to! its! rupture! and! development! of!
clinical! events293.! Several! epidemiological! studies! have! investigated! and! support! an!
association! between! high! levels! of! inflammatory! markers! an! increased! risk! and!
progression! of! CVD342.! A! number! of! potential! sources! of! inflammation! have! been!
investigated! over! the! last! 30! years.! The! possible! etiological! role! of! acute! or! chronic!
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infections!on!CVD!has!attracted!great!attention!in!recent!years.!In!particular!attention!
has! been! drawn! on! the! potential! impact! of! various! infectious! agents! on! systemic!
inflammation! and! autoimmunity! and! subsequently! onset! and! progression! of! CVD343.!













other! investigators149,346.! According! to! these! evidences! the! potential! benefit! of!
periodontal! treatment! in! reducing! CVD!mortality! represents! the! next! logical! step.! A!
recent! position! paper! of! the! American! Heart! Association! reviewed! the! evidence!
available! on! the! association! between! PD! and! CVD! concluding! that! after! 30! years! of!
research,! it! is! still! not! clear!whether! this! link! is! causal164.! The! same!paper! called! for!
new!wellKdesigned!intervention!studies!investigating!the!impact!of!periodontal!therapy!
on!CVD!outcomes.!However!a! large!number!of! small! singleKcentre! intervention! trials!
have!been!published!over!the! last!30!years! focusing!on!various!surrogate!markers!of!
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with! a! wide! range! of! serious! complications.! Therefore,! a! regular! monitoring! of! the!
glucose!levels!is!required.!The!hemoglobin!nonKenzymatic!reaction!with!glucose!occurs!
continuously!in!erythrocytes.!This!bind!is!highly!stable!and!last!for!approximately!123!±!
23! days,! the! whole! life! span! of! the! erythrocytes347.! Therefore,! the! assessment! of!
HbA1c! reflects! the! average! of! the! glycaemia! over! the! preceding! 1–3! months! 348.!
Measurement! of! hemoglobin! A1c! (HbA1c)! is! recommended! at! least! twice! a! year! in!
stable! patients! and! every! 3! months! in! those! who! has! changed! therapy! or! are! not!
meeting! the! treatment!goals.!The!advised!HbA1c! target!value! for!people!with!DM! is!
<7.0%,!with!the!healthy!population!below!6%.!Recent!data!reported!that!only!36%!of!
people! with! T2DM! have! HbA1c! <7.0%349.! Data! from! two! large! trials,! the! United!
Kingdom! Prospective! Diabetes! Study! (UKPDS)! and! the! Diabetes! Control! and!
Complications!trial,!suggest!that!the!risk!of!longKterm!complications!can!be!lowered!by!
an!intensive!treatment!of!hyperglycemia131,183,350.!A!1%!reduction!in!the!HbA1c!in!the!
UKPDS!was!associated!with! a! relative! risk! reduction!of! 21%! for! any!diabetesKrelated!
endpoint,! 21%! for! diabetesKrelated! deaths,! 14%! for! MI! and! 37%! for! microKvascular!







a! mean! percentage! reduction! of! K0.29! (95%! confidence! interval! (CI)! K0.48! to! K0.10;!
effect! P! =! 0.003)! at! 3! or! 4! months! followKup.! Evidence! from! the! 5! studies,! 826!
participants,! describes! no! benefit! of! the! periodontal! intervention! with! mean!
percentage! reduction! in! HbA1c! of! K0.02! (95%! CI! K0.20! to! 0.16;! effect! P! =0.84)! at! 6!
months! followKup.! However,! the! largest! study! included! in! the! analysis! with! 514!
participants! and! accounting! for! 20%!of! the! total! 2565! participants352! has! received! a!
strong!criticism!by!the!scientific!community!for!a!several!number!of!reasons353.!Firstly,!
the! HbA1c! levels! of! the! selected! population! were! already! close! to! the! goal! for! a!
desirable! glycaemia.! Secondly,! the! clinical! improvements! in! periodontal! health!














QKwave! infarction! or! unstable! angina! pectoris! in! a! doubleKblind,! placebo! controlled!
study! with! the! use! of! clarithromycin! for! 3! months.! The! average! followKup! period!
reported!was! of! 519! days! (1.4! years).! The! rationale! of! the! study!was! based! on! the!
assumption! that! antibiotic! therapy! could! impact! on! the! progression! of! chronic!
infections! including! PD! and! therefore! result! in! a! reduction! of! CVD! events! rate.!
Antibiotic! therapy! however! was! not! beneficial! in! prevention! of! recurrent!
cardiovascular! events! in!patients!with!PD! compared! to!healthy! subjects.! The! second!
trial! is!a!feasibility!multicentre,!randomized,!controlled!trial!designed!to!study!effects!
of! periodontal! intervention! on! CVD! secondary! prevention.! Study! participants! were!
randomized!to!either!community!care!or!scaling!and!root!planing!in!University!settings.!
Despite! being! only! a! feasibility! trial,! after! 1! year! of! follow! up,! no! difference! was!
observed! in! CVD! events! rate! between! the! community! control! and! the! treatment!






Hyperlipidaemia! is! considered! a! wellKestablished!modifiable! risk! factor! for! coronary!
heart!disease!together!with!smoking,!hypertension,!glucose! intolerance,!obesity,!and!
physical! inactivity.! Specific! lipid! biomarkers! have! been! identified.! Triglycerides! (TG),!
serum!total!cholesterol!(TC)!and!high/lowKdensity!lipoprotein!cholesterol!(HDL/LDLKC)!
are! considered! traditional! lipid! biomarkers! associated! with! CVD! whilst! recent!
surrogate! markers! include! LpKPLA2! and! oxidized! LDL.! Numerous! studies! have!
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demonstrated! that! lowering! LDLKC! levels! can! positively! influence! cardiovascular!
morbidity! and!mortality357.!A!metaKanalysis! reported! that! a! 1.0!mmol/L! reduction! in!
LDLKC!is!associated!with!more!than!20%!reduction!in!CVD!events358.!Current!guidelines!
refers!to!LDLKC!concentrations!that!should!be!reduced!to!<2.6!mmol/L!(100!mg/dL)!in!




major! vascular! event358.! Epidemiologic! studies! have! shown! an! inverse! correlation!
between! HDLKC! and! CVD! events360.! Low! serum! concentrations! of! HDLKC! are! an!
independent!risk! factor! for!CVD.!Levels!<1!mmol/L! (40!mg/dL),! increase!substantially!
the!risk!for!coronary!heart!disease361,362.!Great!attention!has!been!given!to!changes!in!
HDLKC!as!potential! therapeutic! targets! for! the! treatment!of!CVD.! Indeed!HDLKc! is! an!
essential!regulator!of!the!reverse!cholesterol!transport!pathway:!a!process!that!allows!
excess!cholesterol!stored!in!peripheral!cells,!such!as!foam!cells,!to!be!excreted!by!the!
liver! via! the! bile.! This! process! is! believed! to! protect! against! atherosclerosis363.!
However,!HDLKC!has!multiple!additional!protective!properties! including!its!role! in!the!
reduction! of! LDL! oxidation.! Oxidized! LDL,! easily! absorbed! by! the! macrophage,!
contributes!to!the!formation!of!foam!cells364!!and!therefore!impact!on!the!progression!
of! atheroma.! HDLKC! also! decreases! vascular! inflammation365,! thrombosis,! improve!
endothelial! function366,! promotes! endothelial! repair366! ! and! increases! insulin!
sensitivity367.!HDLKC!may!also! slow! the!progression!of! lesions!by! selectively! reducing!
the! production! of! endothelial! cell–adhesion! molecules! that! facilitate! the! uptake! of!
cells! into! the! vessel!wall368.! It! therefore! follows! that! increasing! the! concentration!of!
HDLKC! has! the! potential! to! reduce! CVD! risk.! In! addition! to! HDL/LDL! close! link! to!
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atherogenesis,!TG! level! is!also!considered!an! independent! risk! factor! for!CVD357.!TGs!
are!not!directly!atherogenic!but!represent!an!important!biomarker!of!CVD!risk!because!
of!their!association!with!proatherogenic!proteins369.!LpKPLA2!has!been!proved!to!be!an!
independent! risk! factor! for! CVD370! ! as! it! can! hydrolyse! oxidized! LDL! into! proK
inflammatory! mediators! contributing! to! the! atherogenic! process.! Two! randomized!
controlled!trials371,372!examined!a!sample!of!otherwise!healthy!individuals!affected!by!
severe! generalized! PD! and! showed! that! nonKsurgical! periodontal! treatment! caused!
reductions!in!total!and!LDL!cholesterol!levels!at!2!and!6!months!followKup.!In!another!
RCT,! Oz! et! al! performed! PD! treatment! in! 50! individuals! also! suffering! from!
hypercholesterolemia!and!evaluated! their! serum! lipid! concentrations!3!months!after!
the! treatment.! There! was! a! substantial! decline! in! TC! and! LDLKC! profiles! in! the!
treatment!group!and!between!the!two!groups373.!Acharya!et!al!described!changes! in!






different! study! arms;! group! 1! included! patients! undergoing! nonKsurgical! periodontal!
therapy!at!baseline!and!reKexamined!after!3!months,!group!2!received!treatment!at!3!
months! follow!up,! and! group! 3! of! no! intervention.! Serum! lipid! concentrations!were!
reported!as!decreased!in!all!groups!but!there!were!no!statistical!significant!differences!
between! the! groups.! Two! clinical! trials379,380! reported! changes! in! oxidized! LDL! after!
periodontal!treatment.!Montebugnoli!et!al!showed!a!mean!reduction!in!oxLDL!of!18%!





three!prospective! studies382K384!HDLKC! concentrations!were! raised!3!months! after! PD!
therapy!and!also!authors!demonstrated!significant!antiKatherogenic!profile!suggesting!
indirectly!that!PD!could!reduce!the!protective!role!of!HDLKC!on!CVD!onset.!More!than!
one! third! of! the! trials! reviewed! reported! an! improvement! in! serum! lipid!
concentrations!after!PD! therapy! (reduction! in! total! cholesterol! and! LDL! in! some!and!
increase! in! HDL! levels! in! other! trials).! This! could! represent! a! potential! mechanism!
explaining!the!increased!CVD!risk!in!people!with!PD!(i.e.!worst!cardioKmetabolic!profile!
of! individuals! diagnosed!with! PD).! If! these! associations!were! proven! causal! then! PD!
therapy! could! be! suggested! as! additional! approach! to! lipid! lowering!medications! in!
further!reducing!CVD!risk!of!the!general!population.!However!there!is!a!wide!variability!
among!different!trials!outcomes!reported.!Factors!such!as!age,!gender,!smoking!status,!
general! health! status,! medications,! severity! of! periodontal! disease! and! sample! size!
should!be!taken!into!account!comparing!outcomes!from!different!studies.!Encouraging!





Inflammatory! processes! are! recognized! to! play! a! central! role! in! the! pathogenesis! of!
atherosclerosis! and! its! complications275,293.! Inflammation,! focally! and! systemically,! is!
involved! in! destabilization! and! rupture! of! atherosclerotic! plaques,! leading! to! acute!
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cardiovascular! events107.! Current! risk! prediction! models! based! on! traditional! risk!
factors!have!the!ability!to!predict!longKterm!CV!risk!in!many!individuals.!However!great!





Circulating! white! blood! cell! (WBC)! count! represents! a! crude! assessment! of! the!
individual! inflammatory! status385! and!has!been!proposed!as!a!biomarker!of!CVD! risk!
prediction386.! A! number! of! observational! epidemiologic! studies! have! reported! a!
consistent!positive!association!between!WBC!count!and!the!risk!of!CVD387K389.!!
Christgau!et!al!in!1998!failed!to!show!any!differences!in!WBC!in!patients!with!diabetes!
and! healthy! controls! 4! months! after! periodontal! treatment390;! these! findings! were!
confirmed!in!other!trials377,379,391K394.!In!contrast,!Christan!et!al.!treated!27!PD!patients!
showing!that!3!months!after!therapy!there!was!a!significant!reduction!in!WBC!and!that!
the! effect! of! the! intervention!was!more! evident! in! nonKsmokers!when! compared! to!
current!smokers395.!Similar!results!were!obtained!in!two!additional!RCTs!examining!the!
effects!of!nonKsurgical!intensive!periodontal!therapy!on!WBC!after!6!months12,372.!Lalla!
et! al.! showed! a! reduction! in! percentage! of! mononuclear! cells! (CD14+! monocytes)!
following!periodontal!treatment396.!A!recent!report!found!that!already!1!month!after!
PD!therapy!individuals!with!CHD!presented!with!a!statistically!significant!reduction!in!
WBC! counts397.! The! efficacy! of! PD! treatment! was! further! confirmed! in! 3! additional!
clinical! trials398,399.! Based! on! the! evidence! examined,! only! 5! trials! reported! a!
statistically! significant! reduction! of! WBC! following! PD! therapy! whilst! 9! other! trials!





AcuteKphase! reactants! are! molecules! produced! during! acute! and! chronic!
inflammation;! they! exert! a! variety! of! functions! including! activation! of! complement!
factors,!neutralization!of!bacterial!pathogens,! stimulate! repair!and! regeneration!of!a!
variety! of! tissues.! These!molecules! are! produced! by! the! liver! following! a! triggering!
stimulus!(increased!circulating!cytokine!levels)!and!have!received!great!attention!over!
the! years! and! in! particular! CKreactive! protein,! plasminogenKactivator! 1! (PAIK1),! and!
fibrinogen400.!
1.7.2.2.2.4. CPreactive"protein"
CRP! is! a! protein! mainly! produced! by! the! liver! but! also! by! adipocytes! and! vascular!
smooth!muscle! cells! in! response! to!a! rise! in! interleukinK6!and! tissue!necrosis! factorK
alpha!(TNFK!α).!It!is!a!very!stable!and!known!acuteKphase!reactant401.!CRP!levels!often!
increase! substantially! in! response! to! a! wide! variety! of! biological! insults,! infections,!
inflammatory!conditions!and!cancer402.!However,!given!its!consistent!association!with!
CVD,! CRP! remains! an! established! marker! of! CVD! risk,! and! it! may! very! well! be! a!
contributor! to! the! vascular! inflammatory! process! in! coronary! arteries! in! humans.!
Multiple! prospective! cohort! studies! have! established! that! increased! CRP! levels! are!
associated!with!increased!CVD!risk!in!both!genders,!across!a!wide!age!range403.!These!
findings!have!been!consistent!in!different!populations!with!diverse!ethnic!backgrounds!




serum!CRP!concentration!has! continuous!associations!with!CVD! risk,! ischemic! stroke!
and!vascular!mortality405.!Risk!ratio!for!CVD!per!1KSD!higher!log(e)!CRP!concentration!
was! 1.37! when! adjusted! for! conventional! risk.! While! CRP! has! multiple! proK
inflammatory! and! proKatherogenic! properties,! recent! studies! have! not! supported! a!
causal! role! for! it! in! atherogenesis406.! CRP! is! primarily! a! nonKspecific! marker! of!
inflammation,!and! its! levels! rise! in! response! to! infections,!autoimmune!diseases!and!
malignant!processes.!In!the!absence!of!inflammation,!hsCRP!levels!of!1!mg/ml!confer!a!
lower! risk! for! CVD,! while! levels! above! 3! mg/ml! almost! double! the! risk! of! CVD407.!
Multiple!measures! known! to! reduce!CVD! risk! (i.e.,! smoking! cessation,! losing!weight,!
exercise)! also! decrease! serum! CRP! levels.! Several!medications,! in! particular,! statins,!
are!also!known! to! reduce! serum!CRP! levels408.! The!association!between!CRP!and!PD!
has!been!shown!in!several!observational!studies!and!at!least!3!systematic!reviews!have!
examined!the!impact!of!PD!therapy!on!CRP!serum!levels!reduction.!In!the!first!metaK





trials! reported! similar! estimates!with! a!mean! overall! difference! in! CRP! serum! levels!
after!PD!of!0.2!mg/L!(95%!CI!K0.15K0.55)410.!The!most!recent!metaKanalysis!including!4!
clinical! trials! reported! a! 0.23! mg/l! reduction! in! CRP! levels! (K0.231;! p=0.000)411.! 2!
additional! trials! performed! in! individuals! with! PD! and! other! comorbidities! including!
diabetes378,412!confirmed!the!potential!antiKinflammatory!effect!of!PD!therapy!also! in!
these! populations.! Sun! et! al,! randomized! 157! individuals! with! diabetes! to! a!
periodontal!intervention!or!control.!After!three!months,!the!serum!level!of!CRP!in!the!
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treatment! reduced! from! 5.81±1.23! mg/L! to! 5.51±1.29! with! a! mean! difference! of! –!
0.30±0.31.!Higashi!et!al,!showed!that!six!months!after!PD!therapy!individuals!with!CVD!
presented!with! a! substantial! reduction! in!CRP! (from!2.7±1.9! to!1.8±0.9!mg/L)! in! the!
test! group! compared! to! the! control413.! Similar! results! were! reported! in! individuals!
affected!by!PD!and!Metabolic!Syndrome!after!eight!weeks!of!PD!therapy!(reduction!of!
0.68!mg/L)374.!Moderate!evidence!supports!the!notion!that!serum!levels!of!CRP!can!be!
reduced! by! periodontal! therapy.! There! is! also! sufficient! evidence! to! suggest! that!




Substantial! evidence!has! accumulated! suggesting! that! fibrinogen! represents! a!major!
risk! factor! for! cardiovascular! disease.! WellKconducted! metaKanalyses! have! clearly!
shown! that! increased! concentrations! of! fibrinogen! are! associated! with! the!
development! or! presence! of! atherothrombotic! disease414.! It! was! also! reported415! ! a!
strong! association! between! fibrinogen! and! coronary! artery! calcification! (CAC)! and!
increased! carotid! intima–media! thickness! (CIMT),! both! being! considered!markers! of!
subclinical! coronary! atherosclerosis416.! Six! studies! reported! a! reduction! whilst! 2!
reported!an! increase! in! fibrinogen! levels! following!periodontal! therapy.!Bokhari!et!al!
confirmed! a! positive! effect! of! nonKsurgical! periodontal! treatment! in! reducing!
fibrinogen!levels!in!both!patients!with!CVD!or!systemically!healthy.!Indeed!individuals!
affected! by! CVD! experienced! a! greater! reduction! in! fibrinogen! levels! compared! to!
healthy!subjects417.!Similarly!Correa!et!al! showed!a!significant!decrease! in! fibrinogen!
levels! in! subjects! with! PD! and! type! 2! diabetes! 3! months! after! periodontal!
intervention418!and!Vidal!et!al!in!people!with!PD!and!hypertension419.!However!a!larger!
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number! of! investigators! were! not! able! to! replicate! these! findings377,379,392,396,420,421.!
Taylor!et!al!showed!a!significant!decrease!of!fibrinogen!level!12!weeks!after!fullKmouth!
tooth! extraction422.! The! same! group! failed! to! replicate! this! finding! in! a! further! trial!
with! a! nonKstatistically! significant! reduction! in! fibrinogen! profile! in! the! treatment!
group! compared! with! the! control! group377.! Some! controlled! clinical! studies! show!
reductions! in! fibrinogen! levels,! but! randomized! clinical! trials! failed! to! demonstrate!
reductions! in! this! marker.! Two! investigations! confirmed! that! periodontal! therapy!
results! in! the! shortKterm! increase! of! Fibrinogen! levels.! Thus,! there! is! insufficient!




affects! HDL! composition! and! function423.! SAA! concentrations! have! been! shown! to!
positively! correlate! with! the! development! of! atherosclerosis423.! SAA! is! raised! in!
subjects!affected!by!PD!and!comorbidity!(i.e.!CVD)!however!not!in!individuals!with!PD!











Cytokines! are! small! soluble! proteins! that! transfer! information! from! one! cell! to!
another.! More! than! 200! cytokines! have! now! been! identified! including! interleukins,!
growth! factors,! chemokines,! and! interferons.! They! are! all! organized! in! complex!
networks!playing!fundamental!roles!in!both!pro/antiKinflammatory!processes!including!
CVD!and!PD.!Several!studies!showed!that!compared!to!control!subjects,!patients!with!
PD! have! higher! concentrations! of! circulating! inflammatory! cytokines426.! In! addition,!
subjects!with! both! CVD! and! PD! show! significantly! higher! concentration! of! cytokines!
compared!to! individuals!with!CVD!only413.!A!bulk!of!evidence!highlights!the!potential!
relevance!of!cytokines!in!mediating!the!inflammatory!processes!during!atherogenesis!








atherogenesis! such! as! the! vessel! wall! inflammation,! leukocyte! chemotaxis! and!
adhesion! or! plaque! rupture429K431.! InterleukinK6! (ILK6)! is! the! main! proKcoagulant!
cytokine432.! It! can! increase! plasma! concentrations! of! fibrinogen! and! plasminogen!
activator! inhibitor!typeK1!(PAIK1)433,!as!well!as! increase!the!hepatic!expression!of!CRP!
which!amplifies!a!range!of!inflammatory!and!proKcoagulant!responses432.!ILK8!is!a!proK




and!mitogenic! effects! on! vascular! smooth!muscle! cells434.! In! addition,! ILK8! plays! an!
important!role!on!the!infiltration!of!monocytes!into!the!subKendothelial!space,!which!is!
a! crucial! process! in! the! early! stages! of! atherosclerosis435.! Serum! levels! of! ILK10,! a!
potent! antiKinflammatory! cytokine,! have! recently! been! shown! to! be! reduced! in!
patients!with! acute! coronary! syndromes436,! thus! suggesting! that!may! favour! plaque!
instability!and!the!development!of!acute!coronary!syndromes.!InterleukinK18!(ILK18)!is!
a! pleiotropic! proKinflammatory! cytokine! which! plays! an! important! role! in! the!
inflammatory! cascade437! ! and! potentially! on! atherosclerotic! plaque! progression! and!
vulnerability438.!Circulating!concentrations!of!ILK18!have!been!prospectively!associated!
with! vascular! events! in! patients! with! stable! and! unstable! angina439! ! or! preKexisting!
CVD440,441.!In!2!RCT!from!the!same!group,!otherwise!healthy!individuals!suffering!from!
PD!showed!a!reduction! in! ILK6!after!PD!therapy372,442.!These!results!are! in! line!with!a!
subsequent! report! showing! reductions! in! ILK6! levels! in! subjects! affected! by! PD! and!
CVD413.Similar!findings!were!shown!in!individuals!suffering!from!PD!and!comorbidities!
like! type! 2! diabetes412,! hyperlipidaemia443,! refractory! arterial! hypertension419.! Buhlin!
et!al!reported!significant!changes!in!ILK18!twelve!months!after!periodontal!therapy!but!
not!in!other!ILs!(K1β,K4,K5,K6,K8,K10)420.!We!found!also!a!number!of!trials!which!reported!
no! efficacy! of! PD! therapy! on! ILs! profile396,418,444.! The!most! consistent! finding! was! a!
reported! increase! of! ILK6! levels! following! periodontal! therapy! in! the! short! term! (1!
month)! and! some! evidence! of! a! reduction! in! ILK6! levels! in! the! medium! terms! (6!






many! human! atheromas446.! It! is! produced! in! murine! and! in! human! atherosclerotic!
lesions,! primarily! by!macrophages/foam! cells,! activated! TKcells,! smooth!muscle! cells,!
and!endothelial!cells447.!On!a! local! level,!TNFKα!has! the!potential! to!promote!cellular!
infiltration! to! the! plaque! via! endothelial! activation448! ! and! may! induce! endothelial!
dysfunction449.! It! also! promotes! the! production! of! other! cytokines! as! well! as!





PD! therapy!and!minocycline!versus!control453,454.!These! results!are! in! line!with!other!
three!clinical!studies412,418,455!on!the!effects!of!PD!therapy!on!TNFKα!in!individuals!with!
other! comorbidities! including! diabetes.! An! equal! number! of! trials! failed! to! show! a!
statistically! significant! effect! of! periodontal! therapy! on! TNFK! α378,382,420,443,456.! Lastly!
Fokkema!et!al!investigated!the!longKterm!effect!of!fullKmouth!tooth!extraction!therapy!
on! the! responsiveness! of! peripheral! blood! monocytes! in! a! single! subject! with!
generalized!terminal!adult!periodontitis!reporting!no!changes!in!TNFKα!release!before!
and!after!therapy398.!We!conclude!that!there!is!some!evidence!on!short!term!increase!




CD40! ligand! is! a! member! of! the! TNF! superfamily,! and! interacts! with! CD40! (a! TNF!
receptor!superfamily!member).!Increased!levels!of!sCD40L!have!been!found!in!a!range!
of! chronic! diseases! including! cardiovascular! diseases,! diabetes,! peripheral! arterial!





detected! suggesting! that! the! CD40! ligand! may! be! increased! in! patients! with!
periodontal! disease.! However! no! differences! in! CD40! ligand! concentrations! were!
found! in! the! periodontal! disease! group! (P! =! 0.41)! 3! months! after! therapy392.! We!
conclude! that! there! is! insufficient! evidence! on! the! effect! of! periodontal! therapy! on!
CD40!ligand.!
1.7.2.2.2.11. Circulating"cell"adhesion"molecules"(CAMs)"
Vascular! cell! adhesion!molecule! (VCAM)K1,! intercellular!adhesion!molecule! (ICAM)K1,!
and! EKselectin! are! expressed! by! endothelial! cells,! macrophages! and! smooth!muscle!
cells! in! response! to! various! inflammatory! stimuli! (shear! stress,! oxidative! stress,!
microbial! stimulation! or! inflammatory! mediators)460.! CAMs! are! also! involved! in! the!
adhesion! and! transmigration! of! leukocytes! into! the! vascular! endothelial! wall! thus!
promoting! atheroma! plaque! growth! and! instability.! Adhesion! molecules! are!
considered! markers! of! vascular! stress! and! their! role! in! the! pathogenesis! of!
cardiovascular!disease!has!been!extensively!investigated107.!Selectins!(CD62)!promote!
transient! rolling! of! leukocytes! along! the! endothelium,! whereas! ICAMK1! (CD54)! and!
VCAMK1!(CD106)!mediate!attachment!and!transKendothelial!migration!of!leucocytes461.!
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CAMs,! particularly! sVCAmK1! are! linked! to! future! CVD! death462.! A! number! of! studies!
indicate!upregulated!CAM!expression! at! the! gingival! and! systemic! levels!when!PD! is!
diagnosed463.!The!impact!of!periodontal!treatment!on!CAMs!expression/levels!has!also!
been!investigated.!We!retrieved!evidence!from!6!different!clinical!trials.!A!statistically!
significant! reduction! of! EKselectin! level! after! PD! therapy! was! reported! in! some! of!
them12,444,464.!No!evidence!of!a!similar!effect!of!PD!therapy!on!sICAMK1!and!sVCAMK1!
was! found392,396,444.!We! found!only! one! report!with! a! reduction!of! sICAmK1! after! PD!




!MCPK1,! a! member! of! the! CC! chemokine! family,! is! involved! in! the! pathogenesis! of!
atherosclerosis!by!promoting!recruitment!of!inflammatory!cells!to!the!vessel!wall466.!!
Serum!MCPK1! concentrations!have!been! found! raised! in! individuals!with!periodontal!
diseases! (1.5! folds! in! gingivitis,! 3! folds! higher! in! PD)! when! compared! to! healthy!
controls467.!Further!Fokkema!et!al!reported!a!twoKfold!reduction!of!serum!MCPK1!after!
dental! clearance! in! a! case! report398.! Despite! this! encouraging! data,! 3! clinical! trials!
comparing! serum!MCPK1! concentration! before! and! after! PD! therapy,! failed! to! show!
any! statistically! significant! reductions392,396.! According! to! the! current! evidence,!
periodontal!treatment!seems!to!not!be!effective!in!the!MCPK1!level!reduction!
1.7.2.2.2.13. Plasminogen"Activator"Inhibitor"1"(PAIP1)"
Plasminogen! activator! inhibitor! 1! (PAIK1)! belongs! to! the! family! of! serine! protease!
inhibitors! (SERPINs)! and! is! produced! in! high! quantity! by! a! number! of! cells! including!
endothelial!cells!in!response!to!inflammatory!cytokines.!Raised!PAIK1!plasma!levels!are!
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consistently! found! in! individuals! with! severe! sepsis! but! also! with! other! acute! or!
chronic! inflammatory! diseases! such! as! atherosclerosis.! PAIK1! is! upregulated! by!
inflammatory! cytokines! and!may! therefore! be! regarded! as! a!marker! for! an! ongoing!
inflammatory! process468.! Increased! plasma! levels! of! PAIK1! are! positively! correlated!
with! the! risk! of! developing! CVD! as! well! as! with! the! extent! of! coronary! sclerosis,!
restenosis,!risk!of!myocardial!infarction!and!deep!vein!thrombosis469.!
Montebugnoli! et! al379! reported! for! the! first! time! that! individuals!with! PD! presented!
with!raised!PAIK1! levels.!Taylor!et!al!showed!significant!reductions! in!PAIK1!3!months!
after! full!mouth!extraction! in!people!with! terminal!dentition!due! to!PD422.!However,!
the!same!group,!in!a!latter!study!could!not!replicate!the!same!findings377.!Tonetti!et!al!
also! confirmed! that! periodontal! therapy! did! only! increase! acutely! PAIK1! 24! hours!
following!periodontal! therapy!whilst! no! greater! reductions!were!observed!6!months!
after! PD! therapy12.! In! addition,! Lalla! et! al! treated! 10! diabetic! patients! affected! by!
moderate/severe! periodontitis! and! analysed! PAIK1! levels! 1! month! after! full! mouth!





DKdimer! is! a! marker! of! coagulation! and! specifically! crossKlinked! fibrin! turnover! as!
derives! from! fibrin! degradation.! In! coagulation! disorders! DKdimer! profile! can! be!
severely! altered!with! increased! expression! and! linked! to! CVD470K472.! DKdimer! plasma!
levels!are!also!considered!a!strong!predictor!of!coronary!disease473.!PD!therapy!in!18!
males! aged! 40–65! years! suffering! also! from! CVD! did! not! produce! a! statistically!
significant! reduction! in!DKdimer379.!On! the!contrary! two!reports! showed!a!significant!
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increase! of! DKdimer! profiles! 1! week! after! an! intensive! session! of! subgingival!
periodontal! therapy! and! a! subsequent! decrease! to! baseline! value! within! 1K3!




Von!Willebrand! factor! (vWF)! is! an!endotheliumKreleased!glycoprotein474.! It! has!been!
proposed! as! a! valid! biomarker! of! endothelial! damage/dysfunction.! Indeed! raised!
plasma! concentrations! are! often! observed! in! inflammatory! and! atherosclerotic!
vascular! diseases458.! High! plasma! vWF! levels! (≥221! IU/dl)! represent! an! independent!
risk! factor! for! adverse! CVD! events475.! Higher! vWF! antigen! levels! were! reported! in!
individuals! with! a! poor! dental! status! among! individuals! with! acute! myocardial!




significant! increase! of! vWF! levels! within! 1! month! after! intensive! periodontal!
treatment12,464.!There!is!insufficient!evidence!on!the!effects!of!periodontal!therapy!on!
vWF! in!the!mediumKlong!term,!there! is!some!evidence!that!periodontal! therapy!may!
increase!vWF!levels!in!the!short!term.!
1.7.2.2.2.16. MMPs"
The! matrix! metalloproteinases! (MMPs)! are! a! family! of! zincKcontaining! endoK
proteinases! that! have! all! similar! structural! domains,! but! differ! in! terms! of! substrate!
specificity,! cellular! source,! expression,! and! regulation.! The! metabolism! of! the!
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extracellular! matrix! is! governed! by! a! balance! between! the! MMPs! and! their! tissue!
inhibitors! (TIMPs)477.! Two! of! the! MMPs! biomarkers! most! consistently! implicated! in!
CVD!development!and!prognosis!are!MMPK9!and!TIMPK1478.!Circulating!levels!of!these!
MMPs! have! been! related! to! most! cardiovascular! disease! risk! factors! in! large!
communityKbased!samples479!and!have!been!associated!with!risk!of!death! in!patients!








al! compared! conventional!PD! treatment!alone!or! in! combination!with!a! low!dose!of!
doxycycline! and! showed! a! not! statistically! significant! reduction! in! MMPK9!
concentrations!and!TIMPK1!increase!in!both!treatment!groups426.!Two!further!reports!










ultimately! contribute! to! a! number! of! pathogenetic! processes! in! a! variety! of!
inflammatory! disorders.! Reactive! oxygen! species! (ROS)! include! oxygenKderived! free!
radicals,! such! as! superoxide,! hydroxyl,! nitric! oxide,! hydrogen! peroxide! and!
hypochlorous! acid484,485.! Oxidative! stress! is! defined! as! the! condition! arising! from! a!
serious! imbalance! between! the! levels! of! free! radicals! in! a! cell! and! its! antioxidant!
defences! in! favour! of! the! former486.! When! antioxidant! systems! are! unable! to!
counteract!the!free!radicals!action!efficiently!tissue!damage!ensues487.!Oxidative!stress!
has!been!implicated!in!a!number!of!inflammatory!diseases,!such!as!typeK2!diabetes488,!
vascular! diseases489! and! chronic! inflammatory! lung! disease490.! Oxidative! stress! does!
compromise! endothelial! cell! function,! a! crucial!mechanism! in! the! development! and!
progression! of! atherosclerosis491.! In! PD,! excessive! production! of! ROS! has! been!
demonstrated!and!appears!as!a!result!of!local!inflammatory!responses492K494.!Oxidative!
stress!byKproducts!including!lipid!peroxidation,!protein!carbonyl!levels!and!antibodies!
against! oxidized! lowKdensity! lipoprotein! are! significantly! elevated! in! individuals!with!
PD!when!compared!to!healthy!controls336,495,496.!Furthermore,!a!significant!difference!
in! antiKoxidant! capacity! between! individuals! with! PD! and! controls! has! been!
reported380,497.! Montebugnoli! et! al! described! a! significant! decrease! in! OxKLDL! in! 18!
males! with! confirmed! CCD! 3!months! after! periodontal! nonKsurgical! therapy379.! In! a!
pilot!study!14!otherwise!healthy!subjects!with!severe!PD!received!a!single!session!of!
intensive!periodontal! treatment! showing!a! substantial! increase!of!oxidative! stress!as!
assessed! by! circulating! ROS! with! a! progressive! reduction! up! to! 1! month497.! These!
findings!were!confirmed!by!Tamaki!et!al!who!showed!that!improvement!in!periodontal!
parameters! 2! months! after! nonKsurgical! periodontal! therapy! was! associated! with! a!
significant!reduction!in!plasma!ROM!level!in!19!systemically!healthy!subjects!affected!




et! al482! ! both! failed! to! report! a! reduction! of! measures! of! oxidative! stress! in! a!
individuals!with!PD!and!diabetes.! In!summary!there! is! little!comparative!evidence!on!






diastolic! blood! pressure! over! 90mmHg! in! subjects! who! are! not! taking! antiK
hypertensive!medication500.! It! has! been! hypothesized! that! the! inflammatory! chronic!
burden!associated!with!PD!could!have!hemodynamic!influences!and!therefore!impact!
on! the! pathogenesis! and! progression! of! hypertension501.! Seinost! et! al! ! reported! no!
changes!in!blood!pressure!measures!(diastolic/systolic)!of!30!patients!with!severe!PD,!
3! months! after! periodontal! intervention393.! Conversely! D’Aiuto! et! al! reported! a!
reduction!of!systolic!blood!pressure!2!months!after!intensive!periodontal!treatment!in!!
patients! affected! by! severe! generalized! PD372.! In! a! subsequent! trial! the! same! group!
failed! to! replicate! these! findings! over! a! longer! followKup! following! nonKsurgical! PD!
therapy12.!Higashi!et!al!in!two!RCTs!reported!notKsignificant!effects!of!PD!treatment!on!
blood! pressure375,413.! Similar! findings! were! reported! in! the! remaining! two! trials!




The!endothelium! is! involved! in! the! regulation!of! vascular!biology;! anticoagulant! and!
antiKinflammatory!mechanisms,!modulation!of! vascular! growth!and! remodelling.! The!
impairment!of! its! functions! is! a! key!process! in! the!early! stage!of! the!atherosclerosis!
and! its! progression502.! Endothelial! dysfunction! can! predict! adverse! CVD! events! and!
longKterm! outcomes503.! FlowKmediated! dilatation! (FMD)! represents! the!most! widely!
used! nonKinvasive! ultrasound! method! to! assess! endothelial! function! measuring!
endotheliumKdependent!vasorelaxation!of!the!brachial!artery504.!A!caseKcontrol!study!
showed! that! otherwise! healthy! subjects! with! severe! PD! had! lower! values! of! FMD!
compared! to! healthy! controls505.! PD! therapy! was! consistently! associated! with! a!
positive! effect! on! endothelial! function! (improvement)165,393,413,506K508.! Of! the!




significantly! affected! by! periodontal! therapy12.! Higashi! showed! similar! results! in!
individuals! suffering! from! hypertension! and! CVD! but! used! different! measures! of!
endothelial! dependent! function375,413.! In! summary! we! report! a! consistent! effect! of!





associated!with! established! CVD! risk! factors510! ! and! outcomes511.! The! intima–media!
thickness! is! the! distance! from! the! lumen–intima! interface! to! the! media–adventitia!
! 132!
interface! of! the! artery!wall,! as!measured! by! ultrasonographic! images! of! the! carotid!
arteries! (not! invasive).! ! Evidence! from!observational! studies! suggests! a!moderate! to!
strong!association!between!PD!and!CIMT!in!otherwise!healthy!individuals512K517.!Piconi!
et!al399!enrolled!35!otherwise!healthy!individuals!affected!by!mild!to!moderate!PD!in!a!
RCT.! Participants! received! a! scan! of! their! carotids! before! and! after! PD! therapy.! An!
intragroup! reduction!of!CIMT!at!6!and!12!months!after! the!periodontal! intervention!
was! reported.! Insufficient! evidence!was! found! on! the! possible! effect! of! periodontal!
therapy!on!the!rate!of!progression!of!CIMT.!
1.7.2.3. Conclusions"
After!more! than! 30! years! from! the! first! reports! on! the! association! between! dental!
infections/periodontitis! and! CVD! outcomes,! we! are! still! debating! on! whether! these!
associations!are!causal!or!casual!in!nature.!Over!the!last!10!years!the!number!of!clinical!
intervention!trials!has!multiplied!including!both!traditional!and!novel!CVD!outcomes!in!
response! to! periodontal! therapy.! However! after! a! critical! appraisal! of! the! evidence!
reported! to! date! we! confirm! that! there! is! still! minimal! or! insufficient! comparative!
evidence! on! the! effect! of! periodontal! therapy! on! CVD! outcomes! and! or! subclinical!
atherosclerosis.! Nevertheless! a! number! of! clinical! trials! have! helped! in! our!
understanding! of! the! potential! systemic! implications! of! periodontal! therapy.! Indeed!
this! therapy! is! strongly! associated! with! a! host! response! which! also! seems! to! be!
modulated!in!a!time!dependent!fashion.! !Periodontal!therapy!which!often!consists! in!
the!mechanical!cleaning!of! the!PD!diseased!dentition! is!often!associated!with!a! local!
and!systemic!amplification!of!the!body!inflammatory!response.!An!acute!inflammatory!
response! (characterized! by! sharp! increase! in! a! number! of! inflammatory! biomarkers!
including,! CRP,! ILK6,! TNFKα)! has! been! consistently! reported! by! several! investigators.!
This! inflammatory! state! is! also! associated! with! a! perturbation! of! the! haemostatic!
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system! (fibrinogen,! dKdimers,! PAIK1)! and! a! state! of! endothelial! cell! activation! (sK
Eselectin,!vWF)!and!impairment!of!endothelial!function!(as!assessed!by!flow!mediated!
dilatation!of!the!brachial!artery).!The!systemic!implications!of!these!acute!effects!are!
not! fully! understood! at! this! time.! This! is!why!we! suggest! that! further! investigations!
should!be!performed!in!further!understanding!this!area!of!research!especially!in!high!
risk! populations! including! individuals! with! associated! coKmorbidities! (i.e.! diabetes!
mellitus! or! diagnosed! CVD).! There! is! already! a! wealth! of! evidence! suggesting! that!
episodes!of!acute! infection/inflammation!are!associated!with!a! short! term! increased!
vascular! risk518! and! one! report! suggests! that! this! finding! could! also! be! true! in!
individuals!undergoing!simple!dental!treatment!procedures! like!a!tooth!extraction519.!!
Following!1K2!months!from!periodontal!therapy,!all!comparative!evidence!retrieved!by!
the!authors! is!suggestive!of!a!progressive!reduction/improvement! in!traditional! (lipid!
markers)!and!novel!(CRP,!ILK6,!fibrinogen,!sKEselectin)!CVD!risk!factors.!Interpreting!this!
data!with! caution! could! represent! the! basis! for! inclusion! of! periodontal! assessment!
and!therapy!as!the!key!determinants!in!controlling!each!individual!CVD!risk.!However!a!
number!of!flaws!were!identified!when!appraising!the!available!evidence!on!the!effect!
of! periodontal! therapy! on! CVD! outcomes.! Firstly! the! majority! of! clinical! trials! is! of!
limited! sample! size! (<500)! and! the! length! of! followKup! limited! to! 6K12!months.! This!
represents! perhaps! the!most! important! limitation! in! interpreting! the! data.! Both! PD!
and!CVD!represent!longKterm!chronic!conditions.!In!particular!atheroma!formation!has!
been! identified! very!early! in! life! (i.e.! already! in! young! children).!We!could! speculate!
therefore! that! performing! some!periodontal! treatment!only! at! the! end!of! atheroma!
evolution! (much! later! in! life)!might!not! represent!an!effective!method!of!preventing!
further!progression!of!the!disease!nor!the!occurrence!of!acute!vascular!events.!Further!
research! efforts! should! be! devoted! in! designed! appropriate! clinical! trials! on! the!
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delivery! of! effective! oral! health! promotion! early! in! life! and! monitor! the! potential!
beneficial! effects! on! systemic! health! much! later! in! life.! Further,! the! multifactorial!
aetiology!of!both!PD!and!CVD!and! the! fact! that!both!share!a!common! inflammatory!
nature!would!indicate!that!the!mere!control/removal!of! local!gingival! infection!might!






a! surrogate! marker! of! CVD.! Insufficient! evidence! was! found! on! the! effect! of!
periodontal!therapy!on!cKIMT!and!other!measures!of!subclinical!atherosclerosis.!Whilst!
endothelial!dysfunction!is!predictive!of!future!CVD!risk/outcomes,!it!is!also!a!research!
measure! greatly! confounded! by! a! number! of! methodological! and! environmental!




the! effect! of! periodontal! therapy! on! traditional! or! nonKtraditional! CVD! risk! factors.!
Further! and! more! importantly! most! of! the! clinical! trials! were! performed! in!




Our! groups! has! previously! shown! that! periodontitis! is! associated! with! a! reversible!
state! of! systemic! inflammation303! oxidative! stress497! and! endothelial! dysfunction12.!
Indeed! an! intensive! session! of! periodontal! therapy! induced! first! an! acute! vascular!
dysfunction! and! increased!oxidative! stress,! but! later! a! resolution!of! these! processes!
with!an!improved!vascular!function12.!
The!specific!aims!of!this!project!were!to:!
1)! To! quantify! the! magnitude! of! association! between! periodontitis! and! surrogate!
markers!of!endothelial!dysfunction!and!subclinical!atherosclerosis.!
2)! To! investigate! the! role! of! periodontal! treatment! on! systemic! inflammation,!
oxidative! stress,! endothelial! function! and!metabolic! control! in! patients!with! PD! and!
T2DM.!
3) To! investigate! the! role! of! chronic! inflammation! related! to! periodontitis! on!
endothelium!integrity!in!patients!with!PD!and!T2DM.!!







































teeth! (excluding! 3rd! molars).! ! At! proximal! sites! (mesioKbuccal,! distoKbuccal,! mesioK





reading,! the!examiner!recorded!the!recession! (REC)!as!a!positive!or!negative!value! if!
the!free!gingival!margin!(FGM)!occurred!coronal!or!apical!respectively!to!the!cementoK
enamel!junction!(CEJ).!In!the!latter!case!the!examiner!reinserted!the!probe!angled!45°!
degrees! into! the! site! in! order! to! detect! the! CEJ.! If! the! CEJ! was! not! detectable! for!
anatomical!or!restorative!reasons!the!examiner!adopted!clinical!landmarks!as!follow:!
• Crown!Margin!(Recorded!as!Cr)!
• Rotated! teeth,!midKbuccal! and!midKlingual! readings!were! taken! from! the! clinical!
midpoints!
Clinical! attachment! level! (CAL)!was! calculated! from! the! formula!PPD!minus!REC.! Full!
mouth! plaque! scores! (FMPS)! was! recorded! as! the! percentages! of! total! surfaces! (6!





Individuals! included! into! the! study! 2! and! 3! were! randomized! to! two! different!
periodontal! therapy! regimens:! standard! (CPT)!or! intensive! (IPT)!periodontal! therapy.!
Patients! in! the! IPT! group! received! an! intensive! treatment! consisting! of! mechanical!
debridement!with!ultrasonic!and!hand!instruments!of!the!diseased!dentition!in!a!single!
session! (2K3! hours).! Any! tooth! that! from! the! baseline! examination! was! defined! as!
hopeless! or! irrational! to! treat! was! extracted! during! the! treatment! session.! Local!
anaesthesia!was!used!as!necessary.!Control!group!patients!(CPT)!received!a!standard!
cycle! of! periodontal! therapy! consisting! of! oral! hygiene! instructions,! supraKgingival!
mechanical! instrumentation! and! polishing! in! one! appointment! performed! as!
appropriate! by! a! single! clinician! using! a! combination! of! hand! and! machine! driven!
(piezoelectric)! instrumentation.! After! initial! periodontal! intervention,! participants! in!
the!IPT!and!CPT!groups!were!reKevaluated!at!2!months!and!received!additional!therapy!
planned! accordingly.! For! the! IPT! group! a!Modified!Widman! Surgical! Flap! procedure!
was! performed! in! all! areas! with! remaining! periodontal! infection! (PPD>4mm! and!
bleeding! on! probing)! as! previously! described! for! those! individuals! with! good! oral!
hygiene! (dental!plaque! scores! less! than!25%)521.! The!goals!of! this! corrective! therapy!
were! to:! 1)! gain! access! for! root! preparation! when! nonKsurgical! methods! were!
ineffective;! 2)! establish! favorable! gingival! contours;! 3)! facilitate! oral! hygiene.! Those!





patient's! oral! hygiene! performance! and! supraK! and! subKgingival! removal! of! bacterial!
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while!a! single! session!of! scaling!and!polishing!was!performed!on!CPT!group.! In!both!
Study!2!and!3,!upon!observation!of!progression!of!periodontitis,!defined!using!the!EFP!
criteria522,! at! anytime! during! the! study! they!were! exited! from! the! investigation! and!





Blood! samples!were! collected! by! single! venepuncture! from!patient’s! arm! complying!
with!the!standard!procedure!of!the!local!hospital.!1!8!ml!silicone!coated!glass!tube,!1!6!
ml! SprayKcoated! K2EDTA! and! 2! 4ml! Buffered! sodium! citrate! 0.105! M! (≈3.2%)! glass!
tubes!were!collected!at!every!visit!and!processed!for!serum!and!plasma!separation!for!
Study! 2,3! and! 4.! Silicone! coated! glass! tubes! were! centrifuged! at! 4000! RPM! for! 15!









ultrasound! is! a! tool! introduced! to! evaluate! the! presence! and! progression! of!
atherosclerosis! and! estimate! future! CV! risk.! Being! a! nonKinvasive,! safe! and! well!
tolerated! exam! contributed! to! its! adoption! in! both! clinical! and! research! settings.!
Pignoli! et! al.! in! 1986! reported! a! good! correlation!between!histology! and!ultrasound!
assessment! even! if! the! latter! could! provide! with! a! minimally! higher! measure! of! cK
IMT523.! The! interest! in! cKIMT! measurements! derives! from! multiple! observational!
studies.!1,257!male!subjects!of! the!Kuopio! Ischemic!Heart!Disease!Risk!Factor! (KIHD)!
study! were! followed! for! 2! years! correlating! cKIMT! with! the! risk! of! myocardial!
infarction.!There!was!an!increased!relative!risk!of!4.1!(95%!confidence!interval![CI]!1.8!
to!9.2)!in!the!presence!of!a!plaque!and!if!cKIMT!was>1!mm!there!was!a!2.1!fold!risk!of!




0.81! to! 1.77)! in!men! after! adjusting! for! CV! risk! factors525.! However,! the! Rotterdam!
study!reported!a!similar!CV!risk!between!genders526.!Additionally,!the!investigators!of!
the! Carotid! Intima! Media! Thickness! [IMT]! and! IMTKProgression! as! Predictors! of!
Vascular! Events! in! a! High! Risk! European! Population! (IMPROVE)! study! indicated! that!
other! parameters! related! to! the! common! carotids,! such! as! the! increased! intraK
adventitia! diameter! can! be! predictors! of! CV! events! independently! from! the!
Framingham!risk! score527.! cKIMT!has!also!been!associated!with!classic!CV! risk! factors!
such! as! diabetes! and! hypercholesterolemia528K530.! Hypertension! is! related! to! an!
increased! cKIMT! possibly! due! to! a! medial! hypertrophy531,532.! Interestingly,!
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pharmaceutical! interventions! seem! to!have! an! impact!on! cKIMT.!Blood!pressure! and!
lipid! lowering!agents!can!reduce!the!progression!of!cKIMT!or!decrease!its!value533K536.!!
Bogalusa!Heart!Study!reported!the!presence!association!between!cKIMT!and!CVD!since!
young! age537.! The! Pravastatin,! Lipids,! and! Atherosclerosis! in! the! Carotid! Arteries! II!
(PLACKII)! study! reported! 0.0295! instead! of! 0.0456!mm/year! of! progression! between!
test! and! controls538.! Rosuvastatin! in! the! The! Measuring! Effects! on! IntimaKMedia!
Thickness:!An!Evaluation!of!Rosuvastatin!(METEOR)!study!showed!changes!of!−0.0014!
and!0.0131!mm/year! comparing! test!and!placebo! in!a!middleKaged!populations!with!
low! Framingham! risk! scores! (FRS)539.! In! addition! the! Monitored! Atherosclerosis!




wall! was! related! to!mainly! intimal! changes.! cKIMT! augments! 2! to! 3! fold! during! life,!
however! gender! and! ethnicity! seems! to! partially! explain! a! certain! heterogeneity!
showing! the! highest! values! in! AfroKCaribbean! population! and! the! lowest! in!
Hispanics541.!!
2.4.1. METHODOLOGY$
cKIMT! can! be! assessed! with! different! ultrasound! techniques.! MKmode! ultrasound!
provides!with! a!higher! temporal! resolution!but! can! assess!only! a! single!point! rather!
than!a!segment.!The!thickening!of!the!carotid! is!not!uniform!therefore!a!single!point!
measurement!could!cause!a!loss!of!important!information.!In!addition,!in!MKmode,!the!
estimate! of! a! dimensional! image! is! related! to! multiples! of! the! pixel! size! increasing!
potential! errors! since! the! thickening! of! the! vascular! walls! could! be! of! a! subKpixel!
magnitude.! cKIMT! is!normally!an!average!measure!of! the!values!detected!during! the!
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cardiac!cycle,!its!most!used!value!is!relative!to!the!endKdiastole!since!there!is!a!lumen!
expansion! observed! during! systolic! phase.! ! There! is! still! no! agreement! on! which!




even! if! atherosclerosis! starts! earlier! in! ICA! or! the! carotid! bulb527.! IMT! could! be!
assessed! also! in! other! arterial! walls! such! as! the! brachial,! radial! or! femoral! arteries.!
However! changes! in! CCA! seems! to! be! mainly! dependent! on! intimal! thickening!
meanwhile! for! other! sites! the! tunica! media! has! an! equal! contribution! to! the!
modification.!The!far!wall!of!CCA!is!preferred!to!the!near!wall!measure!since!it!shows!a!
higher! correspondence! with! histologic! values544.! Therefore! the! current! protocol!
recommended! far! wall! images! of! the! segment! 1K2! cm! distal! to! the! carotid! bulb.!
Following!international!guidelines!the!scanning!protocol!suggest!to!have!the!subject!in!
a! supine! position! with! a! light! hyperextension! and! rotation! of! the! neck! to! the!
contralateral!side!(Figure!11).!
Figure"11"cPIMT"acquisition"technique"
The" subject" lay" supine" with" slight" hyperextension" and"
rotation" of" the" neck" to" the" contralateral" side" of"
acquisition." The" sonographer" (positioned" on" top" of" the"





bulb." B)" With" slow" movements" of" the" probe," the"
longitudinal"axis"of" the"artery"was"visualised."C)" Images"were"optimised"to"obtain"the"best"view"of"the"
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intimaPmedia" thickness" of" the" far" arterial" wall." The" optimal" longitudinal" image" was" acquired"
continuously"for"10"seconds"and"videoPclips"were"stored"for"postPacquisition"analysis."
Right!and!left!carotid!arteries!were!detected!with!a!linearKarray!transducer!at!12!MHz!




The! endothelium! contributes! to! the! regulation! of! the! vessel! tone! therefore! its!
functionality! has! an! impact! on! this! process502.! In! 1980s! experiments! stimulating!
isolated!rabbit!aortic!blood!vessels!with!acetylcholine!showed!vasoKrelaxation!subject!
to! the! integrity! of! the! endothelium! and! mediated! by! nitric! oxide! (NO)545.! The!
administration!of! acetylcholine! and!other!pharmacological! agents! such!as! adenosine!
and! papaverine! can! increase! the! blood! flow546.! In! 1992,! flowKmediated! dilatation!




Inhibitors! of! NO! can! abolish! this! mechanism! suggesting! its! dependence! on! NO!
bioavailability548.! Impaired! FMD! is! associated! to! different! CV! risk! factors! and! it! can!
improve!after!treatment549.!In!addition,!endothelial!dysfunction!of!the!brachial!artery!
is! linked!to!the!coronary!arteries!endothelial! function!suggesting! its!relation!with!the!








required! 8! to! 12! hours! fasting! and! to! be! performed! in! a! temperature! controlled!
room554.! Tobacco! usage! should! be! avoided! for! 4! to! 6! hours555.! However! the!
importance! of! environmental! factors! has! been! recently! reconsidered.! The! protocol!
required! the!participants! to! rest!10!min!before! the!procedure556.!The!brachial!artery!
represented! the! preferred! area! to! evaluate! since! vessel! with! a! smaller! diameter!
reduce!the!accuracy!of!the!reproduction!and!also!variations!in!the!absolute!diameter!
would! be! reflected! in! large! percentage! changes.! Once! the! subject! was! lying! supine!
with! the! arm! placed! on! a! specific! armrest,! a! highKresolution! probe! detected!
longitudinal!images!of!the!brachial!artery.!The!measurements!of!the!brachial!diameter!
were! obtained! at! the! endKdiastole! to! avoid! vessel! changes! during! the! systole557.! In!
order! to! insure! reproducibility! at! different! time! points! the! position! of! the! arm,! the!
distance!between!the!probe!and!the!pneumatic!cuff!together!with!a!thermal!print!of!
the! arterial! image!were! recorded.!A! blood!pressure! cuff!was! placed!on! the! forearm!
within! 2! cm! from! the! antecubital! fossa! in! order! to! obtain! a! higher! reactive!
hyperaemia558.!Positioning!the!cuff!proximally!can!also!affect!the!peak!flow!and!reduce!
the!accuracy!of!the!imaging!since!the!artery!can!collapse!during!the!cuff! inflation.!To!
trigger! a! sufficient! hyperaemia! the! cuff! occlusion! time! is! 5! minutes! and! evidence!
reported! a! nonKsignificant! difference! in! the! dilation! if! the! time! is! increased! to! 10!
min553.!In!order!to!reach!ischemia!the!pressure!inflated!was!50!mmHG!higher!than!the!
systolic! pressure.!Once! the! cuff!was! released,! a! reactive! hyperaemia! in! the! brachial!
! 145!
artery! triggered! the! vessel! dilatation! explicated! by! a! functional! endothelium.! The!
vessel! diameter! reached! its! peak! 45K60! seconds! after! the! cuff! deflation.! A! semiK
automatic! software! allowed! to! evaluate! the! changes! in! the! brachial! artery! diameter!
during! the! hyperaemic! flow.! FMD!was! reported! as! the! change! in! percentage! of! the!










After! 10! minutes! of! rest,! endotheliumKindependent! dilatation! was! measured! after!











centrifuged! at! 22°C! for! 25! minutes! at! 700g! with! no! brake.! A! wide! tipped! Pasteur!
pipette! was! used! to! aspirate! PBMCs!
from! the! buffy! coat! layer! formed!
(Figure! 13)! into! a! fresh! 50ml! conical!
tube,!!
Figure"13"PBMC"gradient"isolation"
which! was! then! washed! with! RPMI! 1640! containing! LKglutamine! (with! 10%! heat!
inactivated! FCS! and! antibiotics! as! before).! Cells! were! centrifuged! at! 500g! for! 10!
minutes! and! the! pellet! reKsuspended! in! RPMI! 1640! (with! FCS! and! antibiotics).! Cells!
were! counted! as! described! previously.! To! allow! batch! analysis! aliquots! of! cells!
(concentration! 5K10x106! cells/ml! calculated! with! a! hemocytometer)! were! reK
suspended! in! heat! inactivated! fetal! bovine! serum! with! 10%! DMSO! and! frozen! in! a!




not! suitable! for! largeKscale! use,! limiting! their! application! in! clinical! practice559K561.! In!
addition,! selecting! one! specific! biomarker! as! representative! of! the! total! oxidative!
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stress!or!antiKoxidant!state!in!specific!patient!categories!is!still!debatable.!Indeed,!each!
disease! can! be! characterized! by! increased! production! of! specific! oxidative! species,!
depending! on! their! intracellular! sources.! Electron! spin! resonance! (ESR)! is! currently!
considered! the!gold! standard!assay! to!measure!different!RS! in!biological! samples562,!
however! this! technique! is! complex! and! not! available! in! most! clinical! laboratories.!
Furthermore,! ESR!uses!different!protocols!depending!on!which!oxidative! species! are!
targeted,!requiring!continuous!adaptation!of!the!experiment!and!machine!parameters!
and!introducing!further!complexity!in!the!measurements.!Ideally,!the!perfect!oxidative!
stress! assay! should! be! easy! to! perform,! reliable,! quick! and! inexpensive.! Automated!
analysers! would! allow! processing! of! a! large! number! of! samples,! avoiding! manual!
sample! and! reagent! handling,! and! reducing! variability! sources.! Among! the! various!
commercially! available! kits,! the! reactive! oxygen!metabolites! (dROM)! test! have! been!
developed! to! assess! in! an! automated,! economic! and! reproducible! fashion! the! total!
amount!of!oxidant!species!in!different!biological!samples.!
2.7.1. dIROM$Test$
The! dKROMs! test! measures! the! blood! concentration! of! hydroperoxides,! a! class! of!
chemical! oxidant! species! belonging! to! the! wider! group! of! reactive! oxygen!
metabolites563,564.!Hydroperoxides!are!generated!by!the!oxidation!of!several!molecules!
such! as! glucosides,! lipids,! amino! acids,! peptides,! proteins,! and! nucleotides,! making!
their!levels!independent!of!the!source!of!oxidative!stress.!In!the!presence!of!free!iron,!






molecules,! in! order! to! recover! their! electron! stability.! By! adding! to! the! solution! a!
stable! and! positively! charged! radical! (N,NKdiethylparaphenilendiamide! radical)!which!







The" reaction" is" starts" by" adding" a" small" amount" of" serum" to" a" solution" containing" N,NP
diethylparaphenilendiamide"radical"and"an"acidic"buffer"(pH"4.8)."The"solution"is"warmed"up"to"37°C."This"
detaches" the" iron" ions" from" serum" protein," making" them" available" for" the" Fenton" reaction" and"
transforming"the"hydorperoxides"in"the"samples"in"alkoxyl"and"peroxyl"radicals."The"latters"rapidly"react"







b)! 1ml! of! a! buffer! containing! HCl! with! pH! 4.8! (Figure! 13! A! and! B).! The! sample! is!
warmed! at! 37°C! for! 1!minute.! The! combination! of! the! high! temperature! and! acidic!
environment! allows! detachment! of! iron! ions! from! serum! proteins,! making! them!
available!for!the!Fenton!reaction!(Figure!14!B!and!C).!Thus,!the!hydorperoxides!in!the!
samples!are!transformed!in!alkoxyl!and!peroxyl!radicals!which!rapidly!react!and!oxidize!




the! level!of! absorbance! is!directly!dependent!on! the!amount!of! the! reactive!oxygen!




CARR! U! =! F(ΔAbs/min)! where! F" is! a! correction! factor! (approximately! 9000! at! 37°C!
according! to! the! results! obtained! with! the! standard);! (ΔAbs/min)! are! the! mean!
differences! of! the! absorbances! recorded! at! 1,! 2,! and! 3! min.! Reference! values! of!
healthy!subjects!are!between!250!and!300!CARR!U;!conditions!of!slight,!medium,!and!
high! oxidative! stress! are! defined,! respectively,! by! values! of! 320–360,! 360–400,! and!
>400!CARR!U;! for! values!up! to!500!CARR!U,! a! sample!dilution! is! required567.!Results!
obtained! with! dKROM! test! have! been! validated! by! electronic! spin! resonance!
spectroscopy!and!it!has!been!experimentally!established!that!1!CARR!U!corresponds!to!
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2.7.2. Flow$ cytometry$ for$ detection$ of$ mitochondrial$ oxidative$ stress$ and$
membrane$potential$
Peripheral! blood! mononuclear! cells! (PBMC)! were! isolated! following! standard!
procedures!by!density!gradient! centrifugation!with!Ficoll! (FicollKPaque!PLUS,!GE,!UK)!
from! an! aliquot! of! heparinised! blood! collected! at! each! study! visit.! Mitochondrial!
oxidative!stress!production!and!membrane!potential!were!assessed!by!flow!cytometry!
using! the!mito! probe!MitoSOX! Red! (Invitrogen,! UK)! and! 5’,6,6’KtetrachloroK1,1’,3,3’K
tetraethylbenzimidazolylcarbocyanine!iodide!(JCK1,!Invitrogen),!respectively.!
2.7.2.1. JCK1"
For! JCK1! staining,!we! followed! the! instructions! recommended! in! the! kit,!which! have!
been!previously! validated! for! PBMC! staining568.! PBMC! suspension!was! adjusted! to! a!
concentration!of!1!x!106!cells/mL!and!incubated!in!!phenol!red!free!RPMI!1640!with!JCK
1!(concentration!2uM)!for!30!min!at!37⁰C!and!5%!CO2!in!the!dark.!Cells!were!washed!
three! times! with! warm! phosphateKbuffered! saline! (PBS)! (PAA! Laboratories),!
resuspended! in!5!mL!of!warm!RPMI!and! immediately!analysed!using!a!FACScan! flow!
cytometer! (Becton! Dickinson).! Data!were! acquired! using! CellQuest! software! version!
3.1f! (Becton! Dickinson)! and! postKacquisition! analysis! was! performed! using! FlowJo!
(FlowJo! LLC,! Oregon,! USA).! The! mitochondrial! uncoupling! agent! CCCP! (carbonyl!
cyanide! 3Kchlorophenylhydrazone,! Invitrogen)! was! used! as! positive! control! for! each!
measurement.! As! CCCP! completely! depolarizes! the! mitochondria! of! all! cells569,! it!
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enables! correction! for! JCK1!aspecific! staining!e.g.,!dye! loading!of! the! cells.!CCCP!was!
added!to!the!samples!at!a!final!concentration!of!50μm,!5!minutes!before!adding!JCK1,!
as! per! manufacturer! protocol.! In! each! sample! (with! and! without! CCCP),! the!
mitochondrial! membrane! potential! was! estimated! from! the! ratio! of! the! median!










for! mitochondria! superoxide! detection! is! considered! the! gold! standard! probe! for!
fluorescent! detection! of! mROS! in! live! cells,! including! PMBC! 262,263,571.! We! used! kit!
instructions!and!a!previously!validated!protocol!to!assess!mtROS!production572.!PBMC!
were! reKsuspended! in!1ml!of!phenol! red! free!RPMI!and! incubated! for!20!minutes!at!




of! the!mitochondrial! superoxide!production.!Mitochondrial!membrane!potential! and!
superoxide!production!was!assessed! in! the!whole!PBMC!population!as!well!as! in! the!
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lymphocyte! and!monocyte! subpopulations! separately! identified! by! forward! and! side!
scatter!characteristics.!
In! each! analysis! an! unstained! sample! was! run! and! used! to! exclude! cell! autoK




gating,! visualization,! and! analysis! of! data! from! flow! cytometry! experiments.! FlowJo!
was!used!to!isolate!different!cell!subsets!and!assess!the!level!of!median!florescence!of!














is! decoupled! from! the!output! signal,!which! is! light,! to! generate! assays!with!minimal!
background.!MSD! labels,! which! are! stable! and! nonKradioactive,! can! be! conveniently!
conjugated!to!biological!molecules.!Additionally,!only!labels!near!the!electrode!surface!
are! detected,! enabling! nonKwashed! assays.! The! MSD! assays! only! require! minimal!




complex! biological! matrices.! This! allows! the! measurement! of! native! levels! of!





The!Human! ProKinflammatory! 7KPlex!Ultrasensitive! Kit! (cat! no.K15008CK1)!was! used.!






study! visits! and! stored! in! K80°C! freezers.! The! assay! was! done! using! the! human!
inflammatory! 7Kplex! assay! (Meso! Scale! Discovery)! in! accordance! to! manufacturer’s!
instructions.!!
2.8.1.1. Assay"procedure:"
The!MSD!plates!were! coated!with!diluent!2! and! incubated! for!30!min!with! vigorous!
shaking!(300–1000!rpm)!at!room!temperature.!Subsequently,!25!μl!of!each!sample!was!












was! added! to! all! wells! and! the! plate! sealed! and! incubated! for! 30! s! at! room!
temperature! on! an! orbital! shaker! (600! rpm).! Samples,! standards! and! controls! were!
added! at! 25! μl! per! well.! The! plate! was! sealed! and! incubated! for! 2! h! at! room!








3.0! software! (MSD).!A! 4Kparameter! logistic! fit! curve!was! generated! for! each! analyte!
using!the!standards!and!the!concentration!of!each!sample!calculated.!
2.8.2. Human$Vascular$Injury$I$Kit$
The! Human! Vascular! Injury! I! 4Kplex! ELISA! detects! soluble! intercellular! adhesion!
moleculeK3!(sICAMK3),!EKselectin,!PKselectin!and!thrombomodulin!(TM)!(Figure!17)!in!a!








HOK1! concentration! was! determined! using! a! HOK1! (human)! enzymeKlinked!
immunosorbent!assay!(ELISA)!kit!(Assay!Designs!Inc.!Ann!Arbor,!MI).!One!hundred!μl!of!
plasma!was! incubated! in! the!wells!of! the! immunoassay!plate,!which!was!preKcoated!
with!antiKHOK1,!at! room! temperature! for!30!min.!After!excess!protein!was!decanted!
and!washed!with!wash!buffer,!100μ!l!of!antiKhuman!HOK1!was!added!to!each!well!and!
the!plate!was! incubated!at!room!temperature!for!a!further!1!h.!After!washing,!horse!






The! use! of! Limulus! Amebocyte! Lysate! (LAL)! for! the! detection! of! endotoxin! evolved!
from!the!observation!by!Bang!that!a!GramKnegative!infection!of!Limulus!polyphemus,!
the! horseshoe! crab,! resulted! in! fatal! intraKvascular! coagulation,! even! if! the! bacteria!
were!killed573.!Levin!and!Bang!later!demonstrated!that!this!clotting!was!the!result!of!a!
reaction! between! endotoxin! and! a! clottable! protein! in! the! circulating! blood! cells!
! 157!
(amoebocytes)!of!Limulus574,575.!Following!the!development!of!a!suitable!anticoagulant!
for! Limulus! blood,! they! prepared! a! lysate! from! washed! amebocytes! which! was! an!
extremely!sensitive!indicator!of!the!presence!of!endotoxin.!This!led!to!the!production!
and!commercialisation!of!the!LAL!assay!for!endotoxin!detection!in!biological!samples.!
According!with! this!assay,!GramKnegative!bacterial!endotoxin!present! in! the!samples!
catalyses! the! activation! of! a! proenzyme! in! the! LAL.! The! initial! rate! of! activation! is!
determined! by! the! concentration! of! endotoxin! present.! The! activated! enzyme!
catalyses! the! splitting! of! pNA! from! the! synthetic! colourless! substrate! AcKlleKGluKAlaK
ArgKpNA,!producing!a!yellow!colour.!This!is!measured!photometrically!at!405K410!nm,!
after! the! reaction! is! stopped! with! stop! reagent.! The! correlation! between! the!
absorbance!and!the!endotoxin!concentration!is!linear!in!the!0.1K1.0!EU/ml!range.!The!




heating! block! adapter.! Meanwhile,! four! dilutions! of! the! lyophilized! endotoxin! at! a!
standardized!concentration!provided!with!the!kit!were!prepared!for!the!determination!
of!the!standard!curve.!The!lyophilized!endotoxin!was!reconstituted!by!adding!1!ml!of!
preKwarmed! LAL! Reagent! Water! provided! with! the! kit.! As! the! concentration! of!
lyophilized! endotoxin! may! vary! from! 15K40! EU! depending! on! the! lot! number,! the!
actual!concentration!of!endotoxin!after!this!step!corresponded!to!the!value!stated!on!
the! certificate! analysis.! For! example,! if! the! value! reported! on! the! vial! of! lyophilized!
endotoxin! was! 20! EU,! after! reconstitution! with! 1! ml! of! LAL! Reagent! Water,! the!




of! endotoxin! in! the! stock! solution.! For! example,! if! κ=20!EU/ml,! then!0.1ml!of! κ!was!
diluted! in! 1.9ml! of! LAL! Reagent! Water,! (20K1)/10ml,! to! obtain! the! first! dilution!
containing! 1.0! EU/ml! of! endotoxin.! Following,! 0.5!ml! of! this! 1! EU/ml! solution!were!
transferred!in!a!new!container!and!0.5!ml!of!LAL!Reagent!Water!was!added!to!obtain!
the! second! endotoxin! dilution! (0.5! EU/ml).! Similarly,! 0.5!ml! of! the! 1! EU/ml! solution!
was! transferred! in!a!vial! containing!1.5!ml!of! LAL!Reagent!Water! to!obtain! the! third!
endotoxin!dilution!(0.25!EU/ml).!Finally,!0.1!ml!of!the!1!EU/ml!solution!was!transferred!
in!a!vial!containing!0.9!ml!of!LAL!Reagent!Water!to!obtain!the!last!dilution!of!endotoxin!
(0.1! EU/ml).! Once! all! dilutions!were! prepared,! 50! μl! of! the! target! sample! or! of! the!
dilution! series! were! added! in! duplicate! into! the! appropriate! microplate! well.! Each!
series!contained!a!blank!well!control,!where!the!samples!or!dilutions!were!substituted!
with! 50! μl! of! LAL! Reagent!Water.! At! time! T=0,! 50μl! of! LAL!were! added! to! the! first!
column!of!microplate!wells!using!a!multiKchannel!pipettor!and!reagent!reservoir.!The!
sequence! of! column! as! the! LAL! is! added! was! taken! into! account! in! order! to! be!
consistent! in! the! order! of! reagent! addition! from! row! to! row,! and! in! the! rate! of!
pipetting.!Once!the!LAL!was!dispensed!into!all!microplate!wells!containing!samples!(or!








was! then! returned! to! the! heating! block! adapter! and! covered.! The! addition! of! the!
substrate! caused! a! progressive! change! in! the! colour! of! the! solution,! which! became!
yellow.!Following!16!minutes,!50μl!of! stop! reagent!was!added!maintaining! the!same!
pipetting!order!as!in!of!LAL!and!substrate!addition.!The!plate!was!again!removed!from!
the! heating! block! and! tapped! to! allow! proper! mixing.! The! absorbance! of! each!
microplate!well!was!read!at!405K410nm,!using!distilled!water!to!adjust!the!photometer!
to! zero!absorbance.! Serum! inhibition!of! LPS!detection!with! the! LAL! tests! is!possible,!
particularly!when!using!the!colorimetric!assay.!This!inhibition!results!in!a!lower,!final!Δ!
absorbance,!indicating!lower!levels!of!endotoxin!than!what!may!actually!be!present!in!
the!test!sample.!Therefore,!the! lack!of!product! inhibition!should!always!be!tested.! In!
this!thesis,!the!possible!inhibition!of!the!LAL!reaction!was!determined!for!each!sample!
using! the! method! reported! in! the! kit! instruction.! To! verify! the! lack! of! product!
inhibition,!an!arbitrary!dilution!(1:5)!of!test!sample!was!spiked!with!a!known!amount!
of! endotoxin! (0.4! EU/ml).! To! prepare! a! 0.4! EU/ml! endotoxin! solution! in! the! diluted!
sample,! the! 1.0! EU/ml! solution! was! diluted! 1:2.5! using! the! diluted! sample! as! the!
diluent.! The! spiked! solution!was! assayed!along!with! the!unspiked! samples! and! their!
respective! endotoxin! concentrations! were! determined.! If! the! difference! between!
these! two!calculated!endotoxin!values!was!not!equal! to! the!known!concentration!of!
the!spike!±!25%,!this!suggested!the!presence!of!inhibitory!factors!to!the!LAL!reaction!in!
the! sample! and! the! sample! was! further! diluted! before! the! LPS! assay.! Using! this!









Kharbanda! et! al.! to! induce! remote! endothelial! preconditioning! in! the! contraKlateral!
limb! in! normal! human! volunteers! 576.! The! ischemia! was! induced! on! the! right! arm!





and! nonKparametric! tests! were! used! in! this! thesis.! Parametric! tests! were! used!




22! analysis! packages! were! used! for! the! analysis! of! the! data.! Parametric! tests! used!
were! independent! tKtest,! paired! tKtest! and! twoKway! analysis! of! variance! (TWOKWAY!
ANOVA)!with!treatment!group!and!time!as!two!main!factors!and!with!Bonferroni!post!
hoc! corrections.! In! all! studies! significance! was! defined! as! αKvalue! of! less! than! 5%,!






















AND$ ITS$ TREATMENT,$ FLOWIMEDIATED$ DILATATION$ AND$
CAROTID$ INTIMAIMEDIA$ THICKNESS:$ A$ SYSTEMATIC$ REVIEW$
AND$METAIANALYSIS$
3.1. Introduction$
Preliminary! electronic! searches! of!Medline,! EMBASE! and!Cochrane! Library! identified!
several! studies! pertaining! to! periodontal! disease! and! of!markers! of! vascular! health,!
such! as! cKIMT! and! FMD,! consisting! of! observational! and! intervention!
studies12,393,476,505,512,513.! No! systematic! reviews! and! metaKanalysis! were! located.!
Research! synthesis! provides! the! background! and! context! for! new! studies! and! new!



































the! existing! evidence! of! an! association! between! PD! (the! exposure)! and! vascular!
alterations! (the! outcomes).! PD! was! defined! to! include! any! measure! of! periodontal!
! 164!
disease! according! to! clinical,! radiographic! and! microbiological! assessment.! This!
includes! measures! of! Pocket! Probing! depth! (PPD),! clinical! attachment! level! (CAL),!
bleeding! on! probing! (BOP),! Plaque! index! (PI),! Gingival! index! (GI),! XKray! and!
microbiological! assay! for! periodontal! pathogens! as! reported.! Surrogate! markers! of!




In! order! to! evaluate! potential! associations! between! PD,! cKIMT! and! FMD,! inclusion!
criteria! were! set! to! be! broad! and! inclusive.! Both! observational! and! experimental!
designs!were! deemed! eligible! including! caseKcontrol,! crossKsectional,! cohort! studies,!
population! surveys,! pilot! studies,! controlled! trials! and! randomized! controlled! trials.!
Comments,! letters,! editorials,! case! studies! and! series,! news! items,! abstracts! not!
followed! by! publication! and! consumer! health! material! were! excluded.! Only! studies!
performed! in!humans!and!containing!measures!of!either!cKIMT! (acquired!by!BKmode!
ultrasound!and!expressed!as!Mean!±!SD)!or!FMD!(performed!using!standard!protocols!
of! ultrasound! imaging! and! reported! as!%! or!mm!of! dilatation! of! the! brachial! artery!
compared! to! the! baseline! diameter)! were! included.! Other! studies! not! eligible! for!
inclusion! in! this! review! were:! those! performed! in! animals,! duplicated! reports! (i.e.!
studies! originating! from! the! same! study! samples! by! the! same! investigators! but!
published! in! different! journals),! studies! providing! associations! between! different!
markers! of! CVD! or! particular! pathogens! involved! in! PD! and! CVD,! studies! defining!
endothelial!function!with!different!methodology!than!FMD!as!well!as!those!providing!




Review! articles! as! well! as! relevant! narrative! or! systematic! reviews! represented! the!








































































Two! investigators! screened! independently! titles!and!abstracts.!Full! text!articles!were!
assessed! after! considering! an! abstract! potentially! suitable.! ! The! following! databases!
were!reviewed:!
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crossKsectional! studies! was! not! located.! The! quality! of! crossKsectional! studies! were!
assessed! using! questions! from! the! NewcastleKOttawa! Quality! Assessment! Scale! for!




Data! abstraction! forms! were! developed! and! piloted! on! three! studies! by! both!






Data! were! then! analyzed! using! descriptive! and! quantitative! methods.! When!
descriptive! methods! were! used,! all! publication! data! were! summarized! in! evidence!
tables! in! order! to! analyze! any! difference! in! study! characteristic! and! to! quantify! the!
body!of!evidence.!The!following!data!were!collected!from!each!research!article:!name!
of! the! first! author,! year! of! publication,! sample! size,! demographic! characteristics,!
covariates! included! for! the! adjustment,! assessment! of! dependent! and! independent!





Statistical! analyses! were! performed! using! Stata! (Version! 10,! StataCorp).! Mean!
differences!in!both!cKIMT!and!FMD!were!used!to!perform!the!following!metaKanalyses;!




information! was! obtained! directly! from! the! authors! (see! Acknowledgements).! The!
pooled! estimates! of! the! mean! differences! were! calculated! using! random! effects!
models! to! take! into! account! a! potential! interKstudy! heterogeneity! and! then! adopt! a!
more!conservative!approach.!The!pooled!effect!was!considered!significant! if!p!was!<!
0.05.!Forest!plots! for!each!metaKanalysis!present! the! raw!data! (i.e.,!means,!SDs,!and!
sample!sizes),!point!estimates!(displayed!as!blocks),!and!CIs!(displayed!as!lines)!for!the!
chosen! effect,! heterogeneity! statistic! (IKsquared),! total! number! of! participants! per!
group,!overall!average!effect,!and!the!weight!given!to!each!study.!Small!study!bias!was!
examined!using! funnel! plot! and! Egger’s! test.! Sensitivity! analyses!were!performed! to!
understand! the! influence!of! individual! studies,!by!omitting!one! study!each! time! in!a!
series!of!metaKanalyses!to!identify!influential!studies.!!
3.2.7. Heterogeneity$
Heterogeneity! was! assessed! by! using! the! χ2Kbased! QKstatistic! method,! considered!
significant!if!P!<!0.05580.!Heterogeneity!was!also!quantified!with!the!IKsquared!statistic,!
a!value!that! indicates!what!proportion!of!the!total!variation!across!studies! is!beyond!
chance,! where! 0%! indicates! no! observed! heterogeneity! and! larger! values! show!
increasing!heterogeneity581.!
3.3. Results$
2066!hits!were!obtained! from!electronic! searches! and!2!papers!were! located! via!on!
line! and! hand! searching! of!mentioned! journals! of! interest.! Following! removal! of! 59!
duplicates,! 2009! potentially! suitable! titles! and! abstracts!were! screened! in! duplicate.!






Among! these! full! text! articles! and! abstracts,! 66!were! excluded;! 30!were! reviews! or!
editorials! and! 36! did! not! report! outcomes! relevant! to! the! review.! This! resulted! in! a!
total! of! 35! publications! eligible! to! be! included! in! the! systematic! review! after! the!
screening! procedure.! Of! these,! 22! papers! were! included! in! the! metaKanalyses.! 6!
publications! did! not! contain! the! full! information! necessary! for! the! metaK







the! chronological! date!of! publication! and! sorted! according! to! the!outcome!measure!
and!study!design!(Tables!16!to!19)!
3.3.1.1. PD"and"cKIMT"
26! publications! included!measures! of! cKIMT! of!which! 25!were! observational! studies!
(Table! 16)! and! 1! intervention! trial! (Table! 17).! There!was! a! considerable! variation! in!
terms!of!definition!of!PD,!observed!population,!study!sample!size,!age!range,!carotid!
segments! studied! and! definition! of! cKIMT! among! the! studies.! 16! publications! were!
included!for!further!analysis!as!10!did!not!provide!estimates!that!were!comparable!to!
the! other! studies.! The! definition! of! the! carotid! segments! was! the! major! source! of!
heterogeneity.!1!uncontrolled! longitudinal!study!evaluated!the! impact!of!periodontal!
treatment!on!cKIMT!in!individuals!with!mild!or!moderate!PD.!After!a!follow!up!of!6!and!




observational! (Table! 18),! and! 7! intervention! studies! (Table! 19).! 2! randomized!
controlled! trials!were! not! suitable! for! the!metaKanalysis! as! endothelial! function!was!
assessed!measuring! the! response! of! the! brachial! artery! blood! flow! to! acetylcholine!
instead!of!FMD375,413!and!one!intervention!pilot!trial!had!no!control!group507.!
3.3.2. Bias$assessment$protection$




the! periodontal! diagnosis,! definition! of! controls! and! not! a! uniform! adjustment! for!
potential! confounders.! In! caseKcontrol! studies,! individuals! included! in! control! groups!
were!recruited!from!hospital!rather!than!from!the!community,!reducing!the!quality!in!
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Leivadarios	   E.	   476	  
(2005/Netherlands)	  
Case-­‐control	  
Included	   in	   the	  
quantitative	  results	  
N	  =	  63	  	  
(Control	  =	  14;	  	  
Mild/Moderate	  periodontitis	  =	  34;	  	  




Age	  range	  =	  not	  reported	  
	  
Case	  definition	  =	  
Severe	  periodontitis	  as	  
≥7	  teeth	  with	  ≥50%	  bone	  loss	  
	  
Control	  definition	  =	  
1	   or	   no	   missing	   teeth	   per	   quadrant	  
(third	  molars	  excluded).	  a	  radiographic	  
distance	   ≤3	   mm	   between	   the	  
cemento-­‐enamel	   junction	   (CEJ)	   and	  
the	  alveolar	  bone	  crest	  on	  all	  teeth.	  





of	  the	  carotid	  artery	  
(c-­‐IMT)	  	  
Bilateral,	   common	   (CCA)	  
bifurcation	   (BCA),	   internal	   (ICA)	  
and	  overall	  IMT.	  
The	   far	   (posterior)	   wall	   of	   the	  
vessel	  along	  a	  1cm	  section.	  
Measurements	   were	   the	   mean	  
of	  the	  six	  segments.	  
Radiographic	  
examination	  with	  
Schei	   ruler	  
technique	  
	  










Severe:	  0.81	  	  
p	  =	  0.023	  




p	  =	  0.153	  
	  
Adjusted	   means	   (mm)	   for	   IMT	   (95%	   CI)	  
ANCOVA	  model	  
-­‐	  CCA	  
Control:	  0.64	  (0.53-­‐0.74)	  
Mild/moderate:	  0.64	  (0.50-­‐0.73)	  
Severe:	  0.64	  (0.54-­‐0.75)	  P=	  0.990	  
-­‐	  BCA	  
Control:	  	  0.72	  (0.59-­‐0-­‐85)	  
Mild/moderate:	  0.66	  (0.56-­‐0.78)	  
Severe:	  0.71	  (059-­‐0.83)	  P=	  0.634	  
-­‐	  ICA	  
Control:	  	  0.61	  (0.43-­‐0.78)	  
Mild/Moderate:	  0.52	  (0.37-­‐0.66)	  
Severe:	  0.76	  (0.59-­‐0.93)	  P=	  0.040	  
-­‐	  Overall	  IMT	  
Control:	  	  0.65	  (0.55-­‐0.76)	  
Mild/Moderate:	  0.61	  (0.53-­‐0.69)	  
Severe:	  0.70	  (0.60-­‐0.81)	  P=	  0.233	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Söder	  P-­‐Öss586	  	  
(2005/Sweden)	  
case-­‐control	  
Included	   in	   the	  
quantitative	  
results	  
N	  =	  113	  
(Test	  =	  82	  [78	  analysed];	  Control	  =	  31)	  
	  
Population	  based	  sample	   	  
	  
Age	  range	  =	  30	  –	  40	  
	  
Case	  definition	  =	  
Periodontitis	  defined	  as:	  
at	  least	  1	  site	  with	  PD	  ≥	  5	  mm	  
Control	  definition	  =	  
Periodontally	  healthy	  
Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
bilateral,	   common	   carotid	   artery	  
(CCA)	  
Far	  wall,	  0.5-­‐1	  cm	  proximal	  to	  the	  
carotid	  bulb.	  
PD,	  PI,	  GI,CAL,	  X-­‐ray	   c-­‐IMT	  mean	  ±	  SD	  (mm)	  
-­‐	   Common	   carotid	   artery	   (right	  
side)	  	  
Cases	  	  	  	  	  0.66	  ±	  0.12	  
Controls	  0.58	  ±	  0.09	  
	  
p	  <0.01	  
-­‐	   Common	   carotid	   artery	   (left	  
side)	  	  
Cases	  	  	  	  	  0.68	  ±	  0.12	  
Controls	  0.58	  ±	  0.08	  
	  
p	  <0.001	  
Söder	  B.587	  	  
(2007/Sweden)	  
case-­‐control	  
Included	   in	   the	  
quantitative	  
results	  
N	  =	  67	  	  





Age	  range	  =	  30-­‐40	  
	  
Case	  definition	  =	  
No	  definition	  of	  periodontitis	  
Control	  definition	  =	  	  
Periodontally	  healthy	  
Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
bilateral,	  common	  carotid	  (CCA)	  
Far	  wall,	  0.5-­‐1	  cm	  proximal	  to	  the	  
carotid	  bulb.	  
PD,	  PI,	  GI,	  CAL,	  X-­‐ray	   c-­‐IMT	  mean	  ±	  SD	  (mm)	  
	  
-­‐Common	   carotid	   artery	   (right	  
side)	  	  
Cases	  	  	  	  	  0.65	  ±	  0.11	  
Controls	  0.60	  ±	  0.09	  
	  
p	  ≤	  0.05	  
	  
-­‐	   Common	   carotid	   artery	   (left	  
side)	  	  
Cases	  	  	  	  	  	  0.67	  ±	  0.11	  
Controls	  	  0.58	  ±	  0.08	  
p	  <	  0.001	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  16	  continued	  
First	  Author	  
(Year/Country)	  















Cairo	  F.513	  	  
(2008/Italy)	  
Case-­‐control	  




(Control=	  45;	  Test	  =	  45)	  
	  
Uni/Hospital	  setting	  
Age	  range	  =	  18-­‐40	  
Case	  definition	  =	  
Severe	  periodontitis	  as:	  
At	  least	  30%	  sites	  with	  CAL	  and	  alveolar	  
bone	   loss	   exceeding	   1/3	   of	   the	   root	   in	  
at	  least	  30%	  of	  the	  entire	  dentition	  
Control	  definition	  =	  	  
Otherwise	   healthy	   subjects	   with	   CAL	   ≤	  
3mm	  at	  each	  site	  




of	  the	  carotid	  artery	  
(c-­‐IMT)	  	  
Bilateral,	  common	  carotid	  (CCA)	  
Far	  wall	  
real-­‐time	  measurement	  of	  carotid	  
IMT	  
represented	   the	   mean	   of	   10	  
measures	  on	  
each	  side	  
PD,	   FMPS,	   FMBS,	  
CAL	  
c-­‐IMT	  mean	  ±	  SD(mm)	  ;	  95%CI	  
	  
Cases	  	  	  	  	  	  0.82	  ±	  0.13;	  [0.61-­‐1.16]	  
	  
Controls	  	  0.72	  ±	  0.07;	  [0.59-­‐0.94]	  
	  
p	  <	  0.0001	  
Cairo	  F.588	  	  
(2009/Italy)	  
Case-­‐control	  
N	  =	  90	  




Age	  range	  =	  18-­‐40	  
	  
Case	  definition	  =	  
Severe	  periodontitis	  as:	  
At	  least	  30%	  sites	  with	  CAL	  and	  alveolar	  
bone	   loss	   exceeding	   1/3	   of	   the	   root	   in	  
at	  least	  30%	  of	  the	  entire	  dent.	  
	  
Control	  definition	  =	  
Otherwise	   healthy	   subjects	   with	   CAL	   ≤	  
3mm	  at	  each	  site	  
Age,	   sex,	   smoking	  
habits	  
Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  	  
Bilateral,	  common	  carotid	  (CCA)	  
Far	  wall	  
real-­‐time	  measurement	  of	  carotid	  
IMT	  
represented	   the	   mean	   of	   10	  
measures	  on	  
each	  side	  
PD,	   FMPS,	   FMBS,	  
CAL	  
c-­‐IMT	  mean	  ±	  SD	  (mm)	  
	  
Cases	  	  	  	  	  	  0.82	  ±	  0.13	  
	  
Controls	  	  0.72	  ±	  0.07	  
	  
	  
p	  <	  0.0001	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(Test	  =	  80;	  Control=	  31)	  
	  
Population	  based	  sample	  
	  
Age	  range	  =	  not	  reported	  
	  
Case	  definition	  =	  
no	  definition	  of	  periodontitis	  
	  
Control	  definition	  =	  
Periodontally	  healthy	  
Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  	  
bilateral,	  common	  carotid	  (CCA)	  
Far	  wall,	  0.5-­‐1	  cm	  proximal	  to	  the	  
carotid	  bulb.	  
PD,	  CAL,	  BOP,	  GI,	  PI	   c-­‐IMT	  	  mean	  ±	  SD	  (mm)	  
	  
-­‐Common	   carotid	   artery	   (right	  
side)	  
Cases	  	  	  	  	  0.66	  ±	  0.12	  
Controls	  0.58	  ±	  0.09	  
p	  <	  0.01	  
-­‐	   Common	   carotid	   artery	   (left	  
side)	  
Cases	  	  	  	  	  0.68	  ±	  0.12	  
Controls	  0.58	  ±	  0.08	  





N	  =	  60	  	  
(Test	  =	  55;	  Control=	  53)	  
	  
Population	  with	  various	  conditions	  
Uni/Hospital	  setting	  
Age	  range=	  not	  specified	  
Case	  definition=	  
Periodontitis	  as:	  
At	  least	  6	  teeth	  with	  PD	  ≥	  4	  mm	  and	  AL	  
≥	  3	  mm	  
Control	  definition	  =	  
Moderate	   to	   severe	   periodontitis	  
treated	   at	   least	   since	   10	   years,	   regular	  
maintenance	   session	   every	   6	   months,	  
pre-­‐trt	   x-­‐rays	   showing	   at	   least	   30%	   of	  
bone	  loss.	  
Age,	   gender,	  
smoking,	   education,	  
diabetes,	   physical	  
activity,	   vegetables	  
intake,	  BMI,	  TC,	  LDL,	  
HDL,	   alcohol,	   statin,	  
aspirine,	   blood	  
pressure	  
Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
Bilateral,	   bifurcation(	   BCA,1	   cm	  
proximal	   to	   the	   flow	   divider),	  
internal(ICA,	   1cm	   distal	   to	   the	  
flow	   divider,	   common	   (CCA,	   1cm	  
proximal	   to	   the	   dilatation	   of	   the	  
carotid	   bulb),	   the	   carotid	  
bifurcation	   and	   the	   internal	  
carotid	  artery)	  	  
Measurements	  were	  the	  mean	  of	  
the	  six	  segments.	  
PD,	  BOP,	  CAL,	  FMPS	   c-­‐IMT	  mean	  ±	  SD	  (mm)	  
	  
Cases	  	  	  	  	  	  	  	  	  0.775	  ±	  0.268	  
	  
Controls	  	  	  	  	  0.683	  ±	  0.131	  
	  
p	  =	  0.027	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Lòpez-­‐Jornet	   P.591	  	  
(2012/Spain)	  
Case-­‐control	  




N	  =	  60	  	  
(Test	  =	  30;	  Control=	  30)	  
	  




Age	  range=	  35-­‐70	  
	  
Case	  definition=	  
Chronic	  periodntitis	  as:	  
≥16	   teeth	   and	   	   ≥10	   sites	  with	   PD	  of	   >5	  
mm.	  
CAL	  >3mm:	  	  
1%	  to	  32%=	  mild	  
33%	  to	  66%	  =	  moderate	  	  
67%	  to	  100%	  =	  severe	  
	  
Control	  definition	  =	  
Otherwise	  healthy	  without	  PD	  
Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  	  
right	  common	  carotid	  artery	  (CCA)	  
the	   far	   (posterior)	   wall	   of	   the	  
vessel	  along	  
a	   1cm	   section	   proximal	   to	   the	  
bifurcation.	  
3	  measurements	  taken,	  	  
maximum	  IMT	  	  measurement	  was	  
recorded.	  
PD,	  CAL,	  BOP,	   c-­‐IMT	  mean	  ±	  SD	  (mm)	  
	  
Cases	  	  	  	  	  	  	  	  0.77	  ±	  0.17	  
	  
Controls	  	  	  	  0.81	  ±	  0.27	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Zahnd	  G.592	  	  
(2012/Australia)	  
Case-­‐control	  




N	  =	  152	  	  
(Test	  =	  125;	  Control=	  27)	  
	  
Subset	  of	  PerioCardio	  study	  
Age	  range=	  not	  reported	  
Case	  definition=	  
Moderate	   periodontitis	   defined	   as:	  
presence	   of	   either	   two	   sites	   between	  
adjacent	   teeth	   with	   ≥4	  mm	   attachment	  
loss	   or	   at	   least	   two	   such	   sites	   with	   ≥5	  
mm	  pockets.	  	  
Severe	   periodontitis:	   at	   least	   two	   sites	  
between	   adjacent	   teeth	   with	   ≥6	   mm	  
attachment	   loss	  and	  at	   least	  one	  pocket	  
≥5	  mm.	  
Control	  definition	  =	  
healthy	  non-­‐smokers	  volunteers,	  	  
Age,	  sex	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  	  
Case=	  
Bilateral,	   common	   carotid	   (CCA),	  
far	  wall,	  within	  10	  mm	  proximal	  to	  
the	  carotid	  bulb.	  
	  
Controls	  =	  
Left	  common	  carotid	  
	  
only	  data	  for	  the	  left	  carotid	  artery	  
were	  used	  
for	  comparative	  analysis.	  
PD,	  CAL	   c-­‐IMT	  mean	  ±	  SD	  (mm)	  
	  
	  
Cases	  	  	  	  	  	  	  	  0.64	  ±	  0.17	  
	  
	  
Controls	  	  	  	  0.57	  ±	  0.09	  
	  
	  
p	  =	  0.007	  
Puhar	   I.585	   (15)	  
(2012/Croatia)	  
Case-­‐control	  
Included	   in	   the	  
quantitative	  
results	  
N	  =	  128	  	  




Age	  range=	  not	  reported	  
	  
Case	  definition=	  
CAL	  ≥3	  mm	  at	  
≥30%	   of	   sites	   was	   used	   to	   define	  
generalized	  forms	  of	  periodontitis.	  
	  
Control	  definition	  =	  
Periodontally	  healthy	  
Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  	  
bilateral,common	   carotid	   artery	  
(CCA)	  
	  
PD,	  CAL,	  BOP,	  PI,	  Rec	   c-­‐IMT	  mean	  ±	  SD	  (mm)	  
	  
Cases	  	  	  	  	  	  	  	  0.7	  	  ±	  0.21	  
	  
Controls	  	  	  	  0.59	  ±	  0.21	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Beck	  J.D.512	  	  	  
(2001/USA)	  
Cross-­‐sectional	  





Subset	   of	   Atherosclerosis	   Risk	   in	  
Communities	   (ARIC)	   In	   1996-­‐1998	  






(<10%	  sites	  with	  AL≥3mm)	  
Moderate	  
(10%	  to	  <30%	  sites	  with	  AL≥3mm)	  
Severe	   	  
(≥30%	  sites	  with	  AL≥3mm)	  
Extent	  of	  AL	  also	  divided	  into	  quintiles	  
(<3.7%,	  3.7%to	  <8.7%,	  8.7%	  to<16.7%	  
16.7%	  to	  30.9%,	  ≥30.9%)	  








smoking,	   waist/hip	  
ratio,	   education,	   and	  
race/center	  
Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
Bilateral,	   bifurcation	   (BCA),	  
internal	  (ICA),	  common	  (CCA).	  	  
The	   far	   (posterior)	   wall	   of	   the	  
vessel	  along	  
a	  1cm	  section.	  
Measurements	   were	   the	  mean	   of	  
the	  six	  segments.	  	  
	  
CAL,	  PD,	  REC	   c-­‐IMT	  mean	  	  ±	  SD	  (mm)	  
	  
Severe	  periodontitis	  
0.82	  	  ±	  0.24	  
Moderate	  periodontitis	  
0.77	  ±	  0.22	  
None	  /	  Mild	  	  
0.74	  ±	  	  0.19	  
	  
p	  =	  0.0001	  
	  
IMT	  ≥1	  mm	  
OR,	  95%	  CI	  
	  
-­‐	  Unadjusted	  
None	  /	  mild	  1.00	  (referent)	  
Moderate	  1.40,	  1.17-­‐1.67	  
Severe	  2.09,	  1.73-­‐2.53	  
	  
-­‐	  Adjusted	  
None	  /	  mild	  1.00	  (referent)	  
Moderate	  1.10,	  0.89	  –	  1.35	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Desvarieux	  M.593	  	  	  
(2004/Germany)	  
Cross-­‐sectional	  
N=	  1710	  	  
Subsample	   of	   Study	   of	   Health	   in	  
Pomerania	  	  (SHIP)	  
	  
Age	  range=	  45-­‐75	  
	  
Case	  definition:	  
Subjects	  categorized	  in	  tertiles	  according	  
to:	  
-­‐TOOTH	  LOSS	  
0	  to	  8,	  9	  to	  15,	  16	  to	  31	  
-­‐%	  of	  SITES	  WITH	  AL≥4	  mm	  
0-­‐20%,	  21-­‐57%,	  ≥57%	  
Age,	  region,	  smoking,	  
diabetes,	   systolic	  
blood	   pressure,	   high	  
blood	   pressure,	   LDL-­‐





of	  the	  carotid	  artery	  
(c-­‐IMT)	  
Bilateral,	   common	   carotid	   (CCA),	  
far	  wall	  
the	   mean	   far-­‐wall	   IMT	   was	  
calculated	  by	  averaging	  
the	  10	  consecutive	  measurement	  
points.	  
PD,	  CAL,	  REC	  using	  
the	  half-­‐mouth	  
method	  on	  the	  right	  
or	  left-­‐side	  in	  
alternate	  subjects.	   	  
Gender	  difference	   in	  c-­‐IMT	  means	  




Tertile	  I	  0.79	  ±	  0.1	  	  
Tertile	  II	  0.80	  ±	  0.001	  	  
Tertile	  III	  0.82	  ±	  0.009	  	  
P=	  0.05	  (highest/lowest	  tertile)	  
Females	  
Tertile	  I	  0.74	  ±	  0.009	  	  
Tertile	  II	  0.74	  ±	  0.009	  	  
Tertile	  III	  0.73	  ±	  0.009	  	  




N=	  657	  	  
	  
Subsample	  from	  The	  Oral	   Infections	  and	  
Vascular	  Disease	  
Epidemiology	  Study	  (INVEST)	  
	  




-­‐	  Cumulative	  Periodontal	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  bacterial	  burden	  
-­‐	  Etiologic	  bacterial	  burden	  
-­‐	  Bacterial	  dominance	  
Age,	  BMI,	  sex	  
race,	  education	   	  





of	  the	  carotid	  artery	  
(c-­‐IMT)	  	  
common,	  bifurcation,	  internal.	  
c-­‐IMT	   was	   calculated	   as	   a	  
composite	   measure	   (mean	   of	   the	  
12	   sites)	   that	   combined	   the	   near	  
and	   the	   far	   wall	   of	   the	   maximal	  
common	   carotid	   artery	   IMT,	   the	  
maximal	   bifurcation	   IMT,	   and	   the	  
maximal	   internal	   carotid	   artery	  
IMT	  bilaterally.	  
PD,	  BOP,	  PI	   	   c-­‐IMT	   mean	   ±	   SE	   (mm)	   across	   increasing	  
tertiles	   of	   perio	   bacterial	   exposure	  
definitions	  
Cumulative	  burden	  	  
P	  for	  linear	  trend	  0.04	  
Tertile	  I	  0.84	  ±	  0.008	  	  
Tertile	  II	  0.86	  ±	  0.008	  	  
Tertile	  III	  0.87	  ±	  0.008	  	  
Etiologic	  burden	  
P	  for	  linear	  trend	  0.03	  
Tertile	  I	  0.84	  ±	  0.010	  
Tertile	  II	  0.86	  ±	  0.008	  	  
Tertile	  III	  0.87	  ±	  0.010	  	  
Etiologic	  dominance	  
P	  for	  linear	  trend	  0.002	  
Tertile	  I	  0.84	  ±	  0.008	  	  
Tertile	  II	  0.85	  ±	  0.007	  	  
Tertile	  III	  0.88	  ±	  0.008	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Subset	  of	  Atherosclerosis	  
Risk	  in	  Communities	  (ARIC)	  
Conducted	  at	  ARIC	  visit	  4	  
In	  1996-­‐1998	  
	  
Age	  range	  =	  45-­‐64	  
	  
Case	  definition:	  
IgG	  antibody	  levels	  to	  17	  
selected	  periodontal	  organisms	  
Age,	   sex,	   race,	  
diabetes,	  
Hypertension,	  waist-­‐




of	  the	  carotid	  artery	  
(c-­‐IMT)	  
Bilateral,	   bifurcation,	   internal,	  
common.	  	  
The	   far	   (posterior)	   wall	   of	   the	  
vessel	  along	  
a	  1cm	  section.	  
Measurements	  were	  the	  mean	  of	  
the	  six	  segments.	  	  
CAL,	  PD,	  REC	   High	  IgG	  level	  and	  c-­‐IMT	  ≥1	  OR	  (95%	  CI)	  
Ever	  smokers	  	  Never	  smokers	  
N=2174	  	  	  	  	  	  	  	  	  	  	  	  N=2895	  
P.	   gingivalis	   1.5	   (1.2-­‐2.1)	   0.0017	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.4	  (1.0-­‐1.9)	  0.0848	  
T.	   forsysthensis	   1.0	   (0.8-­‐1.3)	   0.9568	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.3	  (0.9-­‐1.8)	  0.0936	  
T.	  denticola	  1.3	  (1.0-­‐1.7)	  0.0497	  	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.6	  (1.2-­‐2.3)	  0.0055	  
P.	   intermedia	   1.3	   (1.0-­‐1.6)	   0.0973	   	   	   	   	   	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1.8	  (1.2-­‐2.5)	  0.0016	  
C.	  rectus	  2.3	  (1.7-­‐3.0)	  <0.0001	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.2	  (1.5-­‐3.2)	  <0.0001	  	  
P.	  micros	  1.8	  (1.4-­‐2.4)	  <0.0001	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.2	  (1.6-­‐3.1)	  <0.0001	  
P.	  nigrescens	  1.2	  (0.9-­‐1.5)	  0.3034	  	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.3	  (0.9-­‐1.8)	  0.1673	  
F.	  nucleatum	  1.9	  (1.4-­‐2.5)<0.0001	  	  	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.9	  (1.3-­‐2-­‐7)	  0.0004	  
S.	  noxia	  1.8	  (1.4-­‐2.4)	  <0.0001	  	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  2.0	  (1.4-­‐2.8)	  0.0001	  
A.	  actinmomycetemcomitans	  
1.6	  (1.2-­‐2.1)	  	  0.0012	  
1.6	  (1.2-­‐2.3)	  0.0058	  
E.	  corrodens	  1.9	  (1.4-­‐2.5)	  <0.0001	  	  	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.6	  (1.8-­‐3.8)	  <0.0001	  	  
C.	  ochracea	  2.0	  (1.5-­‐2.6)<0.0001	  	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.8	  (1.3-­‐2.6)	  0.0007	  
V.	  parvula	  2.0	  (1.5-­‐2.7)	  <0.0001	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.4	  (1.7-­‐3-­‐5)	  <0.0001	  
S.	  sanguis	  1.4	  (1.1-­‐1-­‐8)	  0.0170	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.9	  (1.4-­‐2.7)	  0.0002	  
S.	  intermedius	  1.0	  (0.8-­‐1-­‐3)	  0.8478	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.0	  (1.4-­‐2.9)	  <0.0001	  
S.	  oralis	  1.4	  (1.0-­‐1.8)	  0.0295	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  2.1	  (1.5-­‐3.0)	  <0.0001	  	  	  	  	  
A.	  viscosis	  1.4	  (1.1-­‐1.8)	  0.0155	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.7	  (1.2-­‐2.4)	  0.0019	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Pussinen	  P.596	  	  
(2005/Finland)	  
Cross-­‐sectional	  
N=	  1023	  (male	  only)	  
	  
Subset	  of	  Kuopio	  Ischemic	  Heart	  disease	  
Risk	  Factor	  Study	  (KIHD)	  
	  
Age	  Range	  =	  46-­‐64	  	  
	  
Case	  definition:	  
Serum	   antibody	   levels	   to	   periodontal	  
pathogens	  
Aa	  IgA/IgG,	  Pg	  IgA/IgG	  
Subjects	  categorized	  in	  tertiles	  	  
Age,	  smoking	  
plasma	   fibrinogen	  
diabetes,	  BMI	  
med	  for	  HBP	  
socioeconomic	  
status,	   serum	  
HDL/LDL-­‐C	  
Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
bilateral,	  common	  carotid	  (CCA)	  
far	  wall,	  	  
Mean	   IMT	   was	   computed	   as	   the	  
mean	  of	  100	  	  measurements	  in	  the	  
right	   CCA	   and	   another	   100	  
measurements	  in	  the	  left	  CCA.	  
Antibody	  levels	  to	  
periodontal	  
pathogens	  	  
c-­‐IMT	  mean	  ±	  SD	  	  (mm)	  	  	  
Own	  teeth	  0.8459	  ±	  0.009	  
Denture	  0.8844	  ±	  0.009	  
P<0.01	  
-­‐Aa	  IgA	  
Tertile	  I	  0,8609	  ±	  0.009	  
Tertile	  II	  0,8861	  ±	  0.015	  P<0.01	  
Tertile	  III	  0,8733	  ±	  0.02	  P<0.05	  
-­‐Aa	  IgG	  
Tertile	  I	  0,8609	  ±	  0,011	  
Tertile	  II	  0,8574	  ±	  0,01	  
Tertile	  III	  0,8853	  ±	  0,012	  
-­‐Pg	  IgA	  
Tertile	  I	  0,8363	  ±	  0,009	  
Tertile	  II	  0,8711±0,011	  P<0.05	  
Tertile	  III	  0,8988±0,013	  	  
P<0.001	  
-­‐Pg	  IgG	  
Tertile	  I	  0,8443	  ±	  0,01	  
Tertile	  II	  0,884±0,013	  P<0.01	  
Tertile	  III	  0,8769±0,01	  P<0.05	  
-­‐Aa	  IgG	  +	  Pg	  IgG	  
Tertile	  I	  0,818	  ±	  0,014	  
Tertile	  II	  0,8271	  ±	  0,013	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Franek	  E.514	  	  
(2006/Poland)	  
Cross-­‐sectional	  
Included	   in	   the	  
quantitative	  
results	  
N=	  44	  (	  Test	  =	  17	  Control	  =	  27)	  
Uni/Hospital	  setting	  	  
	  
Age	  range	  =	  not	  reported	  
	  
Case	  definition	  =	  
no	   definition	   of	   advanced	   chronic	  
periodontitis	  
Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  	  
bilateral,	  common	  carotid	  
PD,	  CAL,	  PI,	  BI	   c-­‐IMT	  mean	  ±	  SD	  (mm)	  
	  
Test	  0.742	  ±	  0.028	  
	  
Control	  	  0.656	  ±	  0.019	  
	  
p	  <	  0.05	  
Demmer	  R.T.597	  	  
(2008/Germany)	  
Cross-­‐sectional	  
N=	  1745,	  age≥	  45	  
	  




Age	  range	  =	  45-­‐79	  (	  SHIP	  age	  range=	  20-­‐
79)	  
	  
Case	  definition	  =	  
for	   both	   PPD	   and	   AL	   candidate	  
definitions	  
were	  defined	  for	  extent	  of	  PD	  severity	  
thresholds	   ranging	   from	   3-­‐10	   mm	   	   as	  
follow:	  
1	   number	   of	   sites	   ≥	   a	   given	   severity	  
threshold	  
2	   percentage	   of	   sites	   ≥	   a	   given	   severity	  
threshold	  
3	  sum	  of	  mm	  ≥	  a	  given	  severity	  threshold	  
4	   mean	   of	   mm	   ≥	   a	   given	   severity	  
threshold	  
Age	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  (c-­‐IMT)	  
Bilateral,	  common	  carotid,	  far	  wall	  	  
PD,	   CAL	   using	   the	  
half-­‐mouth	   method	  
on	   the	   right	   or	   left-­‐
side	   in	   alternate	  
subjects.	  
BOP	   on	   the	   first	  
molar,	   the	   canine	  
and	   the	   central	  
incisor	  (up	  to	  24	  sites	  
/mouth),	  tooth	  loss	  
c-­‐IMT	  mean	  ±	  SE	  (mm)	  of	  	  
across	  quintiles	  of	  selected	  	  
periodontal	  disease	  definition	  
	  
Men	  (n=879)	  	  
p-­‐	  for	  linear	  trend	  0.005	  
	  
Quintile	  I	  0.80	  ±	  0.01	  	  
Quintile	  II	  0.81	  ±	  0.01	  	  
Quintile	  III	  0.80	  ±	  0.01	  	  
Quintile	  IV	  0.82	  ±	  0.01	  	  
Quintile	  V	  0.84	  ±	  0.01	  	  
	  
Women	  (n=866)	  	  
p-­‐for	  linear	  trend	  0.03	  
	  
Quintile	  I	  0.73	  ±	  0.01	  	  
Quintile	  II	  0.72	  ±	  0.01	  	  
Quintile	  III	  0.72	  ±	  0.01	  	  
Quintile	  IV	  0.76	  ±	  0.01	  	  
Quintile	  V	  0.77	  ±	  0.01	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Included	   in	   the	  
quantitative	  
results	  
N=86	  (Test	  =	  63;	  Control	  =	  23)	  
Sample	   from	   a	   health	   screening	  
programme	  
Age	  Range	  =	  35-­‐80	  
Case	  definition	  =	  
Chronic	   periodontitis	   defined	   if	   subjects	  
fulfilled	  any	  of	  the	  following	  criteria:	  
-­‐	  more	  than	  6	  sites	  with	  PD≥	  4	  mm	  
-­‐	  over	  25%	  sites	  with	  interproximal	  CAL≥	  
5	  mm	  
-­‐	   more	   than	   8	   missing	   teeth	   due	   to	   CP	  
excluding	  the	  third	  molars	  
Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
3	   measurements	   were	   made	   on	  
the	   near	   and	   far	   wall	   of	   the	   left	  
and	   right	   common	   carotid,	  
bifurcation	   and	   internal	   carotid.	  
The	  mean	  maximum	  IMT	  (mmIMT)	  
was	   calculated	   by	   averaging	   the	  
values	  of	  maximum	  IMT	  measured	  
from	   12	   preselected	   segments	   in	  
the	  carotid	  arteries.	  	  
PD,	   CAL,	   REC,	   BOP,	  
Missing	  teeth	  
c-­‐IMT	  mean	  ±	  SD	  (mm)	  
	  
-­‐	  No	  or	  Mild	  PD	  
	  
0.75	  ±	  0.15	  
	  
-­‐	  Moderate	  to	  severe	  PD	  
	  
0.83	  ±	  0.15	  	  
	  
p	  =	  0.039	  
Ylöstalo	  P.598	  	  
(2010/Finland)	  
Cross-­‐sectional	  
Included	   in	   the	  
quantitative	  
results	  
N	  =	  60	  
Subsample	  of	  a	  population-­‐based	  Cohort	  
of	  those	  inhabitants	  of	  Oulu	  born	  in	  1935	  
Age	  Range	  =	  not	  reported	  
Case	  Definition:	  
subjects	  categorized	  in	  3	  groups:	  
1-­‐PD≤3	  mm	  
2-­‐at	  least	  1	  tooth	  with	  PD≥4	  and	  ≤5	  mm	  
3-­‐at	  least	  1	  tooth	  with	  PD≥6	  mm	  
Sex,	  diabetic	  status	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
CPITN	   c-­‐IMT	  mean	  ±	  SD	  (mm)	   in	  relation	  
to	  PD:	  
	  
1-­‐	  0.93	  ±	  0.27	  	  
	  
2-­‐	  0.96	  ±	  0.15	  
	  
3-­‐	  0.93	  ±	  0.26	  	  
Vieira	  C.L.Z.517	  	  	  
(2011/Brazil)	  
Cross-­‐sectional	  
Included	   in	   the	  
quantitative	  
results	  
N=	  79	  (Test	  =	  33	  Control	  =	  46)	  
Patients	  with	  hFH	  followed	  
At	  the	  Lipid	  Clinic	  of	  the	  	  
University	  of	  Sao	  Paulo	  
Age	  range	  =	  	  17-­‐80	  
Case	  definition	  =	  
severe	  periodontitis	  as:	  	  
≥3	  sites	  not	  on	  the	  same	  tooth	  
CAL≥	  7	  mm	  
≥1	  interproximal	  sites	  with	  	  
PD≥	  5	  mm	  




of	  the	  carotid	  artery	  
(c-­‐IMT)	  
right	  common	  carotid	  	  
	  
PD,	  REC,	  CAL	   c-­‐IMT	  mean	  ±	  SD	  (µm)	  
	  
	  
Severe	  periodontal	  group:	  
710.91	  ±	  164.64	  	  
	  
Non	  severe	  periodontal	  group:	  
633.12	  ±	  157.94	  	  
	  
p	  =	  0.03	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Included	   in	   the	  
quantitative	  
results	  
N	  =	  59	  (MS	  group	  =	  26)	  




Age	  Range	  =	  23-­‐76	  (MS	  group)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  37-­‐71	  (non-­‐MS)	  
	  
Case	  definition	  =	  	  	  
periodontal	  disease	  as	  
CAL	  >3mm:	  	  
1%	  to	  32%=	  mild	  
33%	  to	  66%	  =	  moderate	  	  
67%	  to	  100%	  =	  severe	  
	  
	  
Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
Bilateral	  common	  carotid	  
PD,	   CAL,	   BI,	   PI,	  
missing	  teeth	  	  
c-­‐IMT	  mean	  ±	  SD	  (mm)	  
-­‐	  Non	  MS	  group	  
Left	  side	  
No/Mild	  PD	  
0.76	  ±	  0.27	  
Moderate/severe	  
0.85	  ±	  0.24	  
Right	  side	  
No/Mild	  PD	  
0.67	  ±	  0.18	  
Moderate/severe	  
0.89	  ±	  0.37	  
-­‐	  MS	  group	  
Left	  side	  
No/Mild	  PD	  
0.84	  ±	  0.33	  
Moderate/severe	  
1.08	  ±	  0.49	  
Right	  side	  
No/Mild	  PD	  
0.78	  ±	  0.30	  
Moderate/severe	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Franek	  E.582	  	  
(2012/Poland)	  
Cross-­‐sectional	  
Included	   in	   the	  
quantitative	  
results	  
N	  =	  121	  (BGI-­‐H	  16,	  BGI-­‐G	  87,	  BGI-­‐P2	  18)	  
	  
Diabetic	  population	  
Uni/Hospital	  setting	  	  
	  
Age	  range	  =	  not	  reported	  
	  
Case	  definition	  =	  
Differences	  in	  biologic	  phenotype	  
Periodontitis	  as:	  
PD	  ≥	  4	  mm	  and	  BOP	  extent	  scores	  
<	   10%	   as	   BGI-­‐P1;	   deep	   lesion/low	  
bleeding,	  with	  BOP	  extent	  
scores	   10–50%	   as	   BGI-­‐P2;	   and	   deep	  
lesion/moderate	  
bleeding	   and	   with	   BOP	   extent	   scores	   >	  
50%	  as	  BGI-­‐P3-­‐deep	  
lesion/severe	  bleeding.	  
age,	   sex,	   body	   mass	  
index	   (BMI),	   HbA1c,	  
LDL-­‐cholesterol,	  CRP	  
and	   periodontal	  
status.	  
Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
bilateral,	  common	  carotid.	  
3	   recordings	   each	   left	   and	   right	  
artery.	  	  
The	  mean	  value	  was	  calculated	  for	  
each	   side	   and	   for	   all	   six	  
measurements.	  














p	  <	  0.01	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Pinho	  M.584	  	  
(2013/Portugal)	  
Cross-­‐sectional	  
Included	   in	   the	  
quantitative	  
results	  
N	  =	  50	  	  
Uni/Hospital	  setting	  	  
Age	  range	  =	  not	  reported	  
Case	  definition	  =	  
Periodontal	  disease:	  
slight	  	  CAL<	  3	  mm	  
moderate	  CAL	  3	  to	  4	  mm	  




of	  the	  carotid	  artery	  
(c-­‐IMT)	  
Bilateral,	   common	   (CCA),	   internal	  
(ICA).	  	  
Far	   and	   near	   wall	   of	   the	   vessel	  
along	  a	  1cm	  section.	  	  
	  
	  
PI,	  BOP,	  PD,	  CAL	   c-­‐IMT	  mean	  ±	  SD	  (mm)	  
	  









N	  =	  6048	  
	  
Subset	  of	  Atherosclerosis	  
In	  1996-­‐1998	  
Conducted	  at	  ARIC	  visit	  4	  
Risk	  in	  Communities	  (ARIC)	  
	  
Age	  range	  =	  52	  –	  74	  
	  
Case	  definition	  =	  
Periodontitis	  as:	  
	  %	  PD	  ≥	  4	  mm	  and	  CAL	  ≥	  3	  mm	  
None	  	  0%,	  
Mild-­‐moderate	  	  0	  –	  <	  15%,	  	  
Severe	  ≥15%	  
gender,	   age,	  
race/centre,	  
LDL	   and	   HDL	  
cholesterol,	   BMI,	  
triglycerides,	  
hypertension,	  
smoking,	   income	   and	  
education.	  
Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  (c-­‐IMT)	  
Extracranial	   segments	   Bilateral,	  
bifurcation,	  internal,	  common.	  
The	   far	   (posterior)	   wall	   of	   the	  
vessel	  along	  a	  1cm	  section.	  
Measurements	   were	   the	   mean	   of	  
the	  six	  segments.	  When	  recordings	  
of	   the	   6	   sites	   were	   missing	   the	  
means	   at	   the	   missing	   sites	   were	  
imputed	   from	   sex-­‐	   and	   race	  
specificmultivariate	   linear	   models	  
of	  mean	   IMT	  as	   a	   function	  of	   age,	  
body	   mass	   index,	   and	   arterial	  
depth,	   fit	   by	   maximal	   likelihood	  
methods	  using	  BMDP	  5	  V.	  
PD,	  CAL,	  REC	   c-­‐IMT	  ≥1	  mm	  OR,	  95%	  CI	  




Healthy	  	  	  	  	  	  	  	  1.0	  
Mild-­‐Mod	  	  	  	  1.0	  (0.8–1.2)	  




Healthy	  	  	  	  	  	  	  	  	  1.3	  (0.8–2.9)	  
Mild-­‐Mod	  	  	  	  	  1.4	  (0.9–2.0)	  
Severe	  	  	  	  	  	  	  	  	  	  	  2.2	  (1.4–3.5)	  
Hayashida	  H.583	  	  
(2013/Japan)	  
Cross-­‐sectional	  
Included	   in	   the	  
quantitative	  
results	  
N	  =	  1053	  
	  
Population-­‐based	  
Age	  range	  =	  not	  reported	  
Case	  definition	  =	  
No	  definition	  of	  periodontitis	  
Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
Bilateral,	  common	  (CCA),	  
Far	  (posterior)	  wall	  
PD,	  CAL	   c-­‐IMT	  mean	  ±	  SD	  (mm)	  
Severe	  Periodontitis	  
0.94	  ±	  0.19	  
Moderate	  Periodontitis	  
0.91	  ±	  0.18	  
Mild	  or	  no	  Periodontitis	  
0.86	  ±	  0.16	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N	  =	  35	  
University/Hospital	  setting	  
	  
age	  range=	  38-­‐57	  
	  
Case	  definition	  =	  




Not	  adjusted	   Intima-­‐media	  thickness	  
of	  the	  carotid	  artery	  
(c-­‐IMT)	  
bilateral	  
PSR,	  PI,	  BOP	   c-­‐IMT	  Medians	  ±	  SD	  (mm)	  
	  
-­‐	  Carotid	  Bifurcation	  
	  
Bl	  =	  0.55	  ±	  0.03	  	  
6M	  =	  0.40	  ±	  0.04	  	  
12M	  =	  0.45	  ±	  0.04	  	  
BL	  vs	  6M:	  P	  =	  0.001	  
BL	  vs	  12M:	  P	  =	  0.01	  
	  
-­‐	  1	  cm	  from	  Bifurcation	  
	  
BL	  =	  0.49	  ±	  0.02	  	  
6M	  =	  0.38	  ±	  0.042	  	  
12M	  =	  0.37	  ±	  0.03	  	  
BL	  vs	  6M:	  P	  =	  0.003	  
BL	  vs	  12M:	  P	  <	  0.001	  
	  
-­‐	  2	  cm	  from	  Bifurcation	  
	  	  
BL	  =	  0.50	  ±	  0.02	  	  
6M	  =	  0.42	  ±	  0.06	  	  
12M	  =	  0.39	  ±	  0.03	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Included	   in	   the	  
quantitative	  
results	  
N	  =	  55(Test	  =	  26;	  Control	  =	  29)	  
Uni/Hospital	  settings	  
	  
Age	  range	  =	  not	  reported	  
	  
Case	  definition	  =	  	  
Advanced	  periodontal	  disease	  
6	  teeth	  with	  PD>5	  mm	  
CAL≥3	  mm	  in	  3	  aspects	  of	  each	  	  
involved	  tooth	  
	  
Control	  definition	  =	  
Healthy	   subjects	   without	   periodontal	  
disease	  
recruited	  by	  advertisement	  




mediated	   dilatation	   of	   the	   brachial	  
artery	  (EDD)	  
Endothelium	   –independent	   flow-­‐
mediated	  dilatation	  (EID)	  
PD,	  BOP,	  CAL,	  REC	   EDD	  mean	  ±	  SD	  (%)	  
Controls	  11.7	  ±	  5.3	  
Test	  7.8	  ±	  4.6	  
p	  =	  0.005	  
	  
EDD	  mean	  ±	  SD	  (mm)	  
Controls	  0.45	  ±	  0.16	  
Test	  0.31	  ±	  0.15	  
p	  =	  0.003	  
	  
EID	  mean	  ±	  SD	  (%)	  
Controls	  18.9	  ±	  11.0	  
Test	  16.3	  ±	  8.3	  
p	  =	  0.37	  	  
Li	  P.515	  	  	  
(2011/China)	  
Cross-­‐sectional	  
Included	   in	   the	  
quantitative	  
results	  
N	  =	  59	  (MS	  group	  =	  26)	  




Age	  Range	  =	  23-­‐76	  (MS	  group)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  37-­‐71	  (non-­‐MS)	  
	  
Case	  definition	  =	  	  
periodontal	  disease	  as:	  
CAL	  >3mm:	  	  
1%	  to	  32%=	  mild	  
33%	  to	  66%	  =	  moderate	  	  
67%	  to	  100%	  =	  severe	  
	  
	  
Not	  adjusted	   Endothelium-­‐dependent	   flow-­‐
mediated	   dilatation	   of	   the	   brachial	  
artery	  (EDD)	  
	  
PD,	  CAL,	  BI,	  PI,	  missing	  
teeth	  	  
EDD	  	  mean	  ±	  	  SD	  (%)	  
	  
Non	  MS	  group	  	  
	  
No/mild	  PD	  	  
13.12	  ±	  6.57	  
	  
Moderate/severe	  





9.22	  ±	  5.43	  
Moderate/severe	  
6.98	  ±	  4.89	  
p	  =	  0.05	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Included	   in	   the	  
quantitative	  
results	  
N	  =	  30(Test	  =	  15;	  Control	  =	  15)	  
Uni/Hospital	  settings	  
	  
Age	  range	  =	  not	  reported	  
	  
Case	  definition	  =	  	  
Advanced	  periodontal	  disease	  
PD>4	  mm	  
CAL≥5	  mm	  	  
	  
Control	  definition	  =	  
	  





mediated	   dilatation	   of	   the	   brachial	  
artery	  (EDD)	  
	  
PD,	  BOP,	  CAL,	  	   EDD	  mean	  ±	  SD	  (%)	  
	  
Controls	  14.8	  ±	  7.25	  
	  
Test	  13.21	  ±	  7	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Tonetti	  M.12	  	  	  
(2007/UK)	  
RCT	  
N	   =	   120	   (Intensive-­‐treatment	   group	   =	   61,	  




Age	  range	  =	  not	  reported	  
	  
Case	  Definition	  =	  
severe	  generalized	  periodontitis	  	  
PD	  >6	  mm	  and	  bone	  loss	  of	  >30%	  with	  50%	  
or	  
more	  of	  teeth	  affected	  
Age,	  sex,	  smoking	  
race,	  BMI,	  vessel	  




mediated	   dilatation	   of	   the	   brachial	  
artery	  (EDD)	  
Endothelium	   –independent	   flow-­‐
mediated	  dilatation	  (EID)	  
PD,	  REC,	  BOP,	  FMPS	   EDD	  mean	  	  ±	  SD	  (mm	  /	  %)	  
BL	  
-­‐	  IPT	  =	  3.7	  ±	  0.8	  /	  7.1	  ±	  4.2	  
-­‐	  CPT	  =	  3.6	  ±	  0.6	  /	  6.5	  ±	  2.6	  
6M	  
-­‐	  IPT	  =	  3.7	  ±	  0.9	  /	  8.3	  ±	  4.2	  
-­‐	  CPT	  =	  3.5	  ±	  0.6	  /	  6.2	  ±	  2.6	  
6M	  IPT	  vs	  CPT	  	  
p	  =	  0.193	  /	  0.001	  
EID	  mean	  ±	  SD	  (mm	  /	  %)	  
BL	  
-­‐	  IPT	  =	  3.8	  ±	  0.8	  /	  17.8	  ±	  6.4	  
-­‐	  CPT	  =	  3.6	  ±	  0.7	  /	  17.9	  ±	  6.9	  
6M	  
-­‐	  IPT	  =	  3.8	  ±	  0.9	  /	  15.7	  ±	  7.3	  
-­‐	  CPT	  =	  3.5	  ±	  0.7	  /	  16.3	  ±	  6.7	  
6M	  IPT	  vs	  CPT	  	  
p	  =	  0.107	  /	  0.695	  
Higashi	  Y.375	  	  	  
(2008/Japan)	  
RCT	  
N	  =	  52	  Protocol	  1	  (male	  only)	  




Age	  range	  =	  not	  reported	  
	  
Case	  definition	  =	  
Self-­‐reported	  questionnaire	  
No	  definition	  of	  periodontitis	  
Not	  adjusted	   Forearm	   blood	   flow	   (FBF)	   of	   the	  
brachial	  artery	  (Ach	  response)	  
Not	  reported	   Protocol	   1	   =	   Response	   to	   Ach	   was	  
significantly	   lower	   in	   periodontal	  
patients	  (p	  <	  0.001)	  
FBF	   response	   to	   Ach	   was	  
significantly	   higher	   24	   weeks	   after	  
treatment	  
(p	  <	  0.001)	  
Protocol	   2	   =	   Response	   to	   Ach	   was	  
significantly	   lower	   in	   periodontal	  
patients	  (p	  <	  0.001)	  
FBF	   response	   to	   Ach	   was	  
significantly	   higher	   24	   weeks	   after	  
treatment(p	  <	  0.001)	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Age	  range	  =	  not	  reported	  
Case	  definition:	  
Self-­‐reported	  questionnaire	  and	  
Chronic	  periodontitis	  as	  
The	  presence	  of	  at	  least	  2	  teeth	  with	  PD	  ≥	  4	  
mm	  and	  	  
CAL	  ≥	  3mm	  
Not	  adjusted	   Forearm	   blood	   flow	   (FBF)	   of	   the	  
brachial	  artery	  (Ach	  response)	  
PD,	  CAL,	  BOP	   Response	   to	   Ach	   was	   significantly	  
lower	  in	  periodontal	  patients	  	  
(p	  <	  0.001)	  
FBF	   response	   to	   Ach	   was	  
significantly	   higher	   24	   weeks	   after	  
treatment	  
(14.7	  ±	  5.2	  to	  20.1	  ±	  6.1	  ml/min	  per	  
100	  ml	  P<	  0.05	  
Mercanoglu	  F.508	  	  	  
(2004/Turkey)	  
CT	  
Included	   in	   the	  
quantitative	  
results	  




Age	  Range	  =	  not	  reported	  
	  
Case	  Definition	  =	  
diagnosis	  of	  chronic	  
periodontitis	   was	   based	   on	   CAL	   and	  
radiographic	  bone	  loss	  
Age,	  sex,	  BMI	   Endothelium-­‐dependent	   flow-­‐
mediated	   dilatation	   of	   the	   brachial	  
artery	  (EDD)	  
Endothelium	   –independent	   flow-­‐
mediated	  dilatation	  (EID)	  
PD,	  CAL,	  GI,	  PI	   EDD	  mean	  ±	  SD	  (%)	  
BL	  Controls	  19	   .4	  ±	  8.1	  
Final	  Controls	  20.3±8.6	   	  P	  NS	  
BL	  Test	  8.4	  ±	  4.0	  
Final	  Test	  17.7±5.7	  P	  <0.0001	  
EID	  mean	  ±	  SD	  (%)	  
BL	  Controls	  29.5	  ±	  10.0	  
Final	  Controls	  27.1±10.8	  P	  NS	  
BL	  Test	  13.3	  ±	  6.3	  
Final	  Test	  24.9	  ±	  7.3	  	  
p	  <0.0001	  	  
Seinost	  G.393	  	  	  
(2005/Austria)	  
CT	  
Included	   in	   the	  
quantitative	  
results	  




Age	  range	  =	  25-­‐50	  
	  
Case	  definition	  =	  
Severe	  periodontitis	  as	  
involvement	  of	  at	  least	  6	  teeth	  
with	  PD≥5	  mm,	  AL	  ≥3	  mm	  in	  	  
3	  aspect	  of	  each	  involved	  tooth	  




mediated	   dilatation	   of	   the	   brachial	  
artery	  (EDD)	  
Endothelium	   –independent	   flow-­‐
mediated	  dilatation	  (EID)	  
PD,	  BOP,	  REC	   EDD	  mean	  ±	  SD	  (mm)	   	  
Controls	  0.29	  ±	  0.1	  
Test	  before	  Rx	  0.2	  ±	  0.14	  
Test	  aft	  Rx	  0.3	  ±	  0.14	  	  P<	  0.01	  
EDD	  mean	  ±	  SD	  (%)	  
Controls	  8.5	  ±	  3.4	  
Test	  before	  Rx	  6.1	  ±	  4.4	  
Test	  aft	  Rx	  9.8	  ±	  5.7	  P	  <	  0.01	  
EID	  mean	  ±	  SD	  (%)	  
Controls	  22.5	  ±	  6.7	  
Test	  before	  Rx	  23.7	  ±	  3.2	  
Test	  aft	  Rx	  23.5	  ±	  7.9	  	  
	  
	   194	  


















Elter	  J.R.507	  	  
(2006/USA)	  
Pilot	  study	  
N	  =	  22	  (No	  control	  group)	  
	  
Uni/Hospital	   settings	   and	   volunteer	  
subjects.	  
	  
Age	  range	  =	  31-­‐55	  
	  
Case	  definition	  =	  
Moderate	   to	   severe	   periodontal	   disease	  
defined	  as	   at	   least	   4	   sites	  with	  PD	  ≥	  5mm	  
distributed	   in	   at	   least	   2	   quadrants	   and	   at	  
least	  2	  of	  the	  4	  sites	  with	  AL	  ≥	  3	  mm	  
Not	  adjusted	   Endothelium-­‐dependent	   flow-­‐
mediated	   dilatation	   of	   the	   brachial	  
artery	  (EDD)	  
Endothelium	   –independent	   flow-­‐
mediated	  dilatation	  (EID)	  
PD,	  AL,	  PI,	  GI	   EDD	  (%)	  mean	  ±	  SD	  
	  
Baseline1	  	  8.9	  ±	  4.7	  
Baseline2	  	  8.2	  ±	  5.0	  
p	  for	  difference	  from	  
BL1=	  .197	  
Pooled	  Baseline	  8.6	  ±4.7	  
Post-­‐treatment	  	  10.2	  ±	  3.9	  
p	  for	  difference	  from	  	  
Pool	  BL=	  0.034	  
	  
EID	  (%)	  mean	  ±	  SD	  
	  
Baseline1	  19.5	  ±	  7.7	  
Baseline	  2	  	  20.3	  ±	  10.6	  
p	  for	  difference	  from	  
BL1=	  0.450	  
Pooled	  baseline	  19.8	  ±	  8.6	  
Post-­‐treatment	  	  21.3	  ±	  8.0	  
p	  for	  difference	  from	  	  
PoolBl=	  .365	  
Blum	  A.506	  (41)	  	  
(2007/Israel)	  
CT	  
Included	   in	   the	  
quantitative	  
results	  




Age	  Range	  =	  not	  reported	  
	  
Case	  Definition	  =	  
Chronic	  periodontitis	  as	  
at	   least	   18	   teeth	  and	  1	   interproximal	   area	  
of	  PD≥	  5	  mm	  
Not	  adjusted	   Endothelium-­‐dependent	   flow-­‐
mediated	   dilatation	   of	   the	   brachial	  
artery	  (EDD)	  
Endothelium	   –independent	   flow-­‐
mediated	  dilatation	  (EID)	  
PD,	  BOP,	  CAL,	  PI	   EDD	  mean	  ±	  SD	  (%)	  
	  
BL	  Controls	  16.60	  ±	  7.86	  
BL	  Test	  4.12	  ±	  3.96	  
p	  =	  0.0000	  
	  
After	  Treatment	  	  
11.12	  ±	  7.22	  
p	  =	  0.0007	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3.3.3. Quantitative	  results	  
3.3.3.1. Mean	  c-­‐IMT	  value	  in	  individuals	  with	  or	  without	  PD	  
7	  out	  of	   10	   case-­‐control	   studies	   comparing	  differences	   in	   c-­‐IMT	  between	   individuals	  
with	   and	   without	   PD	   could	   be	   included	   in	   a	   meta-­‐analysis476,513,585-­‐587,591,592.	   3	  
publications	  were	  excluded;	  2	  papers	  reported	  data	  on	  the	  same	  population	  analyzed	  
in	  previous	  publications588,589,	  	  and	  1	  study	  was	  biased	  in	  the	  selection	  of	  controls590.	  9	  
out	  of	  15	  cross-­‐sectional	  studies512,514-­‐517,582-­‐584,598	  were	  suitable	  for	  a	  meta-­‐analysis.	  6	  
studies	  were	   excluded	   for	   the	   following	   reasons:	   1	   performed	   analysis	   on	   the	   same	  
sub-­‐sample	   of	   another	   included	   study599,	   3	   related	   c-­‐IMT	   to	   antibody	   levels	   of	  
periodontal	   pathogens594-­‐596,	   2	   calculated	   c-­‐IMT	   values	   across	   quintiles	   or	   tertiles	   of	  
periodontal	   definitions593,597.	   Li	   P.	   et	   al.	   	   assessed	   c-­‐IMT	   in	   two	   different	   samples,	  
individuals	  with	  or	  without	  metabolic	  syndrome	  and	  with	  or	  without	  PD.	  We	  therefore	  
considered	   the	   data	   as	   2	   separate	   studies515.	   In	   some	   of	   the	   included	   studies,	  
individuals	  were	  divided	   in	  different	  groups	  according	  to	  PD	  severity.	   In	  this	  case	  the	  
severe	  PD	  group	  was	  chosen	  for	  the	  analysis.	  The	  mean	  difference	  in	  c-­‐IMT	  values	   in	  
the	   individual	   studies	   ranged	   from	   -­‐	  0.04mm	  to	  0.19mm.	  Adopting	  a	   random-­‐effects	  
model,	  a	  meta-­‐analysis	  (4720	   individuals)	   indicated	  a	  higher	  c-­‐IMT	  in	   individuals	  with	  
PD	  (0.08	  mm	  95%	  CI	   [0.07,	  0.09],	  P	  =	  0.000)	  compared	  to	  controls	   (Figure	  20).	  A	  chi-­‐
squared	  test	  and	  I-­‐squared	  test	  for	  heterogeneity	  did	  not	  show	  statistically	  significant	  
heterogeneity	  (P	  =	  0.832	  and	  I²	  =	  0.0%).	  Funnel-­‐plot	  analysis	  (Figure	  21	  A)	  did	  not	  show	  
evidence	  of	  biases	  using	  the	  Egger	  test	  of	  symmetry	  (P	  =	  0.935)	  and	  sensitivity	  analysis	  
did	  not	  alter	  the	  findings.	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Figure	  20	  Association	  between	  Periodontitis	  and	  Carotid	  Intima-­‐Media	  Thickness	  (c-­‐IMT)	  
Difference	   of	   c-­‐IMT	   means	   between	   individuals	   with	   periodontitis	   versus	   controls	   in	   observational	  
studies.	  Horizontal	   lines	  representing	  95%	  CI;	   lower	  diamond	  represents	  the	  overall	  effect	  size,	  random	  
effects	  models.	  sscase	  sample	  size	  cases,	  sscontrols	  sample	  size	  controls	  
	  
Figure	  21	  Association	  between	  periodontitis,	  c-­‐IMT	  (A)	  and	  FMD	  (B).	  Funnel	  plots	  of	  observational	  studies.	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3.3.3.2. Mean	  FMD	  values	  in	  individuals	  with	  or	  without	  PD	  
Differences	   in	   FMD	   (%)	   between	   individual	   with	   or	   without	   PD,	   reported	   by	   3	  
observational	  studies505,515,600	  and	  baseline	  data	  from	  3	  controlled	  trials393,506,508,	  were	  
included	   in	   the	   meta-­‐analysis.	   Individual	   studies	   mean	   difference	   in	   percentage	   of	  
endothelial	   dependent	   dilatation	   (EDD)	   ranged	   from	   -­‐12.48%	   to	   -­‐2.40%	   with	   all	   4	  
studies	   showing	   statistically	   significant	   difference.	   In	   individuals	   with	   PD,	   EDD	   was	  
lower	  by	  5.1%	  (95%	  CI	  [-­‐8.11,	  -­‐2.08],	  P	  =0.002)	  compared	  to	  controls	  (Figure	  22).	  A	  chi-­‐
squared	   test	   and	   I-­‐squared	   test	   for	   heterogeneity	   showed	   however	   a	   statistically	  
significant	   heterogeneity	   (P	  =	   0.000	   and	   I²	   =	   88.9%).	   Funnel-­‐plot	   analysis	   (Fig.	   21	   B)	  
showed	  a	  discrete	  asymmetry	  that	  could	  be	  an	  evidence	  of	  publication	  bias,	  Egger	  test	  
(P	   =	   0.076)	   and	   sensitivity	   analysis	   did	   not	   alter	   the	   findings.	   The	   funnel	   plot	  
asymmetry	  could	  be	  probably	  attributed	  to	  the	  high	  heterogeneity	  among	  the	  studies.	  
	  
Figure	  22	  Association	  between	  Periodontitis	  and	  Flow	  Mediated	  Dilatation	  (FMD)	  
Difference	   of	   the	   FMD	  means	   between	   individuals	   with	   periodontitis	   versus	   controls	   in	   observational	  
studies.	  Horizontal	  lines	  representing	  95%	  CI;	  diamond	  represents	  the	  overall	  effect	  size,	  random	  effects	  
models.	  sscase	  sample	  size	  cases,	  sscontrols	  sample	  size	  controls.	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3.3.3.3. Effect	  of	  periodontal	  therapy	  on	  EDD	  
It	  was	  possible	  to	  analyze	  the	  summary	  difference	  in	  mean	  FMD	  (%)	  between	  test	  and	  
control	  after	  periodontal	  treatment	  in	  3	  of	  6	  controlled	  trials393,506,508	  (147	  individuals)	  
(Fig.	  23).	  Mean	  improvement	  in	  FMD	  after	  periodontal	  intervention	  ranged	  from	  to	  3.7	  
to	   9.3%.	   The	   overall	   summary	   estimate	   of	   the	   mean	   increase	   in	   FMD	   based	   on	   a	  
random-­‐effects	  model	  was	  6.64%	  (95%	  CI	   [2.83	  to	  10.44],	  p	  <	  0.0001).	  A	  chi-­‐squared	  
test	   for	   heterogeneity	   and	   the	   I-­‐squared	   index	   showed	   statistically	   significant	  
heterogeneity	  (p	  =	  0.011	  and	  I2	  =	  78%).	  The	  Egger	  test	  didn't	  show	  a	  small	  study	  effect	  
(p	  =	  0.956)	  and	  sensitivity	  analysis	  identified	  two	  influential	  studies	  potentially	  related	  
to	  the	  small	  number	  of	  included	  trials.	  
	  
Figure	  23	  Association	  between	  Periodontal	  Treatment	  and	  Flow	  Mediated	  Dilatation	  (FMD)	  
Difference	   of	   the	   FMD	   means	   before	   and	   after	   periodontal	   treatment	   in	   controlled	   clinical	   trials.	  
Horizontal	  lines	  representing	  95%	  CI;	  diamond	  represents	  the	  overall	  effect	  size,	  random	  effects	  models.	  
sscase	  sample	  size	  cases,	  sscontrols	  sample	  size	  controls.	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3.4. Discussion	  
Our	  findings	  indicate	  that	  PD	  is	  associated	  with	  greater	  c-­‐IMT	  and	  impaired	  FMD	  and	  
that	   periodontal	   treatment	   improves	   endothelial	   function.	   Despite	   the	   number	   of	  
reports	  on	  the	  topic,	  this	  is	  the	  first	  systematic	  review	  and	  meta-­‐analysis	  linking	  PD	  to	  
specific	  CVD	  surrogate	  outcomes	  in	  the	  general	  population.	  These	  associations	  further	  
reiterate	   the	   importance	   of	   oral	   health	   as	   a	   possible	   un-­‐recognized	   common	   factor	  
building	   on	   the	   individual	   cardiovascular	   risk.	   Our	   analysis	   relates	   to	   c-­‐IMT	  
measurements	   from	   4720	   individuals	   showing	   that	   individuals	   with	   PD	   have	   on	  
average	   a	   greater	   c-­‐IMT	   (0.08	   mm)	   when	   compared	   with	   individuals	   without	   PD.	  
Despite	  the	  small	  magnitude	  of	  this	  difference,	  current	  evidence	  suggests	  that	   in	  the	  
general	   population	   the	   mean	   estimates	   of	   c-­‐IMT	   progression	   ranged	   from	   0.001	   to	  
0.030	   mm	   per	   year	   for	   mean	   common	   carotid	   artery	   intima-­‐media	   thickness601.	  
Individuals	   with	   PD	   therefore	   present	   with	   greater	   burden	   of	   subclinical	  
atherosclerosis	  compared	  to	  controls.	  This	  finding	  is	  consistent	  with	  a	  previous	  report	  
from	  our	  group	  demonstrating	  in	  a	  case-­‐control	  study	  that	  individuals	  with	  PD	  present	  
with	   shorter	   leucocytes	   telomere	   length	   independent	   of	   age	   differences	   and	   other	  
common	   confounders602.	   Shorter	   telomere	   length	   has	   been	   linked	   to	   increased	  
mortality	   and	   greater	   progression	   of	   other	   common	   chronic	   diseases	   (i.e.	   CVD	   and	  
diabetes)	  implying	  faster	  aging	  processes	  in	  people	  with	  PD603.	  A	  “chronic”	  exposure	  to	  
a	   local	  and	  systemic	  state	  of	   inflammation	  and	  oxidative	  stress	   like	  those	  reported	  in	  
people	   with	   PD	   could	   represent	   one	   of	   the	   possible	   mechanisms	   explaining	   this	  
association.	   A	   number	   of	   factors	   however	   should	   be	   taken	   into	   account	   when	  
interpreting	   collectively	   these	   associations.	   Indeed	   evidence	   suggests	   that	   per	   every	  
0.1	   mm	   difference	   in	   c-­‐IMT,	   the	   relative	   risk	   (RR)	   of	   future	   myocardial	   infarction	  
increases	  to	  1.15	  (95%	  CI,	  1.12	  to	  1.17)	  and	  to	  1.18	  (95%	  CI,	  1.16	  to	  1.21)	  for	  stroke604.	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A	   number	   of	   traditional	   cardiovascular	   risk	   factors	   are	   all	   linked	   to	   this	   rate	   of	  
progression	  in	  the	  following	  order	  of	  importance:	  age,	  gender,	  systolic	  blood	  pressure,	  
HDL	   cholesterol,	   smoking,	   diabetes,	   hypertension	   treatment,	   and	   total	   cholesterol.	  
Clearly	  PD	  shares	  most	  of	  these	  risk	  factors	  and	  therefore	  it	   is	  difficult	  to	  discern	  the	  
potential	   impact	   of	   PD	   alone	   on	   the	   progression	   of	   c-­‐IMT.	   The	   lack	   of	   a	   uniform	  
adjustment	   for	  all	   these	   confounders	   in	  all	   the	   studies	   included	   in	  our	  meta-­‐analysis	  
could	   have	   also	   reduced	   the	   accuracy	   of	   our	   results.	   Increased	   values	   of	   c-­‐IMT	   can	  
truly	  predict	  cardiovascular	  events	   (CVEs).	  A	  c-­‐IMT	  value	  of	  0.9	  mm	  is	  considered	  for	  
instance	  a	  conservative	  estimate	  of	  pre-­‐existing	  abnormalities	  according	  to	  the	  recent	  
Guidelines	   for	   the	   management	   of	   arterial	   hypertension605;	   but	   it	   is	   still	   uncertain	  
whether	   c-­‐IMT	   assessment	   improves	   individual	   risk	   assessment	   in	   primary	   CVD	  
prevention.	  Furthermore,	  it	  is	  no	  clear	  which	  carotid	  segment	  would	  provide	  the	  most	  
relevant	  information	  (common	  carotid,	  bifurcation,	  internal	  carotid	  arteries)	  as	  well	  as	  
which	  summary	  measure	  should	  be	  adopted	  (mean,	  maximal,	  mean	  of	  the	  maximal).	  
Studies	  aimed	  at	  evaluating	  whether	  ultrasound	  measures	  add	  prognostic	  information	  
to	   traditional	   vascular	   risk	   factors	   (VRFs),	   reported	   different	   conclusions89,527,606-­‐608.	  
Only	   few	   of	   them	   showed	   a	   null	   or	  modest	   usefulness	   of	   c-­‐IMT	  measurements	   in	   a	  
general	   population89,606,607	  while	   results	   for	   the	  Rotterdam	  Study	  proved	   its	   utility	   in	  
the	   risk	   assessment	   in	   women	   only608.	   In	   the	   IMPROVE	   study,	   Baldassarre	   et	   al.	  
examined	  a	  population	  with	  high	  CVD	  risk	  (elderly	  with	  ≥	  3	  VRFs)	  and	  explored	  the	  net	  
reclassification	  improvement	  obtained	  with	  the	  addition	  to	  the	  Framingham	  risk	  score	  
(FRS)	  of	  composite	  c-­‐IMT	  variables,	  rather	  than	  common	  c-­‐IMT	  alone.	  Both	  approaches	  
improved	  the	  reclassification	  with	  the	  higher	  changes	  (14.5%	  individuals	  moved	  from	  
intermediate	   to	   a	   high	   risk	   category)	   obtained	  when	  using	   intra-­‐adventitial	   common	  
carotid	  diameter	  and	  the	  value	  of	  c-­‐IMT	  min-­‐max527.	  Despite	  the	  low	  level	  of	  statistical	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heterogeneity	  detected	   in	  our	  analyses	  (I-­‐squared	  0%)	  the	  robustness	  of	  our	  findings	  
could	  be	  affected	  by	  differences	  in	  the	  research	  protocols	  (i.e.	  clinical	  heterogeneity).	  
The	  diagnosis	  of	  PD	  and	  c-­‐IMT	  assessment	  criteria	  varied	  considerably	  throughout	  the	  
studies	   included.	   PD	   was	   assessed	   using	   different	   criteria	   ranging	   from	   validated	  
clinical	  measures	   such	   as	   CAL	   and	   PPD	   to	   self-­‐defined	   criteria	   showing	   the	   lack	   of	   a	  
uniform	   definition	   of	   PD609,610.	   In	   addition	   we	   could	   not	   group	   individuals	   with	   PD	  
according	   to	   disease	   severity	   (mild,	  moderate	   and	   severe)	   as	   in	   the	  majority	   of	   the	  
studies	   retrieved	   such	   differentiation	   was	   not	   performed.	   We	   therefore	   followed	   a	  
conservative	   approach	   by	   comparing	   healthy	   versus	   severe	   PD	   individuals.	   This	  
approach	   could	   have	   resulted	   in	   an	   underestimation	   of	   the	   reported	   associations.	  
Current	   evidence	   does	   not	   allow	   understanding	   whether	   the	   higher	   CV	   risk	   is	  
associated	  with	   diagnosis	   of	   PD	  or	   its	   severe	   forms	  only.	   As	   the	  prevalence	  of	   PD	   is	  
relatively	  high	  in	  the	  general	  population,	  the	  identification	  of	  subgroups	  of	  individuals	  
with	   PD	   at	   increased	   risk	   for	   CVD,	  would	   help	   in	   reducing	   possible	   costs	   associated	  
with	  large	  scale	  screening.	  For	  instance,	  a	  difference	  of	  0.08	  mm	  would	  not	  be	  crucial	  
in	  healthy	  and	  young	  individuals	  with	  PD	  as	  their	  absolute	  c-­‐IMT	  would	  be	  far	  from	  the	  
0.9	   mm	   value	   considered	   abnormal	   following	   the	   current	   guidelines	   for	   CV	   risk	  
assessment.	  Specifically	  to	  c-­‐IMT	  we	  identified	  multiple	  sources	  of	  heterogeneity	  such	  
as	  details	  of	   the	  ultrasound	  protocol,	  definition	  of	   the	  carotid	  segment	  analysed,	   the	  
assessment	  based	  on	   the	  near	  or	   far	  wall	  or	  both	  and	  whether	  c-­‐IMT	  was	  measured	  
only	  on	  1	  side	  or	  on	  both	  sides.	  A	  recent	  consensus	  paper	  recommends	  measurement	  
of	   c-­‐IMT	   in	   plaque-­‐free	   areas611	   and	   we	   did	   not	   find	   explicit	   statements	   about	   this	  
methodological	   aspect	   in	   any	   of	   the	   studies	  we	   analyzed.	   The	   recent	   publication	   of	  
guidelines	   to	  assess	  c-­‐IMT	   is	   likely	   to	   improve	  consistency	  of	   the	   technique	   in	   future	  
studies.	   	   Based	   on	   our	   research	   strategy,	   we	   identified	   only	   one	   longitudinal	   study	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evaluating	   the	   impact	   of	   periodontal	   treatment	   on	   c-­‐IMT	   in	   people	   with	  
mild/moderate	   PD.	   6	   and	   12	  months	   following	   periodontal	   treatment,	   a	   statistically	  
significant	   reduction	   in	   c-­‐IMT	   compared	   to	   the	   BL	   measurements	   was	   reported399.	  
These	  findings	  could	  support	  a	  potential	  causal	  association	  between	  PD	  and	  subclinical	  
atherosclerosis	   assessed	   by	   c-­‐IMT.	   However	   considering	   the	   absence	   of	   a	   control	  
group	   in	   the	   study,	   inclusion	   of	   CVD-­‐free	   individuals	   and	   the	   lack	   of	   multiple	  
measurements	  of	  the	  carotid	  thickness,	  the	  statement	  about	  causality	  is	  not	  supported	  
by	   the	   evidence	   reviewed.	   Further	   clinical	   studies	   should	   be	   performed	   and	   similar	  
findings	   should	   be	   confirmed	   in	   larger,	   controlled	   and	   possibly	   high-­‐risk	   population	  
(e.g.	  greater	  c-­‐IMT).	  The	  relationship	  between	  FMD	  of	  the	  brachial	  artery	  and	  PD	  was	  
also	   an	   objective	   of	   the	   present	   review.	   While	   c-­‐IMT	   is	   a	   measure	   of	   sub-­‐clinical	  
atherosclerosis,	   FMD	   is	   related	   to	   the	   pathogenesis	   of	   atheroma	   and	   provides	  
information	   regarding	   the	   early	   stage	   of	   its	   evolution.	   Endothelial	   function	   and	  
specifically	   FMD	   can	   also	   predict	   future	   CVD	   outcomes,	   a	   recent	   meta-­‐analysis	  
reported	   that	  per	  every	  point	  decrease	   in	  FMD,	   future	  CVD	  risk	   increased	  of	  10%612.	  
Demonstrating	   that	   PD,	   due	   to	   its	   chronic	   inflammatory	   nature,	   could	   contribute	   to	  
atheroma	   formation	   would	   provide	   important	   biological	   information	   useful	   in	   the	  
prevention	  of	  endothelial	  dysfunction.	  	  The	  meta-­‐analysis	  gathered	  data	  from	  baseline	  
measurements	  of	  3	  controlled	  trials393,506,508	  and	  one	  case-­‐control	  study505	  showing	  a	  
mean	   difference	   of	   5.1%	   in	   FMD	   in	   individuals	  with	   PD	   compared	   to	   controls	   and	   a	  
mean	  increase	  of	  6.64%	  following	  periodontal	  treatment.	  Our	  choice	  of	  including	  only	  
3	  controlled	  trials	  was	  based	  on	  the	  fact	  that	  the	  study	  design	  and	  the	  methodology	  in	  
assessing	  FMD	  differed	  considerably	  among	  the	  rest	  of	  the	  trials.	   Indeed	  FMD	  values	  
varied	  considerably	  from	  study	  to	  study,	  with	  an	  average	  baseline	  FMD	  ranging	  from	  
4.1%	  to	  8.4%.	  Further	  to	  this,	  sample	  characteristics	  such	  as	  underlying	  health	  status	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and	  ethnicity	  were	  different	  and	  follow-­‐up	  time	  in	  the	  studies	  ranged	  from	  6	  weeks	  to	  
3	   months.	   All	   these	   differences	   between	   the	   studies	   should	   be	   considered	   when	  
interpreting	  the	  data.	  Lastly,	  assessment	  of	  endothelial	  function	  with	  FMD	  is	  not	  free	  
from	   methodological,	   physiological	   and	   technical	   factors	   that	   can	   influence	   the	  
validity,	   reproducibility	   and	   interpretation	   of	   results	   in	   clinical	   research613.	   As	  
confirmation	  of	  our	   cautious	   interpretation	  of	   the	  evidence,	   a	   statistically	   significant	  
high	  level	  of	  heterogeneity	  was	  found	  (80.1%	  for	  case-­‐control	  and	  78%	  for	  intervention	  
trials).	   Further	   evidence	   supporting	   the	   beneficial	   role	   of	   periodontal	   treatment	   in	  
improving	   endothelial	   function	   derives	   from	   other	   3	   RCT;	   two	   were	   conducted	  
assessing	   endothelial	   function	  with	   a	  more	   invasive	   technique	   (response	   of	   brachial	  
blood	   flow	   to	   acetylcholine	   injection)	   and	   both	   showed	   a	   statistically	   significant	  
improvement	  after	  periodontal	  therapy375,413.	  The	  third	  one	  is	  the	  only	  RCT	  reporting	  
on	  measure	   of	   endothelial	   function	  with	   FMD.	   Our	   group	   concluded	   that	   6	  months	  
after	  intensive	  periodontal	  therapy	  (associated	  with	  a	  substantial	  improvement	  in	  the	  
gingival	  condition)	  individuals	  presented	  with	  a	  2.0%	  greater	  value	  of	  FMD	  (95%	  CI	  1.2	  
to	   2.8;	   P<0.001)	   compared	   to	   controls12.	   Our	   interpretation	   of	   these	   studies	   results	  
and	   the	   meta-­‐analysis	   collectively	   supports	   a	   causal	   association	   between	   PD	   and	  
endothelial	  dysfunction.	   Further	   research	   should	  be	  performed	   in	  understanding	   the	  
exact	  mechanisms	  behind	  this	  link.	  
3.5. Conclusions	  
We	  conclude	  that	  PD	  is	  associated	  with	  greater	  subclinical	  atherosclerosis	  as	  assessed	  
an	  increased	  c-­‐IMT	  which	  is	  considered	  an	  independent	  predictor	  of	  CV	  events	  in	  high-­‐
risk	  populations.	  We	  also	  found	  evidence	  of	  an	   impaired	  FMD	  in	   individuals	  suffering	  
from	  PD.	  Our	  data	  also	  suggest	  a	  beneficial	  effect	  of	  periodontal	   intervention	  on	  this	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marker.	   Robust	   prospective	   studies	   are	   needed	   to	   improve	   understanding	   of	   the	  
mechanisms	  underlying	  this	  association.	  Furthermore,	  intervention	  trials	  will	  help	  the	  
identification	   of	   common	   pathways	   explaining	   the	   link	   between	   evolution	   of	  
atherosclerosis	  and	  PD.	  Standardized	  protocols	  to	  measure	  c-­‐IMT	  and	  FMD	  as	  well	  as	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4. STUDY	  2:	  MITOCHONDRIAL	  OXIDATIVE	  STRESS,	  SYSTEMIC	  
INFLAMMATION,	   ENDOTHELIAL	   FUNCTION	   AND	   METABOLIC	  




4.1.1. Mitochondrial	   dysfunction	   and	   oxidative	   stress:	   the	   missing	   link	   between	  
inflammation	  and	  cardiovascular	  disease	  
It	  is	  now	  accepted	  that	  inflammation	  plays	  a	  key	  role	  in	  the	  appearance	  and	  evolution	  
of	   atherosclerosis107.	   Immune	   cells	   dominate	   early	   atherosclerotic	   plaques,	   their	  
effector	   molecules	   accelerate	   atheroma	   progression	   and	   inflammatory	   activation	  
elicits	   acute	   coronary	   syndromes	   and	   clinical	   events293.	   Loss	   of	   normal	   endothelial	  
function	   (endothelial	   dysfunction)	   is	   one	   of	   the	   earliest	   manifestations	   of	  
inflammation-­‐related	  vascular	  damage80.	   It	   is	  characterized	  by	  reduced	  bioavailability	  
of	  nitric	  oxide	  (NO)	  and	  increased	  expression	  of	  adhesion	  molecules	  and	  inflammatory	  
genes	   by	   endothelial	   cells614.	   We	   have	   previously	   shown	   that	   this	   early	   stage	   of	  
vascular	   damage	   is	   partially	   reversible	   by	   modulating	   the	   levels	   of	   inflammatory	  
exposure12.	  Using	  a	  chronic	   inflammatory	  model	   (periodontitis	  and	   its	   treatment)	  we	  
have	  demonstrated	  that	  effective	  treatment	  of	  oral	  and	  systemic	  inflammation	  results	  
in	   an	   improvement	   of	   endothelial	   function.	   While	   this	   study	   represented	   the	   first	  
evidence	   in	   humans	   of	   the	   crucial	   role	   of	   systemic	   inflammation	   in	   attenuating	   the	  
development	  of	  abnormal	  vascular	  biology,	  the	  molecular	  mechanisms	  accounting	  for	  
these	  results	  have	  not	  been	  fully	  elucidated.	  Animal	  models	  and	  in	  vitro	  studies	  have	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shown	   that	   an	   overproduction	   of	   reactive	   oxygen	   species	   (ROS)	   is	   an	   important	  
mechanism	   by	   which	   inflammation	   drives	   CVD615.	   ROS	   convert	   native	   low-­‐density	  
lipoprotein	   (LDL)	   cholesterol	   to	   oxidised	   LDL	   cholesterol	   (oxLDL),	   highly	   cytotoxic	  
molecules	   that	   reduce	   the	   anti-­‐atherosclerotic	   functions	   of	   the	   endothelium616.	  
Moreover,	  oxidative	  stress	  reduces	  the	  bioavailability	  of	  endothelial	  NO	  and	  increases	  
vascular	  endothelial	  permeability,	  promoting	   leukocyte	  migration	   into	  the	  sub-­‐intima	  
space617.	  Activated	  inflammatory	  cells	  in	  the	  sub-­‐intimal	  space	  produce	  high	  amounts	  
of	   ROS,	   further	   increasing	   the	   oxidation	   of	   LDL	   and	   subsequent	   activation	   of	   local	  
endothelial	   cells.	   Of	   the	  many	   potential	   cellular	   sources	   of	   chronic	   ROS	   production,	  
mitochondria	   represent	   the	   most	   relevant	   under	   physiological	   conditions618.	  
Mitochondrial	  respiration	  represents	  the	  mechanism	  by	  which	  cells	  consume	  nutrients	  
(i.e.	   glucose)	   and	   oxygen	   to	   provide	   energy	   (ATP)	   for	   many	   cellular	   reactions.	   This	  
process	   requires	   the	   presence	   of	   an	   electromotive	   differential	   across	   the	   inner	  
mitochondrial	   membrane	   and	   is	   maintained	   by	   the	   highly	   coordinated	   activity	   of	  
several	   enzymes	   (respiratory	   chain).	   Due	   to	   exogenous	   environmental	   changes	   (i.e.	  
inflammation),	  the	  synchronised	  activity	  of	  the	  respiratory	  chain	  enzymes	  can	  be	  lost	  
(mitochondrial	  dysfunction),	  resulting	  in	  reduced	  trans-­‐membrane	  potential,	  increased	  
ROS	  generation	  and	  reduced	  metabolic	  efficiency619.	  Therefore,	  the	  primary	  marker	  of	  
mitochondrial	   dysfunction	   is	   the	   breakdown	   of	   mitochondrial	   membrane	   potential,	  
often	   associated	  with	  mitochondrial	   DNA	  damage	   (mtDNA).	   Emerging	   evidence	   now	  
suggests	  that	   increased	   levels	  of	  mitochondrial	  ROS	  production	  directly	  contribute	  to	  
the	  evolution	  of	  the	  inflammatory-­‐related	  CVD.	  Accumulation	  of	  mtDNA	  damage,	  and	  
progressive	  respiratory	  chain	  dysfunction	  have	  been	  associated	  with	  atherosclerosis	  or	  
cardiomyopathy	   in	   both	   human	   investigations	   and	   animal	   models	   of	   oxidative	  
stress620,621.	   Moreover,	   major	   precursors	   of	   atherosclerosis	   -­‐hypercholesterolemia,	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hyperglycemia,	   hypertriglyceridemia,	   and	   even	   the	   process	   of	   aging-­‐	   all	   induce	  
mitochondrial	   dysfunction622.	   Chronic	   overproduction	   of	  mitochondrial	   ROS	   leads	   to	  
increased	   oxidation	   of	   LDL	   and	   dysfunction	   of	   endothelial	   cells	   and	   ultimately	  
promoting	   atherogenesis623.	   Much	   of	   what	   is	   known	   regarding	   the	   impact	   of	  
mitochondrial	  dysfunction	  in	  CVD	  has	  been	  generated	  from	  animal	  models	  and	  in	  vitro	  
studies.	  	  
4.1.2. Oxidative	  stress	  and	  mitochondrial	  dysfunction	  can	  account	  for	  the	  increased	  
CVD	  risk	  of	  patients	  with	  type	  2	  diabetes	  and	  periodontitis	  
We	  have	   selected	   two	   common	   diseases	   in	   the	   general	   population,	   type	   2	   diabetes	  
and	   periodontitis,	  which	   often	   coexist	   in	   the	   same	   patient	   and	   are	   characterized	   by	  
high	   levels	   of	   inflammatory	   exposure,	   mitochondrial	   dysfunction	   and	   high	   risk	   of	  
CVD624.	   	   Diabetes	   is	   a	   systemic	   disease	   characterized	  by	   reduced	   insulin	   activity	   and	  
glucose	   consumption	   in	   peripheral	   tissues.	   It	   affects	   more	   than	   150	   million	   people	  
worldwide,	  and	  it	  is	  estimated	  that	  this	  number	  will	  increase	  to	  299	  million	  by	  the	  year	  
2025625.	   CV	  mortality	   is	   two-­‐	   to	   eight-­‐folds	   higher	   in	   subjects	  with	   diabetes	   and	   the	  
generation	   of	   ROS	  may	   play	   an	   important	   role	   in	   the	   aetiology	   of	   diabetic	   vascular	  
complications626,627.	   Indeed,	   exposure	   of	   endothelial	   cells	   to	   high	   glucose	   levels	  
increases	   ROS	   production,	   quenching	   endothelial	   derived	  NO	   and	   reducing	   the	   anti-­‐
atherosclerotic	   properties	   of	   the	   quiescent	   endothelium628.	   Multiple	   studies	   have	  
documented	   that	   human	   insulin	   resistance	   is	   accompanied	   by	   impaired	   in	   vivo	  
mitochondrial	  oxidative	  function629,630.	  The	  development	  of	  mitochondrial	  dysfunction	  
could	  represent	  a	  crucial	  mechanism,	   linking	  hyperglycaemic-­‐induced	  oxidative	  stress	  
production	   and	   the	   development	   of	   vascular	   damage	   in	   patients	   with	   diabetes.	  	  
Periodontitis	   is	  currently	  considered	  an	   important	  global	  oral	  health	  burden	  together	  
with	   dental	   caries;	   its	   reported	   prevalence	   ranges	   from	   20%	   to	   50%	   in	   the	   general	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population166,631,632.	   The	   local	   chronic	   inflammatory	   response	   to	   the	   oral	   bacteria	   is	  
associated	   with	   systemic	   inflammation633,634	   and	   increased	   future	   risk	   of	   other	   co-­‐
morbidities	   including	   cardiovascular	   diseases635.	   Oxidative	   stress	   and	   mitochondrial	  
dysfunction	  may	  play	  a	  central	  role	  in	  the	  association	  between	  periodontitis	  and	  CVD.	  
Indeed,	   an	   excess	   of	   ROS	   coupled	  with	   a	   decreased	   antioxidant	   capacity	   have	   been	  
already	   documented	   in	   the	   peripheral	   blood	   of	   patients	   suffering	   from	  periodontitis	  
497.	   Similarly,	   mitochondrial	   dysfunction	   has	   been	   described	   in	   the	   peripheral	   blood	  
mononuclear	   cells	   and	   gingival	   tissues	   of	   subjects	   affected	   by	   chronic	  
periodontitis636,637.	  	  
In	  patients	  suffering	  from	  type	  2	  diabetes	  and	  periodontitis,	  the	  systemic	  inflammatory	  
response	   associated	   with	   the	   oral	   disease	   is	   linked	   with	   impaired	   gluco-­‐metabolic	  
control185	  and	   increases	  CV	  mortality321.	  There	   is	  also	  evidence	   that	   treatment	  of	  PD	  
could	   improve	   glucose	   management	   in	   patients	   with	   diabetes638	   and	   improve	  
endothelial	   function12.	   As	   the	   biological	   pathways	   accounting	   for	   these	   findings	   are	  
poorly	   understood,	   our	   group	   has	   established	   and	   validated	   a	   novel	   experimental	  
model	  to	  examine	  the	  complex	  mechanisms	  behind	  vascular	  adaptations	  to	  acute	  and	  
chronic	  inflammatory	  responses:	  PD	  treatment	  model.	  The	  primary	  aim	  of	  this	  project	  
was	   to	   determine	   whether,	   in	   patients	   with	   periodontitis	   and	   type	   2	   diabetes,	  
endothelial	   function	   can	   be	   improved	   by	   reducing	   local	   and	   systemic	   inflammation	  
after	  periodontal	  treatment.	  The	  secondary	  aim	  was	  to	  explore	  whether	  mitochondrial	  
function	   correlated	   with	   measures	   of	   endothelial	   function	   and	   gluco-­‐metabolic	  
control.	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4.2. METHODS	  
4.2.1. Study	  Design	  
We	   have	   analyzed	   changes	   of	   mtROS	   production	   and	   mitochondrial	   function	   in	   a	  
parallel	  group,	  single-­‐blind,	  randomized,	  controlled	  trial	  which	  evaluated	  the	  effect	  of	  
periodontal	  therapy	  on	  glycemic	  control	  in	  T2DM.	  	  
Recruitment	  and	  study	  flowcharts	  are	  reported	  in	  Figure	  24.	  
	  
Figure	  24	  Study	  Flowchart	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Consecutive	  patients	  with	  T2DM	  and	  moderate	  to	  severe	  PD	  referred	  to	  the	  Eastman	  
Dental	   Hospital	   (London,	  United	   Kingdom)	   between	  December	   2011	   and	   September	  
2012	  fulfilling	  the	  study	  requirements	  were	  included	  in	  our	  sample.	  	  
The	  inclusion	  criteria	  were:	  	  
	  aged	  over	  18	  years,	  diagnosis	  of	  T2DM,	  a	  minimum	  of	  15	  teeth,	  at	  least	  20	  sites	  with	  
periodontal	  pocket	  depth	  (PPD)	  ≥	  5mm.	  	  
The	  exclusion	  criteria	  were:	  
	  pregnancy/lactation,	   HIV	   or	   Hepatitis	   (B,	   C),	   	   subjects	   with	   uncontrolled	   systemic	  
diseases	   or	   neoplasm,	   chronic	   antibiotic	   therapy	   or	   requiring	   antibiotic	   coverage	   for	  
dental	   procedures,	   chronic	   treatment	  with	  medications	   known	   to	   affect	   periodontal	  
status	  (phenytoin,	  cyclosporine).	  	  
Following	  a	  baseline	  visit,	  each	  participant	  was	  randomly	  allocated,	  with	  the	  use	  of	  a	  
computer-­‐generated	   table,	   to	   receive	   either	   intensive	   periodontal	   therapy	   (IPT)	   or	  
control	   periodontal	   therapy	   (CPT).	   Blood	   samples	   were	   collected	   at	   baseline	   and	   6	  
months	   after	   the	   periodontal	   therapy	   for	   PBMC	   isolation	   and	   assessment	   of	  
mitochondrial	   parameters,	   as	   well	   as	   to	   assay	   levels	   of	   inflammatory	   cytokines	   and	  
cardiovascular	   risk	   factors.	   Endothelial	   function	   was	   assessed	   by	   flow-­‐mediated	  
dilation	   (FMD)	   at	   baseline	   and	   6	   months	   from	   treatment.	   Laboratory	   and	   vascular	  
technicians	  were	   blind	   to	   the	   patient	   treatment	   allocation.	   All	   patients	   gave	  written	  
informed	   consent.	   The	   study	   was	   approved	   by	   the	   local	   ethics	   committee	   (Ref	  
07/H0714/97,	   joint	  UCL/UCLH	  Committees	  on	  Ethics	  of	  Human	  Research,	  Committee	  
A).	  
4.2.2. Periodontal	  Examination	  and	  Therapy	  
Periodontal	   data	   were	   recorded	   at	   baseline	   and	   2	   months	   and	   6	   months	   after	   the	  
therapy.	  The	  data	  included	  the	  PPD	  and	  the	  recession	  of	  the	  gingival	  margin	  relative	  to	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the	   cement-­‐enamel	   junction	   at	   six	   sites	   per	   tooth.	   The	   presence	   or	   absence	   of	  
supragingival	  dental	  plaque	  and	  gingival	  bleeding	  on	  probing	  was	  also	  recorded.	  Oral	  
hygiene	   instructions	  were	  given	   to	  all	  patients.	  The	   IPT	  arm	  underwent	  extraction	  of	  
hopeless	   teeth,	   full	   mouth	   scaling	   and	   root	   planing	   (SRP)	   under	   local	   anaesthesia	  
within	  a	  single	  session.	  As	  described	  in	  Chapter	  2,	  corrective	  periodontal	  therapy	  was	  
also	   performed	   in	   patients	   with	   adequate	   control	   of	   dental	   plaque	   in	   deeper	  
periodontal	   sites	   and	   non-­‐surgical	   treatment	   repeated	   in	   all	   remaining	   sites	   (9	  
participants).	   In	   the	   CPT	   arm	   patients	   had	   a	   repeated	   cycle	   of	   supra-­‐gingival	   scaling	  
and	  polishing.	  
4.2.3. Mitochondrial	  membrane	  potential	  and	  ROS	  production	  
Peripheral	   blood	   mononuclear	   cells	   (PBMC)	   were	   isolated	   following	   standard	  
procedures	  by	  density	  gradient	   centrifugation	  with	  Ficoll	   (Ficoll-­‐Paque	  PLUS,	  GE,	  UK)	  
from	   an	   aliquot	   of	   heparinised	   blood	   collected	   at	   each	   study	   visit.	   Mitochondrial	  
oxidative	  stress	  production	  and	  membrane	  potential	  were	  assessed	  by	  flow	  cytometry	  
using	   the	  mito	   probe	  MitoSOX	   Red	   (Invitrogen,	   UK)	   and	   5’,6,6’-­‐tetrachloro-­‐1,1’,3,3’-­‐
tetraethylbenzimidazolylcarbocyanine	   iodide	   (JC-­‐1,	   Invitrogen),	   respectively	   as	  
described	  in	  previously	  described	  in	  the	  Methods	  section	  of	  this	  thesis.	  
4.2.4. LPS	  assay	  
Serum	   endotoxin	   activity	  was	   determined	   by	   the	   Limulus	   Amebosyte	   Lysate	   test	   kit	  
with	  a	  chromogenic	  substrate	  (Lonza,	  Walkersville,	  MD,	  US).	  The	  steps	  of	  the	  LPS	  assay	  
are	  described	  in	  the	  Methods	  chapter.	  Intra-­‐	  and	  inter-­‐	  coefficient	  of	  variations	  for	  all	  
assays	  were	  <	  5%.	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4.2.5. Endothelial	  function	  
Endothelium-­‐dependent	  vasodilatation	  of	  the	  brachial	  artery	  at	  baseline	  and	  6	  months	  
follow	  up	  was	  assessed	  by	  means	  of	  ultrasound	  imaging	  (Acuson	  XP	  128/10,	  Siemens)	  
with	  the	  use	  of	  a	  7-­‐MHz	   linear	  probe	  and	  automated	  vessel-­‐diameter	  measurements	  
(Brachial	  Tools,	  version	  3.2.6,	  Medical	  Imaging	  Applications),	  as	  previously	  described.	  A	  
single	  examiner	  blind	   to	   the	  patient	   treatment	  allocation	  acquired	   the	   images	  of	   the	  
brachial	   artery	   in	   the	   morning,	   while	   patients	   were	   fasting,	   in	   a	   temperature-­‐
controlled	   room	   after	   10	   minutes	   of	   rest.	   Endothelium-­‐independent	   dilatation	   was	  
measured	   after	   sublingual	   administration	   of	   25	   μg	   of	   nitroglycerin,	   according	   to	   the	  
same	  recording	  protocol.	  
4.2.6. Inflammatory,	  metabolic	  and	  vascular	  injury	  assays	  
Serum	   and	   plasma	   were	   assayed	   for	   a	   variety	   of	   inflammatory	   biomarkers	   at	   the	  
baseline	  and	  6	  months	  visit.	  Sample	  were	  centrifuged	  within	  1	  hour	  of	  collection	  and	  
stored	   at	   –70°C	   for	   future	   analysis.	   The	   circulating	   inflammatory	   markers	   assessed	  
were:	  IL-­‐1β,	  IL-­‐6,	  IL-­‐8,	  IL-­‐10,	  IL-­‐12,	  IFN-­‐γ,	  TNF-­‐α	  (Mesoscale,	  Human	  pro-­‐inflammatory	  
7-­‐plex)	   and	   sICAM-­‐3,	   E-­‐Selectin,	   P-­‐Selectin,	   Thrombomodulin	   (Mesoscale,	   Human	  
vascular	   injury	   Panel	   I)	   serum	   levels.	   HbA1c	   and	   insulin	   levels	   were	   assayed	   on	   an	  
automated	  analyzer	  (Cobas	  8000	  analyzer,	  Roche	  Diagnostics	  Corp).	  All	  samples	  were	  
evaluated	  in	  a	  blinded	  fashion	  and,	  to	  minimize	  variability,	  all	  assays	  were	  performed	  
at	  the	  end	  of	  the	  study,	  in	  duplicates	  and	  on	  the	  same	  ELISA	  plate	  at	  both	  time	  points	  
for	  a	  given	  patient.	  	  
4.2.7. Statistical	  Analysis	  	  
As	  there	  were	  no	  data	  in	  the	  literature	  that	  allow	  predicting	  changes	  of	  mitochondrial	  
function	  after	  anti-­‐inflammatory	   treatment,	  we	  based	   the	   sample	   size	   calculation	  on	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the	   changes	   of	   measures	   of	   inflammation	   and	   cardiovascular	   health	   expected	   after	  
dental	   treatment.	   A	   total	   of	   44	   patients	   (22	   per	   study	   arm)	   provided	   90%	   power	   (2	  
sided,	   p=0.05)	   to	   detect	   a	   2%	  difference	   in	   a	   common	  measure	  of	   vascular	   function	  
(flow-­‐mediated	  dilatation)	  between	  groups	  using	  an	  estimated	   standard	  deviation	  of	  
1.6	  derived	  from	  our	  previous	  published	  data.	  Therefore	  the	  sample	  size	  of	  the	  clinical	  
study	  included	  24	  participants	  per	  group	  (10%	  drop	  out	  rate).	  	  
All	   data	   produced	   by	   the	   laboratory	   analyses	  were	   entered	   in	   a	   computer	   database	  
proofed	   for	   entry	   errors	   and	   loaded	   in	   the	   appropriate	   software	   for	   analysis	   (SPSS	  
ver21).	   Changes	   in	  mitochondrial	   function	  were	   analyzed	   by	   analysis	   of	   variance	   for	  
repeated	  measures	  between	  IPT	  and	  CPT	  groups	  including	  data	  at	  baseline,	  day	  1,	  day	  
7,	  2	  months	  and	  6	  months.	  A	  conservative	  F-­‐test	  was	  used	  to	  interpret	  the	  model	  using	  
the	   Greenhouse-­‐Geisser	   correction	   to	   account	   for	   compound	   symmetry	   violations.	  
Changes	   in	   inflammatory	   biomarkers	  were	   correlated	  with	   changes	   in	  mitochondrial	  
membrane	  potential	  and	  ROS	  production	  at	  day	  1	  and	  6	  months.	  The	  relative	  changes	  
were	  calculated	  by	  subtracting	  the	  value	  at	  day	  1	  or	  6	  months	  from	  the	  baseline	  value	  
of	   the	   outcome	   of	   interest.	   These	   changes	   were	   then	   analyzed	   both	   with	   simple	  
Pearson	   or	   Spearman	   tests	   (depending	   on	   the	   data	   distribution)	   and	  multiple	   linear	  
regression	  analyses	  with	  robust	  standard	  errors.	  Univariate	  analyses	  were	  performed	  
with	   crude	   values	  of	   each	  outcome	  variable	  between	   study	   groups	   at	   different	   time	  
points.	  Further	  multivariate	  models	  were	  constructed	  including	  variables	  that	  showed	  
a	   statistically	   significant	   association	  	  with	   the	   outcome	   from	  univariate	   analyses	   and	  
they	  included	  age,	  gender,	  smoking,	  body	  weight	  and	  ethnicity.	  Significance	  was	  set	  to	  
be	  at	  p	  <	  0.05.	  
	   214	  
4.3. RESULTS	  
Between	  December	  2011	  and	  September	  2012	  we	  screened	  63	  suitable	  participants:	  9	  
declined	   the	   participation	   therefore	   54	   were	   included	   in	   the	   study.	   After	  
randomization	  27	  patients	  were	  allocated	  to	  each	  treatment	  group.	  Three	  participants	  
in	   the	   CPT	   group	   refused	   to	   provide	   additional	   blood	   for	   the	   mitochondrial	   assays	  
following	  the	  baseline	  visit.	  All	  participants	  completed	  the	  trial.	  There	  were	  no	  major	  
adverse	  events	  reported	  in	  both	  groups.	  
4.3.1. Patient	  characteristics	  	  
At	  baseline	  patients	  in	  the	  control-­‐treatment	  group	  and	  the	  intensive-­‐treatment	  group	  
had	   similar	   characteristics	   including	   age,	   gender,	   smoking	   status,	   lipid	   levels,	   body-­‐
mass	  index,	  blood	  glucose	  levels	  (Table	  20)	  and	  medication	  use	  (Table	  21).	  	  
Table	  20	  Baseline	  characteristics	  of	  the	  study	  participants	  
Variable (mean±SD) CPT (N=24) IPT (M=27) 
Age,	  years	   58±11	   56±9	  
BMI,	  Kg/m2	   32±5	   32±7	  
Gender,	  Males	   10(42%)	   15(56%)	  
Smoking,	  Current	   1(4%)	   1(4%)	  
Systolic	  BP,	  mmHg	   134±19	   136±18	  
Diastolic	  BP,	  mmHg	   81±11	   84±11	  
HbA1c	  (%)	   7.7±1.2	   7.9±1.4	  
Cholesterol,	  mmol/l	   4.3±1.0	   4.3±1.1	  
HDL,	  mmol/l	   1.3±0.4	   1.3±0.4	  
LDL,	  mmol/l	  	   2.0±0.9	   2.3±0.9	  
FMD%	   4.18±2.28	   4.13±2.98	  
CRP*,	  mg/l	   1.8	  (3.1)	   2.2	  (3.0)	  
TNF-­‐α*,	  pg/ml	  	   3.7	  (1.8)	   4.0	  (1.7)	  
s-­‐Eselectin*,	  pg/ml	   24.8(20.2)	   25.8(11.0)	  
s-­‐Pselectin*,	  pg/ml	   118.8(35.8)	   103.1(30.1)	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Interferon-­‐γ*,	  pg/ml	   1.1(2.4)	   0.9(1.9)	  
Mitosox,	  MFI	   25.4±12.5	   23.4±10.5	  
JC-­‐1,	  MFI	   5.33±3.98	   5.84±5.02	  
LPS,	  EU/mL	   0.39±1.49	   0.27±1.74	  
Values	  are	  expressed	  as	  means±SD	  or	  *median	  (interquartile	  range)	   for	  non-­‐normally	  
distributed	  variables.	  
	  
Table	  21	  Baseline	  medication	  use	  
Variable	  (mean±SD)	   CPT	  (N=24)	   IPT	  (M=27)	  
Biguanides	   20(84.2%)	   26(96.3%)	  
Sulfonylureas	   11(47.4%)	   13(48.1%)	  
Thiazolidinediones	  Pioglitazone	   4(15.8%)	   1(3.7%)	  
DPP-­‐4	  Inhibitors	   5(21.1%)	   4(14.8%)	  
Incretins	  GLP-­‐1	  analogs	   0(0.0%)	   4(14.8%)	  
Betablocker	   8(31.6%)	   6(22.2%)	  
Diuretic	   5(21.1%)	   4(14.8%)	  
Ca	  channel	  blocker	   4(15.8%)	   5(18.5%)	  
Alpha	  blocker	   1(5.3%)	   3(11.1%)	  
Angiotensin-­‐II	  blocker	   3(10.5%)	   5(18.5%)	  
Ace	  Inhibitors	   13(52.6%)	   12(44.4%)	  
Statin	   19(78.9%)	   22(81.5%)	  
Aspirin	   11(47.4%)	   7(25.9%)	  
	  
4.3.2. Periodontal	  outcomes	  
A	   statistically	   significant	   interaction	   between	   treatment	   and	   time	   (p<0.001)	   was	  
detected	  with	  repeated-­‐measures	  ANOVA	  of	  the	  periodontal	  outcomes.	  The	  intensive-­‐
treatment	   group	   had	   lower	   scores	   for	   plaque	   6	   months	   after	   therapy	   (absolute	  
difference	  of	  27%;	  95%	  CI,	  15-­‐40;	  p<0.001)	  compared	  to	  the	  control	  group	  (Table	  22).	  
Similarly	   patients	   in	   the	   intensive-­‐treatment	   group	   had	   fewer	   periodontal	   pockets	   6	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months	   after	   therapy	   (average	   difference	   between	   groups	   of	   15;	   95%	   CI,	   3-­‐26;	  
p=0.014)	  (Table	  22).	  
Table	  22	  Periodontal	  parameters	  at	  Baseline	  and	  6	  Months	  after	  Periodontal	  Therapy	  
Variable	   Group	   	   Baseline	   6	  months	  
FMPS,	  %	  §	   IPT	   80±13	   42±20	  †	  
	   CPT	   82±15	   69±20	  
FMBS,	  %	  ¶	   IPT	   70±20	   36±21	   †	  
	   CPT	   72±15	   58±18	  
PPD,	  mm	   IPT	   3.9±0.8	   2.9±0.7	  
	   CPT	   3.6±0.7	   3.3±0.7	  
REC,	  mm	   IPT	   1.2±0.9	   1.7±1.0	  
	   CPT	   1.3±0.8	   1.6±0.8	  
NPKTs,	  n	  *	   IPT	   56±28	   17±16	  †	  
	   CPT	   41±19	   32±22	  
Values	  are	  expressed	  as	  means±SD.	  	  
†	  P<0.001	  for	  the	  comparison	  with	  the	  standard-­‐treatment	  group.	  
IPT:	  intensive	  treatment	  group,	  CPT:	  control	  treatment	  group,	  FMPS:	  full	  mouth	  plaque	  
score,	  FMBS:	   full	  mouth	  bleeding	  score,	  PPD:	  periodontal	  pocket	  depth,	  REC:	  gingival	  
recession,	  NPKTS,	  number	  of	  pockets.	  
¶	   Scores	   for	   full-­‐mouth	   gingival	   bleeding	   were	   calculated	   for	   each	   patient	   as	   the	  
number	  of	  sites	  with	  gingival	  bleeding	  on	  probing	  divided	  by	  the	  total	  number	  of	  sites	  
per	  mouth,	  multiplied	  by	  100.	  
§	  Scores	  for	  full-­‐mouth	  plaque	  were	  calculated	  for	  each	  patient	  as	  the	  number	  of	  sites	  
with	  detectable	  plaque	  divided	  by	   the	   total	  number	  of	   sites	  per	  mouth,	  multiplied	  by	  
100.	  
*	  Periodontal	  pockets	  identified	  as	  sites	  with	  probing	  greater	  or	  equal	  to	  5	  mm	  
	  
4.3.3. Mitochondrial	  ROS	  production	  and	  Membrane	  potential	  	  
The	  PBMC	  of	  the	   IPT	  group	  had	  a	  significantly	   lower	  mtROS	  production	  compared	  to	  
the	  CPT	  group	  at	  6	  months	  following	  dental	  treatment	  (unadjusted	  difference	  of	  8.49;	  
95%	   CI,	   1.31-­‐15.68;	   p=0.02)	   (Figure	   25	   A).	   When	   subpopulations	   of	   PBMC	   were	  
analysed	   separately,	   the	   reduced	   mtROS	   generation	   of	   PBMC	   was	   mainly	   due	   to	   a	  
reduction	  in	  oxidative	  stress	  production	  in	  lymphocytes	  (unadjusted	  difference	  of	  6.32;	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95%	   CI,	   0.51-­‐12.14;	   p=0.034),	   although	   a	   non-­‐statistically	   significant	   trend	   was	  
detected	   also	   in	   monocytes	   (unadjusted	   difference	   of	   14.28;	   95%	   CI,	   -­‐28.26-­‐56.81;	  
p=0.501)	   (figure	   25	   B,	   25	   C).	   There	   was	   no	   difference	   between	   groups	   in	   the	  
mitochondrial	  membrane	  potential	  of	  PBMC(unadjusted	  difference	  of	   -­‐0.38;	  95%	  CI,-­‐
1.0-­‐0.23;	   p=0.223),	   lymphocytes	   (unadjusted	   difference	   of	   -­‐0.13;	   95%	   CI,	   -­‐0.76-­‐0.51;	  
p=0.692)	   and	   macrophages	   (unadjusted	   difference	   of	   0.19;	   95%	   CI,	   -­‐0.28-­‐0.65;	  
p=0.423)	  (Figure	  26A,	  26B,	  26C).	  
	  
Figure	  25	  Changes	  in	  mtROS	  production	  during	  the	  study	  period.	  
A) PBMC,	  B)	  Lymphocytes,	  C)	  Monocytes.	  I	  bars	  represent	  SE.	  mtROS	  production	  was	  significantly	  lower	  in	  PBMC	  
(P<0.01)	  and	  lymphocytes	  (P<0.05)	  at	  6	  month	  in	  the	  IPT	  compared	  to	  the	  CPT	  group.	  Data	  adjusted	  for	  age,	  
gender,	  smoking,	  body	  weight	  and	  ethnicity.	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Figure	  26	  Changes	  in	  JC-­‐1	  during	  the	  study	  period.	  
PBMC	  (A),	  Lymphocytes	  (B),	  Monocytes	  (C).	  There	  were	  no	  differences	  between	  IPT	  and	  CPT	  groups.	  I	  bars	  represent	  
SE.	  
4.3.4. LPS	  
A	  statistically	  significant	  difference	  in	  LPS	  plasma	  levels	  between	  CPT	  and	  IPT	  patients	  
was	  observed	  6	  months	  after	  periodontal	   treatment	   (unadjusted	  difference	  of	  2.73	   ;	  
95%	  CI,	  1.15-­‐6.45;	  p=0.023)	  (Figure	  27).	  
	  
Figure	  27	  Changes	  in	  LPS	  during	  the	  study	  period	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4.3.5. Vascular	  function	  	  
There	   was	   a	   significant	   interaction	   between	   treatment	   and	   time	   using	   repeated-­‐	  
measures	  analysis	  of	  variance	  of	   flow-­‐mediated	  dilatation	   (p<0.001)	   (Fig.	  28).	  After	  6	  
months	  from	  treatment,	  FMD	  was	  higher	  in	  the	  intensive	  treatment	  group	  than	  in	  the	  
control-­‐treatment	  group	  (absolute	  difference	  of	  0.9%;	  95%	  CI,	  0.3-­‐1.4;	  p=0.002).	  There	  
was	   an	   average	   increase	   in	   FMD	   from	   baseline	   of	   24.0±10.7%	   in	   the	   IPT	   group	  
compared	  to	  CPT	  (p=0.03),	  (Figure	  29).	  Conversely,	  no	  interaction	  between	  treatment	  
and	   time	   was	   observed	   for	   nitroglycerin-­‐dependent	   dilatation	   or	   for	   brachial	   artery	  
diameters	   and	   no	   changes	   of	   the	   nitroglycerin-­‐dependent	   dilatation	   were	   observed	  
from	  baseline	  to	  6	  months	  (unadjusted	  difference	  of	  0.3;	  95%	  CI,	  -­‐1.5-­‐2.0;	  p=0.65).	  
	  
Figure	  28	  Flow	  mediated	  dilatation	  during	  the	  study	  duration	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Figure	  29	  Average	  FMD	  change	  from	  baseline	  
4.3.6. Markers	  of	  inflammation	  and	  adhesion	  	  
Statistically	   significant	   interaction	   between	   treatment	   and	   time	   for	   plasma	   levels	   of	  
tumor	  necrosis	  factor-­‐α	  (p=0.03),	  interferon-­‐γ	  (p=0.04)	  and	  soluble	  P-­‐selectin	  (p=0.02)	  
were	  noted.	  At	  6	  months,	  patients	  in	  the	  IPT	  group	  had	  lower	  circulating	  levels	  of	  TNF-­‐	  
α	   (average	   adjusted	   between	   groups	   difference	   of	   0.76	   pg/ml,	   95%	   CI,	   0.08-­‐1.44,	  
p=0.02),	  interferon-­‐γ	  (average	  adjusted	  between	  groups	  difference	  of	  1.38	  pg/ml,	  95%	  
CI,	  0.26-­‐2.49,	  p=0.01)	  and	  P	  –Selectin	  (average	  adjusted	  between	  groups	  difference	  of	  
21.38	  pg/ml,	  95%	  CI,	   6.79-­‐35.97,	  p=0.01)	  	  compared	  to	  the	  CPT	  group	  (Table	  23).	  	  
Table	  23	  Circulating	  biomarkers	  at	  baseline	  and	  6	  months	  after	  treatment	  
Variable	   Group	   	   Baseline	   6	  months	  
Interferon-­‐γ ,	  pg/ml*	   CPT	   1.1(2.4)	   2.0	  (1.1)	  
	   IPT	   0.9(1.9)	   0.6	  (1.4)††	  
TNF-­‐α ,	  pg/ml*	   CPT	   3.7	  (1.8)	   4.1	  (5.8)	  
	   IPT	   4.0	  (1.7)	   3.7	  (3.2)††	  
s-­‐Eselectin,	  pg/ml	   CPT	   24.8±20.2	   23.2±8.3	  
	   IPT	   25.8±11.0	   18.1±13.3††	  
s-­‐Pselectin,	  pg/ml	   CPT	   118.8±35.7	   104.8±26.8	  
	   IPT	   103.1±30.1	   82.1±22.5††	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Values	  are	  expressed	  as	  means±SD	  or	  *median	  (interquartile	  range)	   for	  non-­‐normally	  
distributed	  variables.	  ††	  P<0.05	  compared	  to	  baseline	  
	  
No	  statistically	  significant	  between	  group	  difference	  at	  6	  months	  was	  detected	  for	  rest	  
of	  the	  markers	  analysed	  (Table	  24).	  
Table	  24	  Non	  significant	  between	  group	  differences	  a	  t	  6	  months	  
Variable	   Unadjusted	  
between	   group	  
difference	  at	  6M	  
95%	  CI	   p	  value	  
CRP	   1.15	   -­‐3.59-­‐	  5.89	   0.627	  
IL-­‐6	   1.21	   -­‐0.65-­‐3.06	   0.196	  
IL-­‐8	   1.62	   -­‐8.32-­‐11.56	   0.744	  
IL-­‐10	   3.17	   -­‐1.38-­‐7.71	   0.167	  
IL-­‐12	   0.48	   -­‐0.23-­‐1.2	   0.182	  
E-­‐Selectin	   0.73	   -­‐5.44-­‐6.9	   0.810	  
ICAM-­‐3	   0.12	   -­‐0.08-­‐0.32	   0.233	  
Thrombomodulin	   0.45	   -­‐0.31-­‐1.21	   0.241	  
	  
4.3.7. Metabolic	  parameters	  
Patients	   in	   the	   IPT	   group	   exhibited	   an	   improved	   metabolic	   control	   6	   months	   after	  
therapy	  compared	  to	  CPT	  patients	  (average	  between	  group	  difference	  of	  0.65%,	  95%CI	  
0.22-­‐1.14,	  p=0.003).	  In	  addition	  a	  statistically	  significant	  reduction	  in	  Glucose	  (average	  
difference	  between	  group	  1.55mmol/l,	  95%CI	  0.25-­‐2.85,	  p=0.012)	  was	  observed	  in	  IPT	  
when	  compared	  to	  CPT	  patients.	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4.4. DISCUSSION	  
This	  is	  the	  first	  study	  to	  show	  that	  mtROS	  production	  can	  be	  modulated	  in	  humans	  and	  
that	   these	   changes	   are	   associated	   with	   a	   reduction	   of	   systemic	   inflammation,	  
improved	   metabolic	   control	   and	   endothelial	   function	   in	   patients	   with	   T2DM.	   These	  
results	   suggest	   mtROS	   may	   play	   an	   important	   role	   in	   the	   relationship	   between	  
systemic	  inflammation	  and	  risk	  of	  CVD	  in	  T2DM	  and	  PD.	  	  Previous	  reports	  documented	  
mitochondrial	  dysfunction	  and	  altered	  oxidative	  stress	  production	  in	  patients	  with	  PD	  
and	   T2DM.	   However,	   we	   are	   the	   first	   to	   show	   that	  mtROS	   production	   can	   improve	  
following	  intensive	  PD	  treatment.	  This	  was	  associated	  with	  a	  better	  control	  of	  systemic	  
inflammation	   and	   a	   general	   improvement	   of	   PD.	   	   mtROS	   production	   is	   increased	  
following	   activation	   of	   immune-­‐inflammatory	   cells639,640	   and	   is	   considered	   a	   crucial	  
step	   for	   pro-­‐inflammatory	   cytokine	   production262,263,641.	   The	   lower	   mtROS	   observed	  
after	  IPT	  may	  reflect	  a	  reduced	  activation	  of	  the	  immune-­‐inflammatory	  system	  due	  to	  
better	  oral	  health	  and	  reduced	  bacteraemia,	  while	  the	  lower	  circulating	  levels	  of	  IFN-­‐γ	  
may	  result	  from	  the	  reduced	  intracellular	  concentration	  of	  mtROS.	  In	  keeping	  with	  this	  
hypothesis,	   we	   show	   that	   IPT	   is	   associated	   with	   a	   greater	   reduction	   of	   mtROS	   in	  
lymphocytes,	   a	   subpopulation	   of	   PBMC	   that	   produces	   IFN-­‐γ	   under	   condition	   of	  
increased	   intracellular	   levels	   of	   oxidative	   stress.	   IFN-­‐γ	   is	   an	   essential	   regulator	   of	  
immune	  function.	  In	  viral	  or	  bacterial	  infection,	  IFN-­‐γ	  is	  at	  the	  top	  of	  the	  inflammatory	  
cascade	   as	   it	   is	   secreted	   by	   activated	   T	   cells	   and	   can	   subsequently	   activate	  
macrophages,	   resulting	   in	   the	   secretion	   of	   other	   pro-­‐inflammatory	   mediators.	  
Therefore,	   our	   data	   suggests	   that	   a	   dysregulated	   production	   of	   mtROS	   may	   be	   a	  
reversible	  alteration,	  which	  accounts	  for	  the	  immune-­‐inflammatory	  deficits	  commonly	  
described	  in	  people	  with	  PD	  and	  T2DM.	  We	  previously	  documented	  that	  IPT	  induces	  a	  
significant	   improvement	   of	   endothelial	   function	   in	   patients	   with	   PD	   6	  months	   after	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dental	   treatment	   in	   an	   otherwise	   healthy	   population	   affected	   by	   generalized	   severe	  
PD12.	   However,	   the	   underlying	   biological	   pathways	   accounting	   for	   these	   results	  
remained	  unclear.	  We	  now	  replicate	  this	  finding	  in	  subjects	  with	  T2DM	  and	  moderate	  
to	  severe	  PD	  and	  show	  that	  changes	  in	  LPS	  serum	  profile,	  IFN-­‐γ	  and	  mtROS	  production	  
track	   changes	   of	   FMD.	   At	   least	   two	   mechanisms	   could	   account	   for	   these	   findings.	  
Firstly,	   IFN-­‐γ	   could	   act	   as	   a	   transducer	   between	   activated	   inflammatory	   cells	   and	  
endothelial	   cells.	   IFN-­‐γ	   is	   known	   to	   induce	   expression	   of	   endothelial	   cell	   adhesion	  
molecules,	   such	   as	   vascular	   cell	   adhesion	   molecule-­‐1	   and	   intercellular	   adhesion	  
molecule-­‐1,	   which	   are	   early	   markers	   of	   atherogenesis	   and	   are	   crucial	   for	   leukocyte	  
recruitment	   to	   the	  plaque.60	  Their	  expression	  can	  be	   further	   intensified	  by	  cross	   talk	  
between	  IFN-­‐γ	  and	  lipopolysaccharide	  signaling.61	  Therefore,	  it	  is	  possible	  that	  a	  lower	  
concentration	   of	   LPS	   detected	   in	   the	   IPT	   group	   could	   be	   related	   to	   a	   reduced	  
bacteraemia	  achieved	  by	  better	  oral	  health	  combined	  with	  reduced	  circulating	   levels	  
of	  IFN-­‐γ	  following	  IPT	  	  and	  account	  for	  the	  improved	  endothelial	  function	  recorded	  at	  
the	  end	  of	  the	  trial.	  Secondly,	  the	  measure	  of	  mtROS	  in	  circulating	  inflammatory	  cells	  
could	  reflect	  a	  more	  generalised	  state	  of	  increased	  mtROS	  production	  in	  other	  vascular	  
compartments.	   In	   patients	   with	   T2DM,	   the	   up-­‐regulation	   of	   mtROS	   production	   in	  
circulating	  leukocytes	  is	  associated	  with	  higher	  mtROS	  production	  in	  arterioles	  isolated	  
from	   subcutaneous	   fat642,643.	   Furthermore,	   impaired	   endothelium-­‐dependent	  
vasodilation	  in	  freshly	  isolated	  arterioles	  from	  diabetic	   individuals	   is	  reversed	  by	  mild	  
membrane	  depolarization	  or	  mitochondria-­‐targeted	  antioxidants642.	  mtROS	  production	  
in	   circulating	   leukocytes	   could	   have	   considerable	   potential	   as	   a	   reliable	   marker	   of	  
mtROS	   in	   endothelial	   cells,	  with	   the	   advantage	   of	   a	  measure	  which	   can	   be	  made	   in	  
readily	  available	  blood	  cells.	  	  Our	  study	  has	  several	  strengths	  but	  also	  some	  limitations.	  
It	   is	  a	  randomised	  controlled	  trial	  with	  vascular	  and	  laboratory	  technicians	  blinded	  to	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the	  patient	  treatment	  allocation.	  Our	  group	  was	  the	  first	  to	  describe,	  characterise	  and	  
validate	   the	   impact	   of	   IPT	   on	   endothelial	   function,	   markers	   of	   inflammation	   and	  
oxidative	  stress.	  We	  established	  and	  validated	  the	  use	  of	  FMD	  to	  measure	  endothelial	  
function,	  optimising	  its	  reproducibility	  for	   large	  longitudinal	  studies	  and	  clinical	  trials.	  
All	  these	  factors	  highlight	  the	  robustness	  of	  our	  results.	  In	  addition,	  FACS	  analysis	  does	  
not	   represent	   the	   most	   accurate	   assay	   to	   measure	   mtROS.	   However,	   it	   should	   be	  
recognised	   that	   the	   gold	   standard	   techniques	   used	   to	  measure	  mtROS	   are	   normally	  
laborious	   and	   cannot	   be	   used	   in	   human	   clinical	   trials.	   The	   high	   specificity	   and	  
sensitivity	   of	  MitoSOX	   for	  mitochondrial	   superoxide	   production	  has	   been	   repeatedly	  
documented	   and	   the	   probe	   is	   currently	   considered	   the	   gold-­‐standard	   method	   for	  
mtROS	  assessment	  by	  FACS	  analysis.	  To	  minimise	  artefacts	  and	  optimise	  our	  assay,	  we	  
carefully	   followed	   cell	   isolation	   and	   staining	   instructions	   reported	   on	   previously	  
validated	   protocols	   and	   we	   acquired	   the	   FACS	   results	   immediately	   after	   staining.	  
Furthermore,	  as	  staining	  with	  other	  fluorescent	  probes	  is	  known	  modify	  mitochondrial	  
function	  and	  influence	  mtROS,	  we	  performed	  gating	  using	  the	  physical	  characteristics	  
of	   the	   cell	   populations	   rather	   than	   fluorescent-­‐labelled	   antibodies.	   While	   this	  
precluded	   the	   opportunity	   to	   correlate	   mtROS	   with	   markers	   of	  
lymphocytes/monocytes	   activation,	   it	   excluded	   an	   important	   source	   of	   variability	   to	  
our	  results.	  	  
4.5. Conclusions	  
A	  reduced	  mtROS	  production	  following	  IPT	  is	  associated	  with	  a	  general	   improvement	  
of	   inflammation,	  metabolic	   control	   and	   endothelial	   function	   in	   patients	  with	   T2DM.	  
mtROS	   could	   represent	   an	   important	   and	   novel	   therapeutic	   target	   to	   reduce	   risk	   of	  
cardiovascular	  disease	  and	  other	  inflammatory	  complications	  in	  patients	  with	  T2DM.	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5. STUDY	   3:	   Effects	   of	   periodontal	   treatment	   on	   vascular	  
phenotypes	   in	   patients	   with	   type	   2	   diabetes.	   A	   12	   months	  
randomized	  controlled	  clinical	  trial.	  
	  
5.1. Introduction	  
Atherosclerosis	   is	   a	   systemic	   disease	   affecting	   large	   and	   medium-­‐sized	   arteries.	  
Atherosclerotic	   lesions	   are	   asymmetrical	   focal	   thickenings	   of	   the	   innermost	   layer	   of	  
the	   intima,	   consisting	   of	   cells,	   connective-­‐tissue	   elements,	   lipids	   and	   debris644.	  
Atherosclerosis	   and	   its	   clinical	   manifestations,	   such	   as	   MI	   and	   stoke,	   are	   the	   main	  
causes	   of	   death	   and	   disabling	   diseases	   in	   Europe,	   the	   United	   States	   and	   much	   of	  
Asia645,646.	  At	  present,	  CVD	  cause	  almost	  40	  percent	  of	  all	  deaths	  in	  North	  America	  and	  
are	  the	  most	  common	  cause	  of	  death	  in	  European	  men	  under	  65	  years,	  and	  the	  second	  
most	  common	  cause	  in	  women293.	  Furthermore,	  due	  to	  a	  rapidly	  increasing	  prevalence	  
of	   obesity	   and	   diabetes,	   CVD	   is	   expected	  within	   the	   coming	   years	   to	   be	   the	   leading	  
cause	  of	  death	  globally.	  Diabetes	   is	  an	  established	  risk	  factor	  for	  atherosclerosis.	  The	  
hyperglycemia	  can	  lead	  to	  the	  formation	  of	  advance	  glycation	  end	  products	  (AGEs)317.	  
By	   binding	   surface	   receptors	   such	   as	   RAGE	   (receptor	   for	   AGEs),	   these	   AGE-­‐modified	  
proteins	   can	   trigger	   the	   release	   of	   pro-­‐inflammatory	   cytokines	   and	   stimulate	   other	  
inflammatory	   pathways	   in	   the	   vascular	   endothelium.	   In	   addition,	   the	   diabetic	   state	  
promotes	  oxidative	  stress	  mediated	  by	  reactive	  oxygen	  species	  and	  carbonyl	  groups647.	  
Inflammation	   may	   represent	   a	   link	   between	   diabetes	   to	   atherosclerosis.	   Infection	  
and/or	   inflammation	   have	   been	   associated	   with	   the	   initiation,	   progression	   and	  
complications	  of	  atherosclerosis107,	  but	  it	  is	  uncertain	  if	  the	  link	  observed	  in	  humans	  is	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causal.	  If	  it	  is,	  questions	  exist	  about	  the	  mediators	  and	  mechanisms	  involved,	  and	  how	  
the	  response	  might	  be	  modified	  for	  therapeutic	  benefit.	  The	  assessment	  of	  the	  c-­‐IMT	  
is	  a	  noninvasive	  and	  reproducible	  imaging	  parameter	  to	  evaluate	  atherosclerosis.	  The	  
thickness	   of	   the	   carotid	   arteries	   has	   been	   considered	   an	   early	   marker	   of	  
atherosclerotic	  disease	  and	  a	  target	  for	  pharmacological	  treatment	  of	  atherosclerosis.	  
B-­‐mode	  ultrasound	  can	  directly	  assess	  the	  c-­‐IMT	  correlating	  with	  histologic	  intima	  and	  
media	  layers523,542.	  Observational	  evidence	  suggest	  that	  for	  each	  0.03-­‐mm	  increase	  per	  
year	  in	  carotid	  arterial	  intima-­‐media	  thickness,	  the	  relative	  risk	  for	  nonfatal	  myocardial	  
infarction	  or	  coronary	  death	  was	  2.2	  (95%	  CI,	  1.4	  to	  3.6)	  and	  the	  relative	  risk	  for	  any	  
coronary	  event	  was	  3.1	  (CI,	  2.1	  to	  4.5)	  (P	  <	  0.001)648.	  B-­‐mode	  ultrasound	  scan	  of	  c-­‐IMT	  
is	   also	   adopted	   in	   the	   screening	   of	   patients	   with	   CAD649,650.	   Increased	   c-­‐IMT	   was	  
associated	  with	  a	  significantly	  higher	  incidence	  of	  stroke	  and	  myocardial	  infarction526.	  
The	   Cardiovascular	   Health	   Study	   Collaborative	   Research	   Group	   has	   shown	   in	   4476	  
individuals	  without	   clinical	   cardiovascular	  disease	   followed	  up	  over	  6	   years,	   that	   the	  
relative	  risk	  for	  myocardial	  infarction	  or	  stroke	  for	  the	  quintile	  with	  the	  highest	  IMT	  as	  
compared	   with	   the	   lowest	   was	   3.87511.	   In	   addition,	   atherosclerosis	   in	   coronary	  
arteriography	   correlates	   with	   the	   presence	   of	   lesions	   in	   the	   carotid	   arteries510.	  
Diabetes	  is	  a	  condition	  associated	  with	  high	  risk	  of	  CV	  complications	  and	  faster	  c-­‐IMT	  
progression651.	   Evidence	   from	   more	   than	   two	   decades	   suggested	   the	   association	  
between	   PD,	   diabetes	   and	   CVD.	   In	   addition,	   our	   group,	   in	   a	   systematic	   review	   and	  
meta-­‐analysis,	  has	  reported	  an	  association	  between	  PD	  and	  c-­‐IMT7.	  The	  nature	  of	  the	  
association	   remains	   still	   unclear	   since	   data	   from	   observational	   studies	   do	   not	   allow	  
determining	  causality.	  In	  absence	  of	  experimental	  studies	  on	  the	  impact	  of	  periodontal	  
treatment	  on	  CV	  events	  such	  as	  stroke	  and	  myocardial	  infarction,	  the	  current	  research	  
has	   focused	   on	   surrogate	  measures	   of	   CVD.	   Flow-­‐mediated	   dilatation,	   as	   previously	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discussed	  in	  this	  Thesis	  represents	  a	  non-­‐invasive	  measure	  of	  endothelial	  function	  and	  
predictor	   of	   future	   cardiovascular	   risk.	   FMD	  6	  months	   following	  periodontal	   therapy	  
has	  been	  assessed	  in	  previous	  trials12,413	  and	  in	  Chapter	  4	  of	  this	  dissertation.	  However,	  
FMD	   has	   been	   measured	   6	   months	   after	   therapy	   therefore	   designing	   trials	   with	   a	  
longer	   follow-­‐up	   could	   add	  more	   information	   on	   this	   association.	   Piconi	   et	   al.	   have	  
evaluated	  changes	  in	  c-­‐IMT	  after	  periodontal	  treatment	  in	  a	  trial	  with	  no	  control	  group	  
and	   not	   adhering	   to	   the	   guidelines	   for	   the	  measurements	   of	   c-­‐IMT	   diminishing	   the	  
importance	  of	  their	  finding399.	  Kappelas	  et	  al.	  have	  conducted	  a	  RCT	  analyzing	  changes	  
in	  c-­‐IMT	  12	  months	   following	  a	  single	  session	  of	  periodontal	   therapy	   in	  a	  population	  
represented	  by	  Aboriginal	  Australians	  and	  reporting	  a	  reduction	  in	  the	  carotid	  intima-­‐
media	  thickness652.	  The	  systematic	  review	  and	  meta-­‐analysis	  of	  observational	  studies	  
have	  presented	  in	  Chapter	  3	  suggest	  an	  association	  between	  PD,	  c-­‐IMT	  and	  FMD	  and	  
propose	  the	  conduction	  of	  experimental	  trials	  investigating	  the	  causal	  features	  of	  this	  
association7.	  Our	  group	  has	  designed	  a	  randomized,	  controlled	  trial	  to	  determine	  the	  
effect	   of	   a	   periodontal	   intervention	   on	   the	   progression	   of	   carotid	   intima-­‐media	  
thickness,	  an	  established	  noninvasive	  measure	  of	  subclinical	  atherosclerosis	  in	  patients	  
affected	  by	  PD	  and	  T2DM.	  
5.2. Methods	  
5.2.1. Study	  Design	  
Eligible	  participants	  were	  consecutively	  enrolled	  into	  the	  study	  if	  they	  had:	  T2DM	  for	  ≥	  
6	  months	   diagnosis,	  moderate	   to	   severe	   PD	   (≥	   20	   periodontal	   pockets	  with	   probing	  
pocket	   depths	   >4	  mm	  and	  marginal	   alveolar	   bone	   loss	   >30%)	   and	   a	  minimum	  of	   15	  
teeth.	  Exclusion	  criteria	  included:	  i)	  uncontrolled	  systemic	  diseases	  other	  than	  diabetes	  
ii)	  Hepatitis	  B	  or	  HIV	  infection,	  iii)	  chronic	  treatment	  with	  medications	  known	  to	  affect	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periodontal	   tissues,	   iv)	   chronic	   systemic	   antibiotic	   treatment,	   v)	   pregnancy	   or	  
lactation.	  All	  patients	  gave	  written	  informed	  consent,	  and	  the	  study	  was	  approved	  by	  
the	  local	  ethics	  committee	  (Ref	  07/H0714/97).	  
5.2.2. Periodontal	  Examination	  
Clinical	  periodontal	  data	  were	  recorded	  at	  baseline	  and	  2,	  6	  and	  12	  months	  after	  the	  
therapy	  as	  described	  in	  Chapter	  2.	  This	  data	  included	  PPD	  and	  gingival	  recession	  at	  six	  
sites	  per	  tooth.	  The	  presence	  or	  absence	  of	  supra-­‐gingival	  dental	  plaque	  and	  gingival	  
bleeding	  on	  probing	  was	  also	  recorded.	  
5.2.3. Periodontal	  Therapy	  
Essential	  dental	  care	  including	  removal	  of	  compromised	  teeth	  was	  provided	  within	  the	  
trial.	  Oral	  hygiene	  instructions	  were	  given	  to	  all	  study	  participants.	  Patients	  in	  the	  IPT	  
group	   received	   a	   single	   session	   of	   full	   mouth	   scaling	   and	   root	   planing	   under	   local	  
anesthesia.	   At	   2	   months,	   those	   patients	   with	   good	   oral	   hygiene	   (full	   mouth	   dental	  
plaque	  scores	  <	  20%)	  and	  ≥	  6mm	  residual	  periodontal	  pocket	  underwent	  periodontal	  
surgical	  corrective	  therapy	  (20	  participants).	  Patients	  who	  presented	  with	  suboptimal	  
oral	   hygiene	   received	   corrective	   treatment	   in	   form	   of	   additional	   scaling	   of	   the	   root	  
surfaces	   under	   local	   anesthesia	   every	   3	   months	   until	   completion	   of	   the	   study.	   CPT	  
patients	  received	  supra-­‐gingival	  scaling	  and	  polishing	  at	  baseline,	  2,	  6	  and	  9	  months.	  At	  
the	   end	   of	   the	   study,	   all	   CPT	   patients	   received	   any	   required	   additional	   periodontal	  
therapy.	  Any	  patients	  showing	  progression	  of	  PD522	   	  during	  the	  trial	  were	  withdrawn	  
from	  the	  study	  and	  treated	  accordingly.	  	  
5.2.4. Inflammatory,	  vascular	  and	  metabolic	  assays	  
Blood	   samples	  were	   taken	   at	   baseline,	   6	   and	  12	  months	   follw-­‐up.	   Serum	  C-­‐Reactive	  
Protein	  (CRP)	  concentrations	  were	  determined	  by	  immunoturbidimetry	  (Cobas	  Integra	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700,	   Roche,	   Mannheim,	   Germany).	   Full	   blood	   differential	   count	   was	   assessed	   by	  
standard	  biochemistry	  whilst	  Interleukin	  (IL)-­‐1β,	  IL-­‐6,	  IL-­‐8,	  IL-­‐10,	  IL-­‐12,	  Interferon	  (IFN)-­‐
γ	  and	  Tumor	  Necrosis	  Factor	  (TNF)-­‐α	  and	  endothelial	  cell	  surface	  markers	  (E-­‐selectin,	  
P-­‐selectin,	   Intercellular	   Adhesion	   Molecule	   (ICAM)-­‐3	   and	   Thrombomodulin)	   were	  
measured	  by	  multiplex	  assay	  (Meso	  Scale	  Discovery,	  Maryland,	  USA).	  Inter-­‐	  and	  intra-­‐
assays	   coefficient	   of	   variation	   were	   <7%.	   HbA1c	   (liquid	   chromatography)	   was	  
measured	   in	   plasma	   on	   an	   automated	   analyzer	   (Cobas	   8000	   analyzer,	   Roche	  
Diagnostics	  Corp).	  
5.2.5. Vascular	  outcomes	  
5.2.5.1. c-­‐IMT	  
c-­‐IMT	  was	  assessed	  at	  baseline,	  6	  and	  12	  months	  after	  periodontal	  therapy.	  The	  right	  
and	  left	  common	  and	  internal	  carotid	  arteries	  and	  the	  radial	  artery	  were	  scanned	  with	  
a	   linear-­‐array	   transducer	   (Acuson	   XP10	   7-­‐MHz,	   Visualsonic	   55-­‐MHz)	   as	   previously	  
described	  in	  the	  methods.	  IMT	  was	  calculated	  as	  the	  distance	  between	  the	  first	  bright	  
line	   (lumen-­‐intima	   interface)	   and	   the	   leading	   edge	  of	   the	   second	  bright	   line	   (media-­‐
adventitia	   interface).	   Six	  measurements,	   the	   3	  maximum	  measurements	   of	   the	   right	  
common	  carotid	  artery	  in	  3	  different	  frames	  and	  the	  3	  maximum	  measurements	  of	  the	  
left	  common	  carotid	  artery	  in	  3	  different	  frames	  were	  averaged.	  
5.2.5.2. Flow-­‐mediated	  dilatation	  
FMD	   was	   measured	   at	   baseline,	   6	   and	   12	   months	   after	   periodontal	   therapy.	  
Endothelium-­‐dependent	  and	   -­‐independent	  FMD	  was	  assessed	  by	  ultrasound	   imaging	  
of	  the	  brachial	  artery	  with	  a	  high-­‐resolution	  probe	  (7-­‐MHz),	  as	  described	  in	  Chapter	  2.	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5.2.6. Outcomes	  Assessment	  
The	   primary	   outcome	   was	   the	   between	   group	   difference	   in	   c-­‐IMT	   at	   12	   months.	  
Secondary	   outcomes	   included	   differences	   in:	   i)	   HbA1c	   at	   12	   months,	   ii)	   FMD	   at	   12	  
months,	   iii)	   periodontal	   clinical	  parameters,	   inflammatory	  and	  endothelial	   circulating	  
markers	  at	  12	  months.	  
5.2.7. Statistical	  Analysis	  
A	  minimum	  sample	  size	  of	  52	  participants	  per	  group	  was	  required	  to	  detect	  a	  0.02mm	  
difference	  in	  c-­‐IMT	  at	  12	  months	  between	  treatment	  groups,	  with	  a	  standard	  deviation	  
of	   0.036	   (derived	   from	  published	   reports399,652),	   α=0.05	   and	   80%	  power	   (assuming	   a	  
10%	  loss	  to	  follow	  up	  rate,	  a	  total	  of	  58	  patients	  per	  group	  were	  considered).	  Data	  are	  
reported	  as	  mean	  and	  standard	  deviation	  unless	  otherwise	  specified.	  All	  analyses	  used	  
the	   intention-­‐to-­‐treat	   population	   with	   last	   measure	   carried	   forward	   approach	   for	  
missing	  values.	  Primary	  outcome	  was	  analyzed	  with	  analysis	  of	   covariance	   (including	  
baseline	  values	  as	   independent	  variable)	  at	  12	  months.	  Covariates	   included	  also	  age,	  
gender,	   body	   mass	   index,	   smoking	   and	   treatment	   group.	   Repeated	   ANOVA	   models	  
were	   also	   created	   to	   investigate	   changes	   in	   primary	   and	   secondary	   outcomes	   over	  
time	   between	   study	   groups.	   A	   conservative	   F-­‐test	   was	   used	   to	   interpret	   the	  model	  
using	   the	   Greenhouse-­‐Geisser	   correction	   to	   account	   for	   compound	   symmetry	  
violations.	   Univariate	   analyses	   were	   performed	   with	   crude	   values	   of	   each	   outcome	  
variable	   between	   study	   groups	   at	   different	   time	  points.	   Further	  multivariate	  models	  
were	   constructed	   including	  variables	   that	   showed	   a	   statistically	   significant	  
association	  with	  the	  outcome	  from	  univariate	  analyses	  and	  they	  included	  age,	  gender,	  
smoking,	  body	  weight	  and	  ethnicity.	  	  
	  A	  two-­‐sided	  value	  of	  p	  <0.05	  was	  considered	  statistically	  significant.	  SPSS	  version	  22	  
and	  STATA	  version	  12	  were	  used.	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5.3. Results	  	  
5.3.1. Patients	  characteristics	  
From	  October	  2010	  to	  October	  2012,	  270	  patients	  with	  T2DM	  were	  screened	  (Figure	  
30)	   and	   117	   eligible	   patients	   were	   randomized	   to	   either	   IPT	   (N=59)	   or	   CPT	   (N=58).	  
Enrolled	  patients	  were	  predominantly	  middle-­‐aged	  and	  equally	  distributed	   in	  gender	  
of	  white	  background	  and	  smoking	  habits	  (Table	  25).	  3	  participants	  in	  the	  IPT	  and	  5	  in	  
the	  CPT	  group	  were	  lost	  to	  follow-­‐up.	  Adverse	  events	  were	  comparable	  between	  study	  
groups	  as	  well	  as	  changes	  in	  prescribed	  medications.	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Table	  25	  Baseline	  characteristics	  of	  the	  study	  participants	  
Variable (mean±SD) CPT (N=58) IPT (M=59) 
Age,	  years	   59±10	   56±12	  
Gender,	  Males	   35(59%)	   32(62%)	  
Ethnicity,	  Caucasian	   24(41%)	   17(29%)	  
BMI,	  Kg/m2	   30±5	   30±6	  
Smoking,	  Current	   9(15%)	   9(15%)	  
Systolic	  BP,	  mmHg	   138±17	   145±16	  
Diastolic	  BP,	  mmHg	   83±10	   84±10	  
HbA1c	  (%)	   8±1.8	   7.9±1.7	  
Cholesterol,	  mmol/l	   4.2±1.1	   4.3±1.2	  
HDL,	  mmol/l	   1.2±0.4	   1.3±0.4	  
LDL,	  mmol/l	  	   2.3±0.9	   2.3±1	  
FMD%	   4±2	   4±3	  
c-­‐IMT	  mm	   0.64±0.06	   0.61±0.08	  
CRP*,	  mg/l	   1.8	  (3.1)	   1.7	  (3.0)	  
Values	   are	   expressed	   as	   means±SD	   or	   *median	   (interquartile	   range)	   for	   non-­‐normally	   distributed	  
variables.	  
	  
5.3.2. Periodontal	  clinical	  outcomes	  
At	  the	  end	  of	   the	  trial,	  all	  clinical	  periodontal	  parameters	  were	  significantly	  better	   in	  
IPT	  patients	   compared	   to	  CPT	   (Table	  26).	  Dental	  plaque	  and	  gingival	  bleeding	   scores	  
were	   lower	   in	   the	   IPT	  group	  at	  12	  months	   compared	   to	  CPT.	  Probing	  pocket	  depths	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Table	  26	  Periodontal	  parameters	  at	  Baseline	  and	  6	  Months	  after	  Periodontal	  Therapy	  
Variable	   Group	   	   Baseline	   12	  months	  
FMPS,	  %	  §	   IPT	   78±16	   38±18	  
	   CPT	   76±16	   58±23	  
FMBS,	  %	  ¶	   IPT	   66±18	   29±16	  
	   CPT	   66±17	   54±22	  
PPD,	  mm	   IPT	   4±0.8	   2.8±0.6	  
	   CPT	   3.9±0.8	   3.6±1	  
REC,	  mm	   IPT	   1.1±0.8	   1.7±1	  
	   CPT	   1.3±0.8	   1.6±0.9	  
NPKTs,	  n	  *	   IPT	   54±25	   11±13	  
	   CPT	   52±24	   38±27	  
Values	  are	  expressed	  as	  means±SD.	  	  
†	  P<0.001	  for	  the	  comparison	  with	  the	  standard-­‐treatment	  group.	  
IPT:	  intensive	  treatment	  group,	  CPT:	  control	  treatment	  group,	  FMPS:	  full	  mouth	  plaque	  score,	  FMBS:	  full	  
mouth	   bleeding	   score,	   PPD:	   periodontal	   pocket	   depth,	   REC:	   gingival	   recession,	   NPKTS,	   number	   of	  
pockets.	  
¶	  Scores	   for	   full-­‐mouth	  gingival	  bleeding	  were	  calculated	   for	  each	  patient	  as	   the	  number	  of	   sites	  with	  
gingival	  bleeding	  on	  probing	  divided	  by	  the	  total	  number	  of	  sites	  per	  mouth,	  multiplied	  by	  100.	  
§	  Scores	  for	  full-­‐mouth	  plaque	  were	  calculated	  for	  each	  patient	  as	  the	  number	  of	  sites	  with	  detectable	  
plaque	  divided	  by	  the	  total	  number	  of	  sites	  per	  mouth,	  multiplied	  by	  100.*	  




5.3.3. Vascular	  outcomes	  
5.3.3.1. c-­‐IMT	  
c-­‐IMT	   progression	   was	   significantly	   lower	   in	   IPT	   patients	   compared	   to	   CPT	   at	   12	  
months	  after	  therapy	  (Figure	  31).	  The	  average	  between	  groups	  difference	  in	  c-­‐IMT	  was	  
0.025mm	  (95%	  CI,	  0.003-­‐0.048,	  p<0.05)	  at	  12	  months.	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Figure	  31	  Changes	  in	  c-­‐IMT	  during	  the	  study	  period	  
5.3.3.2. FMD	  
FMD	  was	  greater	  in	  IPT	  patients	  compared	  to	  CPT	  at	  12	  months	  after	  therapy	  (p<0.05)	  
(Figure	  32).	  The	  average	  between	  groups	  difference	  in	  FMD	  was	  1.05	  %	  (95%	  CI,	  1.36-­‐
2.47,	   p=0.002)	   at	   12	   months.	  
	  
Figure	  32	  Changes	  in	  FMD	  during	  the	  study	  period	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No	  interaction	  between	  treatment	  and	  time	  was	  observed	  for	  nitroglycerin-­‐dependent	  
dilatation	   or	   for	   brachial	   artery	   diameters	   and	   no	   changes	   of	   the	   nitroglycerin-­‐
dependent	   dilatation	   were	   observed	   from	   baseline	   to	   12	   months.	   (unadjusted	  
difference	  of	  0.5;	  95%	  CI,	  -­‐0.8-­‐3.8;	  p=0.75).	  
5.3.4. Markers	  of	  inflammation	  and	  vascular	  activation/damage	  
IL-­‐10	  serum	  levels	  were	  lower	  in	  the	  CPT	  compared	  to	  the	  IPT	  group	  (Figure	  33).	  The	  
average	  between	  groups	  difference	  in	  IL-­‐10	  levels	  was	  4.73	  pg/ml	  (95%	  CI,	  2.73-­‐6.73,	  
p=0.002)	  at	  12	  months.	  No	  substantial	  differences	  in	  other	  biomarkers	  were	  noted	  
(Table	  27).
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Table	  27	  Non-­‐significant	  between	  group	  differences	  a	  t	  12	  months	  
Variable	   Unadjusted	  
between	  
group	  
difference	   at	  
12M	  
95%	  CI	   p	  value	  
IL-­‐6	   -­‐1.71	   -­‐5.46-­‐2.05	   0.37	  
IL-­‐8	   8.26	   -­‐1.53-­‐18.05	   0.10	  
IL-­‐12	   21.42	   -­‐31.87-­‐74.71	   0.42	  
TNF-­‐α	   0.002	   -­‐0.97-­‐0.98	   1.00	  
IFN-­‐γ	   -­‐0.14	   -­‐3.14-­‐2.86	   0.92	  
E	  selectin	   2.64	   -­‐14.26-­‐19.53	   0.76	  
P	  selectin	   7.57	   -­‐28.16-­‐43.29	   0.67	  
Thrombomodulin	   0.86	   -­‐5.60-­‐7.32	   0.79	  
ICAM	  3	   1.31	   	   -­‐2.29-­‐4.90	   0.47	  
	  
	  
5.3.5. Metabolic	  parameters	  
Metabolic	   control	   improved	   in	   IPT	   patients	   after	   12	  months	   treatment	   compared	   to	  
CPT.	  The	  average	  between	  groups	  difference	  in	  HbA1c	  levels	  was	  0.95	  %	  (95%	  CI,	  1.84-­‐
0.06,	  p=0.002)	  at	  12	  months	  (Figure	  34).	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Figure	  34	  Changes	  in	  HbA1c	  during	  the	  study	  period	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5.4. Discussion	  
In	  this	  trial,	  we	  have	  observed	  a	  statistically	  significant	  difference	  in	  the	  progression	  of	  
c-­‐IMT	   12	   months	   after	   periodontal	   treatment	   in	   patients	   affected	   by	   moderate	   to	  
severe	   PD	   and	   T2DM.	   This	   effect	   was	   associated	   with	   an	   improvement	   of	   the	  
endothelial	   function,	   metabolic	   control	   and	   IL-­‐10	   profile.	   The	   control	   of	   the	  
periodontal	   infection	   seems	   to	   have	   favorable	   effect	   on	   the	   human	   vasculature.	   In	  
chapter	  4	  we	  have	  also	  described	  a	  lower	  circulating	  level	  of	  LPS	  suggesting	  a	  systemic	  
benefit	  of	   the	  periodontal	   therapy.	  Circulating	  bacterial	  endotoxin	   is	  well	  established	  
to	   provoke	   severe	   endothelial	   dysfunction	   and	   exhibits	   a	   variety	   of	   pro-­‐atherogenic	  
features144,653-­‐655.	   Endotoxemia	   does	   not	   occur	   only	   in	   sepsis	   but	   also	   occurs	   in	  
otherwise	   healthy	   individuals	   656.	   Chronic	   or	   recurrent	   bacterial	   infections	   may	  
represent	  sources	  of	  circulating	  bacterial	  byproducts657.	  The	  hypothesis	  that	  infections	  
could	   contribute	   to	   the	   pathogenesis	   of	   atherosclerosis	   has	   been	   extensively	  
researched	   over	   the	   last	   20	   years658-­‐661.	   	   Seroepidemiologic	   studies	   supported	   an	  
involvement	  of	  common	  chronic	   infections	   in	  atherogenesis658,661.	  Specifically,	  herpes	  
viridae,	   gram-­‐negative	   bacteria	   (Helicobacter	   pylori	   ,	   Chlamydia	   pneumoniae	   )	   and	  
chronic	  dental	  infections	  were	  associated	  with	  atherosclerosis142,144,658,662,663.	  However,	  
there	   is	   no	   evidence	   reporting	   that	   infections	   are	   causally	   related	   to	   atherosclerotic	  
disease	  664.	  	  Common	  chronic	  infections,	  including	  PD,	  have	  been	  suggested	  as	  markers	  
of	  increased	  risk	  for	  carotid	  arteries	  atherosclerosis	  in	  a	  prospective	  population-­‐based	  
survey	  343.	  Chronic	  infections	  such	  as	  PD,	  could	  contribute	  to	  CVD	  even	  in	  individuals	  in	  
the	  low-­‐risk	  category	  and	  in	  absence	  of	  common	  traditional	  vascular	  risk	  factors	  such	  
as	  smoking,	  obesity,	  hypertension	  and	  dyslipidemia.	  	  Approximately	  108	  –	  1012	  bacteria	  
can	  be	  detected	  in	  periodontal	  lesions	  and	  it	  has	  been	  reported	  that	  a	  large	  number	  of	  
oral	   microorganisms,	   including	   those	   associated	   with	   PD,	   can	   enter	   the	   circulation	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through	   the	   microvasculature	   following	   tooth	   brushing	   and	   other	   dental	   invasive	  
procedures665.	   Indeed,	   using	   PCR	   techniques,	   bacteremia	   was	   confirmed	   in	   blood	  
samples	  taken	  from	  30	  patients	  after	  ultrasonic	  scaling,	  periodontal	  probing	  and	  tooth	  
brushing	  666.	  Further,	  data	  from	  an	  observational	  study	  including	  194	  patients	  with	  PD,	  
suggested	   that	   periodontal	   site	   bleeding	   after	   tooth	   brushing	   was	   associated	   with	  
approximately	  8-­‐fold	  increase	  in	  bacteremia667.	  Similarly,	  bleeding	  on	  probing	  has	  been	  
associated	   with	   systemic	   inflammation	   and	   bacteremia463,667.	   Periodontal	   bacteria	  
could	  reach	  the	  vascular	  endothelium	  through	  two	  mechanisms;	  either	  direct	  invasion	  
as	   a	   consequence	   of	   bacteremia	   or	   dissemination	   via	   internalization	   in	   migrating	  
phagocytic	  cells.	  P.	  gingivalis	  	  and	  A.	  actinomycetemcomitans	  have	  both	  demonstrated	  
migration	   capacities668,669	   .	   Eikenella	   corrodens	   and	   Prevotella	   intermedia	   were	   also	  
shown	   to	   invade	   human	   endothelium	   and	   smooth	   muscle	   cells670.	   DNA	   from	  
periodontal	   organisms	   such	   as	   A.	   actinomycetemcomitans	   and	   P.	   gingivalis	   was	  
detected	   in	  atherosclerotic	   lesions	  by	  PCR.	  Using	  16S	  rDNA	  PCR,	   it	  was	  reported	  that	  
1.5-­‐2.2%	   of	   the	   total	   DNA	   in	   the	   atheroma	   samples	   was	   bacterial	   with	   a	   large	  
proportion	  of	  oral	  origin.	  P.	  gingivalis	  had	  the	  higher	  incidence671	  
IL-­‐10	   is	   a	   potent	   anti-­‐inflammatory	   cytokine672-­‐674	   secreted	   primarily	   by	   the	  
macrophages	  and	  Th2	  subtype	  T	  lymphocytes.	  Evidence	  form	  an	  animal	  model	  report	  
that	   it	  preserves	  endothelial	   function	  after	  an	   inflammatory	  stimulus675	  and	   impedes	  
mechanisms	   of	   endothelial	   dysfunction	   in	   diabetes676.	   IL-­‐10	   protects	   endothelial	  
function	   after	   LPS	   treatment	   by	   attenuating	   increases	   in	   superoxide	   in	   the	   vessel	  
wall675.	  In	  addition,	  it	  inhibits	  the	  synthesis	  of	  pro-­‐inflammatory	  cytokines	  by	  activated	  
monocytes	  and	  reduces	  the	  adhesiveness	  of	  monocytes	  to	  stimulated	  endothelial	  cells	  
in	   vitro	   inhibiting	   endothelial	   cell	   adhesion	   molecules	   ICAM-­‐1	   and	   VCAM-­‐1677,678.	  
Furthermore,	   IL-­‐10	   knock-­‐out	   mice	   develop	   severe	   atherosclerosis	   in	   response	   to	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hypercholesterolemia679.	   IL-­‐10	   protective	   features	   include	   inhibition	   of	   macrophage	  
activation,	  matrix	  metalloproteinase,	  pro-­‐inflammatory	  cytokines	  and	  cyclooxygenase-­‐
2	   expression	   in	   lipid-­‐loaded	   and	   activated	  macrophage	   foam	   cells.	   Recent	   evidence	  
also	   reports	   its	   ability	   to	   alter	   lipid	   metabolism	   in	   macrophages679.	   Periodontal	  
treatment	   seems	   to	   be	   effective	   in	   elevating	   systemic	   IL-­‐10	   levels	   in	   patients	   with	  
T2DM680.	  In	  addition	  a	  recent	  meta-­‐analysis	  reported	  a	  favorable	  effect	  of	  periodontal	  
treatment	  on	  serum	  inflammatory	  levels	  such	  as	  TNF-­‐α	  and	  CRP	  of	  subjects	  with	  T2DM	  
and	  PD681.	  We	  have	  previously	  reported	  the	  beneficial	  effect	  of	  periodontal	  therapy	  on	  
FMD	  in	  T2DM	  at	  6	  months	  follow-­‐up.	  This	  trial	  provides	  the	  evidence	  of	  a	  prolonged	  
effect	   observable	   12	   months	   following	   treatment	   supporting	   the	   importance	   of	  
controlling	   the	   periodontal	   infection	   in	   T2DM	   and	   its	   potential	   association	   with	   the	  
pathogenesis	  of	  atherosclerotic	  disease.	  According	  to	  the	  response-­‐to-­‐injury	  model	  of	  
atherosclerosis502,	   various	   factors	   can	   cause	   alterations	   in	   the	   endothelium	  
predisposing	   arteries	   to	   the	   development	   of	   atherosclerosis.	   Changes	   in	   the	  
adhesiveness	   of	   the	   endothelium	   to	   leukocytes,	   its	   permeability,	   and	   expression	   of	  
vasoactive	  molecules	   could	   favor	   atherogenesis275.	   Increased	   c-­‐IMT	   in	   subjects	   with	  
impaired	   FMD	   is	   associated	   with	   CV	   risk	   factors682	   supporting	   the	   concept	   that	  
endothelial	   function	   might	   reflect	   the	   propensity	   of	   arteries	   to	   develop	  
atherosclerosis683.	  Impaired	  brachial	  FMD	  has	  been	  related	  to	  increased	  carotid	  IMT682	  
suggesting	   an	   inverse	   relation	   between	   brachial	   FMD	   response	   and	   c-­‐IMT684,685.	  
Plausible	   pathophysiological	  mechanisms	   linking	   infections	   and	   atherosclerosis	   could	  
include	   direct	   infection	   of	   the	   arterial	   wall664,686,	   inference	   of	   acute-­‐phase	   response	  
with	   a	   pro-­‐coagulant	   state	   and	   induction	   of	   autoimmunity687-­‐690.	   In	   addition,	  
endotoxemia	   can	   cause	   endothelial	   dysfunction	   in	   the	   course	   of	   severe	   systemic	  
infections,	   thus	   driving	   vasculature	   into	   a	   pro-­‐atherogenic	   mode664.	   LPS	   from	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Escherichia	   coli	   augments	   the	   expression	   of	   endothelial	   adhesion	   molecules	   and	  
subsequent	   leukocyte	   adherence691-­‐693	   and	   is	   considered	   an	   activator	   of	   cytokine	  
production	   in	   atheroma655.	   Further	   atherogenic	   properties	   include	   induction	   of	  
intravascular	   coagulation	   and	   lowering	   of	   HDL,	   which	   is	   a	   natural	   scavenger	   of	  
endotoxins694.	   Exposure	   of	   human	   volunteers	   to	   LPS	   provokes	   endothelium	  
dysfunction	   in	   vivo296.	   Subclinical	   atherosclerosis	   should	   preferably	   detected	   at	   an	  
early	   stage	   allowing	   primary	   preventive	   measures695.	   The	   development	   of	  
atherosclerosis	  usually	  takes	  decades,	  and	  the	  thickening	  of	  the	  arterial	  wall	  is	  one	  of	  
the	  first	  detectable	  signs.	  B-­‐mode	  ultrasound	  measurement	  of	  c-­‐IMT	  is	  frequently	  used	  
for	  non-­‐invasive	  evaluation	  of	  subjects	  at	  risk	  of	  atherosclerosis.	  Still,	  the	  exact	  risk	  of	  
cardiovascular	  events	  associated	  with	  an	  increased	  c-­‐IMT	  in	  general	  populations	  is	  not	  
entirely	   clear.	   Evidence	   from	   the	   Carotid	   Atherosclerosis	   Progression	   Study	   (CAPS),	  
reported	   that	   the	   incremental	   predictive	   value	   of	   c-­‐IMT	   in	   the	   general	   population	  
might	   not	   necessarily	   improve	   the	   CV	   classification.	   C-­‐IMT	   measured	   by	   B-­‐mode	  
ultrasound	   is	   associated	   with	   future	   CV	   events,	   however	   when	   a	   model	   using	   the	  
classical	  risk	  factors	  was	  compared	  with	  a	  model	   including	  c-­‐IMT,	  the	  classification	  of	  
individual	  risk	  did	  not	  result	  consistently	  improved607.	  On	  the	  contrary,	  the	  maximum	  
IMT	  value	  along	  the	  whole	  carotid	  artery	  or	  the	  presence	  of	  plaques	  seem	  to	  have	  the	  
better	  prognostic	  value696.	  The	  improved	  glycemic	  control	  observed	  in	  our	  population	  
12	   months	   following	   the	   periodontal	   therapy	   needs	   validation	   with	   a	   sample	   size	  
adequate	  to	  answer	  such	  research	  question.	  However,	  a	  reduced	  level	  of	  Hb1Ac	  would	  
support	  a	  lower	  vascular	  risk	  expressed	  by	  an	  amelioration	  of	  brachial	  FMD,	  c-­‐IMT	  and	  
IL-­‐10	   profile.	   In	   our	   study	   we	   have	   adopted	   a	   standardized	   protocol	   to	   assess	   both	  
FMD	  and	  c-­‐IMT.	   In	  addition,	   the	  same	  vascular	   technician	  has	  acquired	  and	  analyzed	  
all	  the	  vascular	  data	  reducing	  potential	  sources	  of	  variability.	  	  We	  have	  demonstrated	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that	  treating	  PD	  could	  improve	  c-­‐IMT.	  However,	  thickening	  of	  the	  carotid	  intima-­‐media	  
layers	   could	   not	   necessarily	   represent	   subclinical	   atherosclerosis.	   The	   presence	   of	  
atherosclerotic	  plaque	  on	  carotid	  B-­‐mode	  ultrasound	  is	  a	  better	  individual	  predictor	  of	  
future	  cardiovascular	  events	  than	  c-­‐IMT.	  Therefore,	  our	  results	  support	  the	  association	  
between	   PD	   and	   c-­‐IMT	   but	   do	   not	   prove	   that	   periodontal	   treatment	   can	   effectively	  
lower	  the	  future	  CV	  risk.	  
5.5. Conclusions	  
The	  c-­‐IMT	  reduction	  12	  months	  following	  periodontal	  therapy	  supports	  a	  link	  between	  
PD	   and	   atherosclerosis.	   Further	   studies	   should	   evaluate	   the	   mechanism	   by	   which	  
periodontal	  treatment	  could	  reduce	  the	  c-­‐IMT	  progression.	  To	  evaluate	  the	  impact	  of	  
periodontal	   health	   on	   CV	   conditions,	   large	   scale/multinational	   intervention	   trials	  
should	  be	  conducted	  on	  the	  effect	  of	  periodontal	  therapy	  on	  hard	  CVD	  endpoints	  such	  
as	   myocardial	   infarction	   and	   stroke	   identifying	   settings	   representing	   the	   every-­‐day	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6. STUDY	  4:	  Remote	  ischemic	  preconditioning	  (RIPC)	  reduces	  




The	   phenomenon	   of	   ischemic	   preconditioning	   was	   firstly	   described	   in	   a	   canine	  
experimental	  model	   in	   1986697.	  Murry	   et	   al.	   reported	   a	   substantial	   reduction	   in	   the	  
extent	  of	  a	  myocardial	  infarction	  area	  exposing	  the	  circumflex	  coronary	  artery	  territory	  
to	  brief	  periods	  of	  ischemia	  as	  four	  cycles	  of	  5	  min	  of	  ischemia	  followed	  by	  reperfusion	  
before	  40	  minutes	  of	  complete	  occlusion	  of	  the	  artery.	  This	  finding	  suggested	  that	  the	  
myocardial	   tissue	  could	  be	  prepared	  prior	   to	  an	   ischemia-­‐reperfusion	   insult	   reducing	  
the	   subsequent	   damage	   extent.	   However,	   a	   longer	   period	   of	   occlusion,	   3hours,	  
nullified	  the	  protective	  effect	  of	  this	  procedure.	  The	  myocardium	  is	  not	  the	  only	  tissue	  
responsive	   to	   the	   ischemic	   preconditioning,	   numerous	   studies	   have	   proven	   similar	  
effects	  in	  other	  body	  tissues.	  The	  mechanisms	  involved	  in	  ischemia	  preconditioning	  are	  
multiple	   and	  not	   fully	   elucidated.	   The	   induction	   of	   a	   cascade	  of	   intracellular	   kinases	  
and	   changes	   in	   the	   mitochondrial	   function,	   via	   opening	   of	   ATP-­‐sensitive	   potassium	  
channels	   and	   closure	   of	   mitochondrial	   permeability	   transition	   pores	   have	   been	  
suggested698,699.	   However,	   their	   role	   and	   nature	   needs	   to	   be	   fully	   understood700,701.	  
The	  window	  of	  protection	  observed	  after	  the	  preconditioning	  procedure	  has	  also	  been	  
extensively	   researched.	   Its	   vascular	   protection	   vanishes	   after	   few	   hours,	   however	  
Marber	   et	   al.	   described	   a	   secondary	   effect	   starting	   in	   the	   following	   24-­‐48	   hours,	  
defined	   as	   a	   second	   window	   of	   protection,	   persisting	   for	   up	   to	   3-­‐4	   days702.	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Subsequently,	  it	  was	  reported	  that	  a	  brief	  ischemia	  of	  a	  coronary	  artery	  could	  protect	  
the	  myocardial	   territory	  not	  perfused	  by	  the	  same	  vessel,	   introducing	  the	  concept	  of	  
intra-­‐organ	  preconditioning703.	  Further	   research	   then	  reported	  myocardial	  protection	  
subsequent	  to	  transient	  ischemia	  of	  the	  kidney	  or	  the	  small	  bowel704,705	  suggesting	  the	  
concept	  of	  remote	  ischemic	  preconditioning	  (RIPC).	  This	  theory	  has	  been	  supported	  by	  
the	  multi-­‐organ	  protection	  obtained	   following	   transient	   ischemia	   of	   a	  wide	   range	  of	  
tissues706,707.	   RIPC,	   compared	   to	   local	   preconditioning,	   shares	   similar	   mechanisms	  
providing	  two	  phases	  of	  protection;	  recent	  evidence	  however	  suggested	  differences	  in	  
the	   pathways	   underlying	   the	   two	   procedures708.	   Kharbanda	   et	   al.	   described	   the	  
protective	  action	  of	  ischemic	  preconditioning	  on	  the	  endothelial	  dysfunction	  following	  
ischemia	  reperfusion	  damage	  in	  a	  human	  model709.	  Furthermore,	  Loukogeorgakis	  et	  al.	  
reported	   that	   RIPC	   prevents	   endothelial	   dysfunction	   following	   ischemia	   reperfusion	  
injury	  in	  conduit	  vessels	  identifying	  two	  temporally	  distinct	  phases	  of	  protection.	  A	  first	  
window	  presented	  straight	  after	  RIPC	  and	  lasting	  approximately	  4	  hours	  followed	  by	  a	  
second	  phase	  detectable	  24	  hours	  after	  the	  RIPC	  stimulus	  and	  continuing	  for	  at	   least	  
48	  h577.	  In	  addition,	  the	  authors	  demonstrated	  that	  RIPC	  exert	  its	  protective	  effects	  via	  
an	  intact	  autonomic	  function.	  The	  endothelial	  function	  is	  involved	  in	  the	  regulation	  of	  
multiple	  physiological	  processes	  such	  as	   the	  vascular	   tone,	  permeability,	   response	  to	  
inflammation,	   wound	   healing	   and	   coagulation.	   Multiple	   stimuli	   including	   diabetes,	  
hypercholesterolemia,	   oxidative	   stress,	   inflammation	   may	   induce	   endothelial	  
dysfunction	  and	  lead	  to	  atherosclerosis.	  A	  decreased	  bioavailability	  of	  NO	  seems	  to	  be	  
mechanism	  related	  to	  the	  alteration	  of	  the	  endothelial	  regulation	  of	  the	  vascular	  tone.	  
Up	   regulation	   of	   the	   endothelial	   expression	   of	   adhesion	   molecules,	   immune	   cell	  
recruitment	   to	   vascular	   wall,	   smooth	   muscle	   cell	   activation	   are	   all	   involved	   in	   the	  
endothelial	  dysfunction710.	  Impaired	  NO-­‐dependent	  vasodilatation	  has	  been	  related	  to	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atherosclerosis711.	   Therefore,	   preventing	   endothelial	   dysfunction	   is	   of	   great	  
importance	   in	   avoiding	   or	   ameliorating	   the	   development	   of	   CVD.	   Acute	   vascular	  
inflammation	   is	   characterized	   by	   vasodilation,	   increased	   permeability	   of	  
microvasculature,	   and	   vascular	   stasis.	   Endothelial	   cells	   undergo	   cytoskeletal	   changes	  
that	   disrupt	   junctions	   4–6	   h	   after	   the	   mediator	   stimulus	   and	   lasting	   for	   days.	   The	  
release	   of	   pro-­‐inflammatory	   mediators	   such	   as	   IL-­‐1,	   TNF-­‐α,	   INF-­‐γ	   mainly	   by	  
lymphocytes	   and	   macrophages	   after	   stimulation	   by	   toxins,	   injury	   or	   inflammatory	  
mediators	   leads	   to	   endothelial	   inflammatory	   activation,	   increased	   expression	   of	  
selections,	   vascular	   cell	   adhesion	   molecule-­‐1	   (VCAM-­‐1),	   and	   intercellular	   adhesion	  
molecule-­‐1	  (ICAM-­‐1)	  promoting	  the	  adherence	  of	  leukocytes712.	  Infections	  can	  provoke	  
endothelial	   dysfunction.	   Hingorani	   et	   al.	   suggested	   that	   intramuscular	   injection	   of	  
capsular	   polysaccharide	   typhoid	   vaccine	   produced	   a	   mild	   systemic	   inflammatory	  
response	   in	   healthy	   volunteers	   that	   was	   associated	   with	   a	   transient	   impairment	   of	  
FMD	   in	   the	   forearm	  circulation296.	  Periodontal	   treatment	   relies	  upon	   the	  mechanical	  
cleaning	  of	  the	  diseased	  dentition,	  which	  reduces	  local	  bacterial	  load	  and	  clinical	  signs	  
of	   gingival	   inflammation713.	   The	   treatment	   procedure	   often	   though	   results	   in	   an	  
intense	  transient	  bacteremia	  as	  well	  as	  significant	  local	  gingival	  soft	  tissue	  damage714.	  
Acute	  release	  of	  cytokines	  in	  serum	  (i.e.	  TNF-­‐α)	  has	  been	  reported	  to	  occur	  as	  early	  as	  
60	  minutes	  following	  dental	  cleaning.	  We	  have	  undertaken	  extensive	  characterization	  
of	   the	   time-­‐course	   and	   validation	   of	   a	   non-­‐drug	   in	   vivo	   model	   to	   study	   human	  
inflammation.	   A	   single	   intensive	   session	   of	   periodontal	   treatment	   (IPT)	   is	   associated	  
with	   a	   one-­‐week	   acute	   inflammatory	   response11.	   The	   bacterial	   and	   inflammatory	  
burden	   produced	   during	   dental	   instrumentation	   also	   alters	   markers	   of	   coagulant	  
pathways	   and	   markers	   of	   endothelial	   cell	   activation	   assessed	   by	   increased	   plasma	  
concentrations	  of	  fibrinogen	  and	  D-­‐dimers	  and	  soluble	  E-­‐Selectin	  and	  Von	  Willebrand	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factor	   respectively.	   The	   acute	   inflammatory	   response	   and	   haemostatic	   alterations	  
correlate	  with	  the	  degree	  of	  the	  pre-­‐existing	  periodontal	  infection	  (number	  of	  gingival	  
pockets)	   and	   the	   extent	   of	   periodontal	   treatment	   (minutes	   of	   dental	   cleaning).	   The	  
substantial	   inflammatory	   response	  generated	  by	   IPT,	  which	   is	  greater	   than	  that	  seen	  
following	   vaccination,	   is	   also	   associated	   with	   profound	   and	   transient	   reductions	   in	  
systemic	   endothelial	   function	   assessed	   by	   FMD	   of	   the	   brachial	   artery	   at	   24	   hrs.	  
Therefore	   IPT	   might	   represent	   a	   valid	   model	   for	   studying	   inflammatory	   endothelial	  
dysfunction	  since	  the	  inflammatory	  response	  generated	  is	  substantial	  (mean	  increase	  
in	   serum	   CRP	   of	   15-­‐20	   mg/L	   24hrs	   after	   therapy),	   In	   addition,	   the	   effects	   on	  
inflammatory	   cytokines,	   acute	   phase	   reactants,	   circulating	   markers	   of	   endothelial	  
damage,	   coagulant	   factors	   and	   endothelial	   function	   itself	   are	   highly	   consistent.	  
Furthermore,	  the	  duration	  of	  response	  which	  is	  sustained	  for	  up	  to	  one	  week	  from	  the	  
therapy	  allows	  better	  assessment	  of	   the	  time	  course	  of	   the	   inflammatory	  changes	   in	  
relation	   to	   the	   change	   in	  endothelial	   function;	   this	   could	  be	   important	   in	   identifying	  
which	   components	   of	   the	   inflammatory	   response	   are	  most	   important	   in	   generating	  
endothelial	   dysfunction.	   It	   is	   also	   a	   standard,	   safe	   therapy	   with	   benefits	   for	   the	  
participant,	   since	   the	   procedure	   is	   associated	   with	   better	   periodontal	   health	  
outcomes.	  IPT	  also	  allows	  the	  conduction	  of	  mechanistic	  studies	  on	  a	  larger	  scale	  than	  
has	  hitherto	  been	  possible	  with	  other	  models	  since	  a	  large	  number	  of	  patients	  require	  
treatment	   for	   severe	  periodontal	  disease.	   In	  animal	  models,	  an	   initial	  observation	  of	  
endothelial	  dysfunction	  can	  be	  followed	  up	  by	  mechanistic	  experiments	  in	  vitro	  and	  in	  
knockout	   models	   to	   dissect	   the	   likely	   cause(s)	   of	   the	   effect;	   deeper	   exploration	   in	  
clinical	  studies	  is	  considerably	  more	  difficult.	  Since	  intensive	  treatment	  of	  periodontal	  
disease	   induces	   an	   acute	   inflammatory	   response	   that	   transiently	   impairs	   endothelial	  
function,	  we	  now	  wish	  to	  determine	  whether	  remote	   ischaemic	  pre-­‐conditioning	  will	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prevent	  acute	  inflammatory	  endothelial	  dysfunction	  observed	  24	  hours	  following	  IPT.	  
This	   study	   would	   provide	   the	   first	   insight	   into	   whether	   the	   acute	   adverse	   vascular	  
changes	   associated	   with	   inflammation	   can	   be	   modified	   by	   treatment.	   If	   so	   these	  
findings	   would	   be	   of	   relevance	   to	   a	   range	   of	   clinical	   situations	   in	   which	   systemic	  
inflammation	  has	  been	  associated	  with	  a	  short-­‐term	  increase	  in	  risk	  of	  cardiovascular	  
events.	  
6.2. Methods	  
6.2.1. Study	  Design	  
We	  designed	  a	  single	  blind,	  parallel	  group,	  randomized	  controlled	  trial	  to	  evaluate	  the	  
effect	  of	  RIPC	  on	  endothelial	  function	  assessed	  by	  FMD	  within	  7	  days	  of	  IPT	  (Figure	  35).	  
	  
Figure	  35	  Study	  Flowchart	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Consecutive	   patients	   referred	   to	   the	   Eastman	   Dental	   Hospital	   in	   London	   for	  
periodontal	   therapy	  were	   invited	   to	   participate	   in	   this	   study	   if	   they	   had	   at	   least	   30	  
periodontal	   pockets	   with	   probing	   pocket	   depth	   >	   4mm	   and	   confirmed	   radiographic	  
alveolar	   bone	   loss.	   Patient	   were	   excluded	   if	   they	   were:	   a)	   pregnant,	   lactating	   or	   of	  
childbearing	  potential,	  b)	  on	  chronic	  treatment	  (i.e.,	  two	  weeks	  or	  more)	  with	  specific	  
medications	  known	  to	  affect	  periodontal	  status	  (phenytoin	  or	  cyclosporine)	  within	  one	  
month	  of	   baseline	   visit,	   c)	   suffering	   from	  any	   systemic	   disease	   (assessed	  by	  medical	  
history	   questionnaire),	   d)	   with	   limited	   mental	   capacity	   or	   language	   skills	   such	   that	  
simple	  instructions	  cannot	  be	  followed	  or	  information	  regarding	  adverse	  events	  could	  
not	   be	   provided,	   e)	   on	   any	   chronic	  medications	   or	   requiring	   antibiotic	   coverage	   for	  
dental/periodontal	  procedures	  and	  f)	  had	  received	  a	  course	  of	  periodontal	  therapy	  in	  
the	   preceding	   6	  months.	   All	   patients	   gave	  written	   informed	   consent.	   The	   study	  was	  
approved	  by	  the	  London	  Queen	  Square	  Ethics	  Committee	  (06/Q0512/107).	  	  
A	   baseline	   periodontal	   examination	   was	   performed,	   and	   full	   medical	   and	   dental	  
histories	   were	   collected	   by	   a	   single	   trained	   examiner.	   Arterial	   blood	   pressure	   was	  
measured	   in	   triplicate,	   and	   the	   average	   of	   the	   readings	   was	   recorded.	   The	   study	  
participants	  were	   randomly	   assigned	  with	   the	  use	  of	   a	   computer-­‐generated	   table	   to	  
receive	  intensive	  periodontal	  treatment	  preceded	  by	  RIPC	  (test	  group)	  or	  placebo	  RIPC	  
(control)	  in	  a	  1:1	  ratio.	  To	  prevent	  an	  imbalance	  between	  the	  two	  groups	  with	  respect	  
to	   smoking	   status,	   sex,	   age,	   and	   severity	   of	   periodontitis,	   restricted	   randomization	  
(minimization)	  was	  performed	  by	  the	  study	  registrar715.	  Treatment	  assignments	  were	  
concealed	  in	  opaque	  envelopes	  and	  revealed	  to	  the	  research	  staff	  performing	  the	  RIPC	  
on	  the	  day	  the	  treatment	  was	  administered.	  Patients	  underwent	  dental	  examinations,	  
blood	  samples	  and	  endothelial	  function	  assessment	  at	  Baseline,	  1	  and	  7	  days	  following	  
periodontal	  treatment.	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6.2.2. Periodontal	  examination	  and	  therapy	  
A	   single	   trained	   dental	   examiner	   at	   baseline	   recorded	   periodontal	   data.	   The	   data	  
included,	  number	  of	  teeth,	  periodontal	  pocket	  depth	  (PPD)	   in	  mm,	  gingival	  recession	  
and	   clinical	   attachment	   levels	   as	   previously	   described.	   The	   presence	   or	   absence	   of	  
supragingival	  dental	  plaque	  and	  gingival	  bleeding	  on	  probing	  on	  whole	  mouth	  was	  also	  
recorded.	   All	   study	   participants	   received	   standard	   oral	   hygiene	   instructions	   and	  
underwent	   a	   single-­‐sitting	   full-­‐mouth	   session	   of	   scaling	   and	   root	   planing	   (IPT)	   by	  
means	  of	   hand	   and	  ultrasonic	   instruments	   under	   local	   anesthesia	  within	   one	  month	  
from	   the	  baseline.	  A	   single	  experienced	  clinician	   completed	  all	   treatments	   in	  a	  blind	  
fashion	  (unaware	  of	  to	  the	  preconditioning	  assignment).	  
6.2.3. Remote	  ischemic	  preconditioning	  (RIPC)	  
RIPC	   consisted	   of	   three	   5	   minutes	   cycles	   of	   upper	   arm	   ischemia	   alternated	   by	   5	  
minutes	   of	   reperfusion	   using	   a	   9cm	   blood	   pressure	   cuff	   inflated	   to	   a	   pressure	   of	  
200mmHg.	   Sham	   procedure	   consisted	   of	   three	   5	   minutes	   cycles	   alternated	   by	   5	  
minutes	   of	   reperfusion	  with	   the	   blood	   pressure	   cuff	   being	   placed	   around	   the	   upper	  
arm	  with	  10mmHg.	  IPT	  commenced	  after	  the	  completion	  of	  the	  RIPC	  protocol.	  
6.2.4. Vascular	  function	  
For	   this	   study,	   endothelium-­‐dependent	   vasodilatation	   of	   the	   brachial	   artery	   was	  
assessed	  using	  high-­‐resolution	  ultrasound	  imaging	  (Acuson	  XP128	  with	  a	  7-­‐MHz	  linear	  
probe)	   in	   a	   quiet,	   temperature	   controlled	   room.	   All	   patients	   were	   fasting	   for	   a	  
minimum	  of	  6	  hours	  prior	  to	  their	  assessment.	  Images	  of	  the	  right	  brachial	  artery	  were	  
measured	  for	  1	  minute	  at	  baseline,	  5	  minutes	  of	  ischemia	  (using	  a	  blood	  pressure	  cuff	  
inflated	  to	  300mmHg)	  and	  during	  deflation.	  Flow	  measurements	  were	  derived	  by	  using	  
a	   pulsed	  wave	  Doppler	   signal.	   	   Vessel	   diameter	  measurements	  were	   analyzed	   using	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automated	   brachial	   software	   (Medical	   Imaging	   Applications,	   vascular	   research	   tools,	  
version	  5.6.7)	  and	  dilation	  was	  calculated	  as	  a	  percentage	  change	  from	  BL	  to	  the	  peak	  
diameter.	   	   Endothelium-­‐independent	   vasodilatation	   was	   also	   assessed	   following	   a	  
25μg	  dose	  of	  GTN	  administered	  sublingually.	  A	  single	  examiner	  who	  was	  blinded	  to	  the	  
RIPC	  or	  sham	  procedure	  assessed	  all	  patients.	  
6.2.5. Inflammatory	  and	  vascular	  biomarkers	  
Serial	   blood	   samples	  were	   collected	   in	   fasting	   condition	   at	   baseline,	   24	   hours	   and	  7	  
days	  after	  IPT.	  Samples	  were	  immediately	  processed	  and	  aliquots	  of	  serum	  and	  EDTA	  
plasma	  were	  stored	  at	  -­‐70	  degrees	  as	  previously	  reported.	  At	  the	  end	  of	  the	  study	  all	  
samples	   were	   processed	   in	   a	   blind	   fashion	   for	   a	   broad	   panel	   of	   inflammatory	  
biomarkers	  using	  multiplex	  high	  sensitivity	  assays	  including	  interleukin-­‐1β	  (IL-­‐1β),	  IL-­‐6,	  
IL-­‐8,	  IL-­‐10,	  IL-­‐12,	  interferon-­‐γ	  (IFN-­‐γ)	  and	  tumor	  necrosis	  factor-­‐α	  (TNF-­‐α)	  according	  to	  
manufacturer’s	  instructions	  (Meso	  Scale	  Discovery,	  Maryland,	  USA).	  Serum	  C-­‐reactive	  
protein	   (CRP)	   was	   measured	   by	   immunoturbidometry	   (Cobas,	   Roche	   Diagnostic,	  
Mannheim,	  Germany).	  E-­‐selectin,	  P-­‐selectin,	  intercellular	  adhesion	  molecule-­‐3	  (ICAM-­‐
3)	  and	   thrombomodulin	  were	  assayed	  with	  a	  multiplex	  assay	   (Meso	  Scale	  Discovery,	  
Maryland,	  USA)	  
6.2.6. LPS	  assay	  
A	  quantitative,	  endpoint	  assay	  for	  the	  detection	  of	  Gram-­‐negative	  bacterial	  endotoxin	  
was	  used	  (QCL-­‐1000™,	  Lonza)	  was	  adopted.	  At	  the	  end	  of	  the	  study	  all	  samples	  were	  
processed	  in	  a	  blind	  fashion.	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6.2.7. d-­‐ROM	  test	  
In	   this	   study,	   D-­‐ROM	   test	   was	   used	   to	   estimate	   the	   total	   amount	   of	   oxidative	  
metabolites	  of	  each	  sample.	  At	  the	  end	  of	  the	  study	  all	  samples	  were	  processed	   in	  a	  
blind	  fashion.	  
6.2.8. Mitochondrial	  membrane	  potential	  and	  superoxide	  production	  
Peripheral	   blood	   mononuclear	   cells	   (PBMC)	   were	   isolated	   following	   standard	  
procedures	  by	  density	  gradient	   centrifugation	  with	  Ficoll	   (Ficoll-­‐Paque	  PLUS,	  GE,	  UK)	  
from	   an	   aliquot	   of	   heparinised	   blood	   collected	   at	   each	   study	   visit.	   Mitochondrial	  
oxidative	  stress	  production	  and	  membrane	  potential	  were	  assessed	  by	  flow	  cytometry	  
using	   the	  mito	   probe	  MitoSOX	   Red	   (Invitrogen,	   UK)	   and	   5’,6,6’-­‐tetrachloro-­‐1,1’,3,3’-­‐
tetraethylbenzimidazolylcarbocyanine	   iodide	   (JC-­‐1,	   Invitrogen),	   respectively	   as	  
described	  in	  previously	  described	  in	  the	  Methods	  section	  of	  this	  thesis.	  
6.2.9. HEME	  H0-­‐1	  ELISA	  
Plasma	  HO-­‐1	  concentrations	  were	  determined	   from	  100	  μL	  of	  plasma	  using	  an	  HO-­‐1	  
(human)	  enzyme-­‐linked	  immunosorbent	  assay	  kit	  (Enzo	  Life	  Sciences,	  Farmingdale,	  NY,	  
USA).	  This	  assay	  can	  detect	  HO-­‐1	  in	  the	  range	  of	  0.78–25	  ng/mL	  of	  undiluted	  plasma.	  
6.2.10. Statistical	  analysis	  
All	   data	   is	   presented	   as	   mean	   and	   standard	   error	   of	   the	   mean	   unless	   specified.	  
Demographic	  data	  at	  baseline	  was	  compared	  between	  groups	  (RIPC	  versus	  placebo)	  at	  
baseline	   by	   paired	   t-­‐Test	   for	   numerical	   variables	   and	   Fisher’s	   exact	   for	   categorical	  
variables.	  	  Changes	  in	  FMD	  24	  hours	  after	  IPT	  were	  the	  primary	  outcome.	  Changes	  in	  
all	   biomarkers	   were	   analysed	   as	   secondary	   outcomes	   using	   ANOVA	   for	   repeated	  
measures	   (with	   post-­‐hoc	   Bonferroni	   corrections	  when	   between	   groups	   comparisons	  
were	  performed).	  For	  those	  variables	  with	  a	  statistical	  significant	  difference	  between	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groups	   at	   day	   1,	   a	   relative	   increase	   was	   calculated	   as	   follows:	   day	   1	   serum	  
concentrations	  minus	  baseline,	  divided	  by	  baseline	  and	  multiplied	  by	  100.	  Comparison	  
of	   relative	   increases	  at	  day	  1	  between	  groups	  was	  performed	  by	   t-­‐test	  or	  equivalent	  
non-­‐parametric	  method.	  Data	  were	  graphically	  tested	  for	  normality	  and	  logarithmic	  or	  
square	  root	  transformations	  were	  made	  as	  needed	  before	  applying	  the	  adequate	  non-­‐
parametric	   tests.	   Univariate	   analyses	   were	   performed	   with	   crude	   values	   of	   each	  
outcome	  variable	  between	  study	  groups	  at	  different	  time	  points.	  Further	  multivariate	  
models	   were	   constructed	   including	  variables	   that	   showed	   a	   statistically	   significant	  
association	  	  with	  the	  outcome	  from	  univariate	  analyses	  and	  they	  included	  age,	  gender,	  
smoking,	   body	   weight	   and	   ethnicity.	   All	   analysis	   was	   performed	   with	   the	   statistical	  
software	  package	  SPSS	  22	  (SPSS	  Inc.	  Chicago,	  IL,	  USA).	  
A	  minimum	  of	  22	  patients	  per	  group	  were	  needed	  to	  demonstrate	  a	  2%	  difference	  in	  
FMD	   between	   groups	   after	   24	   hrs	   (90%	   power,	   α	   0.05,	   standard	   deviation	   of	   1.6	  
(Tonetti	  et	  al.	  2007)).	  A	  final	  sample	  of	  24	  participants	  per	  group	  was	  planned	  including	  
a	  10%	  drop-­‐out	  rate.	  	  
6.3. RESULTS	  
From	   April	   2013	   to	   December	   2013,	   64	   patients	   met	   the	   inclusion	   criteria	   for	   the	  
study.	   49	   accepted	   to	   be	   enrolled	   into	   the	   study	   and	   underwent	   randomization	   of	  
whom	  47	  completed	  the	  trial.	  An	  intention	  to	  treat	  analysis	  was	  performed	  including	  
24	  patients	   in	   the	  Placebo	  Group	  and	  23	  patients	   in	   the	  RIPC	  Group	   (Figure	  34).	  The	  
patients’	   baseline	   characteristics	   were	   similar	   in	   both	   groups,	   recruited	   individuals	  
were	   middle	   aged,	   60%	   Caucasians,	   equally	   distributed	   between	   genders,	   slightly	  
overweight	  and	  with	  25-­‐30%	  of	  current	  smokers	  (Table	  28).	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Table	  28	  Baseline	  charactheristics	  
	   Placebo	  (N=24)	   RIPC	  (N=23)	  
Age	   47±9	   45±9	  
BMI	   26.5±3.8	   26.1±3.7	  
Gender,	  Male	   14(56.0%)	   11(45.8%)	  
Ethnicity,	  Caucasian	   15(60.0%)	   15(62.5%)	  
Smoking,	   7	  (28.0%)	   8	  (33.3%)	  
Systolic	  BP,	  mmHg	   120±16	   118±10	  
Diastolic	  BP,	  mmHg	   77.58±8.51	   76.43±8.08	  
FMD,	  %	   6.28±2.56	   6.28±3.68	  
GTN,	  %	   17.40±7.14	   19.52±7.64	  
	  
No	  serious	  adverse	  events	  were	  reported	  during	   the	  study.	  All	   study	  participants	  did	  
not	  report	  any	  major	  changes	   in	   lifestyle	  for	  the	  entire	  duration	  of	  the	  trial.	  Baseline	  
periodontal	  and	  multiplex	  parameters	  are	  described	  in	  Table	  29	  and	  30.	  
Table	  29	  Periodontal	  baseline	  data	  
	   Placebo	  (N=24)	   RIPC	  (N=23)	  
PPD,	  mm	   4.16±.82	   3.84±.56	  
REC,	  mm	   .85±.86	   .86±.82	  
NPKTS,	  n	  *	   69.33±28.96	   61.00±21.81	  
FMPS,	  %	  §	   63.97±16.23	   58.90±15.6	  
FMBS,	  %	  ¶	   49.86±21.97	   50.05±16.04	  
NTEETH,	  n	   28.46±2.72	   28.57±2.84	  
FMPS:	   full	  mouth	  plaque	   score,	   FMBS:	   full	  mouth	  bleeding	   score,	  PPD:	  periodontal	  pocket	  depth,	  REC:	  
gingival	  recession,	  NPKTS,	  number	  of	  pockets,	  NTEETH,	  number	  of	  teeth.	  
¶	  Scores	   for	   full-­‐mouth	  gingival	  bleeding	  were	  calculated	   for	  each	  patient	  as	   the	  number	  of	   sites	  with	  
gingival	  bleeding	  on	  probing	  divided	  by	  the	  total	  number	  of	  sites	  per	  mouth,	  multiplied	  by	  100.	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§	  Scores	  for	  full-­‐mouth	  plaque	  were	  calculated	  for	  each	  patient	  as	  the	  number	  of	  sites	  with	  detectable	  
plaque	  divided	  by	  the	  total	  number	  of	  sites	  per	  mouth,	  multiplied	  by	  100.*	  
*	  Periodontal	  pockets	  identified	  as	  sites	  with	  probing	  greater	  or	  equal	  to	  5	  mm	  
Table	  30	  Multiplex	  baseline	  data	  
	   Placebo	  (N=24)	   RIPC	  (N=23)	  
IL-­‐6,	  pg/ml	   1.15	  (0.63-­‐1.79)	   0.92(0.38-­‐2.00)	  
IL-­‐8	  pg/ml	   11.22±3.45	   11.64±4.47	  
TNF-­‐alpha	  pg/ml	   4.00±1.92	   3.52±1.85	  
E-­‐Selectin	  pg/ml	   21.26±16.43	   20.75±15.20	  
P-­‐Selectin	  pg/ml	   122.89±62.12	   114.92±43.91	  
s-­‐ICAM3	  pg/ml	   1.92±3.86	   2.02±3.39	  
Thrombomodulin	  pg/ml	   5.30±3.98	   5.47±6.06	  
	  
6.3.1. Vascular	  function	  
FMD	  was	   lower	   in	   the	   Placebo	   group	   at	   24	   hours	   after	   IPT	  when	   compared	   to	   RIPC	  
(unadjusted	   difference	   of	   2.11%;	   95%	   CI,	   0.44-­‐3.78;	   p=0.015).	   This	   difference	  
disappeared	   at	   7	   days	   after	   IPT	   (unadjusted	   difference	   of	   0.89;	   95%	   CI,	   0.97-­‐2.74;	  
p=0.339)	   (Figure	   36).	   A	   30%	   reduction	   of	   FMD	   was	   noted	   in	   the	   placebo	   group	   24	  
hours	   after	   IPT	   when	   compared	   to	   RIPC	   (Figure	   37).	   A	   greater	   reduction	   in	  
endothelium	  independent	  vasodilatation	  (GTN)	  was	  further	  noted	  24	  hours	  after	  IPT	  in	  
the	   placebo	   group	   when	   compared	   to	   RIPC	   (unadjusted	   difference	   of	   4.77;	   95%	   CI,	  
0.76-­‐8.78;	  p=0.021),	  (Figure	  38).	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Figure	  36	  Flow	  mediated	  dilatation	  during	  the	  study	  duration	  
I	   bars	   represent	   SE.	  Data	  are	   for	   the	  23	  patients	   in	   the	   test	   group	  and	   the	  24	  patients	   in	   the	   control-­‐
treatment	  group.	  FMD	  %	  changes,	  asterisks	   indicate	  significant	  between-­‐group	  differences	  (P<0.001).	   .	  
Data	  adjusted	  for	  age,	  gender,	  smoking,	  body	  weight	  and	  ethnicity.	  
	  
	  
Figure	  37	  Flow	  mediated	  dilatation	  relative	  changes	  during	  the	  study	  duration	  
I	   bars	   represent	   SE.	  Data	  are	   for	   the	  23	  patients	   in	   the	   test	   group	  and	   the	  24	  patients	   in	   the	   control-­‐
treatment	  group.	  FMD	  relative	  %	  changes.	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Figure	  38	  GTN	  mediated	  dilatation	  relative	  changes	  during	  the	  study	  duration	  
I	   bars	   represent	   SE.	  Data	  are	   for	   the	  23	  patients	   in	   the	   test	   group	  and	   the	  24	  patients	   in	   the	   control-­‐
treatment	  group.	  GTN	  %	  changes,	  asterisks	   indicate	   significant	  between-­‐group	  differences	   (P<0.001).	   .	  
Data	  adjusted	  for	  age,	  gender,	  smoking,	  body	  weight	  and	  ethnicity.	  
6.3.2. Markers	  of	  inflammation	  and	  vascular	  activation	  
Among	  all	  inflammatory	  biomarkers,	  repeated	  ANOVA	  analysis	  confirmed	  a	  statistically	  
significant	   difference	   in	   CRP	   and	   TNF-­‐α	   between	   groups	   over	   time.	   Similarly	   all	  
endothelial	   markers	   were	   statistically	   significant	   different	   between	   groups.	   In	  
particular	  patients	  in	  the	  RIPC	  group	  exhibited	  lower	  CRP	  level	  at	  day	  1,	  and	  lower	  TNF-­‐
α	  at	  day	  1	  and	  day	  7	  after	  IPT	  when	  compared	  to	  placebo	  group	  patients	  (p<0.05	  for	  all	  
comparisons),	   (Figure	   39).	   An	   inverse	   trend	   of	   acute	   release	   of	   endothelial	  markers	  
was	  noted	  following	  IPT	  between	  groups.	  Indeed	  patients	  in	  the	  RIPC	  group	  presented	  
with	  lower	  s-­‐Eselectin	  at	  24	  hrs,	  P-­‐selectin	  at	  7	  days,	  lower	  s-­‐ICAM3	  both	  at	  24	  hours	  
and	   7	   days	   after	   IPT	   when	   compared	   to	   placebo	   group	   patients.	   Thrombomodulin	  
levels	   between	   study	   groups	   although	   different	   at	   baseline,	   changed	   following	   an	  
opposite	  trend.	  Patients	  in	  the	  RIPC	  group	  showed	  statistically	  significant	  lower	  levels	  
of	  thrombomodulin	  at	  7	  days	  after	  IPT	  when	  compared	  to	  placebo	  patients	  (Figure	  40).	  
Non	  adjusted	  data	  presented	  in	  Table	  31	  and	  32.	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Figure	  39	  Inflammatory	  mediators	  during	  the	  study	  duration	  
I	   bars	   represent	   SE.	  Data	  are	   for	   the	  23	  patients	   in	   the	   test	   group	  and	   the	  24	  patients	   in	   the	   control-­‐




Figure	  40	  Vascular	  markers	  during	  the	  study	  duration	  
I	   bars	   represent	   SE.	  Data	  are	   for	   the	  23	  patients	   in	   the	   test	   group	  and	   the	  24	  patients	   in	   the	   control-­‐
treatment	   group.	   Asterisks	   indicate	   significant	   between-­‐group	   differences	   (P<0.05).	  Data	   adjusted	   for	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Table	  31	  Non	  adjusted	  between	  group	  differences	  of	  markers	  of	  inflammation	  an	  vascular	  activation	  at	  Day	  1	  
Marker	   Unadjusted	  
between	   group	  
difference	   at	  
Day	  1	  
95%	  CI	   p	  value	  
CRP	   5.55	   0.36-­‐11.47	   0.035	  
IL-­‐1	   -­‐1.19	   -­‐2.63-­‐0.25	   0.096	  
IL-­‐6	   0.58	   -­‐1.04-­‐2.21	   0.474	  
IL-­‐8	   1.63	   -­‐2.29-­‐5.54	   0.408	  
IL-­‐10	   4.35	   -­‐0.05-­‐8.76	   0.053	  
IL-­‐12	   1.29	   0.15-­‐2.42	   0.028	  
TNF-­‐α	   1.34	   0.11-­‐2.79	   0.041	  
IFN-­‐γ	   9.95	   0.44-­‐19.46	   0.041	  
E	  selectin	   5.96	   -­‐4.51-­‐16.43	   0.257	  
P	  selectin	   22.55	   -­‐8.47-­‐53.57	   0.15	  
Thrombomodulin	   0.28	   -­‐2.80-­‐3.37	   0.854	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Table	  32	  Non	  adjusted	  between	  group	  differences	  of	  markers	  of	  inflammation	  an	  vascular	  activation	  at	  Day	  7	  
Marker	   Unadjusted	  
between	   group	  
difference	   at	  
Day	  7	  
95%	  CI	   p	  value	  
CRP	   0.87	   0.13-­‐1.86	   0.086	  
IL-­‐1	   -­‐0.15	   -­‐0.63-­‐0.34	   0.511	  
IL-­‐6	   0.52	   -­‐0.74-­‐1.78	   0.411	  
IL-­‐8	   0.94	   -­‐2.01-­‐3.89	   0.525	  
IL-­‐10	   0.29	   -­‐5.44-­‐6.02	   0.919	  
IL-­‐12	   -­‐4.81	   -­‐11.73-­‐2.12	   0.161	  
TNF-­‐α	   0.96	   0.25-­‐2.17	   0.03	  
IFN-­‐γ	   -­‐1.17	   -­‐8.31-­‐5.96	   0.737	  
E	  selectin	   3.65	   -­‐6.12-­‐13.43	   0.455	  
P	  selectin	   28.31	   0.32-­‐61.93	   0.04	  
Thrombomodulin	   0.84	   0.16-­‐3.85	   0.044	  




6.3.3. d-­‐ROM	  test	  
Patients	  in	  the	  placebo	  group	  exhibited	  higher	  levels	  of	  reactive	  oxygen	  metabolites	  at	  
baseline	   and	   no	   other	   differences	  were	   noted	   between	   groups	   over	   time	   (P<0.001).	  
When	   analysing	   the	   relative	   changes	   in	   d-­‐ROM	   %	   after	   day	   1	   and	   day	   7	   following	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therapy,	  patients	  in	  the	  RIPC	  group	  presented	  with	  approximately	  30%	  more	  reactive	  
oxygen	  metabolites	  compared	  to	  the	  patients	  in	  the	  placebo	  group	  (Figure	  41).	  
	  
Figure	  41	  Reactive	  oxygen	  metabolites	  during	  the	  study	  duration	  
I	   bars	   represent	   SE.	  Data	  are	   for	   the	  23	  patients	   in	   the	   test	   group	  and	   the	  24	  patients	   in	   the	   control-­‐
treatment	  group.	  Asterisks	  indicate	  significant	  between-­‐group	  differences	  (P<0.05).	  
6.3.4. Mitochondrial	  ROS	  production	  and	  membrane	  potential	  	  
PBMC	   isolated	   in	   the	   RIPC	   group	   had	   a	   non-­‐statistically	   significant	   higher	   mtROS	  
production	   compared	   to	   those	   in	   the	   placebo	   group	   24	   hours	   following	   dental	  
treatment	   (unadjusted	  difference	  of	   -­‐5.30;	  95%	  CI,	   -­‐17.35-­‐6.75;	  p=0.380)	   (Figure	  42).	  
When	  subpopulations	  of	  PBMC	  were	  analysed	  separately,	  the	  increased	  production	  of	  
mtROS	  from	  PBMC	  was	  mainly	  due	  to	  a	  higher	  superoxide	  production	  in	  lymphocytes	  
(unadjusted	   difference	   of	   -­‐4.23;	   95%	   CI,	   -­‐10.25-­‐2.30;	   p=0.198).	   Further	   a	   non-­‐
statistically	   significant	   trend	   of	   increased	   oxidative	   stress	   was	   also	   detected	   in	  
monocytes	  (unadjusted	  difference	  of	  -­‐0.93;	  95%	  CI,	  -­‐45.35-­‐43.48;	  p=0.966)	  	  (Figure	  41).	  
No	   differences	   between	   groups	   in	   the	   mitochondrial	   membrane	   potential	   of	   PBMC	  
(unadjusted	  difference	  of	  1.07;	  95%	  CI,	  -­‐1.22-­‐3.77;	  p=0.349),	  lymphocytes	  (unadjusted	  
difference	   of	   -­‐0.33;	   95%	   CI,	   -­‐1.81-­‐2.46;	   p=0.759)	   	   	   and	   macrophages	   (unadjusted	  
difference	  of	  -­‐0.08;	  95%	  CI,	  -­‐0.50-­‐0.34;	  p=0.694)	  24	  following	  RIPC	  were	  observed.	  
	  




Figure	  42	  Changes	  in	  mtROS	  production	  during	  the	  study	  period	  
6.3.5. LPS	  
Patients	   in	   the	   RIPC	   and	   placebo	   group	   presented	  with	   similar	   plasma	   LPS	   levels	   at	  
their	   baseline	   visit.	   24	   hours	   following	   therapy,	   no	   substantial	   differences	   were	  
detected	  in	  LPS	  profiles	  between	  the	  two	  study	  groups	  (unadjusted	  difference	  of	  0.07;	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95%	  CI,	   -­‐0.44-­‐0.58;	  p=0.775).	  Both	  groups	  exhibited	  a	   reduction	   in	   LPS	  plasma	   levels	  
following	  one	  week	  of	  periodontal	  treatment.	  	  
6.3.6. Heme	  oxygenase	  1	  	  
No	   statistically	   significant	   differences	   were	   detected	   in	   HO-­‐1	   levels	   at	   baseline	   and	  
overtime	  between	  the	  two	  study	  groups	  (day	  1	  unadjusted	  difference	  of	  14.67;	  95%	  CI,	  
-­‐8.63-­‐37.96;	   p=0.211),	   	   (day	   7	   unadjusted	   difference	   of	   8.13;	   95%	   CI,	   9.04-­‐25.29;	  
p=0.344)	  	  .	  
6.4. Discussion	  
This	   study	   demonstrated	   that	   in	   patients	   suffering	   from	   periodontitis,	   24	   hours	  
following	   intensive	   periodontal	   treatment,	   endothelial	   function	   was	   only	   mildly	  
impaired	   when	   preceded	   by	   RIPC	   when	   compared	   to	   placebo.	   This	   benefit	   on	   the	  
endothelium	  was	  associated	  with	  a	  reduction	  of	  all	  soluble	  markers	  of	  endothelial	  cell	  
activation	  and	  some	  common	  inflammatory	  markers.	  Some	  of	  these	  differences	  were	  
still	  present	  1	  week	  after	   IPT,	  although	  vascular	   function	  had	  returned	  to	  normal.	  An	  
increased	   oxidative	   stress	   response	   was	   also	   observed	   parallel	   to	   the	   decreased	  
vascular	  function.	  These	  findings	  corroborate	  the	  impact	  of	  systemic	  inflammation	  on	  
vascular	   function	   and	   provide	   evidence	   on	   the	   possible	   mechanisms	   behind	   the	  
vascular	  benefit	  of	  RIPC.	  
Full	  mouth	   scaling	  and	   root	  planing	   (IPT)	   induced	  a	   transient	   inflammatory	   response	  
and	   endothelial	   impairment	   as	   previously	   reported12.	   Acute	   impairment	   of	   vascular	  
function	   was	   associated	   with	   increase	   in	   systemic	   inflammation	   and	   endothelial	  
activation.	  Previous	  evidence	  suggested	  that	  RIPC	  is	  protective	  for	  the	  vasculature	  via	  
two	   different	   windows577.	   The	   earliest	   phase	   of	   protection	   is	   active	   within	   4	   hours	  
following	  RIPC,	   the	   second	  and	   longer	  protective	  effect	  has	  been	   identified	  between	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24	  and	  72	  hours.	  As	  the	  IPT	  was	  initiated	  within	  30	  minutes	  from	  preconditioning,	  it	  is	  
plausible	  to	  consider	  that	  the	  beneficial	  effects	  on	  the	  vascular	  endothelium	  observed	  
in	  this	  study,	  related	  to	  the	  first	  window	  of	  protection.	  	  
RIPC	   has	   been	   previously	   used	   in	   human	   models	   in	   order	   to	   prevent	   endothelial	  
dysfunction	   following	   different	   inflammatory	   stimuli	   (typhoid	   vaccination,	   strenuous	  
exercise)	  and	  it	  has	  shown	  a	  protective	  effect	  towards	  the	  endothelium716.	  This	  is	  the	  
first	   trial	   that	   explores	   its	   effects	   on	   markers	   of	   inflammation	   and	   endothelial	  
activation	  following	   IPT.	  The	  changes	   in	  some	  serum	  inflammatory	  markers	  observed	  
in	   this	   study	  suggest	   that	   the	  protective	  effect	  of	  RIPC	  on	  the	  endothelium	  might	  be	  
partially	   mediated	   by	   the	   modulation	   of	   systemic	   inflammation.	   Similarly	   we	   could	  
infer	  that	  the	  inflammatory	  mediators	  profile	  could	  be	  responsible	  for	  the	  endothelial	  
impairment	  observed	  24	  hours	  following	  the	  dental	  treatment.	  Substantial	  changes	  in	  
endothelial	   activation	   markers	   between	   the	   RIPC	   and	   placebo	   groups	   were	   noted.	  
Macromolecular	   adhesive	   associations	   between	   cells	   are	   important	   for	   transmitting	  
spatial	  and	   temporal	   information	   that	   is	   critical	   for	   immune	  system	  function.	  Among	  
such	   group	   of	   proteins,	   the	   intercellular	   adhesion	   molecules	   (ICAMs)	   have	   multiple	  
functions	   including	   intracellular	  signaling	  events717.	  The	  normal	  expression	  pattern	  of	  
ICAM3	   is	   high	   on	   all	   leukocytes	   but	   lacking	   on	   endothelium.	   It	   is	   likely	   that	   this	  
molecule	   plays	   an	   important	   role	   in	   early	   events	   during	   leukocyte-­‐leukocyte	   contact	  
including	   B	   cell	   activation	   mediated	   by	   T	   cell	   help	   or	   T	   cell	   activation	   by	   antigen-­‐
presenting	  cells	  (APCs).	  Monoclonal	  antibodies	  (MAbs)	  to	  ICAM-­‐3	  have	  been	  shown	  to	  
inhibit	  peripheral	  blood	   lymphocyte	  proliferation	   in	   response	  to	  phytohemagglutinin,	  
allogeneic	  stimulator-­‐cells,	  and	  specific	  antigens718.	  	  
Endothelial	  activation	  often	  precedes	  endothelial	  dysfunction.	  Differential	  cell	  surface	  
molecule	  expression	  between	  quiescent	  and	  activated	  endothelial	  cells	  influences	  not	  
	   265	  
only	  the	  relative	  balance	  between	  pro-­‐	  and	  anti-­‐coagulant	  activity,	  but	  also	  the	  degree	  
of	  adhesion	  of	  circulating	  blood	  cells.	  E-­‐selectin	   is	  expressed	  on	  activated	  endothelial	  
cells,	  where,	  in	  combination	  with	  P-­‐selectin,	  it	  facilitates	  rolling	  of	  leukocytes	  along	  the	  
endothelial	  layer	  as	  a	  prelude	  to	  leukocyte	  adhesion	  (facilitated	  by	  the	  upregulation	  of	  
ICAM-­‐1	  and	  VCAM-­‐1	  [vascular	  cell	  adhesion	  molecule-­‐1])	  to	  activated	  endothelial	  cells	  
and	   subsequent	   transmigration	   across	   the	   endothelial	   barrier	   to	   a	   site	   of	   injury	   or	  
inflammation719.	   Given	   their	   specificity	   for	   endothelial	   cells	   in	   the	   activated	   state,	  
soluble	   forms	   of	   these	   cell-­‐surface	   molecules,	   shed	   from	   endothelial	   cells	   after	  
activation,	  have	  been	  widely	  studied	  as	  diagnostic	  and	  prognostic	  markers	  in	  a	  variety	  
of	   infectious	   diseases.	   Thrombomodulin	   (TM)	   is	   present	   in	   large	   quantities	   on	   the	  
surface	   of	   the	   endothelium,	   particularly	   in	   the	  microcirculation,	   where	   it	   acts	   as	   an	  
anticoagulant720.	   The	   TM-­‐thrombin	   complex	   catalyses	   the	   formation	   of	   the	  
anticoagulant	  molecule	   activated	   protein	   C,	   and	   prevents	   thrombin	   from	   converting	  
fibrinogen	  to	  fibrin	  and	  from	  exerting	  other	  pro-­‐coagulant	  effects.	  Consistent	  with	  the	  
pro-­‐coagulant	   properties	   of	   the	   activated	  endothelium,	   cell-­‐surface	   thrombomodulin	  
expression	   is	   reduced	   during	   sepsis.	   This	   phenomenon	   is	   likely	   to	   be	   linked	   to	  
secondary	   to	   shedding	   of	   the	   molecule.	   	   Soluble	   TM	   (sTM)	   has	   therefore	   been	  
proposed	   as	   both	   a	   diagnostic	   and	   prognostic	   marker	   of	   endothelial	  
activation/dysfunction721.	   Lower	   serum	   levels	   of	   s-­‐ICAM3,	   sE-­‐Selectin	   and	   sTM,	  
together	   with	   the	   reduction	   of	   TNF	   and	   CRP,	   reported	   24	   hours	   after	   RIPC	   and	   IPT	  
suggest	  that	  RIPC	  could	  act	  as	  a	  modulator	  of	  the	  immune	  system	  and	  subsequently	  of	  
endothelial	   activation.	   These	   properties	   could	   explain	   the	   differences	   observed	   in	  
vascular	  function	  assessed	  by	  FMD	  in	  our	  study.	  For	  the	  first	  time,	  we	  have	  analysed	  
Heme	  oxygenase	  1	  (HO1)	  concentration	  in	  plasma	  in	  a	  human	  model	  of	  acute	  systemic	  
inflammation.	  HO1	  is	  an	  inducible	  heat	  shock	  protein	  that	  seems	  to	  be	  involved	  in	  the	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protection	   from	   ischemia-­‐reperfusion	  damage	  provided	  by	  RIPC.	   In	  our	   study	  we	  did	  
not	   detect	   a	   difference	   in	   the	   (HO1)	   profile	   between	   test	   and	   control	   groups.	   An	  
alternative	   mechanism	   could	   have	   been	   mediated	   on	   the	   immune	   response	   to	   the	  
acute	  bacterial	  burden	  that	  the	  invasive	  dental	  treatment	  could	  have	  produced.	  In	  our	  
trial	   we	   have	   not	   detected	   substantial	   differences	   in	   LPS	   levels	   between	   the	   study	  
groups.	   This	   finding	   could	   rule	   out	   a	   potential	   action	   of	   RIPC	   on	   the	   systemic	  
bacteremia	  following	  IPT.	  However,	  the	  time	  points	  in	  which	  we	  have	  obtained	  blood	  
samples	  could	  not	  be	  the	  most	  adequate	  to	  analyse	  the	  relationship	  between	  RIPC	  and	  
bacteremia.	  Further,	  assays	  measuring	  LPS	  circulating	  levels	  are	  rather	  not-­‐specific	  (gut	  
versus	  oral	  microflora).	  We	  could	   speculate	   that	  a	   lower	   level	  of	   inflammation	  could	  
have	   reduced	   the	   permeability	   of	   blood	   vessel	   in	   the	   periodontium	   reducing	   the	  
amount	   of	   bacterial	   dissemination.	   There	   is	   increasingly	   interest	   on	   the	   impact	   of	  
invasive	  dental	  procedure	  both	  with	  regards	  to	  the	  long-­‐term	  risk	  of	  vascular	  diseases	  
as	   well	   as	   on	   the	   myocardial	   tissues	   (risk	   of	   endocarditis).	   Evidence	   from	   an	  
observational	  study	  suggests	  an	   increased	  risk	  of	  CV	  events	   in	   the	  4	  weeks	   following	  
invasive	   dental	   procedures519.	   	   Therefore,	   reducing	   the	   amount	   of	   acute	   endothelial	  
dysfunction	  could	  be	  beneficial	  in	  populations	  at	  high	  risk	  for	  CVD.	  Our	  data	  have	  also	  
associated	   RIPC	   with	   a	   higher	   level	   of	   mitochondrial	   superoxide	   production	   and	   a	  
potential	   higher	   level	   of	   systemic	   oxidants.	   A	   potential	   explanation	   for	   this	   finding	  
could	   be	   related	   to	   the	   production	   of	   ROS	   during	   the	   ischemia-­‐reperfusion	   cycles	  
provoked	  by	  the	  RIPC.	  It	  is	  now	  accepted	  that	  ROS	  could	  be	  generated	  in	  both	  phases	  
of	  RIPC	  and	  not	  only	   following	  reperfusion	  as	   initially	  proposed722.	   	  The	  concept	  of	  a	  
detrimental	   role	   of	   ROS	   should	   also	   be	   carefully	   evaluated.	   Vanden	   Hoek	   et	   al.	  
reported	   the	   loss	   of	   preconditioning	   protection	   treating	   in	   cardiomyocytes	   with	  
antioxidants723,724.	  We	   have	   reported	   the	   increase	   in	   ROS	   production	   both	   in	   PBMC	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mitochondria	   and	  whole	   blood	   in	   a	   human	  model.	   Therefore	   this	   increase	   could	   be	  
potentially	   partially	   involved	   in	   the	   explication	   of	   the	   protective	   effect	   of	   RIPC.	  
However,	  a	  more	  detailed	  assessment	  of	  the	  oxidative	  status	  following	  RIPC	  should	  be	  
investigated	   including	   more	   in	   depth	   and	   specific	   measure	   of	   oxidative	   stress	   over	  
time.	   In	   addition,	   we	   recognize	   a	   limitation	   in	   our	   study.	   Indeed	   in	   support	   to	   our	  
finding,	   an	   additional	   control	   group	   could	   have	   been	   recruited.	   Individuals	   not	  
undergoing	  periodontal	  treatment	  could	  have	  been	  recruited	  and	  assessed	  for	  changes	  
in	  Mitosox	  and	  d-­‐Rom	  levels	  after	  24	  hours	  and	  one	  week.	  
Although	  this	  study	  is	  the	  first	  one	  to	  investigate	  possible	  mechanisms	  underlying	  the	  
transient	  effect	  of	  IPT	  on	  the	  vasculature	  there	  are	  some	  limitations	  to	  consider.	  This	  
study	   included	  a	   small	   group	  of	   individuals	  and	   the	   results	  might	  not	  be	  valid	   for	  all	  
patients	   suffering	   from	   periodontitis	   as	   well	   as	   following	   other	   dental	   invasive	  
procedures	  (i.e.	  tooth	  extraction	  or	  surgical	  procedures).	  Although	  we	  included	  healthy	  
individuals	   with	   no	   other	   systemic	   conditions	   known	   to	   impact	   on	   the	   endothelium	  
such	   as	   hypertension,	   heart	   failure,	   atherosclerosis,	   hypercholesterolemia,	   diabetes	  
mellitus,	   smoking	   and	   aging,	   we	   cannot	   rule	   out	   an	   alternative	   mechanism	   of	  
protection	  of	  RIPC	  on	  vascular	  dysfunction.	  Strengths	  of	  the	  study	  though	  include	  the	  
adoption	  of	   a	   validated	   flow	  mediated	  dilatation	  protocol	   and	  using	   a	   single	   trained	  
vascular	  examiner	  masked	  to	  the	  group	  allocation,	  who	  performed	  and	  analysed	  all	  the	  
scans	  with	  a	  standardized	  protocol.	  In	  addition,	  a	  single	  clinician	  performed	  all	  the	  IPT	  
blind	  to	  the	  patients’	  randomization.	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6.5. Conclusion	  
In	   conclusion	   intensive	   periodontal	   therapy	   is	   associated	   with	   acute	   impairment	   of	  
vascular	   function	   associated	   with	   systemic	   inflammation	   and	   endothelial	   cell	  
activation.	   RIPC	   performed	   30	   minutes	   before	   IPT	   can	   prevent	   both	   acute	  
inflammation	   and	   endothelial	   dysfunction.	   Further	   research	   is	   needed	   to	   ascertain	  
whether	  RIPC	  could	  be	  performed	  when	   IPT	  or	  other	   invasive	  dental	  procedures	  are	  
performed	   in	   individuals	   with	   known	   comorbidities	   and	   increased	   vascular	   risk	   and	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7. FINAL	  DISCUSSION	  
7.1. Summary	  of	  the	  main	  findings	  
This	  thesis	  aimed	  to	  address	  the	  impact	  of	  the	  chronic	  exposure	  to	  inflammation	  and	  
oxidative	   stress	   on	   the	   human	   vasculature	   homeostasis	   observed	   in	   patients	   with	  
periodontitis	  and	  investigate	  biologically	  plausible	  mechanisms	  underlying	  this	  link.	  
Specifically,	   this	   project	   analyzed	   the	   relationship	   between	   PD	   and	   two	   recognized	  
measures	  of	  vascular	  health	  and	  potential	  indicators	  of	  a	  future	  cardiovascular	  risk:	  the	  
endothelial	   function,	   involved	   in	   the	   very	   early	   stage	   of	   the	   atherosclerotic	   disease	  
pathogenesis	   and	   the	   c-­‐IMT,	   a	   measure	   of	   structural	   arterial	   disease	   linked	   to	  
atherosclerotic	   progression.	   The	   results	   of	   the	   systematic	   review	   and	   meta-­‐analysis	  
supported	   this	   association;	   PD	   could	   contribute	   to	   a	   faster	   progression	   of	   the	   c-­‐IMT	  
leading	   to	   the	   development	   of	   atherosclerosis	   and	   increased	   risk	   of	   future	  
cardiovascular	   events.	   This	  was	   further	   confirmed	  by	   an	   additional	   and	   independent	  
systematic	   review	   and	   meta-­‐analysis	   by	   Zeng	   et	   al.	   on	   17330	   participants.	   They	  
showed	  that	  periodontitis	  is	  associated	  with	  carotid	  atherosclerosis	  (OR:	  1.27,	  95%	  CI:	  
1.14-­‐1.41;	  P<0.001)725.	  	  
The	   current	   epidemiological	   findings	   of	   a	   moderate	   association	   between	   PD	   and	  
atherosclerosis	  do	  not	  allow	  defining	  PD	  as	  an	  independent	  casual	  factor	  in	  the	  onset	  
and	   progression	   of	   atherosclerosis.	   Reviewing	   the	  modified	   Hill’s	   criteria	   to	   explore	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Table	  33	  Bradford-­‐Hill	  criteria	  for	  the	  causal	  association	  between	  PD	  and	  CVD	  
Bradford-­‐Hill	  Criteria	   	  
Statistical	  strength	  of	  association	  
	  
The	  strength	  of	  association	  between	  PD	  and	  CVD	  
is	  considered	  weak	  to	  moderate.	  	  
Consistency	  
	  
The	   association	   between	   PD	   and	   CVD	   is	  
consistent	   among	   a	   large	   number	   of	   studies.	  
However,	  consistency	  of	  the	  findings	  of	  available	  
studies	  is	  not	  absolute.	  
Specificity	  
	  
Positive	   association	   between	   periodontal	   and	  
cardiovascular	  diseases	  was	  evidenced	  adjusting	  
for	  traditional	  cardiovascular	  risk	  factors	  
Temporal	  relationship	  
	  
PD	  preceded	  CVD	  after	  adjustment	  for	  traditional	  
cardiovascular	  risk	  factors.	  
Biological	  gradient	   Increasing	   severity	   of	   PD	   resulted	   in	   higher	  




Experimental	   evidence	   proves	   the	   biological	  




The	   association	   does	   not	   conflict	   with	   currently	  
established	   theory	   and	   scientific	   knowledge	   on	  
the	  development	  of	  CVD.	  
Experimental	  reversibility	  
	  
In	   vitro	   and	   in	   vivo	   evidence	   supports	   a	   causal	  
role	  for	  PD	  in	  the	  development	  of	  CVD.	  However,	  
RCT	   on	   hard	   CV	   outcomes,	   ie	   MI	   and	   stroke,	  
need	  to	  be	  designed.	  
Analogy	   Other	   inflammatory	   conditions	   such	   as	   diabetes	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Despite	  the	  overall	  modest	  association,	  the	  consistency	  of	  data	  across	  different	  study	  
populations,	  exposures	  and	  outcome	  variables	  suggests	  that	  these	  findings	  might	  not	  
be	  spurious	  or	  attributable	  to	  confounders.	  There	  is	  lack	  of	  experimental	  evidence	  on	  
the	   reversibility	   of	   the	   association	   obtained	   from	   systematic	   review	   of	   randomized	  
controlled	  clinical	  trials	  testing	  the	  hypothesis	  that	  control	  of	  PD	  will	  result	  in	  a	  stop	  or	  
reversion	  of	  atherosclerosis.	  	  
Multiple	   plausible	  mechanisms	   have	   been	   suggested	   to	   support	   the	   causality	   of	   the	  
association.	   Periodontal	   lesions,	   characterized	   by	   an	   exaggerated	   inflammatory	  
gingival	   response	   and	   interface	   with	   a	   dysbiotic	   microflora,	   represent	   a	   constant	  
source	   of	   transient	   systemic	   bacteraemia665.	   Periodontal	   pathogens	   or	   their	  
byproducts	   gaining	   access	   to	   the	   circulation	   could	   trigger	   a	   systemic	   inflammatory	  
response	  involving	  the	  endothelium	  and	  immune	  cells	  (Figure	  43).	  	  
	  
Figure	  43	  Mechanisms	  of	  causal	  association	  adapted	  from	  Hajishengallis	  et	  al.	  2015	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This	  mechanism	  has	   been	  demonstrated	  plausible	   in	   experimental	   animal	  models	   of	  
periodontitis	  and	  atherogenesis726-­‐728.	  	  
Further,	   evidence	   suggests	   the	   necessity	   of	   pattern-­‐recognizing	   receptors	   for	  
atherosclerotic	  lesion	  formation729-­‐733.	  TLR2	  recognition	  of	  Porphyromonas	  gingivalis	  is	  
fundamental	   for	   the	   impact	   of	   the	   pathogen	   in	   the	   periodontium734,735	   and	   in	  
atherosclerosis325,736.	  P.	  Gingivalis	  has	  been	  shown	  to	  invade	  the	  endothelial	  cells	  and	  
potentially	   induce	   endothelial	   dysfunction737,738,	   a	   key	   step	   in	   the	   development	   of	  
atherosclerosis739.	   Circulating	   endothelial	   progenitor	   cells	   (EPC)	   contribute	   to	   the	  
maintenance	  of	  a	  healthy	  endothelium740	  and	  their	  number	  has	  been	  related	  to	  both	  
endothelial	   function	   and	   CV	   outcomes741,742.	   Li	   et	   al	   has	   reported	   an	   increased	   EPC	  
counts	   in	   otherwise	   healthy	   periodontal	   patients	   compared	   to	   controls	   without	  
periodontitis516	   and	   that	   periodontal	   treatment	   was	   related	   to	   a	   decrease	   of	   CD34	  
positive	  cells743.	  In	  an	  experimental	  animal	  model	  of	  periodontitis,	  it	  has	  been	  reported	  
that	  recurrent	  bacteraemia	  induce	  endothelial	  progenitor	  mobilization	  from	  the	  bone	  
marrow	  and	  subsequent	  higher	   levels	  of	  EPC744,	  a	  potential	  counter-­‐measure	  against	  
the	  bacteraemia-­‐mediated	  endothelial	  damage.	  Similar	  findings	  are	  also	  detectable	  in	  
other	   inflammatory	   conditions	   such	   as	   rheumatoid	   arthritis745,	   or	   in	   acute	   tissue	  
damage	  events,	  such	  as	  MI746	  or	  percutaneous	  coronary	  intervention747.	  
An	  alternative	  causal	  mechanism	  has	  been	  suggested	  by	  a	  recent	  experiment	  on	  mice	  
reporting	   that	   P.	   gingivalis	   can	   cause	   alterations	   to	   the	   gut	   microbiota,	   leading	   to	  
indirect	   induction	  of	   systemic	   inflammation748.	  Mice	  orally	   infected	  with	  P.	   gingivalis	  
showed	   changes	   in	   their	   gut	  microbiota	   with	   increased	   proportion	   of	   Bacteroidetes	  
and	  a	  decreased	  proportion	  of	  Firmicutes	  compared	   to	  controls.	  The	  gut	  micriobiota	  
shift	  correlated	  with	  the	  decreased	  expression	  of	   tight-­‐junction	  proteins	   in	   the	   ileum	  
and	   with	   the	   onset	   of	   endotoxaemia	   and	   systemic	   inflammation.	   However,	   the	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mechanism	  by	  which	  P.	  Gingivalis	   causes	  changes	   to	   the	  gut	  microbiota	   remains	   still	  
uncertain.	  
	  Our	  meta-­‐analysis	   has	   confirmed	   both	   an	   impaired	   endothelial	   function	   in	   patients	  
with	  PD	  and	  a	  beneficial	  effect	  of	  periodontal	  treatment	  on	  the	  same	  marker	  in	  clinical	  
trials	   involving	  otherwise	  healthy	  patients.	  Our	  group	  previously	  conducted	  a	  RCT	  on	  
otherwise	  healthy	  patients	  with	  severe	  and	  generalized	  PD	  reporting	  an	  improvement	  
of	  endothelial	  function,	  assessed	  by	  FMD,	  6	  months	  after	  periodontal	  treatment12.	   In	  
the	   review,	   we	   could	   not	   draw	   robust	   conclusions	   on	   the	   effect	   of	   periodontal	  
interventions	  on	  c-­‐IMT	  since	  our	  search	  did	  not	  find	  reliable	  evidence	  published.	  	  
Piconi	  et	  al.	  conducted	  an	  uncontrolled	  12months	  cohort	  clinical	   trial	  and	  concluding	  
that	  periodontal	  therapy	  has	  a	  favourable	  effect	  on	  c-­‐IMT	  progression.	  Due	  to	  its	  low	  
level	  of	  evidence,	  however	  no	  firm	  conclusions	  can	  be	  drawn	  399.	  Recently,	  Kappelas	  et	  
al.	  conducted	  a	  RCT	  on	  168	  Aboriginal	  Australians	  suffering	  from	  PD	  and	  observing	  a	  c-­‐
IMT	   decrease	   after	   12	   months	   of	   a	   single	   session	   of	   periodontal	   therapy	   in	   the	  
intervention	  group	  (mean	  reduction=−0.023	  [95%	  CI,	  −0.038	  to	  −0.008]	  mm)	  but	  not	  in	  
the	  control	  group	  (mean	  increase=0.002	  [95%	  CI,	  −0.017	  to	  0.022]	  mm).	  The	  difference	  
in	   intima-­‐media	   thickness	   change	   between	   treatment	   groups	   was	   statistically	  
significant	   (−0.026	   [95%	   CI,	   −0.048	   to	   −0.003]	   mm;	   P	   =0.03)652.	   However,	   the	  
participants	  received	  a	  single	  session	  of	  periodontal	  therapy	  with	  a	  lack	  of	  SPT	  sessions	  
and	  reported	  modest	  periodontal	  improvements.	  In	  addition,	  all	  participants	  were	  free	  
to	   receive	   periodontal	   treatment	   during	   the	   course	   of	   the	   study.	   Furthermore	   two	  
loops	   were	   obtained	   from	   each	   side	   of	   the	   carotid,	   and	   averaged	   to	   obtain	   the	  
maximum	   carotid	   IMT	   increasing	   the	   variability	   of	   the	   measurements.	   The	   Oral	  
Infections	   and	   Vascular	   Disease	   Epidemiology	   Study	   (INVEST)	   has	   documented	   that	  
higher	   levels	   of	   periodontopathogens	   were	   cross-­‐sectionally	   associated	   with	   thicker	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carotid	   IMT594.	   In	   addition,	   the	   same	   investigators	   reported	   longitudinal	   change	   in	  
periodontal	  health	   to	  be	  concurrent	  with	   longitudinal	   carotid	  artery	   IMT	  progression	  
over	  an	  average	  period	  of	  3	  years749.	  Desvarieux	  et	  al.	  detected	  a	  difference	  in	  c-­‐IMT	  
among	   participants	   of	   approximately	   0.1	   mm	   in	   3	   years	   follow-­‐up	   suggesting	   the	  
importance	  of	   the	   improvement	   in	  periodontal	   status.	  Evidence	   suggests	   that	  a	  0.03	  
mm/year	  increase	  in	  c-­‐IMT	  is	  associated	  with	  a	  2.3-­‐fold	  increased	  risk	  for	  CV	  events648.	  
In	   addition,	   experimental	   studies	   on	   the	   impact	   of	   statins	   on	   the	   c-­‐IMT	   progression	  
rate	  reported	  as	  clinically	  significant	  a	  difference	  of	  0.0082	  mm/year	  in	  c-­‐IMT	  between	  
test	   and	   controls538.	  Our	  meta-­‐analysis,	   in	   line	  with	   previous	   evidence,	   supports	   the	  
role	  of	  PD	  as	  a	  contributor	  to	  the	  pathogenesis	  of	  CVD	  and	  indicates	  the	  endothelium	  
as	  the	  main	  target	  of	  the	  systemic	  effect	  of	  PD.	  	  
We	   designed	   3	   RCTs	   to	   explore	   the	   nature	   of	   the	   association	   between	   PD	   and	  
atherosclerosis	   including	   the	   first	   in	   vivo	   exploration	   of	   plausible	   underpinning	  
mechanisms.	  In	  Study	  2,	  we	  randomized	  patients	  with	  PD	  and	  T2DM	  to	  receive	  either	  
sub-­‐gingival	  scaling	  and	  root	  planing	  and	  where	  appropriate	  Modified	  Widman	  flap	  (as	  
described	   in	   Chapter	   2)	   or	   supra-­‐gingival	   scaling	   and	   polishing	   over	   a	   period	   of	   6	  
months	  and	  adopted	  FMD	  to	  analyzed	  changes	  in	  endothelial	  function	  in	  the	  two	  study	  
groups.	   The	   choice	  of	   a	  high	  CVD	   risk	  population	  was	   justified	  by	   the	   importance	  of	  
both	  diseases	  (PD	  and	  CVD)	  in	  patients	  with	  diabetes.	  A	  wealth	  of	  evidences	  link	  both	  
T1	   and	   T2DM	   to	   a	   deterioration	   of	   the	   endothelial	   function	   showing	   an	   impaired	  
endothelial-­‐dependent	  vasodilation750-­‐752.	  Despite	  many	  proposed	  mechanisms	  for	  this	  
relationship,	   the	   definitive	   pathogenesis	   remains	   unclear;	   multiple	   homeostatic	  
imbalances	   and	   hyperglycemia	   suggest	   a	   multifactorial	   etiology753-­‐755.	   The	   chronic	  
inflammatory	   state	   observed	   in	   T2DM	   including	   higher	   levels	   of	   pro-­‐inflammatory	  
cytokines,	   chemokines,	   and	   adhesion	   molecules	   could	   affect	   the	   endothelial	   cells	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phenotype756.	   The	   adipose	   tissue	   has	   been	   identified	   as	   the	   major	   source	   of	  
inflammatory	  mediators	  such	  as	  TNF-­‐α757,758	  that	  activates	  nuclear	  factor	  κB	  (NFκB),	  a	  
transcription	   factor	   inducing	   the	   expression	   of	   inflammatory	   genes759.	   In	   addition,	  
overexpression	  of	  either	  TNF-­‐α	  or	  NFκB	  kinase	  could	  contribute	  to	  the	  development	  of	  
insulin	   resistance760.	   The	   association	   of	   insulin	   resistance	   with	   inflammation	   could	  
reduce	   NO	   bioavailability761.	   The	   oxidative	   status	   is	   also	   implicated	   in	   the	   reduced	  
endothelial	  integrity	  in	  T2DM.	  The	  accumulation	  of	  ROS	  such	  as	  superoxide	  anion	  (O2-­‐)	  
could	   diminish	   NO	   bioavailability,	   either	   through	   direct	   degradation	   by	   ROS,	   or	  
alterations	   in	   the	   functional	   capacity	   of	   eNOS762.	   Xanthine	   oxidase,	   nicotinamide	  
adenine	   dinucleotide	   phosphate	   (NADPH)	   oxidase	   and	   mitochondria	   represent	  
important	   sources	   of	   O2-­‐762.	   Mitochondria	   produce	   negligible	   ROS	   in	   physiological	  
circumstances	  but	  high	  glucose	  concentrations	  increase	  the	  proton	  gradient	  within	  the	  
electron	   transport	   chain	   with	   a	   consequent	   overproduction	   of	   superoxide763.	  
Furthermore,	   mitochondrial	   dynamics	   such	   as	   increased	   mitochondrial	   fission	   and	  
fragmentation	  could	  affect	  ROS	  production	  in	  DM764.	  Altered	  mitochondrial	  function	  is	  
linked	   to	   several	   acute	   and	   chronic	   inflammatory	   diseases641.	   The	   mitochondrial	  
respiratory	   chain	   is	   the	  main	   source	   of	   ROS	   765.	   Furthermore,	  mitochondria	   are	   also	  
targets	  of	  oxidants.	  Under	  physiological	  conditions,	  about	  1	  to	  3%	  of	  molecular	  oxygen	  
is	  incompletely	  reduced	  during	  redox	  reactions	  in	  the	  mitochondrial	  respiratory	  chain	  
leading	   to	   the	   production	   of	   the	   superoxide	   anion.	   However,	   under	   pathological	  
conditions,	  an	  excess	  superoxide	  causes	  the	  activation	  of	  redox-­‐sensitive	  transcription	  
factors	   such	   as	   nuclear	   factor-­‐κB	   and	   a	   subsequent	   increase	   in	   the	   expression	   of	  
cytokines,	   chemokines,	   eicosanoids,	   inducible	   nitric	   oxide	   synthase	   (iNOS),	   and	  
adhesion	  molecules766.	   Several	   inflammatory	  molecules	   such	  as	  TNF-­‐α	  and	   IL-­‐1β	  and	  
the	   reactive	   nitrogen	   intermediate	   NO,	   may	   induce	   mitochondrial	   damage767-­‐769	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decreasing	   the	   activity	   of	   the	   respiratory	   chain,	   ATP	   production	   and	   mitochondrial	  
membrane	   potential.	   In	   addition,	   these	   mediators	   induce	   the	   accumulation	   of	  
significant	   amounts	   of	   ROS770,771.	   This	   project	   for	   the	   first	   time	   proposes	   PD	   as	   an	  
underestimated	   factor	  driving	   systemic	   inflammation	  and	  oxidative	   stress	   in	  patients	  
with	   T2DM	   and	   driving	   their	   increased	   risk	   of	   macrovascular	   complications.	   The	  
improvement	   of	   the	   endothelial	   function	   was	   associated	   with	   the	   lowering	   of	   the	  
mitochondrial	   superoxide	   production,	   IFN-­‐γ,	   TNF-­‐α,	   and	   s-­‐Eselectin.	   Superoxide	  
overproduction	  is	  a	  mediator	  of	  tissue	  damage	  in	  T2DM;	  it	  activates	  multiple	  pathways	  
involved	  in	  the	  pathogenesis	  of	  complications	  and	  inactivates	  protective	  enzymes	  such	  
as	  eNOS	  and	  prostacyclin	  synthase772.	  The	  pro-­‐inflammatory	  cytokine	  IFN-­‐γ	  is	  secreted	  
by	   T	   helper-­‐1	   (Th1)	   cells	   during	   infections.	   IFN-­‐γ	   can	   subsequently	   activate	  
macrophages,	   resulting	   in	   the	   secretion	   of	   inflammatory	   mediators	   to	   enhance	  
antibacterial	  actions.	  Endogenous	  pro-­‐inflammatory	  mediators,	  such	  as	  tumor	  necrosis	  
factor	   (TNF),	   may	   also	   induce	   the	   production	   of	   IFN-­‐γ.	   IFN-­‐γ	   stimulates	   the	  
endothelium	   to	   express	   cell	   adhesion	   molecules	   and	   leukocyte	   recruitment	   to	   the	  
plaque773.	  In	  addition,	  the	  presence	  of	  LPS	  can	  increase	  the	  process774.	  Therefore,	  the	  
beneficial	   effect	   of	   the	   periodontal	   treatment	   reported	   in	   our	   sample	   might	   be	  
justified	  by	  a	  minor	   level	  of	  bacterial	   dissemination	  associated	  with	   improvement	  of	  
the	   periodontal	   health.	   This	   is	   consistent	   with	   the	   findings	   of	   a	   reduced	   LPS	   levels	  
observed	   within	   6	   months	   of	   periodontal	   therapy.	   However,	   our	   analysis	   does	   not	  
allow	   discriminating	   the	   source	   of	   LPS	   detected.	   More	   in	   depth	   analysis	   on	   the	  
potential	  oral	  source	  of	  the	  bacterial	  toxins	  should	  be	  pursued	  in	  the	  future.	  	  
In	  study	  3,	  we	  have	  evaluated	  the	  impact	  of	  periodontal	  treatment	  on	  c-­‐IMT	  in	  a	  RCT	  
on	  117	  patients	  suffering	   from	  periodontitis	  and	  T2DM	  reporting	  a	  different	  trend	   in	  
the	  progression	  of	  the	  carotid	  thickening	  between	  the	  two	  groups.	  Our	  results	  suggest	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that	   the	   chronic	   inflammatory	   stimulus	   of	   PD	   induces	   structural	   changes	   of	   the	  
vascular	   wall	   reflected	   by	   progressive	   increased	   thickness	   of	   the	   intima	   media	  
layer775,776.	   Therefore	   changes	   in	   cIMT	   might	   be	   a	   marker	   of	   the	   chronic	   vascular	  
inflammation	  and	  oxidative	  stress	  burden	  in	  each	  individual.	  	  
Study	  3	  reported	  an	  improvement	  in	  endothelial	  function	  in	  T2DM,	  which	  in	  turn	  could	  
represent	  a	  clinically	  relevant	  benefit	  in	  these	  patients	  and	  possibly	  lowering	  their	  CVD	  
risk.	  Indeed,	  we	  observed	  an	  absolute	  difference	  of	  0.9%	  (95%	  CI,	  0.3-­‐1.4;	  p=0.002)	  in	  
FMD	  after	  12	  months	  of	  periodontal	  therapy.	  Several	  prospective	  studies	  reported	  an	  
inverse	  association	  between	  brachial	  FMD	  and	  CVD	  risk777-­‐780	  although	  some	  evidence	  
do	  not	   support	   this	   association781,782,	   particularly	   in	   the	   asymptomatic	   population783-­‐
785.	  Hence	  the	  diagnosis	  of	  co-­‐morbidities	  may	   impact	  the	  relationship	  between	  FMD	  
and	  CVD.	  A	  meta-­‐analysis	  of	  14	  prospective	  studies	  reported	  a	  13%	  lowering	  of	  future	  
CVD	   per	   every	   1%	   increase	   in	   FMD786.	   This	   finding	   corroborates	   the	   previous	  
conclusion	  of	  our	  group12	  and	  report	  an	  improvement	  of	  the	  vascular	  health	  not	  only	  
in	  cases	  of	  severe,	  generalized	  periodontitis	  but	  also	  in	  moderate	  forms	  of	  periodontal	  
infection.	  
Further	   evidence	   of	   an	   intimate	   relationship	   between	   PD	   and	   vascular	   function	  
(assessed	   by	   FMD	   of	   the	   brachial	   artery)	   comes	   from	   the	   observed	   acute	   vascular	  
dysfunction	   following	   periodontal	   intensive	   treatment.	   Our	   group	   reported	   a	  
consistent	  transient	  endothelial	  dysfunction	  24	  hours	  following	  IPT	  associated	  with	  an	  
increase	  of	  systemic	  markers	  of	  inflammation	  12.	  This	  further	  corroborates	  the	  role	  of	  
inflammation	  in	  driving	  atherogenesis	  and	  its	  complications.	  PD	  is	  a	  common	  source	  of	  
local	   and	   systemic	   inflammation.	   We	   recently	   confirmed	   that	   the	   degree	   of	  
inflammatory	   exposure	   periodontal	   therapy	   represents	   is	   linked	   to	   the	   extent	   of	  
periodontal	  therapy	  performed787.	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Further,	   this	   evidence	   poses	   an	   additional	   question,	   which	   is	   whether	   acute	  
inflammation	   following	   invasive	  dental	   treatments	   could	  be	  detrimental	  on	  patients’	  
overall	  homeostasis	  and	  whether	  this	  could	  be	  prevented.	  Our	  group	  was	  the	  first	  to	  
report	   on	   the	   possible	   association	   between	   dental	   treatment	   and	   acute	   increase	   in	  
vascular	   risk.	   Minassian	   et	   al.	   adopted	   the	   self-­‐controlled	   case	   series	   method	   to	  
investigate	   the	   incidence	  of	  acute	  CV	  events	   such	  as	   ischemic	   stroke	  and	  myocardial	  
infarction	  following	  invasive	  dental	  treatment	  by	  using	  Medicaid	  claims	  data	  from	  the	  
United	   States.	   The	   authors	   reported	   “invasive	   dental	   procedures	  may	   be	   associated	  
with	  a	  transient	   increase	  in	  the	  risk	  for	  stroke	  and	  myocardial	   infarction	  in	  the	  first	  4	  
weeks	  after	  treatment”519.	  	  	  
Lower	  FMD	  values	  have	  been	  associated	  with	  a	  higher	  risk	  of	  CV	  events.	  In	  Study	  4	  we	  
therefore	  we	  chose	  a	  simple	  and	  effective	  procedure	  of	  vascular	  protection:	  RIPC.	  This	  
has	   been	   elegantly	   demonstrated	   in	   different	   experimental	   models	   of	   systemic	  
inflammation	   such	   as	   the	   Typhoid	   vaccination,	   ischemia-­‐reperfusion	   injury	   and	  
strenuous	   exercise297,577,716.	   For	   the	   first	   time	   we	   experimented	   whether	   RIPC	   just	  
performed	   before	   a	   long	   session	   of	   intensive	   periodontal	   therapy	  would	   prevent	   or	  
reduce	   the	   acute	   endothelial	   dysfunction	   observed	   following	   IPT.	   The	   results	  
demonstrated	   in	   the	  patients	   recruited,	   that	  RIPC	  modulates	   the	  acute	   inflammatory	  
response	  following	  IPT	  and	  resulting	  in	  increased	  FMD	  compared	  to	  the	  placebo	  group.	  
Although	  RIPC	  could	  not	  prevent	  endothelial	  dysfunction,	  a	  significant	  30%	  difference	  
was	  observed	  between	  the	  two	  study	  groups.	  This	  could	  represent	  a	  relevant	  finding	  in	  
patients	   with	   known	   co-­‐morbidities	   or	   unstable	   medical	   conditions	   who	   require	  
essential,	   emergency	   or	   elective	   dental	   care.	   Further	   research	   is	   warranted	   with	  
particular	   emphasis	   on	   the	   possible	   implications	   on	   the	   provision	   of	   dental	   care	   in	  
special	  care	  units.	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Study	   4	   concluded	   that	   changes	   in	   mtROS	   production	   in	   PBMC	   and	   whole	   oxidant	  
status	   of	   patients	   undergoing	   IPT	   might	   relevant	   to	   the	   development	   of	   vascular	  
dysfunction.	  In	  particular	  the	  increase	  in	  oxidative	  circulating	  molecules	  might	  exert	  a	  
vasculo-­‐protective	   effect.	   Vanden	   Hoek	   et	   al.	   reported	   the	   loss	   of	   preconditioning	  
protection	   with	   antioxidants	   in	   cardiomyocytes723,724.	   Isolated	   cardiomyocytes	  
demonstrated	   significant	   preconditioning	   protection	   with	   exposure	   to	   a	   10-­‐min	  
ischemic	  preconditioning	  trigger	   just	  before	  1	  h	  of	   ischemia	  and	  reperfusion.	  Oxidant	  
generation	  was	  observed	  to	  occur	  during	  the	  brief	  10	  min	  of	  preconditioning	  ischemia	  
that	  could	  be	  attenuated	  with	  antioxidants	  and	  mitochondrial	  inhibitors.	  
This	   finding	   is	   in	   apparent	   conflict	   with	   the	   reduced	   systemic	   release	   of	   pro-­‐
inflammatory	   mediators	   and	   vascular	   activation/damage	   molecules	   observed	   in	  
patients	  receiving	  RIPC.	  Further,	  no	  substantial	  difference	  in	  LPS	  levels	  were	  noted	  and	  
within	   the	   limitations	   of	   this	   assay,	   we	   can	   at	   least	   conclude	   that	   bacterial	   burden	  
might	   be	   less	   important	   in	   the	   link	   between	   acute	   inflammation	   and	   vascular	  
function/dysfunction.	   The	   mechanism	   by	   which	   intensive	   periodontal	   treatment	  
triggers	   acute	   endothelial	   dysfunction	   seems	   to	   be	   attributable	   to	   a	   systemic	  
inflammatory	  response.	  Increase	  in	  C-­‐reactive	  protein	  and	  TNF	  are	  both	  involved	  in	  the	  
amplification	   of	   the	   immune	   response.	   In	   our	   trial	   is	   also	   evident	   that	   there	   is	   a	  
modulation	   of	   the	   vascular	   activation.	   The	   adhesion	   molecules	   levels	   increase	   and	  
higher	  thrombomodulin	  (TM)	  suggest	  a	  direct	  effect	  on	  the	  endothelium.	  Whilst	  higher	  
levels	   of	   vascular	   activation	   could	   account	   for	   an	   increased	   endothelial-­‐leukocytes	  
interaction,	   TM	   might	   be	   an	   expression	   of	   an	   acute	   endothelial	   damage	   following	  
periodontal	  treatment.	  TM	  plays	  a	  pivotal	  role	  in	  endothelial	  homeostasis	  by	  inhibiting	  
coagulation	   and	   fibrinolysis788	   and	   mediating	   inflammation789.	   This	   gives	   the	  
endothelium	   protection	   against	   apoptosis,	   inflammation,	   fibrinolysis	   and	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thrombosis790.	   The	   sample	   population	   recruited	   for	   Study	   4	   exhibited	   baseline	   low	  
circulating	  levels	  of	  TM.	  Elevated	  plasma	  TM	  levels	  have	  been	  found	  to	  correlate	  with	  
several	   clinical	   conditions	   such	   as	   atherosclerosis791,792	   and	   ischemic	   stroke793.	   Our	  
data	  report	  an	  increase	  in	  sTM	  levels	  up	  to	  7	  days	  after	  invasive	  periodontal	  treatment.	  
Using	   sTM	   as	   a	   marker	   of	   vascular	   damage,	   our	   project	   results	   could	   support	   the	  
hypothesis	  that	  the	  systemic	  perturbation	  subsequent	  periodontal	  intervention	  might	  
temporarily	   increase	   CV	   risk	   through	   endothelial	   dysfunction.	   Further	   research	   is	  
required	   to	   confirm	  our	   result	   in	   a	   high	   risk	   population	   and	   also	   investigate	   if	   other	  
invasive	  dental	  procedures	  such	  as	  single	  or	  multiple	  extractions	  and	  dental	   implants	  
placement	  could	  represent	  a	  potential	  trigger	  for	  acute	  endothelial	  dysfunction.	  	  
7.2. Limitations	  
Our	   systematic	   search	   and	   meta-­‐analysis,	   for	   the	   first	   time,	   summarized	   all	   the	  
available	   evidence	   from	   observational	   and	   intervention	   studies	   on	   the	   relationship	  
between	   PD	   and	   specific	   CV	   biomarkers.	   However,	   the	   relatively	   limited	   number	   of	  
patients	  included,	  the	  lack	  of	  systematic	  adjustment	  for	  confounders	  and	  difference	  in	  
the	  methodology	  adopted	  for	  the	  assessment	  of	  both	  the	  dependent	  and	  independent	  
variables	  could	  represent	  significant	  limitation	  of	  Study	  1.	  We	  detected	  a	  high	  level	  of	  
heterogeneity	  in	  studies	  retrieved	  when	  gathering	  the	  data	  on	  FMD	  and	  PD	  due	  to	  the	  
high	  variability	  in	  the	  FMD	  technique.	  In	  Study	  2,	  our	  main	  limitation	  was	  the	  relatively	  
low	  sample	  size	  and	  short	  follow-­‐up	  (6	  months)	  which	  might	  not	  be	  representative	  of	  
the	   evolution	   of	   atherosclerosis.	   In	   addition,	   we	   adopted	   one	   technique	   for	   the	  
assessment	  of	  PBMC	  mitochondrial	  ROS	  production.	   This	   is	  not	  necessarily	   the	  most	  
sensitive	  technique	  for	  oxidative	  analyses.	  Similarly,	  in	  Study	  4	  we	  have	  used	  a	  generic	  
measure	   of	   oxidative	   stress	   (d-­‐ROM	   test)	   and	   FACS	   analysis	   for	   the	   mitochondrial	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superoxide	  production.	  These	  methodological	  steps	  could	  have	  introduced	  bias	  in	  the	  
interpretation	  of	  our	  results.	  In	  Study	  3	  although	  the	  sample	  size	  calculation	  based	  on	  
recent	   evidence	   suggested	   sufficient	   power	   for	   detection	   of	   c-­‐IMT	   changes,	   the	  
majority	  of	  RCTs	  and	  evidences	  assessing	  the	  progression	  of	  atherosclerosis	  are	  for	  a	  
minimum	  of	  2	  years	  of	  follow-­‐up.	  This	  is	  also	  coupled	  with	  the	  lack	  of	  any	  evidence	  of	  
changes	   in	   the	   occurrence	   in	   clinical	   vascular	   events	   which	   would	   represent	   the	  
ultimate	  goal	  of	  this	  area	  of	  research.	  	  
7.3. Relevance	  of	  the	  project	  	  
This	  project	  contributed	  to	  the	  advancement	  in	  the	  understanding	  of	  the	  link	  between	  
PD	   and	   CVDs.	   	   Adopting	   a	   systematic	   approach	   to	   the	   available	   evidence,	   we	  
confirmed	   a	   moderate	   association	   between	   PD	   and	   CVD.	   Dentists	   and	   physicians	  
should	  be	  more	  aware	  of	  this	   link.	  Furthermore	  in	  2	  RCT	  we	  have	  demonstrated	  that	  
periodontal	   treatment	   has	   a	   beneficial	   effect	   on	   the	   endothelial	   regulation	   of	   the	  
vessel	   tone	   in	   a	   high	   CVD	   risk	   population	   represented	   by	   patients	   with	   T2DM.	   In	  
addition,	  the	  amelioration	  of	  the	  vascular	  health	  is	  expressed	  by	  a	  slower	  progression	  
of	  the	  c-­‐IMT	  thickening	  assessed	  within	  12	  months	  after	  the	  periodontal	  treatment	  in	  a	  
population	   affected	   by	   T2DM.	   PD	   could	   represent	   a	   modifiable	   risk	   factor	   for	  
endothelial	   dysfunction	   and	   the	   atheroma	   progression.	   Therefore,	   considering	   the	  
prevalence	  of	  PD,	   its	   treatment	  could	  be	   relevant	   to	   the	  management	  of	  CVD	   in	   the	  
general	   population.	   The	   most	   plausible	   mechanism	   linking	   the	   two	   conditions	   is	  
represented	   by	   inflammation.	   Acute	   and	   chronic	   changes	   in	   inflammation	   and	  
oxidative	  stress	  could	  influence	  this	  link.	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Furthermore,	   we	   have	   proven	   the	   protective	   effect	   of	   RIPC	   towards	   the	   transient	  
endothelial	  dysfunction	  observed	  within	  24	  hours	  from	  intensive	  periodontal	  therapy	  
providing	   a	   potential	   tool	   in	   the	   prevention	   of	   CV	   risk	   in	   population	   with	   co-­‐
morbidities.	  Our	   research	  has	   increased	   the	  number	  of	  evidence	   suggesting	  a	   causal	  
role	  of	  PD	  in	  the	  pathogenesis	  of	  atherosclerosis.	  Evaluating	  the	  effect	  of	  periodontal	  
treatment	  on	  CVD	  hard	  outcomes	  such	  as	  stoke	  and	  MI	  should	  be	  the	  future	  goal	  for	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